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Οἶδα οὐκ εἰδώς  
Ich weiß, dass ich unwissend bin. 
 
entlehnt aus der Apologie des Sokrates, Volksgericht von Athen 399 v. Chr. 
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Zusammenfassung 
 
Bakterielle Sekundärmetabolite haben oft starke biologische Aktivität und hohe „Target“-spezifität, 
weshalb sie wertvolle Wirkstoffleitstrukturen darstellen. Es besteht jedoch eine große Diskrepanz 
zwischen der Anzahl der aus Bakterien unter Laborbedingungen nachweisbaren Sekundärmetaboliten und 
der in ihrem Genom codierten Produktionskapazität für Naturstoffe. Sowohl die Zuordnung bakterieller 
Sekundärmetabolom-Bestandteile zu Biosynthesegenclustern als auch die Entdeckung neuer 
Kandidatensubstanzen verlangen daher nach verbesserten analytischen Methoden gekoppelt mit 
Genomanalysetechniken. Methoden, die auf statistischer Analyse großer Mengen hochauflösender 
Massenspektrometriedaten sowie automatischer Genclusterannotation beruhen, verändern derzeit die 
Naturstoffforschung grundlegend. Diese Arbeit beschreibt Beiträge zu Massenspektrometrie- und 
Genomikgeleiteter Identifizierung, Strukturaufklärung, Beschreibung von Biosyntheserouten sowie 
Evaluierung der Bioaktivität fünf verschiedener neuartiger Grundstrukturen von Sekundärmetaboliten aus 
Myxobakterien. Spezielles Augenmerk liegt dabei auf der Verbesserung der Arbeitsabläufe um 
Sekundärmetaboliten mittels Massenspektrometrie zu identifizieren. Die Studien zeigen, wie durch 
erfolgreiche Kombination mehrerer Ansätze zur Identifizierung neuer bakterieller Sekundärmetabolite 
und zur Beschreibung ihrer Diversität die Lücke zwischen Genomik- und Metabolomikbasierten Ansätzen 
geschlossen werden kann. 
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Abstract 
 
Bacterial secondary metabolites often exhibit potent biological activities with precise target 
specificity, making them a valuable asset for the identification of drug leads. However, a striking 
discrepancy is regularly seen between the genome-inscribed capacity for the production of secondary 
metabolites and the number of known compound classes detected from many microorganisms under 
laboratory cultivation conditions. Methods using improved analytical approaches  to connect the bacterial 
secondary metabolome to biosynthetic gene clusters, aiming to uncover new candidate compounds from 
high resolution mass spectrometric ‘big data’ by statistical data treatment, as well as automated secondary 
metabolite biosynthetic gene cluster annotation coupled to various genome mining techniques are 
therefore about to transform natural product discovery. This work describes contributions to mass 
spectrometry- and genomics-guided compound identification, structure elucidation, investigation of 
biosynthesis routes and biological activity evaluation covering five different myxobacterial secondary 
metabolite scaffolds. Special focus lies on improving workflows for secondary metabolite identification 
using mass spectrometry data. By successfully combining several approaches to find novel bacterial 
secondary metabolites, this study underlines current prospects for closing the gap between genomics- and 
metabolomics-centric approaches to access bacterial secondary metabolite diversity. 
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1 Introduction 
Natural products, small molecules synthesized by living organisms, are an extremely diverse group of 
compounds that have been used by humans throughout history. The importance of natural products in 
human civilization is well exemplified by traditional Chinese medicine, a more than 2000 years old science 
that treats all kinds of illnesses with – among others – herbal remedies. Advances in technology provided 
the means to analyze the biologically active ingredients in these remedies, which led to a boost in 
pharmaceutical development.[1] While plant natural products have been used for a long time, the 
emergence of natural products of microbial origin was set off by the discovery of penicillin by Alexander 
Fleming in 1928, which also marked the starting point of antibiotics discovery. Ever since, bacterial and 
fungal natural products, termed secondary metabolites, have proven to be a valuable source of 
pharmaceutically relevant substances. These compounds are metabolites, which the host organism 
produces, but which are not imminently necessary for the host organism’s survival.[2] From an evolutionary 
perspective, it is commonly thought that secondary metabolites confer a competitive advantage to the 
producing organism in terms of securing its habitat, e.g. by outcompeting concurring organisms as part of 
a permanent rivalry for food sources. Evolution has promoted the development of species that are 
especially fit to outcompete their contestants, which is often based on their ability to produce specific 
secondary metabolite for this purpose. It is thus unsurprising that many known secondary metabolites 
have evolved to be bactericidal, cytotoxic or to block virulence of competing species. As natural 
evolutionary processes have been driving the optimization of effectiveness and specificity of secondary 
metabolites over an extended timeframe, these compounds have also contributed many important lead 
structures to human medicine over several decades.[3] Especially in the field of antibiotics, secondary 
metabolites have been foundational for the discovery of new active scaffolds.[4] But not only antibiotics 
discovery has relied heavily upon natural products in order to obtain drug leads. To date, most of the 
clinically used drugs are either natural products, or semisynthetic compounds and synthetic compounds 
based on a natural product pharmacophores, revealing the large importance of natural products for drug 
discovery and pharmacological development.[6] 
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Figure 1. Discovery of antibiotics classes over several decades: natural products derived drug scaffolds depicted in 
green, synthetic antibiotic scaffolds depicted in blue.[5] 
There is currently an urgent need for new antibiotics that comes with the idea to refocus antibiotics 
discovery towards new natural products, since, as depicted in Figure 1, very few fundamentally new 
antibiotics were approved by the FDA and EMA since the late 1960’s, while at the same time antibiotics 
resistance skyrocketed.[7] This bleak picture comprises several threatening aspects. On the one hand there 
are Gram positive pathogen borne infections, often considered a more treatable problem compared to 
infections caused by their Gram negative counterparts, which have become increasingly deadly.[8] More 
and more of these pathogens such as the ESKAPE panel pathogens – namely Enterococcus faecium 
Staphylococcus aureus Klebsiella pneumoniae Acinetobacter baumannii Pseudomonas aeruginosa and 
Enterobacter – are resistant to many common antibiotics forcing hospitals to resort to reserve antibiotics 
that are often accompanied with detrimental side effects. Gram negative pathogens – often gram negative 
representatives of the ESKAPE panel known for nosocomial infections – are now among the main driving 
forces for raising fears that infective diseases might become a major cause of death by 2050.[9] Combined 
with efforts to improve sanitation in all parts of human life, especially in Hospital environments, new 
antibiotics classes are desperately needed to prevent the advent of a ‘post antibiotics era’ in the near 
future.[10] As mentioned above, most antibiotics scaffolds used today were first discovered from bacteria 
and fungi. This historical perspective translates into prospects that bacterial secondary metabolomes 
might still contain a large and diverse reservoir of new bioactive agents that could become part of the 
solution to the massive antimicrobial resistance problem. 
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 Secondary metabolite production in light of species 
differentiation 
The three main sources of biologically active secondary metabolites found in Nature are plants, fungi 
and eubacteria. While other sources of secondary metabolites such as archaea have been hypothesized, 
their production potential for novel biologically active scaffolds remains to be shown.[11] These three main 
secondary metabolite sources synthesize compounds that are very different in view of their structures and 
biogenesis. Plant metabolites are dominated by alkaloids, small molecules rich in nitrogen, that are 
biosynthesized using a combination of amino acids and terpene precursors.[12] Fungi on the other hand 
mainly rely on non-ribosomal peptides, alkaloids, terpenes and polyketides that represent their secondary 
metabolite arsenal.[13] Last but not least, bacteria are the biggest contributors to the known secondary 
metabolite diversity on earth, providing a wide variety of non-ribosomal peptides, ribosomally synthesized 
and post translationally modified peptides, alkaloids, terpenes and polyketides. According to the current 
phylogeny as well as metagenomics analyses, the vast majority of DNA existing on earth is of bacterial 
origin and most of the bacteria have not been cultured.[14]  
 
Figure 2. Tree of life depicting the genetic diversity of Archaea, Eukaryota and Bacteria created by iTOL[15]  
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Figure 2 shows that only a fraction of all different species are ‘higher organisms’ or part of the archaea 
clade. During evolution, as bacteria were competing for limited space and resources, they evolved a 
number of means to outcompete other bacteria such as efficient replication and fast growth as well as 
production of toxins and secondary metabolites. It is therefore not surprising that most of the secondary 
metabolite encoding biosynthetic gene clusters (BGCs) known today are of bacterial origin. Among the 
bacteria kingdom, some phyla have proven to be highly prolific secondary metabolite producers, such as 
the actinobacteria.[16] However, as the main effort to uncover novel bacterial secondary metabolites relied 
on this phylum, these bacteria have been extensively screened leading to decreased chances for novel 
findings. Nowadays, renewed efforts to detect microbial secondary metabolites therefore involve 
screening microorganisms found in uncommon habitats e.g. marine bacteria, plant or sponge symbionts, 
and bacteria from the human microbiome. These approaches are boosted by the development of genetic 
tools to access the ‘hidden’ biosynthetic potential and making use of the deeper insights offered by state 
of the art analytical methods.[17] One of the bacterial orders that rather recently received more attention 
as secondary metabolite producer are the myxobacteria. 
 Myxobacteria as prolific secondary metabolite producers 
Myxobacteria are ubiquitous soil dwelling gram negative eubacteria belonging to the δ-
proteobacteria clade. They feature “social behavior” that is unique among bacteria, such as fruiting body 
formation which goes along with a sophisticated cell differentiation process.[18]  
 
Figure 3. Fruiting bodies of the myxobacterium Myxococcus xanthus.[19] 
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Furthermore, myxobacteria of the cystobacterinae subclade are predatory organisms that thrive 
through feeding on other soil-dwelling microbes. Interestingly, this predation process is a cooperative 
effort by myxobacteria, where a deadly cocktail of antibiotic compounds and secreted enzymes allows 
them to collectively feed on prey organisms.[18,20] 
 
Figure 4. Cooperative preying behavior displayed by Myxococcus xanthus (left) upon an E. coli colony (right) 
Figure 4 shows the coordinated preying behavior of M. xanthus while moving over and preying on E. 
coli, macroscopically visible as rippling patterns.[21] As it has been shown for M. xanthus DK1622, this 
predatory behavior of myxobacteria is often reliant on “chemical warfare”.[22] Thus it stands to reason that 
many of these compounds used to support prey activity exhibit strong biological activities. 
 Myxobacterial secondary metabolites and their bioactivities 
Secondary metabolites that have previously been isolated from myxobacteria cover a large chemical 
space. Myxobacterial secondary metabolite structures belong to several classes of secondary metabolites 
including polyketides, non-ribosomal peptides, polyketide-non-ribosomal peptide hybrids, ribosomally 
produced and post-translationally modified peptides and terpenes.[23] The vast majority of known 
compounds from myxobacterial strains belong to the polyketide and non-ribosomal peptide secondary 
metabolite classes or hybrid structures thereof. Polyketide biosynthesis alone has afforded a plethora of 
different myxobacterial structures exhibiting various bioactivities, including cytotoxic and anti-bacterial 
activities as prominent examples.[24] 
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Scheme 1. Myxopyronin and Corallopyronin, strong α pyrone antibiotics with a selectivity for Gram positive pathogens 
[25,26] 
A prominent example for promising antibiotic agents from myxobacteria are the α-pyrone antibiotics 
of the myxopyronin and corallopyronin family. These compounds that were isolated from Myxococcus 
fulvus Mx f50 (myxopyronin) and Corallococcus coralloides Cc c127 (corallopyronin) are strong inhibitors 
of the bacterial RNA polymerase (RNAP) that act by binding to the ‘switch’ region of RNAP.[25,26,27]  These 
compounds do not share the binding pocket with the most widely used RNAP inhibitor Rifampicin and are 
therefore still able to kill rifampicin resistant bacteria. Corallopyronin A is investigated as a drug to target 
sleeping sickness because the compound is able to kill the Wolbachia bacteria that live in symbiosis within 
the sleeping sickness parasite.[28] 
 
Scheme 2. The cytotoxin stigmatellin produced by Stigmatella aurantiaca 
Other polyketides from myxobacteria such as the stigmatellins are strong cytotoxins.[29] Stigmatellin 
is a polyketide that acts by blocking the cytochrome bc-1 complex.[30] Therefore, respiratory processes are 
inhibited which leads to quick cell death. Stigmatellins have been used as tool compounds for 
understanding the action of bc-1 inhibitors on the heme centers of this important protein as well as 
deciphering the reduction of the protein’s iron-sulfur clusters once the protein is inhibited.[31] 
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The other rather large group of myxobacterial secondary metabolites are the non-ribosomal 
peptides. These types of peptidic secondary metabolites often display of unusual activities and building 
blocks reaching far beyond the 21 canonical amino acids. One particular example from the ever expanding 
panel of non-ribosomal peptides that was recently discovered from different Cystobacter species is mainly 
composed of head-to-tail linked p-aminobenzoeic acid building blocks and was thus named cystobactamid. 
Members of this compound class bind very strongly to the gyrase (topoisomerase II) of a wide range of 
gram positive and gram negative bacteria, notably without presenting any apparent cytotoxicity.[32]  
 
 
Scheme 3. Structure of the topoisomerase II inhibitor cystobactamid. 
On the contrary, Pyxidicoccus fallax An d48 produces non-ribosomal peptides exhibiting strong 
cytotoxicity: The so-called tubulysins are non-ribosomal peptides belonging to a class of strong cytotoxins 
that act on mammalian cells – as the name suggests – by dissolution of the tubulin skeleton.[33]  
 
Scheme 4. Structure of the tubulin depolymerizing agent tubulysin A. 
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The peptide chain of the tubulysins is completely different from ribosomally produced peptides as 
the building blocks used for tubulysin biosynthesis are in part non-canonical amino acids such as pipecolic 
acid, and in part heavily modified by acylation, N-methylation or cyclisation to form the thiazole ring 
structure.[33,34] 
Many myxobacterial secondary metabolites are in fact polyketide/non-ribosomal peptide hybrids. 
Among those, the most prominent candidate is epothilone, a tubulin stabilizing agent that is clinically used 
in chemptherapy. The corresponding drug, the aza-analogue of epothilone B, is called ixabepilone, which 
is marketed as Ixempra® by Bristol-Meyers Squibb.[35] 
 
Scheme 5. Structures s of Epothilone B and the clinically used Ixabepilone 
As this compound contains a thiazole moiety that originated from cysteine, this compound thus 
qualifies as a hybrid structure made from polyketide synthase and non-ribosomal peptide synthase.[36] 
Apart from epothilone, there is another myxobacterial compound showing strong cytotoxicity by 
interfering with the cytoskeleton called rhizopodin. This compound produced by Myxococcus stipitatus 
leads to cell death in eukaryotes as stabilization of the cell’s actin skeleton impairs cell division.[37] While 
this compound was first thought to be monomeric, the compound has later been shown to consist of a C2-
symmetric dimer.[38] 
 
Scheme 6. Structure of the actin stabilizing agent Rhizopodin 
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While there are many examples of myxobacterial secondary metabolites exhibiting potent biological 
activities as listed in this paragraph, a number of myxobacterial secondary metabolites have been 
uncovered, where the biological target remains to be determined. One prime example is Antalid, a non-
ribosomal peptide – polyketide hybrid for which no apparent biological activity has been found yet.[39] 
 
Scheme 7. Structure of Antalid from Polyangium spumosum. 
Still, this scaffold was developed during myxobacterial evolution and it is likely that production of this 
secondary metabolite gave the bacterium a competitive advantage. It is therefore likely that this 
compound shows strong affinity for a target structure in an unknown competitor’s proteome or 
metabolome and this secondary metabolite – target interaction – albeit as yet unrecognized - might in the 
future become useful for therapeutic applications. 
In addition to the classical non-ribosomal peptides, polyketides and hybrid secondary metabolite 
structures, myxobacterial secondary metabolites also cover ribosomally produced and post-translationally 
modified peptides (RIPPs). The prime myxobacterial example in this case is an alkaloid structure called 
crocagin produced by Chondromyces crocatus Cm c5.[40]  
 
Scheme 8. Structure of crocagin from Chondromyces crocatus Cm c5 
As concluded from the crocagin structure, this compound is constructed from the amino acids Ile – 
Tyr – Trp, which are subsequently processed through oxidative coupling reactions to form the crocagin 
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backbone. The structure is a strong inhibitor of the carbon storage regulator protein CsrA that is involved 
in pathogen virulence and is therefore under investigation as an anti-infective.[40] 
Finally, the myxobacterial secondary metabolism also includes terpenes, although their discovery 
rate is significantly lower than the discovery rate for the compound classes described above. As terpene 
clusters are rather abundant in myxobacterial genomes this seems rather surprising. On the other hand, 
many terpenes, especially those having a low oxygen content, are hardly detectible in  electrospray 
ionization (ESI) based mass spectrometry (MS) screening workflows while being very non-polar, which 
might be one of the reasons why these compounds are often missed in LC-MS screening. One of these 
terpenes was isolated from Cystobacter ferrugineus Cb fe23 and is called Cystodienoeic acid, a cytotoxic 
diterpene structure that exemplifies the potential of myxobacteria to synthesize uncommon terpene 
structures.[41] 
H
OH
O
OH
O
OH
 
Scheme 9. Structure of the myxobacterial terpene cystodienoeic acid 
The myxobacterial secondary metabolite structures are a chemically very diverse group of secondary 
metabolites that, as shown in this paragraph, span a wide range of different biological functions. All these 
compounds are synthesized using a small number of biological precursors like amino acids, acyl-CoA esters 
and isoprene pyrophosphate. To achieve synthesis of such complex molecules from these rather simple 
precursors, bacteria evolved a complex set of biosynthetic enzymes that catalyze the transformation of 
these building blocks into secondary metabolites. In bacteria, these enzymes are grouped together on the 
bacterial chromosome to form biosynthetic gene clusters (BGCs). The chemical diversity seen in 
myxobacterial natural products – as exemplified in this section – is thus also reflected by the amount and 
diversity of biosynthetic gene clusters in the myxobacterial genomes. 
 The biosynthetic proficiency of myxobacteria 
Myxobacteria possess the largest bacterial genomes known to date, with chromosomes featuring up 
to 15 MBps. The genomes of species in the Sorangineae subclade are particularly large.[42] In secondary 
metabolite research, however, the number of gene clusters potentially encoding secondary metabolite 
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biosynthesis pathways is of higher importance than the absolute genome size, as this number reflects the 
theoretical secondary metabolite production capacity more accurately. The number of biosynthetic 
pathways per strain is mostly estimated through analysis by antiSMASH, a program that detects and 
annotates secondary metabolite biosynthetic enzymes using hidden markov models.[43] This tool is able to 
predict prototypical secondary metabolite biosynthesis pathways such as non-ribosomal peptide 
synthetases (NRPS) or polyketide synthases (PKS) but also ribosomally produced and post-translationally 
modified peptides (RiPPs) such as lantipeptides.[44] Furthermore, antiSMASH is able to predict terpene and 
indole biosynthetic pathways in the myxobacterial genomes.[45] These capabilities agree well with most of 
the compounds characterized from myxobacteria to date, which are of NRPS or PKS origin or are based on 
PKS-NRPS hybrid pathways. The myxobacterial pathways which are the subject of this thesis also fall into 
these categories, and the underlying biosynthetic machinery is thus described in more detail in the 
following. 
 Polyketide and non-ribosomal peptide biosynthesis 
1.5.1 Multimodular polyketide biosynthesis 
Multimodular polyketide synthases are large megaenzymes that function like an assembly line in 
secondary metabolite biosynthesis. These megaenzymes are organized in modules, grouping domains into 
functional units. A domain is the smallest functional unit of the megaenzyme that is responsible for a 
specific catalytic transformation. The core biosynthetic principle of polyketide biosynthesis is the 
construction of large molecules based on condensation of malonyl-CoA on an acyl carrier protein (ACP) 
bound carboxyl group which subsequently creates a 1,3-diketo moiety that is further processed. The 
biosynthetic step is catalyzed in a multistep process by ketosynthase (KS) and acyl transferase (AT) 
domains as depicted in Scheme 10. Alternative extender units such as methylmalonyl-CoA or 
methoxymalonyl-CoA can also be used as extender units in polyketide biosynthesis.[46] Substrate specificity 
for the different CoA esters as extender units is conferred by the AT domain. Polyketide synthase pathways 
can be divided into several groups depending on their architecture. Multimodular polyketide synthases  - 
also termed type I polyketide biosynthesis pathways - are characterized by a modular organization of PKS 
modules meaning that every module catalyzes chain elongation by one malonyl-CoA unit, variably 
followed by different tailoring steps such as ketoreductase domains (KR) to produce an alcohol, KR and 
dehydratase domains (DH) to produce a double bond and finally KR, DH and an enoyl-reductase domain 
(ER) that produces a saturated C2 unit.[47] 
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Scheme 10. Schematic view of the decarboxylative claisen condensation that constitutes the core reaction of 
polyketide biosynthesis 
 
Scheme 11. Schematic view of the different module organizations in modular type I polyketide synthases as well as 
the corresponding redox state of the C2 unit that is used as an extender. 
However, not all multimodular polyketide synthases are organized strictly as depicted in Scheme 11. 
In comparison to these architectures that are called cis polyketide synthases, since the acyl transferase 
functionalities are encodes as domains in-cis on the megasynthase, the other type of modular type I 
polyketide synthase proteins are named as trans AT type I polyketide synthases.[48,49] In this case, the AT is 
encoded on a separate open reading frame (orf) near to the biosynthetic gene cluster. Instead of AT 
domains located in cis, these megasynthases possess so called docking domains that recognize the stand 
alone acyl transferase and dock the AT domain so that it is located at the right position within the 
multidomain enzyme complex to perform catalysis.[49] 
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Scheme 12. Schematic view of polyketide extension on a trans AT type I PKS assembly line 
1.5.2 Iterative polyketide biosynthesis 
Contrary to PKS biosynthesis in modular type I PKS systems, PKS type II and type III systems work 
iteratively. Instead of having one module per malonyl-CoA incorporation, these types of polyketide 
synthases work by polykondensation of malonyl-CoA to a poly-1,3-diketone chain that is subsequently 
cyclized and tailored to form the final products.[50,51] PKS type II systems are characterized by the so-called 
minimal PKS system consisting of a catalytically active ketosynthase called KSα, a protein controlling the 
chain length named chain length factor (CLF) or KSβ, and the ACP that bears the growing polyketide chain. 
These three subunits form a tightly interacting protein complex that represents the catalytically active PKS 
machinery. 
 
Scheme 13. Schematic view of polyketide extension in PKS type-II systems 
After creation of this nascent polyketide chain growing on the ACP as seen in Scheme 13, whose 
length is determined by the KSβ, the core structure is typically aromatized as in subsequent reactions that 
create the polyaromatic backbone structure of PKS type-II products. Examples for this eaction sequence 
can be seen in the chelocardin or tetracycline biosynthesis.[52] It is worth mentioning that to date most 
bacterial secondary metabolites of PKS type-II origin have been reported from gram-positive bacteria while 
the corresponding pathways also exist in gram-negatives. Type-III PKS systems on the other hand are also 
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iterative like PKS type-II systems. Contrary to PKS type-II systems, these pathways rely on a single enzyme 
of the Chalcone/Stilbene synthase (CHS) enzyme family that is responsible for polyketide chain formation 
as an active homodimer.[53] Polyketide synthesis in PKS type-III systems is independent of Acyl carrier 
proteins and relies on a ping pong mechanism of the two CHS which pass the growing polyketide chain on 
in every catalysis cycle. The CHS enzyme that possesses a thiolase fold catalyzes a decarboxylative 
thioester claisen condensation where the growing polyketide chain remains bound to coenzyme A instead 
of an acyl carrier protein.[51]  
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Scheme 14. Schematic view of polyketide extension catalyzed by PKS type-III systems 
Like in PKS type-III systems, PKS type-II systems create a mostly polyaromatic core structure out of 
malonyl-CoA building blocks. This core structure is subsequently decorated by tailoring enzymes to 
synthesize the final secondary metabolite. These tailoring enzymes frequently comprise oxidase and 
reductase enzymes, aminotransferases, acyl transferases, methyl transferases and halogenases.[54] 
 Non-ribosomal peptide biosynthesis 
The other large family of modular assembly lines other than type I PKS systems (section 1.5.1) are the 
non-ribosomal peptide biosynthetic enzymes. Contrary to most other peptides in living organisms, non-
ribosomal peptides are not synthesized by the ribosome but instead their formation relies on catalysis 
mediated by megasynthetase enzymes. As described earlier, megasynthetase enzymes are grouped into 
functional units called modules consisting of a set of domains linked to one amino acid extension step. 
Generally, peptide bond formation is achieved by activation of the carboxylic acid function of an amino 
acid as an adenosylmonophosphatidyl ester catalyzed by the adenylation domain (A) and subsequent 
condensation onto the phosphopantheinyl arm of a peptidyl carrier protein (PCP) domain. Subsequently, 
a condensation domain (C) tethers the incoming nascent non-ribosomal peptide to the freshly bound 
amino acid and the amino group of said amino acid forms a peptide bond elongating the non-ribosomal 
peptide by one amino acid. 
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Scheme 15. Loading of an amino acid on a peptidyl carrier protein catalyzed by an A domain 
A combination of multiple of the loading steps visible in Scheme 15 finally leads to stepwise 
elongation of the non-ribosomal peptide as described in Scheme 16. 
 
Scheme 16. Schematic view of non-ribosomal peptide biosynthesis on the assembly line 
While non-ribosomal peptide biosynthesis is significantly slower than ribosomal peptide biosynthesis, 
non-ribosomal peptide synthesis opens up access to a chemical space that is a lot more diverse as it is not 
limited to the usage of the 21 canonical amino acids. Adenylation and condensation domains have been 
shown to incorporate diverse building blocks such as p-aminobenzoeic acid, β-amino acids and pipecolic 
acid for example; but in theory any small building block featuring an amino group as well as a carboxylic 
acid could be used.[32,34,55] Even more uncommon amino acids such as tubuvalin, that is incorporated in 
tubulysin biosynthesis or 6-chloromethyl-5-methoxy-pipecolic acid can be incorporated.[34,56] Even more 
variable is the incorporation of starter units that are loaded onto the first PCP domain. Biosynthesis may 
start with incorporation of a fatty acyl group as in cystomanamide or vioprolide biosynthesis, but also with 
2,3-dihydroxybenzoeic acid as in bacillibactin biosynthesis for example.[57]  
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 Non-ribosomal peptide - polyketide hybrid biosynthesis  
Non-ribosomal peptides and polyketides both rely on biosynthetic schemes that involve 
condensation of an extender unit to a carboxylic acid moiety, thereby creating another terminal carboxylic 
acid. While polyketide biosynthesis forms an 1,3-diketone, non-ribosomal peptide biosynthesis relies on 
formation of a peptide bond.  
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Scheme 17. Comparative analysis of the overall reaction in NRPS and PKS biosynthesis 
Evolution has consequently come up with a number of PKS-NRPS hybrid biosynthesis pathway that 
combine both reaction principles. Examples for these types of biosynthesis – among many others – are 
antalid and epothilone that have already been discussed in section 1.4.[36,39] 
The presence of these assembly lines in bacterial genomes therefore significantly further their 
potential to biosynthesize structurally diverse secondary metabolite molecules that are well adapted to a 
certain target, which gives the producer bacterium a competitive edge over its competitors. In many 
instances, these molecules have proven extremely valuable for human use not only to combat infections 
but to provide treatment options for a number of different human diseases as they bind to 
pharmaceutically relevant targets in the human body. 
 The missing link in compound to gene cluster correlation 
With the significant drop in genome sequencing cost, which is largely attributed to the development 
of next generation sequencing techniques, the number of genomes available to the scientific community 
exploded rapidly.[58] Although secondary metabolite biosynthetic gene clusters are abundant in bacteria 
not evenly distributed across different bacteria and many bacterial families have only limited biosynthetic 
potential regarding secondary metabolite production, secondary metabolite production potential seems 
to correlate with genome size.[59] As myxobacteria have the largest genomes identified so far, this finding 
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underlines the importance of investigating the biosynthetic potential thereof. Still, on the one hand the 
vast majority of all biosynthetic gene clusters predicted so far have not been assigned to its corresponding 
secondary metabolite yet while on the other hand the number of gene clusters predicted by tools such as 
antiSMASH exceeds the number of known bacterial secondary metabolites already.[61] Although many 
bacterial secondary metabolite gene clusters are transcriptionally tightly controlled making it close to 
impossible to observe the corresponding secondary metabolite, improved analytical techniques are a key 
factor to close the gap between the number of biosynthetic gene clusters and the number of observed 
secondary metabolites. 
 Challenges accessing the secondary metabolome 
Bacterial secondary metabolism is extremely complex. Consequently, bacterial extracts often 
containing more than 1000 molecular features detectable in a single LC-MS run.[60] As in many cases, only 
one technique is applied in order to separate and analyze the bacterial secondary metabolome, it is even 
likely that this number of molecular features per extract is still a grave underestimation of the fundamental 
analytical problem. As the so called ‘low hanging fruits’ of the bacterial secondary metabolome, namely 
secondary metabolites that are abundantly produced and easy to detect due to prominent UV and/or MS 
signals, are increasingly harvested already, analysis turns towards looking at compounds that are less easy 
to detect and isolate. Additionally, in the past many compounds have been isolated on the basis of 
biological activity detected in an enzyme or whole cell assay. Still, many bacterial secondary metabolites 
are clinically used on targets that are different from the activity that was initially found and reported. 
Furthermore, as many natural products have stringent target specificities, potent biological activities 
might be missed in ‘standard’ screening approaches. It seems therefore likely that many secondary 
metabolite scaffolds for whom no primary activity has been found initially can in fact be used on different 
cellular targets later. In order to discover novel secondary metabolite scaffolds potentially targeting novel 
structures and exhibiting novel biological activities, great efforts to utilize state of the art analytics with 
downstream big data processing to obtain the previously ‘hidden’ metabolome appear justified. Recent 
developments in analytical methods regarding limit of detection (LOD) and separation power led to an 
immense increase of detectable molecular entities. In order to transform this ”well of complexity” into a 
feasible starting point for natural products discovery, a combination of highly standardized LC conditions 
combined with fast scanning high resolution MS data allows for a statistical data treatment approach that 
allows unprecedented insights into the myxobacterial secondary metabolome.  
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1.9.1 Molecular features as a valuable tool in LC-HRMS 
If LC conditions are tightly controlled, a whole LC-MS chromatogram can be dissected into so called 
molecular features, solely characterized by exact mass and standardized retention time. The molecular 
feature is noise-free and combines all isotopic peaks of one molecular entity seen in the mass 
spectrometer and assigns it the retention time of the intensity maximum as well as the observed 
mass/charge ratio of the monoisotopic peak. If the molecular features present in a LC-MS run of a bacterial 
extract are plotted we obtain a more informative picture of the molecular entities constituting a bacterial 
extract compared to a view of all raw signals. 
 
Figure 5. 3D plot of all molecular features present in a methanol extract of P. fallax MCy10649 in a retention time-
intensity-mass/charge ratio diagram 
While in former times secondary metabolite detection mainly focused on the molecular features that 
are visible in the base peak chromatogram (BPC), this diagram shows that there are many features ‘hidden’ 
by features that ionize well and are of higher abundance. As a word of caution, we must consider that the 
secondary metabolome consists of a variety of effective and specialized compounds with a high energy 
demand during their production, consequently we are bound to find many of them among the molecular 
features of low intensity. In order to mine the low abundance metabolome and to obtain an unbiased view 
on the myxobacterial secondary metabolome, we must introduce methods of statistical data treatment 
based on the molecular features so that finding new molecules becomes less a matter of serendipitous 
discovery.[60] 
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1.9.2 Bucketing to classify features in an LC-MS run 
One way to make sets of molecular features accessible for statistical data treatment is the binning of 
these features in matrices to prepare them for comparative statistics. A technique to achieve this data 
binning for LC-MS data is ‘bucketing’. Bucketing consists of dividing the whole RT and m/z value plane 
depicted in Figure 5 into rectangular subspaces of a defined m/z value width called Δ m/z and a defined 
RT value width called Δ RT.[60] These subspaces are called buckets. With this method, LC-MS 
chromatograms can be binned into matrices of all different possible buckets that get assigned the Intensity 
value of the molecular feature inside this bucket or zero if no molecular feature is present in this bucket.  
  
Figure 6. Schematic view of a filled LC-MS bucket (left side) and an empty LC-MS bucket (right side) 
Provided the parameters of an LC-MS system are well controlled so that neither measurement of 
retention time nor measurement of the high resolution mass of a feature varies significantly during 
measurement of one sample set, the hereby created matrix, called ‘bucket table’ can be used to apply 
comparative statistics.[62] 
1.9.3 Principal component analysis as a means to treat LC-MS ‘big data’ 
As bacterial extracts often contain more than thousand molecular features detected in one single LC-
MS run, it would be close to impossible to conduct meaningful analysis on these bucket tables by manual 
inspection of the data.[60] An extremely valuable tool to apply comparative statistics to the rather large 
data sets represented by a bucket table is principal component analysis (PCA).[63] PCA is a data analysis 
tool for tables representing observations linked by several interconnected variables.[64] This method 
consists of reducing the complexity of the bucket table which represents the complete LC-MS dataset into 
´eigenvector´ type data subsets that are called principle components. One can now identify the principal 
component (PC) that accounts for most of the difference between the samples which is called PC1 and the 
principal component which accounts for the second biggest difference PC2 and so forth while the total 
number of principal components equals the number of data sets e.g. LC-MS chromatograms one started 
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the analysis with. In a contribution analysis one can now determine which buckets, meaning which 
molecular features, meaning which LC-MS observations largely contribute to PC1, indicating these 
molecular features can be used to distinguish analyses from each other.[63,64] Metabolomics experiments 
can now efficiently make use of this technique as these experiments most often rely on comparison of two 
or more different groups of experiments. Examples from myxobacterial secondary metabolomics where 
this technique was efficiently employed include complete separation of the bacterial metabolome from 
its medium derived matrix peaks or differential profiling of bacterial mutants and their wild types to detect 
metabolites associated with said genetic change.[60,62,65] One of the drawbacks of solely applying PCA is 
that the amount of information available about the identified metabolite linked MS signals remains 
limited. Provided mass spectrometry data were acquired using a high resolution mass spectrometer one 
can use a combination of the feature’s mass accuracy and its relative isotope ratio to predict the 
compounds sum formula.[66] Still, with regard to chemical complexity of molecules originating from 
bacterial secondary metabolism, further structural information is needed in order to make educated 
guesses on which molecules should be followed up in a prospective isolation endaveour. 
 Database assisted secondary metabolite dereplication 
One of the major problems of natural products research are rediscoveries of already known 
substances. Thus, in addition to methods to discriminate between significant molecular features and the 
rather noisy background, there is high demand for methods to reproducibly annotate already known 
molecular features. The most important determinant in this workflow are databases that store a maximum 
amount of information available about known secondary metabolites relevant to the study at hand. If 
analytical conditions are well controlled, parameters other than the molecular mass such as metabolite 
retention times can be used for extended secondary metabolite dereplication. If one has a comprehensive 
database that stores high resolution masses as well as retention time on a specific system – such as the 
myxobase in  our case – one can use secondary metabolite annotation tools such as Bruker Compass target 
analysis (TA) or Bruker Metaboscape to annotate all the ‘knowns’ in a bacterial extract thus limiting the 
possibilities of rediscoveries. There are a couple of on-line tools available to facilitate this process such as 
DEREP-NP for example.[67] 
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 Extracting structural similarity information from MS data 
In comparison to other analytical techniques such as NMR, the big advantage of mass spectrometry 
lies in its sensitivity. LC-MS is able to generate limited structural information about compounds from small 
amounts and/or from crude mixtures. The only way to use mass spectrometry to extract structural 
information from mass spectrometry experiments is the application of multidimensional mass 
spectrometry. Multidimensional mass spectrometry in general describes the isolation of a molecular ion 
called precursor ion in the mass spectrometer followed by fragmentation of said ion into so called product 
ions. Isolation of a molecular ion followed by fragmentation and product ion analysis is called MS² or 
tandem MS while isolation of a product ion from this first fragmentation step followed by another 
fragmentation step is called MS³. Fragmentation of molecules in a mass spectrometer is mainly done by 
colliding ionized molecules with collision gas (mostly Ar or N2) in a collision cell or by bombarding the 
molecules with fast electrons. Fragmenting molecules by colliding them with a collision gas is called 
collision induced dissociation (CID). One of the basic principles used in multidimensional mass 
spectrometry is that molecules preferentially break at specific bonds in dissociation reactions creating 
smaller, more stable fragments. All these fragments combined are called the fragmentation pattern. It is 
therefore unsurprising that similar molecules present – in most cases – similar fragmentation patterns. 
1.11.1 Computational metrics to assign structural information to fragment spectra 
Fragmentation patterns are generally complex, as they usually comprise large numbers of mass 
peaks, and they are often counter-intuitive, as ion gas phase chemistry significantly differs from chemical 
reactions occurring in solution.[68] Thus, mass spectrometry has relied on computer tools that allow 
comparison of the fragmentation pattern at hand in term of their similarity. This would allow to either 
identify the substance behind this fragmentation pattern or assigning it to a group of similar fragmentation 
patterns. Met Frag for example is an web based tool that can be used to identify an unknown analyte solely 
using the exact mass of the parent ion and its fragmentation pattern as a peak list.[69] While the Met Frag 
framework has tremendous identificative power as it relies on a large number of reference spectra, the 
method does not assign unknown compounds to related mass spectra whose structures are already 
known. For the identification of previously unknown secondary metabolites, this method is thus of minor 
interest. Methods to increase the accuracy of the molecular formula prediction by taking sub formula of 
the fragments into account can help to determine the molecular formula by limiting the amount of possible 
sum formulas for one high resolution mass.[70] Especially for larger secondary metabolites this is of vital 
importance since even high resolution MS is not able to unambiguously pinpoint the molecular formula 
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for values above 600-700 Da. Finally, the fragmentation pattern interpretation tool of highest value for 
bacterial secondary metabolomics is GNPS.[71] This program relies on a metric called spectral networking. 
Spectral networking is a technique where spectra are compared to each other and spectra having similar 
fragmentation patterns are linked to each other. Thus all input fragment spectra are positioned in a 
network in a way that similar molecular features cluster together. 
 
 
Figure 7. Example for parts of a spectral network from MS² spectra acquired from a Myxococcus xanthus DK1622 
crude extract (Every node represents the MS² spectrum of a molecular feature, every dash represents a similarity 
relationship based on a cosine score value of more than 0.75) 
In this network, families of structurally novel secondary metabolites would cluster together as all 
their derivatives fragment very similarly while overall the fragmentation pattern would be significantly 
different from all other fragmentation patterns. Thus, looking for outlier clusters in this spectral network 
is likely to uncover novel bacterial secondary metabolites with uncommon chemical structures. Therefore, 
a statistics based spectral networking approach to chemical screening in secondary metabolomics has 
significantly increased chances to find novel bacterial secondary metabolites with uncommon chemical 
structures and interesting biological activities than the traditional ‘grind and find’ approach. 
 Mining the ‘hidden’ secondary metabolome by pathway activation 
Under laboratory conditions, bacteria have little incentive to produce secondary metabolites to 
outcompete competitors as sterile laboratory conditions aim to represent ‘unnatural’ quasi optimal 
growth conditions. Under these conditions, bacteria have a large incentive to replicate as fast as possible 
while a lot of external stimuli, which would trigger interaction and defense mechanism are missing in 
bacterial monocultures. One way to circumvent this problem is to ‘force’ bacteria to produce certain 
secondary metabolites through the pathway specific activation of secondary metabolite gene clusters. 
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There are several different techniques to achieve secondary metabolite BGC activation in a bacterial strain 
which depend on necessary genetic tools being developed to alter the strain’s genome. The most 
conceivable approach to activate or overexpress a biosynthetic gene cluster is promotor insertion 
upstream of the biosynthetic gene cluster, which has been successfully applied to Myxobacteria.[62,65] 
Other techniques applied to activate ‘cryptic’ biosynthetic gene clusters in bacterial wild type strains 
include deletion or overexpression of pathway specific regulators or overexpression of the exporter 
machinery.[72] 
 Heterologous expression of biosynthetic gene clusters 
A common problem in bacterial secondary metabolite discovery – and a point that has oftentimes 
been made regarding myxobacteria - is that the host strains that harbor biosynthetic potential are often 
hard to cultivate, intolerant to stress and inaccessible to genetic tools for targeted genetic manipulation. 
Moreover, many secondary metabolites, especially those found by described highly sensitive analytical 
techniques, are initially produced in minute quantities only. These kinds of strains are thus unlikely to be 
used as host strains for industrial scale fermentation, as problems with productivity, genetic stability of 
the strain, reaching sufficient cell density and strain growth speed are foreseeable. Thus, after 
identification of a promising secondary metabolite and characterization of its pathway, said secondary 
metabolite pathways are often transferred into so-called chassis microbes. These microbes are well 
adapted to transcription and translation of secondary metabolite gene clusters, rather easy to handle – as 
protocols for genetic manipulation, fermentation condition optimization and upscaling have already been 
developed – and have a streamlined metabolism that limits side product biosynthesis.[73] On an industrial 
scale, heterologous expression of secondary metabolites is in many cases more likely to result in a process 
that is able to compete with the costs of large scale chemical synthesis. This is especially true for 
biosynthetic gene clusters stemming from bacteria like myxobacteria that have very slow growth kinetics 
and thus limited space time yield. Another application of heterologous expression in secondary metabolite 
discovery is the activation of ‘silent’ secondary metabolite pathways. The activation of the ‘hidden’ 
secondary metabolite potential offers additional potential to obtain secondary metabolites that are not 
produced in the wild type.[65] Even for rather well-characterized bacteria such as the myxobacterial model 
strain Myxococcus xanthus DK1622, of the 18 predicted NRPS-PKS pathways encoded in the genome only 
5 have been to date connected to their corresponding metabolites.[74] As cloning of biosynthetic genes 
from one organism and transferring these assembly lines to one of these chassis hosts extracts these BGCs 
from their natural regulatory network, it is likely that these assembly lines which were tightly controlled 
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in their host organisms are producing their corresponding secondary metabolites in the heterologous 
host.[73] This does not only extend to ‘silent’ biosynthetic gene clusters, one can also apply this technique 
to biosynthetic gene clusters of so far ‘uncultured’ bacteria such as symbionts or bacteria only known from 
metagenomics analyses. Modern heterologous expression techniques allow mining this previously hidden 
secondary metabolite potential. E. coli based Rec/ET direct cloning and S. cerevisiae based transformation 
associated recombination (TAR) of secondary metabolite gene clusters are two techniques that allow 
efficient cloning of larger genomic regions as for example a biosynthetic gene cluster. 
1.13.1 Direct cloning of biosynthetic gene clusters 
Direct cloning of biosynthetic gene clusters describes the technique to cut an entire BGC out of its 
locus in the genomic DNA followed by a recombineering step to recombine the ends of said BGC with 
homologous ends on a designed capture vector which leads to a synthetic vector harboring the entire BGC 
in the strain corresponding to the capture vector. The other commonly used recombineering technique is 
yeast based TAR, which allows direct cloning of larger fragments as yeast cells are more adapted to 
handling of larger DNA fragments.[75] 
 
Figure 8. Schematic view of a direct cloning experiment for a BGC flanked by the restriction endonucleases nuc 1 and 
nuc 2 into a capture vector using a recombineering technique 
First, restriction endonucleases that cut in the flanking regions to the desired biosynthetic gene 
cluster are employed to free the desired biosynthetic gene cluster from the bulk DNA. Additionally, so-
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called anchor sequences that are inversely homologous to the genomic region one wants to clone are put 
on a so-called capture vector. Both the digested genomic DNA as well as the capture vector are then 
transformed into an E. coli strain harboring the redα, redβ and recE, recT, redγ, recA under separate 
promotors.[76] Both of these gene sets can be used to perform Red/ET recombineering, but while for linear 
to circular homologous recombination e.g. for plasmid modification the red proteins have shown to have 
good recombination activity, linear to linear direct cloning of entire gene clusters seems to work more 
efficiently using the rec genes.[77] This technique was successfully employed for direct cloning of a wide 
range of biosynthetic gene clusters as for example the alkylpyrones, syringolins or salinomycins.[78]  
1.13.2 PCR based TAR cloning for secondary metabolite cluster assembly 
A new recombineering technique that emerged, which is especially useful for assembly and 
heterologous expression of smaller biosynthetic gene clusters, is recombineering based assembly of PCR 
products spanning a whole biosynthetic gene cluster in yeast. 
 
Figure 9. Schematic view of the protocol for PCR based transformation associated recombination to assemble 
biosynthetic gene clusters 
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Contrary to E. coli strains used in Rec or Red ET experiments, yeast cells have high recombinase 
activity. Therefore it is possible to co-transform several PCR products with overhangs into said yeast which 
will subsequently assemble the heterologous expression vector in a series of recombination events as can 
be seen in Figure 9.[65,79] So in total, one can assemble a variety of different PCR products with overlapping 
ends in one transformation step to the final expression vector. The big advantage of this approach is the 
possibility to reorganize a BGC during the assembly step including the possibility of introducing foreign 
DNA into the gene cluster during the assembly. Connectivity of the fragments during the recombination 
steps is guided by homology arms introduced via the primers as can be seen in Figure 9. Furthermore one 
has the ability to assemble DNA from multiple origins by solely adapting the overhangs necessary for 
recombination. That way, direct cloning of a biosynthetic gene cluster combined with gene cluster 
reorganization and gene cluster manipulation e.g. promotor exchanges is possible using only one 
transformation step.[65] Still, this technique has significant drawbacks, as on the one hand PCR 
amplification of the complete cluster can lead to SNPs or frame shifts in the assembled biosynthetic gene 
cluster, while this recombineering technique is inherently bad for the assembly of BGCs with repetitive 
homologous sequences. These repeats of homologous genetic regions, which occur for example in PKS or 
NRPS modules that extend a secondary metabolite with the same building block, might be recognized by 
the recombinases and parts of these megaenzymes might be crossed out. To assemble such biosynthesis 
pathways containing these repetitive sequences, dummy sequences can be used during the assembly 
process that are later replaced by the repetitive elements using conventional cloning. 
 Outline of this work 
In this work, myxobacterial secondary metabolism is approached from two sides. Firstly, bacterial 
secondary metabolism is investigated from a genetic point of view in order to evaluate the genome-
encoded potential for the production of secondary metabolites, aimed at connecting selected BGCs to yet 
unknown compounds. Secondly, a stringent chemical-analytical perspective is applied in order to gain 
access to the fraction of compounds from the secondary metabolome that are actually produced and 
seizable. Although myxobacterial genomes and secondary metabolomes are fundamentally 
interconnected, their connection is neither as straightforward nor as well studied as the interconnection 
of genes and proteins. It is therefore an additional objective of this work to improve the genome- and 
metabolome-mining toolbox to further strengthen our capability for both the “gene-to-compound” as well 
as the “compound first” discovery approach (Figure 10). 
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Figure 10. Representation of the different parts of this thesis as part of the secondary metabolome mining workflow.  
By combining in silico analysis, genetic manipulation techniques, state of the art mass spectrometry 
amended by statistical data treatment and also the full complement of methods for natural product 
isolation and structural characterization, this work highlights the tremendous chances for the discovery of 
novel natural products offered by myxobacteria throughout the following six chapters. The study on 
pyxidicyclines (chapter 2) exemplifies the genomics-driven discovery of a new myxobacterial secondary 
metabolite class ultimately revealed as potent topoisomerase inhibitors: in silico based gene cluster 
prioritization is carried out based on self-resistance determinants encoded within the BGC and statistics-
based mass spectrometry is employed to distinguish myxobacterial mutant- from wild type-metabolomes 
to facilitate compound identification, using both BGC activation as well as targeted gene inactivation. In 
the study leading to discovery und full structure elucidation of fulvuthiacenes (chapter 3), the focus is on 
improving methods to identify secondary metabolite families from bacterial crude extracts including the 
assignment of minor derivatives, based on high resolution mass spectrometry and also exploiting tandem-
MS data for tentative compound family identification. In line with the high value of high-resolution MS 
data for mining the secondary metabolomes, a method is described (chapter 7) to automatically predict 
the presence of uncommon elements solely from isotope patterns, which enhances the amount of 
information that can be drawn from any high resolution MS spectrum. This technique can become a 
   Chapter 1 Introduction    39 
 
 
discovery tool in itself, as it enhances prospects for finding novel uncommon myxobacterial secondary 
metabolites - exemplified by the discovery of new chlorine-containing tetrapeptides called the 
chloromyxamides from Myxococcus (chapter 4). Furthermore, this work contains contributions to the 
discovery of two additional new secondary metabolite families from myxobacteria: the cytotoxic 
pyxipyrrolones (chapter 5) and the homospermidine lipids, a compound class specifically formed during 
fruiting body formation of Myxococcus xanthus (chapter 6). 
 The work on pyxidicyclines, fulvuthiacenes, chloromyxamides, pyxipyrrolones and the 
homospermidine lipids is accompanied by elucidation of the corresponding biosynthesis, leading in each 
case to a biosynthesis model that explains structural peculiarities found in these scaffolds. After dissecting 
these structures using retrobiosynthetic reasoning, in silico methods for generalized analysis of 
biosynthetic gene clusters are first used to approach the biosynthetic architecture of a secondary 
metabolite biosynthesis pathway and analysis is refined with predictions reliant on sequence or 3D 
alignment to provide hints for the enzymatic functions of tailoring enzymes involved in compound 
maturation. Moreover, the results from targeted mutagenesis in the producer strains, results from feeding 
experiments using stable isotope labelled precursors as well as heterologous expression are presented to 
underpin the molecular basis for compound formation. 
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 Abstract 
There is astounding discrepancy between the genome-inscribed production capacity and the set of 
known secondary metabolite classes from many microorganisms as detected under laboratory cultivation 
conditions. Genome-mining techniques are meant to fill this gap, but in order to favor discovery of 
structurally novel as well as bioactive compounds it is crucial to amend genomics-based strategies with 
selective filtering principles. In this study, we followed a self-resistance guided approach aiming at the 
discovery of inhibitors of topoisomerase, known as valid target in both cancer and antibiotic therapy. A 
common host self-defense mechanism against such inhibitors in bacteria is mediated by so-called 
pentapeptide repeat proteins (PRP). Genes encoding the biosynthetic machinery for production of an 
alleged topoisomerase inhibitor were found on the basis of their collocation adjacent to a predicted PRP 
in the genome of the myxobacterium Pyxidicoccus fallax An d48, but to date no matching compound has 
been reported from this bacterium. Activation of this peculiar polyketide synthase type-II gene cluster in 
the native host as well as its heterologous expression led to the structure elucidation of new natural 
products that were named pyxidicyclines and provided an insight into their biosynthesis. Subsequent 
topoisomerase inhibition assays showed strong affinity to - and inhibition of - unwinding topoisomerases 
such as E. coli topoisomerase IV and human topoisomerase I by pyxidicyclines as well as precise selectivity, 
since E. coli topoisomerase II (gyrase) was not inhibited at concentrations up to 50 µg/ml. 
 Introduction 
Natural products of bacterial origin have continuously provided drug leads to combat infectious 
diseases and cancer.[1] However, as certain groups of microorganisms have been screened extensively for 
natural products, the discovery of novel secondary metabolite scaffolds becomes increasingly challenging. 
Recent approaches to find valuable novel and biologically active natural products include screening of 
underexploited bacterial species, genera and families in different culture conditions as well as improving 
the bioinformatics, genetic and analytical toolset to access the “hidden” secondary metabolome of 
respective microorganisms.[2–4] As the quest for new bioactive compounds is thriving, combinations of 
these methods are increasingly applied to uncover previously unidentified classes of natural products from 
a range of microbes, including – amongst others - marine streptomycetes, plant endosymbionts, 
cyanobacteria and the myxobacteria.[3,4,5] Myxobacteria are ubiquitous Gram-negative, soil dwelling 
bacteria that exert a unique life-style involving the formation of multicellular fruiting bodies.[6] Among 
myxobacteria the suborder Cystobacterineae - to which the genus Pyxidicoccus investigated in this work 
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belongs - is typically represented by predatory strains displaying a high level of sophisticated multi-cellular 
coordination and cooperation.[6] The complex life-style is reflected by large genome sizes exceeding 10 
Mbps as observed from many myxobacteria.[7] Moreover, the sheer number of biosynthetic gene clusters 
present in myxobacterial genomes according to bioinformatics analysis suggests myxobacteria constitute 
a highly prolific source of natural products. Nonetheless, the number of characterised compound families 
is still strikingly lower than expected from the genome-encoded capacity.[8] Even for myxobacterial model 
strains such as Myxococcus xanthus DK1622 or Stigmatella aurantiaca DW4/3-1 only a fraction of the more 
than 15 secondary metabolite biosynthesis pathways found in their genomes have been assigned a natural 
product to date, indicating that the corresponding natural products are absent or below detection limits 
under standard laboratory conditions.[8,9] Whereas several reasons might account for this observable 
discrepancy, it has emerged as a common picture for secondary metabolite-producing microorganisms. A 
range of genome-mining approaches has consequently been devised in order to “harvest” the untapped 
genome-encoded promise for novel natural products.[10,11,12] One straight-forward concept to bring to light 
the natural products supposedly originating from biosynthetic pathways that are repressed under 
standard laboratory conditions employs gene cluster activation via insertion of a heterologous promotor 
upstream of biosynthesis genes. 
Figure 1. Workflow scheme illustrating the genomics-based gene cluster prioritization and activation approach 
towards novel bioactive natural products from ‘silent’ gene clusters. 
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This approach however is typically laborious and time-consuming. Success is critically depending on 
pre-established cultivation conditions, an understanding of the regulation of the respective pathway and 
genetic manipulation protocols specific to the target organism. A strong rationale is therefore required to 
prioritise the plethora of eligible biosynthetic gene clusters for well-directed gene cluster activation. A 
conceivable prioritization approach is based on the finding that potential genetic self-resistance 
determinants are often co-located to candidate biosynthetic gene clusters.[13] Considering topoisomerase 
inhibitors, the occurence of a gene encoding a pentapeptide repeat protein (PRP) might serve as an 
indicator for the nearby BGC to potentially produce a congener of this compound class. Adopting this 
strategy in the current study was inspired by a specific example recently reported from myxobacteria, i.e. 
the cystobactamid gene cluster where a pentapeptide repeat protein is responsible for self-resistance 
against the gyrase inhibitor cystobactamid, even allowing for simplified mode of action determination of 
this compound class.[14]  
Along these lines, we report here the identification and full structural characterization of a new 
bioactive secondary metabolite family connected to a biosynthetic gene cluster not previously attributed 
to any natural product from the myxobacterium Pyxidicoccus fallax An d48. In agreement with the 
rationale used for their discovery, the new polyketide-type compounds named pyxidicyclines A (1) and B 
(2) display potent inhibition of bacterial and human topoisomerases. In addition, the heterologous 
expression of the underlying pcy gene cluster permits insights into the intriguing biosynthesis of a new 
myxobacterial secondary metabolite class featuring an unprecedented tetracene quinone scaffold. 
 Results and Discussion 
2.3.1 Genome mining for topoisomerase inhibitors 
The starting point of this study is defined by our aim to find novel topoisomerase inhibitors connected 
to matching BGCs hidden in the genomes of myxobacteria and guided by signature genes likely to encode 
the required self-resistance mechanism. We reasoned that CysO from the cystobactamide pathway in 
Cystobacter ferrugineus and AlbG from the albicidin pathway in Xanthomonas albilineans should be 
suitable templates to identify putative pentapeptide repeat proteins conferring self-resistance to 
topoisomerase poisons.[14,15] Searching for genes encoding topoisomerase-targeting pentapeptide repeat 
protein (TTPRP) sequences similar to AlbG and CysO yielded 31 candidate sequences among myxobacterial 
genomes in our in-house database.[15] Eight of those hit sequences were located close to uncharacterised 
biosynthetic gene clusters as predicted by antiSMASH (Figure 3).[10,11] Based on primary sequence 
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similarity, these genes were regarded as candidates which could plausibly be responsible for 
topoisomerase inhibitor self-resistance against the products afforded by said BGCs. In view of desired 
structural novelty of products to be discovered, our attention was drawn to a candidate encoded near a 
type II polyketide synthase (PKS) gene cluster present in the myxobacterial strains P. fallax An d30 and An 
d48. However, no compound resembling a type II PKS product has been found and no topoisomerase 
inhibitor was reported in these strains. While type II PKS compounds are well known from Gram-positive 
actinobacteria, there are only few examples of type II PKS products from Gram-negative bacteria as 
exemplified by anthraquinones from Phodorhabdus luminescens  or aurachin from Stigmatella 
aurantiaca.[16] Therefore, the envisaged BGC was considered likely to be responsible for the biosynthesis 
of hitherto unknown secondary metabolites with uncommon structures. Besides the biosynthetic genes 
encoding polyketide synthase machinery, the pcy cluster features an obvious operon comprising ABC 
transporter genes and the 639 bp open reading frame (ORF) encoding the proposed PRP (pcyQ-T, Figure 
3). Thus, this gene ensemble hints at a combined export- and topoisomerase protection mechanism 
allowing immunity of the bacterium to the hypothetical product. The proposed PRP in this cluster named 
PcyT was compared via MUSCLE alignment  to CysO, AlbG as well as E. coli McbG, M. tuberculosis MfpA 
and Qnr proteins known to mediate resistance against the fluoroquinolone gyrase and topoisomerase IV 
inhibitor drug class (Figure 2).[17,18] 
Figure 2. (A) Neighbour joining tree constructed from a MUSCLE alignment including TTPRP primary sequences known 
to confer topoisomerase inhibitor resistance, (B) comparison of the Phyre-2 3D structure homology model of PcyT 
from Pyxidicoccus fallax to (C) the protein crystal structure of the topoisomerase targeting pentapeptide repeat 
protein (TTPRP) QnrB1 from K. pneumoniae.  
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The alignment tree clearly supports functional similarities among these proteins, although amino acid 
sequence similarity between these short (200-300 AA) PRP is generally not higher than 50 %.[19] Their 3D 
structures are characterised by a consensus motif of five [S,T,A,V][D,N][L,F][S,T,R][G] repeats forming a 
right handed quadrilateral helix, indicating this 3D fold to be more important than the primary 
sequence.[19] Therefore, the 3D structure of PcyT was further analysed using the Phyre-2 homology 
modelling tool (section S 2.1-2.2).[20] The modelled structure of PcyT suggests the presence of the right 
handed quadrilateral helix structure thought to account for DNA mimicry plus a dimerization domain 
consisting of the alpha helical part and the terminal loop (depicted in red in Figure 2), both of which are 
required for mediating topoisomerase poison resistance.[15,19] The striking difference between the 
quinolone resistance protein QnrB1 (PDBe: 2xtx) and PcyT is the predicted absence of loop structures Loop 
A and Loop B suggesting PcyT falls into the category of “loopless” TTPRPs like CysO and AlbG.[19] 
Thus, since in silico analysis suggested the possibility for production of a topoisomerase inhibitor by 
P. fallax we set out to identify the small molecules associated with said type II PKS BGC to ultimately assess 
their bioactivity. P. fallax An d48 has been the subject of natural product screening in the past and turned 
out to be a viable bioactive secondary metabolite producer.[21] However, no known small molecule from 
this strain resembles a structure likely to stem from type II polyketide synthase machinery. Furthermore, 
we could not detect any inhibition of E. coli DNA gyrase and E. coli DNA topoisomerase IV in assays using 
wild type crude extract (data not shown), pointing towards absence of a matching bioactive compound 
under standard laboratory conditions. 
We thus took a closer look at the prioritised gene cluster (designated pcy) which comprises 20 ORFs 
encoded within three apparent operons (Figure 3). Operon 1 contains the minimal PKS genes pcyA-I, 
encoding a ketosynthase unit composed of the ketosynthase α (KSα, pcyE), the chain length factor (CLF or 
KSβ, pcyF) and the acyl carrier protein (ACP, pcyG) which are fundamental for the function of any type II 
PKS assembly line (Figure 3, Table 1, and KS assignments in sections S 2.3, S 2.4).[22] Operon 2 encodes 
proposed tailoring enzymes (pcyJ-P) while Operon 3 encodes ABC transporter-related genes as well as the 
putative resistance protein (pcyQ-T). 
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Table 1. ORFs within the pyxidicycline BGC, their nearest neighbours according to blastp against the nr protein data 
base at NCBI and putatively assigned functions (see also Table S 6). 
gene putative function 
closest annotated homologue – 
 organism of origin 
pcyA 
precursor release from the 
acyl carrier protein 
acyl-CoA thioester hydrolase – 
multispecies 
pcyB 
polyketide cyclisation 
(B-ring cyclisation) 
polyketide cyclase – 
Streptomyces nogalater 
pcyC 
polyketide cyclisation 
(A-ring cyclisation) 
polyketide cyclase – 
Streptomyces atratus 
pcyD C9’ type ketoreductase 
ketoacyl reductase – 
Sorangium cellulosum 
pcyE ketoacyl synthase KSα subunit 
3-oxoacyl-ACP synthase II – 
Dendrosporobacter quericolus 
pcyF 
ketoacyl synthase KSβ subunit 
(chain length factor) 
3-oxoacyl-ACP synthase II – 
Pelosinus sp. 
pcyG acyl carrier protein 
acyl carrier protein – 
Terriglobus saanensis 
pcyH 
4’-phosphopanthenyl 
transferase 
holo-ACP synthase – 
Sorangium cellulosum 
pcyJ serine incorporation 
4-coumarate-CoA ligase family protein – 
Modestobater species 
pcyK heterocycle formation 
muconolactone delta-isomerase –  
Acidovorax valerianellae 
pcyL heterocycle formation 
polyketide cyclase – 
Streptomyces species 
pcyQ export 
ABC transporter, ATP binding protein – 
Myxococcus xanthus 
pcyR export 
ABC transporter permease   – 
Myxococcus xanthus 
pcyS export 
ABC transporter substrate binding protein –
Myxococcus xanthus 
pcyT 
putative self-resistance 
mechanism 
pentapeptide repeat containing protein – 
Myxococcus fulvus 
 
In order to connect a chemotype to the candidate gene cluster we initially followed a strategy 
combining single crossover inactivation with subsequent LC-MS profiling of ‘inactivation’ mutants vs. the 
wild type strain. Strikingly, disruption of either pcyE or pcyC located within Operon 1 did not lead to any 
detectable change in the P. fallax An d48 metabolome, as corroborated by in-depth statistical evaluation 
of the LC-MS chromatograms of replicate mutant extracts compared to wild type extracts (Figure 4 and 
sections S 3.1 to 3.4).  
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2.3.2 Reviving a ‘silent’ type II PKS gene cluster 
Expecting the small molecule product of the pcy cluster to be absent or below the detection limit, 
gene cluster activation by insertion of a heterologous promotor was performed.[23] Since operon 1 contains 
the minimal PKS genes, promotor exchange via single crossover homologous recombination upstream of 
this operon should boost transcription of these genes and thus facilitate subsequent detection of the 
matching PKS-type metabolites. Similar pathway-refactoring strategies have been successfully employed 
for the activation of ‘silent’ gene clusters in Streptomyces and Burkholderia.[24][25] Furthermore, promotor 
insertions have been reported to improve secondary metabolite production by myxobacteria, although 
the approach did not afford a previously unknown myxobacterial natural product class to date.[2,26] 
Figure 3. BGC activation and heterologous expression strategy for the pcy biosynthetic gene cluster. (A) the native 
gene cluster in An d48 and its operon structure, (B) the gene cluster activated by two promotor exchanges, (C) the 
TAR cloning strategy including PCR pieces necessary to complete the pClY vector and (D) the assembled heterologous 
expression plasmid. PKS type-II biosynthesis genes depicted in blue, regulation and resistance genes in red, exporter 
genes in orange, auxiliary genes for the cloning strategy in light green and ORFs of unknown function in grey colour. 
P. fallax An d48 mutants controlling the expression of the minimal PKS operon by a heterologous tn5 
promotor and alternatively via the vanillate promotor/repressor system were created through single 
crossover homologous recombination using the plasmids pSBtn5 pcyA and pFPvan pcyA, respectively 
(section S 1.10). The vanillate promotor repressor system was chosen as it has been shown to work in 
myxobacteria.[27]  
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Figure 4. BPC comparison of (a) Pyxidicoccus fallax An d48 wild type extract, the extracts of the (b) pcyC and (c) pcyE 
gene inactivation mutants, and anthraquinones produced in P. fallax An d48 (d) vanillate-induced and (e) tn5 
activation mutants. The three anthraquinone metabolites 340 (3), 296 (5) and 325 (4) are displayed as LC-MS EICs at 
341.06 [M+H]+ (light green), 325.07 [M+H]+ (dark blue) and 297.075 [M+H]+ (orange). The corresponding structure 
formula is shown in the same colour. Differences visible in traces (a) to (e) at retention times later than 12 minutes 
are unrelated to the investigated biosynthetic route. 
LC-MS analysis of the corresponding crude extracts revealed three newly emerging substances 
exhibiting strong UV absorption, indicating the presence of a chromophore as it would be expected from 
a type II PKS derived compound (Figure 4, Figure S 13). Their intensity is reduced to basal level shown by 
both LC-UV and LC-MS measurements if the An d48 pcyA::pFPVan pcyA mutant is grown without induction 
of the vanillate promotor, further indicating a direct link of found compounds to the target type II PKS 
machinery. Comparison of LC-UV and LC-MS peak areas suggests the tn5 promotor leads to higher 
expression levels than the induced vanillate promotor/repressor system (Table S 21). Purification of the 
new compounds appearing as a result of promotor integration into An d48 using a combination of 
chromatographic methods and NMR-based structure elucidation consequently revealed a series of 
anthraquinones (3-5) (Figure 4; section S 3.5.1 and 3.8), resembling literature-known secondary 
metabolites described from actinomycetes.[28,29] UV/Vis spectra and NMR signals agree well with the 
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previously published data (section S 3.5.1, 3.8 and 3.9). These anthraquinones show moderate in vivo 
activity against Gram-positive pathogens and efflux deficient E. coli (Table 2). 
From a biosynthetic perspective 3 was described as a polyketide synthesis derailment product 
occurring when the frenolicin minimal PKS was complemented with the actinorhodin ketoreductase (KR) 
and the cyclases CYC1 and CYC2 from the griseorhodin and oxytetracycline pathways, respectively, and 
homologues of these genes also exist within the activated minimal PKS operon of the pcy gene cluster.[28]  
We thus reasoned that the products observed upon promotor insertion upstream of the pcyA-I operon 
could stem from incomplete processing of polyketide biosynthesis intermediates as a consequence of non-
expressed tailoring enzymes located within the second operon pcyJ-P. Therefore, a second promotor was 
integrated via single crossover homologous recombination upstream of pcyJ, whereby this operon was 
activated in addition to the pcyA-I operon (Figure 3). The resulting ‘dual promotor’ mutant strain P. fallax 
An d48 pcyA :: pFPVan pcyA, pcyJ :: pFPtettn5 pcyJ (named An d48 pcy in short) was cultivated in small 
scale following successful confirmation of correct promotor integration via PCR. Notably, we found that 
this strain lysed upon vanillate induction when XAD-16 adsorber resin was absent from the medium, while 
cultivation and induction was possible with added XAD-16. Thus, the second promotor exchange 
apparently led to the production of biologically active entities other than the previously detected 
anthraquinones, and these yet unidentified products seemed to exhibit significant autotoxicity. 
Concomitantly, it was not possible to introduce simultaneously two constitutive tn5 promotors upstream 
of both operons pcyA-I and pcyJ-P despite several attempts (data not shown), further indicating 
autotoxicity effects associated with the observed metabolites. 
2.3.3 Structure elucidation of the pyxidicycline class of natural products 
 Induction of the newly engineered double-promotor mutant strain with vanillate and subsequent LC-
MS analysis of XAD-16 extracts led to the detection of two novel peaks with an UV absorption at 500 nm 
(Figure S 16). Isolation and structure elucidation of both candidate compounds (section S 3.5.2, 3.6, 3.7 
and 3.9) ultimately revealed them as two novel type II PKS derived nitrogen containing tetracene quinones 
named pyxidicycline A (1) and B (2) (Figure 5). The two anthraquinones 3 and 5 referred to as polyketide 
derailment products are still present even though their yields are significantly reduced (Figure 5, Table S 
21), whereas 4 could not be detected in the extract of An d48 pcy.  
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Figure 5. Overlay of three EICs of the two novel mature type two PKS compounds (1 and 2) in Pyxidicoccus fallax An 
d48 pcy extract accompanied by two anthraquinones (3 and 5). 3 and 5 are displayed as LC-MS EICs at 341.06 [M+H]+ 
(light green) and 297.075 [M+H]+ (orange); the two pyxidicyclines are displayed as LC-MS EICs at 366.10 [M+H]+ (1 in 
orange; 2 in red). 
Figure 6. Structures of the two pyxidicycline derivatives A (1) and B (2) as well as the corresponding formate esters 
(1b and 2b) as determined by structure elucidation using NMR and X-ray crystallography. 6 and 7, structures of 
mitoxanthrone and camptothecin.[30,31] 
The pyxidicyclines are difficult to dissolve in organic solvents except for DMSO and DMF, which 
unfortunately both degrade the compound over time. However, they are well soluble and stable in pure 
formic acid. Dissolution in formic acid leads to reversible formation of formate esters as shown by an 
increase of the compound’s masses by 28 Daltons as seen in the LC-MS chromatogram. Fortunately, both 
isomers formed dark red crystals from formic acid solution and the corresponding crystal structures 
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obtained by single-crystal X-ray diffraction experiments afforded the structures depicted in Figure 6 
(section S 3.6 and 3.7). The structures of both pyxidicycline formate esters were subsequently confirmed 
by NMR analysis in formic acid-d2 (section S 3.11). These compounds represent a novel type II PKS scaffold, 
as nitrogen-containing tetracene quinone-like four ring structures have – to best of our knowledge - not 
been reported to date. Among the rare examples of type II PKS products containing nitrogen in their 
backbone structure (albeit not as part of a tetracene system) are the jadomycins and nitrogen-containing 
congeners of fredericamycins.[32,33] 
The pyxidicyclines were subjected to antimicrobial and cytotoxic activity testing against a panel of 
bacterial pathogens and cancer cells. The anthraquinone precursors were tested against a reduced set 
since low isolation yields did not allow full bioactivity profiling. 1 and 2 show moderate antibacterial 
activity but strong cytotoxicity in the nano molar range (Table 2). The complete lack of activity against wild 
type Gram-negative pathogens is likely due to compound efflux as the efflux deficient E. coli ΔTolC strain 
shows the lowest MIC values among bacteria. While the yeast strains C. albicans and P. anomala show 
very high MIC values, the pyxidicyclines inhibit the growth of filamentous fungi displayed by M. hiemalis 
at intermediate concentrations (Table 2). 
2.3.4 Investigating the pyxidicyclines’ molecular target 
Our motivation for activating the pcy BGC was based on the finding of pentapeptide repeat protein 
PcyT, which suggested the compounds afforded by this gene cluster could act as topoisomerase inhibitors. 
Structural similarity of pyxidicyclines to clinically used mitoxanthrone (Figure 6) - a topoisomerase II and 
topoisomerase IV inhibitor used in breast cancer treatment with an IC50 of 12 µM and 2 µM against E. coli 
topoisomerase II (gyrase) and topoisomerase IV, respectively [30] – increased our suspicion that 
pyxidicyclines might indeed target topoisomerases. Hence their topoisomerase inhibition activity towards 
two bacterial topoisomerases was tested, namely E. coli topoisomerase II (gyrase) and E. coli 
topoisomerase IV (section S 4). Contrary to the assumption based on the predicted structure of PcyT, the 
pyxidicyclines showed no inhibition of E. coli gyrase up to 60 µg/ml. We thus conclude that gyrase is not 
the molecular target as the in vitro MIC values of these substances are significantly lower (Table 2). On the 
other hand, topoisomerase IV was inhibited with IC50 values of 6.25-3.2 µg/ml for 1 and 3.2-1.6 µg/ml for 
2 (section S 4). These IC50 values match the observed bactericidal activity against E. coli ΔTolC, the 
prokaryote in our testing panel that is most sensitive to pyxidicyclines. Therefore, topoisomerase IV 
inhibition is likely their main mode of action with respect to bactericidal effects. We reason that Gram-
negative pathogens are likely pyxidicycline-resistant due to compound efflux, as topoisomerase IV 
inhibition should otherwise also kill wild type E. coli strains.  As the pyxidicyclines exhibited pronounced 
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cytotoxicity in our bioassays, inhibition of human topoisomerase I was evaluated. This enzyme is the 
human counterpart for unwinding topoisomerases such as topoisomerase IV. 1 and 2 exert potent activity 
on this protein, which is an established target in anticancer research [34].  
Table 2. Minimum inhibitory concentrations (MIC) values of the pyxidicyclines A and B (1 and 2) and the precursor 
anthraquinones (3-5) against common pathogens and cancer cell lines. 
 
The IC50 values of 1 and 2 against human topoisomerase I were 1.6-0.4 µg/ml for 1 and 0.2-0.05 
µg/ml for 2, respectively. The MIC of pyxidicyclines against HCT-116 cells was determined to 0.06 µg/ml 
and 0.03 µg/ml for 1 and 2, respectively, which is significantly lower than the on-target IC50 values 
determined in the cell free assay. This discrepancy has already been reported for the topoisomerase I 
inhibitor camptothecin (Figure 6),[31] which shows some structural similarity to the pyxidicyclines and this 
comparison also underlines topoisomerase I as the pyxidicycline’s likely molecular target in mammalian 
cells. 
Taken together, the pyxidicyclines are a novel class of type II PKS products with promising in vitro 
bioactivity based on the unprecedented nitrogen-containing tetracene quinone scaffold. Since the 
preferential inhibition of topoisomerase I by pxidicyclines might inspire further development of the 
compounds towards an anti-cancer drug, biotechnological production of the molecule is desirable. In order 
to pave the way for optimizing pyxidicycline production we thus decided to pursue the in-depth 
investigation of pyxidicycline biosynthesis. This was however met with challenges, as available genetic 
tools for the producer strain An d48 are limited to single-crossover recombination. We therefore sought 
to establish a heterologous expression system to facilitate investigation of this particular type II PKS 
biosynthetic pathway. 
Test Organism 1 2 3 5 4 
S. aureus Newman 16 µg/ml 32 µg/ml 2 µg/ml 16 µg/ml n.d. 
C. albicans DSM 1665 64 µg/ml 64 µg/ml n.d. n.d. n.d. 
M. luteus DSM 1790 16 µg/ml 32 µg/ml n.d. n.d. n.d. 
B. subtilis DSM 10 16 µg/ml 32 µg/ml 64 µg/ml 64 µg/ml 16 µg/ml 
M. smegmatis mc2-155 32 µg/ml 64 µg/ml n.d. n.d. n.d. 
E. coli Δ TolC 4 µg/ml 2 µg/ml 8 µg/ml 64 µg/ml 16 µg/ml 
P. aeruginosa PA 14 > 64 µg/ml > 64 µg/ml n.d. n.d. n.d. 
C. violaceum DSM 30191 > 64 µg/ml > 64 µg/ml n.d. n.d. n.d. 
E. coli DSM 1116 > 64 µg/ml > 64 µg/ml n.d. n.d. n.d. 
M. hiemalis DSM 2656 16 µg/ml 16 µg/ml n.d. n.d. n.d. 
P. anomala DSM 6766 > 64 µg/ml > 64 µg/ml n.d. n.d. n.d. 
HCT-116  
(Human colon carcinoma) 
0.06 µg/ml 0.03 µg/ml n.d. n.d. n.d. 
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2.3.5 Heterologous expression of the pcy gene cluster  
The myxobacterium P. fallax An d48 is related to model strains M. xanthus DK1622 and S. aurantiaca 
DW4/3-1 through membership of the same suborder Cystobacterinae and these two strains were thus 
chosen as host for heterologous expression. Since the promotor-activated pcy cluster in the P. fallax An 
d48 pcy mutant strain was already constructed, genomic DNA of this strain was used for PCR-based 
transformation assisted recombination (TAR) assembly of the gene cluster as described by Bylik et al. 
(Figure 3). [35] Through this assembly method, the whole cluster is reassembled during the cloning step and 
additional modifications can be engineered into the final construct by co-transformation of PCR products 
(Figure 3). The method also allows reorganising the native operon structure of the biosynthetic gene 
cluster. Thus, the minimal PKS operon (operon 1, pcyA-I) responsible for the creation of the polyketide 
chain was placed upstream of the tailoring enzyme operon (operon 2, pcyJ-P) likely responsible for the 
incorporation of an nitrogen-containing moiety into the molecule backbone (section S 1.12, Table 1) and 
subsequent dehydration to complete the fourth ring of the tetracyclic ring system. The putative resistance 
and export operon (operon 3, pcyQ-T) was relocated downstream of the tailoring enzyme operon. As 
already achieved in the An d48 double mutant, the minimal PKS system was kept under the control of the 
vanillate promotor/repressor system to control compound production through induction, thereby 
avoiding self-toxicity effects. The tailoring enzymes were subjected to control by the tn5 promotor as in 
the An d48 pcy mutant to ensure sufficient supply of tailoring enzymes for formation of mature 
pyxidicyclines. To boost the host’s self-resistance towards the pcy cluster derived compounds, the putative 
resistance operon consisting of the ABC-transporter subunits and the pentapeptide repeat protein PcyT 
was placed under control of the native P. fallax An d48 gyrase subunit A promotor (PGyrA) to achieve 
strong and stable expression of the putative export and self-resistance system. That way, all pcy cluster 
related genes are transcribed in the same direction and the vanillate repressor’s transcription and 
translation cannot interfere with the transcription of operon 2 or 3, and vice versa (Figure 3). The 
heterologous promotors for operon 1 and 2 were PCR amplified from the double mutant gDNA together 
with their gene starts, while the gyrase promotor was taken out of P. fallax An d48 by an additional PCR 
(section S 1.11). Finally, in addition to the vector described by Bilyk et al.[35] the pClY vector backbone used 
in this study does not only carry two replication origins ori15A for E. coli and Cen-Ars6 for replication in S. 
cerevisiae, but also a yeast auxotrophy marker plus kanamycin and apramycin resistance genes. The vector 
additionally contains the Mx8 integrase system for later integration of the cloned construct into S. 
aurantiaca DW4/3-1 and M. xanthus DK1622 (Figure 3).[36] Therefore the vector assembled in yeast can be 
used for M. xanthus transformation following retransformation in E. coli. The assembled vector was 
subsequently inserted into M. xanthus DK1622 and S. aurantiaca DW4/3-1 via Mx8 integrase mediated 
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chromosome integration (section S 1.9.3 and 1.9.4). The M. xanthus DK1622 and S. aurantiaca DW4/3-1 
attB :: attP pClY pyxidicycline cluster (M. xanthus DK1622 pcy and S. aurantiaca DW4/3-1 pcy in short) 
integration clones were cultivated, induced with vanillate, extracted and measured by LC-MS according to 
the standard protocol (section S 3.1 to 3.4). Compared to the non-induced strain we noted the appearance 
of two novel UV and MS signals that correspond to pyxidicycline A and B by retention time, high resolution 
mass and UV pattern indicating successful heterologous production of the pyxidicyclines. 
Figure 7. (A) Heterologous production of the pyxidicycline gene cluster in M. xanthus DK1622 pcy and (B) S. aurantiaca 
DW4/3-1 pcy. Compounds 3 and 5 are displayed as LC-MS EICs at 341.06 [M+H]+ (light green) and 297.075 [M+H]+ 
(orange); the two pyxidicyclines are displayed as LC-MS EICs at 366.10 [M+H]+ (1 in orange; 2 in red). 
Comparison of the relative LC-UV and LC-MS peak areas (Figure 7) reveals another peculiarity of this 
biosynthesis. The ratio of 1 to 2 shifts strongly depending on the host strain: 1 is by far the major product 
in the P. fallax An d48 pcy mutant while this ratio shifts to 2 in M. xanthus DK1622 pcy. Finally, S. aurantiaca 
DW4/3-1 pcy produces almost exclusively 2 (Figure 5, Figure 7, Table S 21) suggesting the corresponding 
oxidation to the quinone scaffold to be loosely controlled. This observation may be seen as a hint that this 
oxidation reaction is a spontaneous process as has been described for many anthraquinone type secondary 
metabolites such as steffimycin,[37] and that the regioselectivity of this reaction depends on the strain-
specific cytoplasmic redox power. 
2.3.6 Characterization of pyxidicycline biosynthesis  
Following successful heterologous expression of the pyxidicyclines we set out to further investigate 
their biosynthesis. Formation of the nitrogen-containing D ring is probably mediated by the tailoring 
enzyme operon comprising pcyJ, pcyK and pcyL. Considering the structure of pyxidicyclines and in light of 
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biosynthetic logic, the nitrogen atom involved in fourth ring closure could stem from ethanolamine, serine 
or glycine incorporation. However, it was not obvious whether this moiety originally derives directly from 
incorporated ethanolamine, from serine that is decarboxylated after incorporation or from glycine that is 
subsequently reduced. LC-MS analysis of extracts following addition of stable isotope labelled precursors 
to a M. xanthus DK1622 pcy mutant culture showed that feeding of 3,3,2-serine-d3 leads to a +2 Daltons 
mass shift explained by incorporation of serine into the molecule. In contrast, feeding of 2,2-glycine-d2 or 
13C2 ethanolamine did not lead to any labelling of pyxidicyclines. The nitrogen atom present in the D ring 
of the tetracene quinone-like backbone as well as the attached side chain are therefore originating from 
serine, which is decarboxylated following incorporation. In order to localise the position of the two 
incorporated deuterium atoms the labelled molecule was subjected to LC-MS² analysis revealing the 
position of the incorporated deuterium atoms in the molecule (section S 3.10). This finding is additional 
proof that the ring nitrogen N1 and the adjacent 2-hydroxyethyl moiety consisting of C19, C20 and O6 
derive from serine. To investigate the effect of the three genes pcyJ, pcyK and pcyL on pyxidicycline 
biosynthesis they were deleted by λ red prophage mediated recombination (RedE/T) (section 1.12). The 
resulting plasmids called pClY pyxidicycline cluster Δ pcyJ, Δ pcyK and Δ pcyL were subsequently 
transformed into M. xanthus DK1622 to study the consequences of deleting these tailoring enzymes for 
pyxidicycline biosynthesis. The corresponding M. xanthus DK1622 Mx8 integration mutants are called M. 
xanthus DK1622 pcy Δ pcyJ, Δ pcyK and Δ pcyL. As shown in Figure 8 presence of PcyJ is indispensable for 
formation of the final product. Therefore, the And48 mutants where only the minimal PKS is activated as 
well as the M. xanthus DK1622 pcy Δ pcyJ mutant show no pyxidicycline formation. Interestingly, the 
activation mutants of the minimal PKS in An d48 show production of 4 that cannot be observed in any of 
the heterologous expression systems. However, the connection of this metabolite to the biosynthesis of 
the 3 is explained by reduction of the ketone moiety by an An d48 enzyme, which does not have an 
isoenzyme in DK1622 or DW4/3-1, and subsequent intramolecular lactone formation (Figure 9). 
Furthermore, deletion of pycK and pcyL clearly impairs the production of the pyxidicyclines whereas not 
only the peaks of 1 and 2 become significantly smaller, but at the same time their biosynthetic precursors 
3 and 5 accumulate significantly (Figure 8, Table S 21). Therefore, although the gene pcyJ is sufficient to 
obtain the final product from the reduced analogue of 3 (Figure 9), efficient recruitment of serine into the 
pyxidicyclines and subsequent decarboxylation is only possible if the biosynthetic gene cluster possesses 
functional copies of pcyK and pcyL. Since the role of pcyO in the biosynthesis was unclear, the gene was 
placed under the control of a strong constitutive T7A1 promotor to boost its expression. 
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Figure 8. (A) LC-MS chromatograms of M. xanthus DK1622 pcy; (B) pcy ΔpcyJ; (C) pcy ΔpcyK; (D) pcy ΔpcyL and (E) 
pcy T7A1 pcyO, producing the pyxidicyclines and pyxidicycline precursors. Compounds 3 and 5 are displayed as LC-MS 
EICs at 341.06 [M+H]+ (light green) and 297.075 [M+H]+ (orange); the two pyxidicyclines are displayed as LC-MS EICs 
at 366.10 [M+H]+ (1 in orange; 2 in red). 
The pcyO gene shows similarities to transglycosylases that might be involved in glycosyl transfer to 
the pyxidicycline core. However, no novel products were obtained from this overexpression, but the 
mutant afforded slightly better yields of 1 and 2 when compared to the gene cluster on the initial pClY 
pyxidicycline cluster vector. A complete summary of the relative pyxidicycline and anthraquinone 
precursor productivities in the different strains can be found in Table S 21. 
To complete the biosynthetic model for pyxidicyclines the assignment of the different cyclase 
proteins to their respective cyclisation reaction was done starting from in silico considerations. The 
anthraquinone backbone of the pyxidicyclines is probably assembled by two cyclases responsible for first 
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ring and second ring cyclisation, while third ring formation is thought to occur spontaneously.  Zhang et al. 
could show this for structure 3, called SEK 26 in their study.[28] To determine which cyclase enzyme is 
responsible for which cyclisation/aromatisation reaction of the pyxidicyclines we used a combination of 
gene deletion studies studies on the pClY pyxidicycline cluster plasmid and in silico analysis. From the 
deletion experiments, it is evident that aromatase/cyclase like enzymes PcyJ and PcyL cannot affect this 
biosynthetic step as they have been deleted in the heterologous expression host - showing only effects on 
the total pyxidicycline production but not on the strain’s potential to produce the precursor 
anthraquinones (Figure 8). Furthermore, upon activation of the minimal PKS operon in the And48 mutant 
strains via tn5 or vanillate promotor the precursor anthraquinones were still produced but not the full-
length pyxidicyclines. Therefore, we conclude that genes pcyJ to pcyP are not involved in anthraquinone 
precursor formation. The two remaining candidate cyclase/aromatase genes are pcyB and pcyC. The 
pyxidicyclines undergo C-7’ to C-12’ “S-type” first ring cyclisation like steffimycin and tetracycline.[38] The 
corresponding cyclase genes were compared to the first and second ring cyclases of the steffimycin and 
oxytetracycline pathway by MUSCLE alignment[17] (Figure S 12), since first and second ring cyclases typically 
differ by primary sequence.[38] As the cyclase PcyC resembles the oxytetracycline and steffimycin first ring 
cyclases it is safe to assume that PcyC is responsible for first (A) ring cyclisation (section S 2.6). On the 
contrary, PcyL is not part of the minimal PKS operon, which produces the anthraquinone core and has 
already been demonstrated to be involved in the formation and aromatisation of the nitrogen-containing 
D heterocycle by gene inactivation experiments. It is therefore not involved in A- and B-ring cyclisation 
steps. The second ring cyclases StfY and OxyN share high similarity with PcyB and all three proteins form 
a group with high phylogenetic distance to other proteins in the alignment tree (section S 2.6).  PcyB is 
therefore likely to be the second (B) ring cyclase in pyxidicycline biosynthesis. The enzyme PcyJ is singled 
out in this alignment; this is unsurprising as our gene inactivation experiments determined the protein to 
be responsible for serine integration and heterocyclisation, an unprecedented step in type II polyketide 
biosynthesis. This enzyme was therefore expected to contain a rather uncommon cyclase/aromatase fold 
that does not fit very well to the enzymes known from streptomycetes (section S 2.5 and 2.6). 
2.3.7 The biosynthetic route to pyxidicyclines  
Based on the results of activation studies, stable isotope labelling, in silico analysis as well as the 
knockout experiments we are able to devise a comprehensive biosynthetic model for the formation of 
pyxidicyclines (Figure 9). The biosynthesis route shown with dotted arrows on the lower right hand side of 
the picture additionally illustrates formation of the anthraquinone shunt products mainly occurring if pcyJ 
is inactivated or repressed. Similar to known type II polyketide synthase pathways like the oxytetracycline 
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pathway,[39] the biosynthesis of pyxidicyclines starts with polycondensation of nine malonyl-CoA units by 
the KSα PcyE with its chain length factor PcyF, whereas intermediates are tethered to the ACP cyG. he next 
acting enzyme is the C-9’ type ketoreductase (KR) PcyD reducing the nascent polyketide chain at C-9’ 
counting from the thioester bond (C-10 in the final molecule). This step is necessary to pre-orientate the 
polyketide chain for the first ring cyclisation/aromatization catalysed by the C-7’ to C-12’ ‘S type’ cyclase 
PcyC that forms the pyxidicyclines’ A ring.[38] The second ring cyclase/aromatase PcyB is subsequently 
responsible for ring closure and aromatization of the B ring by C-C bond formation between C5’ and C14’ 
on the nascent polyketide chain. As it has been shown for tetracycline biosynthesis, third ring (C) formation 
occurs spontaneously with these scaffolds.[39] This is also likely to be the case for the pyxidicyclines as the 
minimal PKS operon does not contain additional cyclases and it was shown experimentally that the 
minimal PKS operon is sufficient to produce anthraquinones 340, 296 and 324, all of which contain the C 
ring. Following C ring cyclisation the product is released and the AMP-dependent synthethase and ligase 
protein and aromatase/cyclase di-domain protein, PcyJ, attaches a serine moiety and closes the D ring 
with the help of PcyK and PcyL (section S 2.5). Serine recruitment into pyxidicyclines is notably different 
from amino acid incorporation during jadomycin biosynthesis, as it is not a spontaneous process but relies 
on catalysis by PcyJ.[32] Fredericamycin A formation on the other hand invloves catalysis by the asparagine 
synthethase homologue FdmV, leading to the nitrogen-containing six membered ring structure.  FdmV 
does not transfer an amino acid but synthesizes a cyclic amide by transfer of an ammonium equivalent.[33] 
Our feeding experiments unambiguously showed that only 3,3,2 serine-d3 feeding leads to labelling of the 
pyxidicyclines, indicating that serine is incorporated and decarboxylated on the scaffold, since 13C2 
monoethanolamine did not lead to any labelling (section S 3.10). Subsequent aromatization of the D ring 
can be spontaneous as indicated by the gene inactivation experiment of the muconolactone δ-isomerase 
type enzyme PcyK and the aromatase-like enzyme PcyL (Table 1). On the other hand, those experiments 
also revealed that the yield of pyxidicyclines compared to the corresponding anthraquinone shunt 
products drops dramatically upon inactivation of PcyK or PcyL (Table S 21). However, the exact timing for 
decarboxylation remains unresolved, as decarboxylation is too efficient to detect carboxylated derivatives 
by LC-MS. It is therefore unclear whether decarboxylation occurs before or after D ring aromatization. 
From the enzyme characteristics, we assume that PcyK - a muconolactone δ-isomerase homolog - is more 
likely to help with decarboxylation while the cyclase/aromatase homolog PcyL is more likely to assist D 
ring aromatization. Other enzymes cannot be involved in these transformation steps, as proven by 
successful production in the heterologous hosts S. aurantiaca DW 4/3-1 and M. xanthus DK1622, both 
considered unlikely to furnish suitable isoenzymes encoded in their genomes. 
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Figure 9. Biosynthetic gene cluster organization in An d48 wild type and biosynthesis proposal for the pyxidicyclines 
(1 and 2) and the detected anthraquinone shunt products (3-5), according to experiments made in this study. PKS type 
II biosynthesis genes are depicted as blue arrows, regulatory and resistance elements are depicted as red arrows, 
exporter genes are depicted as yellow arrows and orfs of unknown function are depicted as grey arrows. Proteins 
participating in polyketide biosynthesis are depicted as blue spheres. 
 Conclusion 
This study presents an efficient approach for prioritizing particular BGCs out of over 93 myxobacterial 
genomes containing 10 to 30 BGCs each with focus on desired bioactivity and chemical novelty of the 
products to be discovered. Using the known host-defense mechanism of pentapeptide repeat proteins as 
the rationale behind our genome-mining strategy, a new small-molecule product was uncovered featuring 
an intriguing nitrogen-containing tetracene quinone scaffold constructed by a type II polyketide synthase 
pathway, a biosynthetic route rarely found in Gram-negative bacteria. Comprehensive in vitro bioactivity 
profiling ultimately allowed us to conclude the pyxidicyclines’ molecular target. Consequently, the 
pyxidicyclines could become interesting leads mainly for anticancer research as they share the target and 
the order magnitude of activity with the camptothecins, an approved anti-cancer drug for an established 
anti-cancer drug target.[31,34] 
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As much as this work highlights the promise of contemporary genome-mining techniques applied to 
myxobacteria as a still underexploited group of microbes, it hints at the same time at the limitations 
currently faced by genomics-based methods for natural products discovery. While it was reasonably likely 
that the new compounds would exhibit biological activity in the direction of topoisomerases, it was 
impossible to forecast the precise range of bioactivities as well as the type of topoisomerase that would 
be targeted. Future developments in bioinformatics analysis are undoubtly needed for well-directed 
genome-mining, but this notion just as much underlines the importance to advance knowledge of 
biosynthetic pathway enzymatics and to develop the required genetic tools further, in order to increase 
our chances for translating genome-encoded potential for novel natural products into real candidate 
molecules, ideally for human therapy. 
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 Molecular biology protocols 
S 2.1.1 Culture media used in this study 
Table S 1. Comprehensive list of culture medium recipes used for myxobacterial fermentation in this study 
CTT medium 
Amount Ingredient Concentration Supplier 
10 g/L Bacto Casiton - BD 
10 ml/L Tris solution 1 M Sigma Aldrich 
1 ml/L KH2PO4 solution 0.1 M Sigma Aldrich 
10 ml/L MgSO4 solution 0.8 M Grüssing 
Dissolved in milliq. water pH adjusted to 7.6 with 1N KOH 
TS-6 medium 
Amount Ingredient Concentration Supplier 
6g/L Bacto Trypton - BD 
10 ml/L Tris solution 1 M Sigma Aldrich 
4 g/L Starch (soluble) - Roth 
10 ml/L MgSO4 solution 0.8 M Grüssing 
Dissolved in milliq. water pH adjusted to 7.6 with 1N KOH 
YM – Medium 
Amount Ingredient Concentration Supplier 
5 g/L Bacto Pepton Phyton - BD 
10  g/L Glucose - Roth 
3  g/L Bacto Malt extract - BD 
3 g/L Bacto Yeast Extract - BD 
1 g/L CaCl2 - Sigma Aldrich 
1 g/L MgSO4  x 7H2O - Grüssing 
1 mL/L KHPO4 solution 0.1 M Sigma 
10 mM TRIS - Sigma Aldrich 
Dissolved in milliq. water pH adjusted to 7.5 with 1N KOH 
SC leucine dropout – Medium 
Amount Ingredient Concentration Supplier 
6.8 g/L Yeast Nitrogen base - Sigma Aldrich 
20  g/L Glucose - Roth 
5 g/L Leucine dropout amino 
acid mix 
- Sigma Aldrich 
Dissolved in milliq. water  
YPAD  – Medium 
Amount Ingredient Concentration Supplier 
10 g/L Yeast extract - BD 
10  g/L Phytopeptone - BD 
20 g/L Glucose - Roth 
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100 mg/L Adenine hemisulfate - Sigma Aldrich 
Dissolved in milliq. water  
YMS 20 – Medium 
Amount Ingredient Concentration Supplier 
5 g/L Bacto Pepton Phyton - BD 
10  g/L Glucose - Roth 
20 g/L Soluble Starch - Roth 
3  g/L Bacto Malt extract - BD 
3 g/L Bacto Yeast Extract - BD 
1 g/L CaCl2 - Sigma Aldrich 
1 g/L MgSO4  x 7H2O - Grüssing 
1 mL/L KHPO4 solution 0.1 M Sigma 
10 mM TRIS - Sigma Aldrich 
Dissolved in milliq. water pH adjusted to 7.5 with 1N KOH 
LB medium 
Amount Ingredient Concentration Supplier 
10 g/L Tryptone - Roth 
5 g/L Yeast extract - Roth 
5 g/L NaCl - Grüssing 
Dissolved in milliq. water pH adjusted to 7.2 with 1N KOH 
 
For the preparation of Agar, 7.5 g/L agar is added to the medium before autoclaving, Soft agar is 
prepared by addition of 4 g/L agar to the medium broth. 
 
S 2.1.2 Isolation of genomic DNA from myxobacteria 
To isolate bigger amounts of higher quality genomic DNA e.g. to amplify the PCR products for TAR 
cloning, the alkaline lysis gDNA preparation protocol is used. 
S 2.1.3 List of oligonucleotides used in this study 
Oligonucleotides used in this study are ordered from Sigma Aldrich. Nucleotides with a length below 
40 bp are ordered as desalted primers, while all longer oligonucleotides were ordered as RP-HPLC purified 
primers. 
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Table S 2. List of all oligonucleotides used in this study 
Primer name Primer sequence 
FP_pSBtn5verif_in CCTTTGGACAGCAAGCGAAC 
FP_pSBtn5verif_out CACTCATTAGGCACCCCAGG 
And48_pcyA_PromEx_verif_fwd ATTCATTGGAGTGAGGGC 
And48_pcyA_PromEx_verif_rev GATGTACTCGCAGCGGATGA 
And48_pcyJ_PromEx_verif_fwd TGTGATGGATGGACTTCGCG 
And48_pcyJ_PromEx_verif_rev CGAAGATGAGGACGTTGCCT 
FP_pFPtettn5verif_in GCCTCTTCGCTATTACGCCA 
FP_pFPtettn5verif_out CACTCATTAGGCACCCCAGG 
FP pCR2.1 in CCTCTAGATGCATGCTCGAGC 
FP pCR2.1 out GGATCCACTAGTAACGGCCG 
FP t2PKS KS1 SCveriv fwd CGGCAACTACTAACCCCACA 
FP t2PKS KS1 SCveriv rev CATGAAGTCGGTGGGGTTGA 
And48 KS1 SC Primer rev AAGACCTCCCTCGTAGTCCG 
And48 KS1 SC Primer fwd GGACCGGTACATCCAGTTCG 
t2PKS_Synthlig_tn5fusion_fwd 
AGACAGGATAAGGAGGTACAGCATATGTCCGAAACCGCATCCTTC 
t2PKS_Synthlig_tn5fusion_RC 
GAAGGATGCGGTTTCGGACATATGCTGTACCTCCTTATCCTGTCT 
t2PKS_AMPdepSynth_rev 
TCAGAATTCTCATGCTCCTGTGGGGATG 
tn5_Promotor_primer_XbaI 
AGTCTAGAGTAATACGACTCACTATAGGG 
t2PKS_Synthlig_tn5fusion_fwd 
AGACAGGATAAGGAGGTACAGCATATGTCCGAAACCGCATCCTTC 
t2PKS_Synthlig_tn5fusion_RC 
GAAGGATGCGGTTTCGGACATATGCTGTACCTCCTTATCCTGTCT 
t2PKS_AMPdepSynth_rev 
TCAGAATTCTCATGCTCCTGTGGGGATG 
tn5_Promotor_primer_XbaI 
AGTCTAGAGTAATACGACTCACTATAGGG 
t2PKS_Synthlig_tn5fusion_fwd 
AGACAGGATAAGGAGGTACAGCATATGTCCGAAACCGCATCCTTC 
p15A_rev 
GTGCACCTCTGGCTCACCGAC 
p15A_fwd 
TCTGTCCCTCCTGTTCAGCT 
VanR_pCLY_fwd GACTCCAACGTCAAAGGGCGATCAGTCGGCGCGAATGCTCCA 
VanR_pCLY_RC TGGAGCATTCGCGCCGACTGATCGCCCTTTGACGTTGGAGTC 
pCLY_mx8_RC GCGTACCCGAAGTTCACCGAAAATTCAGAAGAACTCGTCAAGAAGGCGATAGAAGGCG 
pCLY_mx8_fwd CGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAATTTTCGGTGAACTTCGGGTACGC 
And48_t2PKS_PCR1_rev CGGGCTGGAAGTAGGTGATG 
And48_t2PKS_PCR2_fwd CGCAACCAGGAGTTCGTGAT 
And48_t2PKS_PCR2_rev GCACGTATGAAATGGCGTCC 
And48_t2PKS_PCR3_fwd CACTCCCTTCACGTACCTGG 
And48_t2PKS_PCR4_rev AACCACTGGGAGATGTGCTG 
And48_t2PKS_PCR5_fwd GGAGGCCTACAAGGAATCCG 
And48_PGyrA_fwd TTCATGCGGAAGTAGCGAGGCGGAAGGGCCCTCATTTTTC 
And48_PGyrA_rev AAGATGGGAGGCCGGGGGACGCCATGAGCTCTGGAAGTGTTCGGA 
And48_t2PKS_PCR3_rev AAAACCCTGGCGTTACCCAACCTCCCCTACCCCGTAGTC 
And48_t2PKS_PCR4_fwd GACTACGGGGTAGGGGAGGTTGGGTAACGCCAGGGTTTT 
And48_t2PKS_PCR5_rev GAAAAATGAGGGCCCTTCCGCCTCGCTACTTCCGCATGAA 
And48_t2PKS_PCR6_fwd TCCGAACACTTCCAGAGCTCATGGCGTCCCCCGGCCTCCCATCTT 
And48_t2PKS_PCR6_rev CGCTCGACAAGCGCGGCCGTCCGGTTCAGCGGCTCTTCC 
And48_t2PKS_resOperon_mx8 GGAAGAGCCGCTGAACCGGACGGCCGCGCTTGTCGAGCG 
mx8_attB_up CGAGGAGTACGGGACTTGAAC 
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mx8_attB_down CGGATAGCTCAGCGGTAGAG 
mx8_attP_up CATGGTCGACGCCTACACGAC 
mx8_attP_down GGCTTGTGCCAGTCAACTGCG 
CmR_Ampdep_fwd 
GATGGCGCAGGGGATCAAGATCTGATCAAGAGACAGGATAAGGAGGTACAGCATCTGAACAGG
AGGGACAGCTG 
CmR_Ampdep_rev 
CACCTGCGACGCGGACAGGTGGCGTGGGTCTTCCTGGGTGATGCAGGCAATCAACATTTACGCCC
CGCCCTGCCACTCATCGCAGTA 
CmR_Mucono_fwd 
AGCAGAGCGCGGCGTCCCAGAAGGGCCCGTCCGCCATCCCCACAGGAGCATGAGCCTGAACAGG
AGGGACAGCTG 
CmR_Mucono_rev 
TCGCCCGGAGCGGCCTCGGTCAGTACGGCGAACAGCATGGGTGGGTTCTCCGGTAGGGTTACGC
CCCGCCCTGCCACTCATCGCAGTA 
CmR_Cyclase_fwd 
TCACCCACGCGATGGCCGAGAACGCCTGACCCCCTACCGGAGAACCCACCCCTGAACAGGAGGGA
CAGCTG 
CmR_Cyclase_rev 
TCAGGGGCCGAGAGCGGAACGCCGCGTCGTGTGTCCGGGAAGCTTCCGTCCATTTACGCCCCGCC
CTGCCACTCATCGCAGTA 
CmR_T7A1_fusion_fwd TACTGCGATGAGTGGCAGGGCGGGGCGTAAATCCATTACGCCAAGCTTATCA 
CmR_T7A1_fusion_fwd TGATAAGCTTGGCGTAATGGATTTACGCCCCGCCCTGCCACTCATCGCAGTA 
T7A1_glycohydr_rev GCGGCGCTCTTCTGCGGAAGCGCGGTGGGCTTGGACAGGGCTTTGGTCATATGTACACCTCTCGA
TGG 
TipA_CmR_fwd CCGATTCACCCGTGACGCCATCATCGCGAACGCGGAGCGGCACGGCGAGTAGCTGAACAGGAGG
GACAGCTG 
 
S 2.1.4 Ligation protocol used in this study 
Ligations performed in this study are done with Thermo scientific T4 ligase. 
T4 DNA Ligase mix: 
2µL vector DNA (1h dephosphorylated using FastAP (shrimp alkaline phosphatase, Thermo 
scientific)) 
2 – 6.5 µL insert DNA (triple the molar amount of the vector DNA) 
1 µL T4 DNA ligase buffer 
0.5 µL T4 DNA ligase 
to 10µL ddH2O 
The ligase mix is incubated at 16°C for 15-24h and 1-5 µL ligation mix are subsequently electroporated 
into E. coli DH10ß using standard E. coli electroporation protocol. 
S 2.1.5 List of polymerase chain reaction protocols used in this study 
 Thermo scientific Taq Polymerase 
Taq Polymerase Protocol: 
2µL NH4SO4 Buffer 
(Alternatively 2µL KCl Buffer) 
2µL MgCl2 solution (25mM) 
4µL dNTP’s (2mM) 
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4µL 50% Glycerol 
1µL Primer fwd and rev (50mM) 
0.2 µL Taq DNA Polymerase 
1µL gDNA Template (~50 ng/µL) 
4.3µL ddH2O 
Taq Polymerase cycler program: 
Table S 3. Taq DNA Polymerase PCR program 
Step Time [min:s] Temperature [°C] 
Initial denaturation 4:00 95 
Cycle, repeat 30x 
0:30 95 
0:15 63 
1:20 72 
Final elongation 10 72 
Store forever 8 
 
 Thermo scientific Phusion Polymerase 
Phusion Polymerase Protocol: 
5µL GC Buffer 
2.5µL dNTP’s (2mM) 
1.25µL DMSO 
0.5µL Primer fwd and rev (100mM) 
0.2 µL Phusion DNA Polymerase 
0.5µL gDNA Template (~50 ng/µL) 
14.55µL ddH2O 
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Phusion Polymerase cycler program: 
Table S 4. Phusion DNA Polymerase PCR program 
Step Time [min:s] Temperature [°C] 
Initial denaturation 4:00 95 
Cycle, repeat 30x 
0:30 98 
0:15 63 
1:20 72 
Final elongation 10 72 
Store forever 8 
Table S 5. Phusion DNA Polymerase PCR program for long PCR products and long oligonucleotides 
Step Time [min:s] Temperature [°C] 
Initial denaturation 4:00 95 
Cycle, repeat 2x 
0:30 98 
0:15 61.5 
6:00 68 
Cycle, repeat 30x 
0:30 98 
3:00 66 
6:00 68 
Final elongation 10 72 
Store forever 8 
 
S 2.1.6 Pyxidicoccus fallax An d48 antibiotics sensitivity tests 
In order to determine available resistance markers for genetic manipulation of An d48 the strain’s 
resistance towards different antibiotics was assayed by adding respective antibiotic concentrations to an 
YM medium agar plate. The strain shows resistance against 12 µg/ml tetracycline and partial resistance 
against 25 µg/ml zeocin. On the other hand the strain is sensitive to 50 µg/ml kanamycin, 25 µg/ml 
chloramphenicol and 12 µg/ml oxytetracycline. For practical reasons kanamycin and oxytetracycline is 
chosen as a second resistance marker, since the pCR2.1 Topo and pSWU22 vectors will be used. The pCR2.1 
Topo is based on kanamycin.  The pSWU22 vector harbors a tetracycline resistance cassette as well as a 
   Chapter 2 The Pyxidicyclines Supporting Information    75 
multiple cloning site and has no overlap with the pCR2.1 Topo backbone as overlap could lead to wrong 
backbone-backbone recombinations. 
S 2.1.7 Transformation protocols 
Transformation protocol E. coli DH10ß TOPO TA kit cloning 
1) Take competent E. coli DH10ß from -80°C on ice 
2) Mix competent cells with pCR2.1 TOPO reaction mixture 
(0.5µL salt solution, 0.5µL pCR2.1 TOPO vector (linearized), 1-5 µL PCR product cleaned by gel 
electrophoresis incubated for 10 minutes) 
3) Electroporate the cells at 1250 V, 25 µF, 200 Ohm and 1mm in a standard electroporation cuvette 
(100 µL). 
4)  Add 500 µL of fresh LB medium 
5)  Incubate on a shaker at 37°C for 1h 
6) Plate on LB Kan50 Agar and incubate the plates overnight at 37°C 
7) Pick around 6 clones and cultivate them for plasmid preparation via alkaline lysis 
S 2.1.8 Plasmid verification 
 Plasmid preparation via alkaline lysis 
1) Centrifuge 2-4 ml E. coli culture in LB medium in a 2ml Eppendorf tube (13000-15000 rpm table 
centrifuge 2 min) 
2) Resuspend the Pellet in 250 µl Solution I (Store at +4°C after addition of RNAse A) 
3) Incubate for 5 min approximately 
4) Add 250 µL Solution II, mix well via inverting the Eppendorf tube 
5) Add 250 µL Solution III (fast to avoid denaturing the supercoiled plasmid DNA), mix well via 
inverting the Eppendorf tube 
6) Centrifuge for 30 minutes at 13000-15000 rpm with a table centrifuge 
7) Transfer the supernatant into fresh 1.5 ml Eppendorf tubes 
8) Add 850µL analytical grade Isopropanol 
9) Centrifuge the sample for 30 min at 13000-15000 rpm, possibly at 4°C 
10) Remove the supernatant and add 350 µL EtOH to wash the plasmid DNA 
11) Centrifuge the mixture for 5 min and remove the ethanolic supernatant, this step can be repeated 
to clean up the DNA 
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12) Dry the pellet by inverting the tube on a clean piece of paper or at 65°C (make sure to avoid 
residual EtOH in your plasmid preparations in order to avoid re-precipitation of the vector over 
time) 
13) Add 50 µL of nuclease free H2O and resuspend the Pellet at 55°C for 1h. 
 Plasmid verification by restriction digestion 
1) Find a restriction Enzyme that cuts one time on the vector backbone and one time on the insert. 
2) Mix 8.5µL Plasmid from alkaline lysis with 1µL restriction enzyme buffer and 0.5 µL enzyme. 
3) Incubate for 3-4 h 
4) Verify the bands on agarose gel (0.8 %) by gel electrophoresis 
S 2.1.9 Transformation of the myxobacterial strains used in this study 
 Devising a reliable mutagenesis protocol for the myxobacterium p. fallax And48 
Electro competence of the myxobacterium p. fallax And48 was assayed with the plasmid pMycoMar-
Kan that confers kanamycin resistance via the defective transposon magellan-4 [1]. Following optimization 
of electroporation parameters, a reliable protocol was created that allowed site directed mutagenesis via 
single crossover homologous recombination (detailed information in the supplementary information). 
S 2.1.10 Single crossover homologous recombination in P. fallax And48 
Since Silica membrane prepared plasmid (GeneJET Plasmid Miniprep kit, Thermo scientific) 
transposon mutagenesis of And48 yields more than 400 clones per 500 µg plasmid while standard alkaline 
lysis led to clone numbers inferior to 10, all manipulations of Pyxidicoccus fallax And48 are done using 
silica membrane purified plasmid. 
Transformation protocol 
1) Centrifuge 2ml of an And48 culture in YM Medium at OD600 of approx. 0.3 at 8000 rpm for 2 
minutes at a table centrifuge. 
2) Wash the residual cell pellet 2 times with 500 µL autoclaved ddH2O and discard the supernatant. 
3) Resuspend cells in 50µL of ddH2O, add 5 µL of plasmid solution (prepared from E. coli with Thermo 
Scientific Miniprep Kit) at a conc. of 0.3-0.4 ng/µL and transfer the solution into an 
electroporation cuvette. 
4) Electroporation at 675 V, 400 Ohms, 25µF and 1mm cuvette settings for optimum electroporation 
efficiency.  
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5) Flush out the cells with 1 mL fresh YM medium, transfer the Cell suspension into a 2ml Eppendorf 
tube. 
6) Incubate the Cells for 5h on a Shaker thermostated to 37°C at 300 rpm. 
7) Plating the cells on Kan50 YM Agar after mixing the cell suspension with 3 ml of Kan50 YM 
Softagar. 
8) Slightly red, spherical clones appear after 7-12 Days in the 30°C incubator. 
S 2.1.11 Transformation protocol for M. xanthus DK1622 
The transformation protocol for M. fulvus SBMx132 was elaborated from CTT medium cultures, since 
CTT medium leads to growth in perfect suspension. This is a prerequisite for efficient electro 
transformation of myxobacteria. 
Transformation protocol 
9) Centrifuge 2ml of an Mx132 culture in CTT Medium at OD600 of approx. 0.3 at 8000 rpm for 2 
minutes at a table centrifuge. 
10) Wash the residual cell pellet 2 times with 500 µL autoclaved ddH2O and discard the supernatant. 
11) Resuspend cells in 50µL of ddH2O, add 5 µL of plasmid solution (prepared from E. coli with Thermo 
Scientific Miniprep Kit) at a conc. of 0.3-0.4 ng/µL and transfer the solution into an 
electroporation cuvette. 
12) Electroporation at 675 V, 400 Ohms, 25µF and 1mm Cuvette Settings for optimum 
electroporation efficiency.  
13) Flush the cells out with 1 mL fresh CTT medium, transfer the Cell suspension into a 2ml Eppendorf 
tube. 
14) Incubate the Cells for 5h on a Shaker thermostated to 37°C at 300 rpm. 
15) Plating the cells on Kan50 CTT Agar after mixing the cell suspension with 3 ml of Kan50 CTT 
Softagar. 
16) Clones appear after 5-7 Days in the 30°C incubator. 
S 2.1.12 Transformation protocol for S. aurantiaca DW 4/3-1 
The transformation protocol for S. aurantiaca DW4/3-1 was elaborated from TS-6 medium cultures, 
since TS-6 medium leads to growth in perfect suspension. 
Transformation protocol 
17) Centrifuge 2ml of a S. aurantiaca DW4/3-1 culture in TS-6 Medium at OD600 of approx. 0.3 at 8000 
rpm for 2 minutes at a table centrifuge. 
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18) Wash the residual cell pellet 2 times with 500 µL autoclaved ddH2O and discard the supernatant. 
19) Resuspend cells in 50µL of ddH2O, add 5 µL of plasmid solution (prepared from E. coli with Thermo 
Scientific Miniprep Kit) at a conc. of 0.3-0.4 ng/µL and transfer the solution into an 
electroporation cuvette. 
20) Electroporation at 650 V, 400 Ohms, 25µF and 1mm cuvette Settings for optimum 
electroporation efficiency.  
21) Flush the cells out with 1 mL fresh TS-6 medium, transfer the cell suspension into a 2ml Eppendorf 
tube. 
22) Incubate the Cells for 5h on a Shaker thermostated to 37°C at 300 rpm. 
23) Plating the cells on Kan50 TS-6 Agar after mixing the cell suspension with 3 ml of Kan50 TS-6 
Softagar. 
24) Clones appear after 10-14 Days in the 30°C incubator. 
S 2.1.13  Elaboration of the plasmids used for single crossover integration 
 Single crossover inactivation plasmids for the pyxidicycline cluster 
In order to disrupt the pyxidicycline cluster, ca. 1 kb single crossover homology arms targeting the 
KSα on the pcyE gene and the cyclase on pcyC were amplified from An d48 genomic according to the 
protocol for gDNA isolation from gram-negative bacteria (DNA Puregene Core Kit A, Quiagen) and ligated 
into pCR2.1-TOPO (TOPO-TA cloning, Thermo scientific TOPO-TA Kit). Single crossover integration was 
achieved by electro-transformation of An d48 using a protocol elaborated in this work (section S 1.9) and 
resulting mutants were checked for correct integration by PCR using the TAQ PCR protocol (section S 1.5). 
For single crossover inactivation of the pyxidicycline secondary metabolite cluster a pCR 2.1 vector from 
the TOPO-TA cloning kit (TOPO-TA cloning KIT, Thermo scientific) was used.  Amplification of the 1 kb 
homology fragments was done with TAQ Polymerase (Thermo scientific) from And48 gDNA according to 
the TAQ polymerase amplification protocol (section S 1.5).  The vector containing the KSα encoded on pcyE 
insert was verified by restriction digestion with the restriction Enzyme NcoI that cuts once on the pCR2.1 
backbone and once on the KSα homology arm insert and analogously the vector containing homology to 
the cyclase pcyC was verified with NaeI. Two E. coli clones whose plasmids show the correct restriction 
pattern are selected for plasmid isolation with the plasmid isolation kit (GeneJET Plasmid Miniprep kit, 
Thermo scientific). 
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Figure S 1. pCR2.1 vector from the pTOPO Kit carrying a 1kb homology arm for single crossover inactivation of the 
KSα on the pcyE gene. 
 Plasmids used for promotor exchange of the pcyA gene 
The first utilized construct was designed in order to exchange the alleged native promotor against a 
tn5 promotor. This promotor was chosen as it was known to successfully drive the kanamycin resistance 
gene expression in M. xanthus. The plasmids used for overexpression of the minimal PKS operon are called 
pSBtn5 and pFPVan, consisting of a pCR2.1 vector backbone from the TOPO-TA cloning kit (Thermo 
scientific, U.S.A) and a tn5 promotor or a vanillate promotor repressor system. The plasmids created in 
this section serve as tool to control the transcription and translation of operon 1 of the pyxidicycline cluster 
via a heterologous promotor. 
 
 
 
Figure S 2. pSBtn5 vector used for placing the pyxidicycline gene cluster under the control of the contained tn5 
promotor 
 The first 1-1.5 kb of a biosynthetic assembly line are inserted into the pSBtn5 with the restriction 
enzymes EcoRI and NdeI that are introduced during PCR with restriction sites on the primers.  NdeI is 
necessary as it contains the start codon and usage of EcoRI as a complementary enzyme facilitates cloning 
as both enzymes are working in Thermo scientific 1x Orange buffer. In order to get good cloning efficiency 
and avoid vector relegation clones it is necessary to dephosphorylate the vector backbone thoroughly 
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before ligation. This is done by utilizing the FastAP shrimp phosphatase (Thermo Scientific) which is also 
compatible with Thermo Scientific 1xO buffer. Electroporation of Pyxidicoccus fallax An d48 is done 
according to the devised protocol (see section S 2.1.9) with the assembled and purified pSBtn5 plasmid 
harboring the first gene of the type 2 PKS minimal PKS Operon. As this gene is called pcyA, this assembled 
plasmid will be called pSBtn5 pcyA. 
 
Figure S 3. pSBtn5 pcyA construct used for overexpression of p. fallax And48 pyxidicycline cluster 
In order to avoid self-toxicity a second vector for single crossover insertion is created that harbors a 
promotor-repressor system inducible by vanillate. As the pCR2.1 Vector from the TOPO-TA Kit (Thermo 
scientific) works well for single crossover insertions of foreign DNA in P. fallax An d48, pCR2.1 is taken as 
a basis for this second vector system. The first gene of the t2PKS assembly line pcyA is amplified and the 
vanillate promotor-repressor system is added via overlap extension PCR using the Phusion PCR protocol 
that also introduced NdeI as well as EcoRI restriction sites on the Primers (Table S 3). This PCR fusion 
product is ligated into the cut vector via TOPO-TA cloning (TOPO TA Kit, Thermo scientific). 
 
Figure S 4. pFPVan pcyA used for overexpression of the t2PKS cluster in Pyxidicoccus fallax An d48 
Since both of these vectors are designed to work with the restriction enzymes EcoRI and NdeI, these 
gene cluster overexpression vectors can be utilized with the same PCR product into which NdeI and EcoRI 
restriction sites have been introduced. 
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 Creation of an orthogonal tetR based vector for a second single crossover integration 
In order to introduce a second promotor exchange into the bacterial chromosome of Pyxidicoccus 
fallax And48 pcyA :: pFPVan pcyA, a vector with an orthogonal resistance marker had to be created. As 
preliminary studies showed oxytetracycline to be a usable selection marker for P. fallax An d48 (section S 
1.6), a vector harboring a p15A origin, the tetR gene as well as a fusion of a tn5 promotor to the pcyJ gene 
was created by standard restriction cloning based on the pSWU22 plasmid. This plasmid solely consists of 
the tetracycline exporter gene as resistance marker, a pUC origin and a multiple cloning site. The plasmid 
pSWU22 possesses a pUC origin which is not usable in this case as this might lead to single crossover 
integration of pUC :: pUC which is not desired. Therefore, the origin was exchanged against a p15A origin 
by restriction ligation using DraI and ApaLI. This also leads to elimination of the NdeI cutting site on the 
plasmid backbone that would impede efficient use of the created plasmid later. Overlap extension PCR 
with the Phusion PCR protocol was subsequently used to amplify a fusion PCR product consisting of a tn5 
promoter and the pcyJ gene harboring XbaI cutting sites on the primer sequences. Standard restriction 
cloning is subsequently used to insert the tn5-pcyJ fusion sequence into the modified pSWU22 plasmid to 
create the pFPtettn5 pcyJ vector. 
 
Figure S 5. schematic view of the pFPtettn5 vector used for creation of the Pyxidicoccus fallax An d48 pcyA :: pSBtn5 
pcyA; pcyJ :: pFPtettn5 pcyJ (An d48 pcy) mutant 
This allowed exchange of the native pcyJ promotor against a tn5 promotor via single crossover 
homologous recombination in Pyxidicoccus fallax An d48 pcyA :: pFPVan pcyA to obtain Pyxidicoccus fallax 
An d48 pcyA :: pFPVan pcyA; pcyJ :: pFPtettn5 pcyJ (An d48 pcy). Single crossover integration of this plasmid 
into the Pyxidicoccus fallax An d48 pcyA :: pFPVan pcyA strain was achieved by electroporation according 
to standard protocol (section S 1.9). As mentioned in the results, despite serious efforts we were unable 
to obtain integration clones of said plasmid into Pyxidicoccus fallax An d48 pcyA :: pSBtn5 pcyA. Plasmid 
integration verification was done by PCR using the TAQ PCR protocol (section 1.5). 
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 Verification of plasmid integration into the myxobacterial strains 
Verification of the myxobacterial mutant clones is done by PCR with TAQ DNA Polymerase (Thermo 
Scientific). Therefore, genomic DNA from the myxobacterium is isolated with the Puregene Core Kit A 
(Quiagen) according to the protocol for gDNA isolation from gram-negative bacteria. The Taq DNA 
Polymerase master mix is prepared according to Table S 3. Primers are in all cases 2 primers that bind on 
the genomic DNA next to the homologous region if homologous recombination is used or next to the 
integration site if phage integrase based integration is used as well as two complementary primers that 
bind on the integrated vector. Therefore the appearance of PCR products of the right size proves 
homologous recombination to have occurred in the correct position. 
S 2.1.14  Protocols for transformation assisted recombination (TAR cloning) 
 Stock solutions needed for TAR cloning of biosynthetic gene clusters 
PEG 3500 solution 
50 % [w/v] PEG 3500 (Sigma Aldrich) in milliq Water 
Single strand carrier DNA stock solution 
2 mg/ml salmon sperm DNA (Sigma Aldrich) in autoclaved milliq Water 
Boil for 5 min at 95 °C and freeze aliquots of 500 µL, these aliquots can be used several times 
LiOAc stock 
1M LiOAc in TE Buffer 
TE Buffer 
1 mM EDTA 
10 mM Tris 
in milliq water 
pH 8.0 
 TAR cloning protocol adapted from Bylik et al. [2] 
Previous day: 
1) Inocculate the S. cerevisiae strain ATCC4004247 in 10 ml YPAD medium a 50 ml baffled flask over 
night at 30°C on a rotary shaker at 200 rpm. Simultaneous pre - warm one 300 ml baffled flask 
containing 50 ml of sterile YPAD medium to 30°C 
TAR cloning day: 
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2) Determine approximate culture titer by measuring OD 600 of 10µL yeast culture in 1ml of milliq 
H2O, OD of 0.1 is approximately 106 yeast cells. 
3) Add ca. 2 x 108 yeast cells to the pre warmed YPAD medium and incubate for 4h at 30°C 200 rpm.  
4) Denature one aliquot of the SS carrier DNA stock solution for 5 min at 95°C and chill the solution 
on ice. 
5) Harvest the yeast cells at 3000g for 5 min in a 50 ml falcon, wash twice with 25 ml sterile milliq 
H2O and re suspend the cells in 1000 µL of sterile milliq H2O. 
6) Pipet aliquots of 200 µL of this solution in 1.5 µL Eppendorf tubes and remove the water by 
centrifuging at 3000g for 5 min 
7) Add 360µL of transformation mix to the pellets and mix by pipetting up and down 
8) Place the Eppendorf tubes (closed) in a floating device and heat shock the S. cerevisiae cells at 
42°C for 30 min 
9) Centrifuge at top speed for 30s and remove residual transformation mix by pipetting 
10) Re suspend the pellet in 1ml of sterile milliq H2O 
11) Streak the cells on a SC leucine dropout agar plate and incubate the plate for 2-3 days 
12) Pick the clones on a replica plate and select for positive clones via colony PCR 
13) S. cerevisiae clones that give a positive colony PCR signal are grown in 5 mL of sterile SC leucine 
dropout medium and the plasmid is prepared from 2ml of S. cerevisiae culture 
 Plasmid preparation from yeast strains 
Plasmids from TAR cloning for heterologous expression were prepared from the Δ Leu2 leucine 
auxotrophy strain S. cerevisiae ATCC 4004247 [2].  
Plasmid preparation follows the following scheme: 
1) Centrifuge 1.5 ml S. cerevisiae culture in SC dropout medium in a 1.5 ml Eppendorf tube (13000-
15000 rpm table centrifuge 2 min) 
2) Re suspend the Pellet in 150 µl Solution I  
3) Add 2ml of Zymolyase solution (10mg/ml) to each tube 
4) Incubate for 30 min approximately 
5) Add 150 µL Solution II, mix well via inverting the Eppendorf tube 
6) Add 150 µL Solution III (fast to avoid denaturing the supercoiled plasmid DNA), mix well via 
inverting the Eppendorf tube 
7) Centrifuge for 30 minutes at 13000-15000 rpm with a table centrifuge 
8) Transfer the supernatant into fresh 1.5 ml Eppendorf tubes 
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9) Add 700µL analytical grade Isopropanol and mix well by inverting the tube several times 
10) Centrifuge the sample for 30 min at 13000-15000 rpm, possibly at 4°C 
11) Remove the supernatant and add 500 µL 70% EtOH to wash the plasmid DNA 
12) Centrifuge the mixture for 5 min and remove the ethanolic supernatant, this step can be repeated 
to clean up the DNA 
13) Dry the pellet by inverting the tube on a clean piece of paper or at 65°C (make sure to avoid 
residual EtOH in your plasmid preparation in order to avoid re-precipitation of the vector over 
time) 
14) Add 30 µL of nuclease free H2O and re suspend the pellet at 55°C for 1h. 
S 2.1.15  TAR cloning based pyxidicycline gene cluster assembly 
Pxyidicoccus fallax An d48 pcyA :: pFPVan pcyA, pcyJ :: pFPtetp15Atn5 pcyJ strain’s genomic was 
prepared according to alkaline lysis genomic DNA preparation standard protocol for all further PCR 
reactions (section S 1.2). For naturally overlapping PCR fragments e.g. PCR2 and PCR3 the PCR product 
overlap necessary for TAR cloning was introduced by PCR, for non-overlapping fragments as PCR3 and 
PCR4, the overlap was introduced with the primer sequences (main text Figure 3 and Figure S 6). 25-30 Bp 
homology introduced through the primers are sufficient for recombination in yeast. Amplification of the 
cluster sequence was done by using the PCR program for long PCR products (section S 1.5.2). Co-
transformation of the PCR products of the pyxidicycline cluster into the TAR yeast S. cerevisiae ATCC 
4004247 is done at a total concentration of 25 pg x Number of nucleotides per PCR product to get an 
equimolar PCR product mix in the yeast transformation mix. The capture vector was designed to harbor 
all genes necessary for replication and auxotrophy selection in S. cerevisiae analogous to the vector 
described by Bylik et al.[2] The last fragment imperative for the heterologous expression of the pyxidicycline 
cluster in Myxococcus xanthus DK1622 is the Mx8 integrase prophage with the attP site that mediates 
stable and efficient integration of plasmids into the DK1622 chromosome’s attB site [3],[1]. This fragment 
also contains a kanamycin resistance cassette necessary for the latter selection of integration clones in M. 
xanthus DK1622. Furthermore this resistance is helpful during the retransformation of the constructs in E. 
coli as since it is located on a PCR product different of the one harboring the p15A origin - it helps to 
prevent selecting plasmids consisting only of the pClY backbone as these would not confer kanamycin 
resistance. TAR cloning was done according to a protocol by Bylik et al.[2] that was slightly adapted (section 
S 1.11). Yeast clones appearing on leucine deficient medium were checked by PCR for a fragment of the 
pcyE gene by colony PCR. Clones that gave a positive result were prepared from yeast (Zymo Prep Kit, 
Zymo Research, U.S.A) and transformed into E. coli DH10ß by electroporation. Plasmid preparation and 
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plasmid digestion with the enzymes NdeI, BstEII and NotI were used to confirm the plasmid by restriction 
digestion. The vector pClY pyxidicycline cluster was sequenced by Illumina sequencing at GMAK 
(Brunswick, Germany). The sequence was proven correct except for a single nucleotide polymorphism that 
leads to a silent mutation in the ATP binding protein of the ABC transporter encoded on pcyQ. The plasmid 
is transformed into M. xanthus DK1622 and S. aurantiaca DW 4/3-1 according to standard protocol 
(section S 1.9.3 and 1.9.4). Correct integration via the Mx8 integrase was checked by PCR using the TAQ 
PCR protocol (section 1.5).[1] 
 
Figure S 6. Schematic view of the pClY Pyxidicycline vector. PKS type-II biosynthesis genes depicted in blue, regulation 
and resistance genes in red, exporter genes in orange, auxiliary genes for the cloning strategy in light green and orfs 
of unknown function in gray. 
S 2.1.16  Protocols for λ-Red prophage recombination (Red E/T) 
The strain used for all λ-Red based recombination experiments was E. coli HS996 carrying the 
thermosensitive pSC101 Bad red gba plasmid. As the origin of this plasmid stops replicating at 37°C the 
strain has to be grown at 30°C for cryo cultures. 
 Incorporation of the target plasmid into the λ-Red recombination strain 
1) Inoculate 25 ml LB containing 12 µg/ml oxytetracycline and grow the strain overnight at 30°C 200 
rpm on a rotary shaker 
2) Inoculate 20 µL of the well grown E. coli overnight culture into a 2 ml Eppendorf tube with a 
punctured lid containing 1.5 ml LB with 12 µg/ml oxytetracycline 
3) Incubate the culture for 4h until OD reaches approx. 0.6 
4) Mix target vector or Ligation mixture (ca.1-3µL) with competent E. coli and pipet the mixture into 
a Electroporation cuvette (100µL) 
5) Electroporate the mixture at 1250V, 25µF, 200 Ohm, 1mm Cuvette 
6) Add 1mL fresh sterile LB medium, incubate for 1h at 900 rpm 30°C in a 2ml Eppendorf tube with 
a punctured lid 
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7) Plate on LB Kan50 Otc12 Agar (provided the plasmid has kanamycin resistance, if not use 
appropriate antibiotic) and incubate the plates overnight at 30°C 
8) Pick around 6 clones and cultivate them for plasmid preparation via alkaline lysis 
9) Confirm the electroporated plasmid via restriction digestion 
 Modification of plasmids via Red E/T 
1) Inoculate 25 ml LB containing 12 µg/ml oxytetracycline and 50 µg/ml Kanamycin and grow the 
strain overnight at 30°C 200 rpm on a rotary shaker 
2) Inoculate 20 µL of the well grown E. coli overnight culture into a 2 ml Eppendorf tube with a 
punctured lid containing 1.5 ml LB with 12 µg/ml oxytetracycline and 50 µg/ml Kanamycin 
3) Incubate the culture for 2h until OD reaches approx. 0.2 (sometimes longer incubation times are 
necessary) 
4) Centrifuge the culture at 8000 x g for 5 minutes to pellet the cells 
5) Wash the residual cell pellet 2 times with 1000 µL autoclaved milliqH2O and discard the 
supernatant. 
6) Re suspend the cell pellet in 50 µL autoclaved milliq H2O and add the PCR product for modification  
7) Electroporate the mixture at 1300V, 25µF, 600 Ohm, 1mm Cuvette 
8) Add 1mL fresh sterile LB medium, incubate for 1h at 900 rpm 30°C in a 2ml Eppendorf tube with 
a punctured lid 
9) Transfer the mixture into 50 ml LB Kan50 containing appropriate concentration of the antibiotic 
on the modification PCR product (in my case Chloramphenicol 25µg/ml) and incubate over night 
at 30°C 
10) Prepare plasmid from this mixture via alkaline lysis 
11) Electroporate the plasmid mix into E. coli DH10ß according to the E. coli DH10ß electroporation 
protocol and plate it on LB Kan50 Cm25 
12) Pick around 4 clones and cultivate them for plasmid preparation via alkaline lysis 
13) Confirm the electroporated plasmid via restriction digestion 
The retransformation is necessary in order to avoid having clones harboring both plasmids (the modified 
and the unmodified one) in the same E. coli clone as well as to get rid of the pSC101 Bad Red gba plasmid 
S 2.1.17  Elaboration of the Red E/T deletion plasmids utilized in this study 
To elucidate functions of the genes in the pcy cluster’s operon two, genes were subsequently 
replaced by a chloramphenicol cassette on the heterologous expression construct. Therefore, the plasmid 
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was transformed into the host strain E. coli HS996 harboring the pSC101BAD RedγβαA plasmid. Ca. 80 bp 
homology arms to the neighboring regions of the genes selected for deletion via Red/ET were put on 
primers suited to amplify the chloramphenicol resistance cassette (Table S 2). PCR products were obtained 
using the Phusion PCR protocol (section S 1.5). Subsequent Red/ET replacement of the target genes led to 
the creation of deletion plasmids for the genes pcyJ, pcyK and pcyL. For overexpression of the pcyO gene, 
a T7A1 promotor was fused to the chloramphenicol resistance cassette equipped with 80 bp homology 
arms to replace the pcyO promotor region. Red/ET recombination was done according to standard linear 
to circular Red/ET (section S 1.13). The resulting plasmids were transformed into Myxococcus xanthus 
DK1622 via Mx8 mediated integration and the resulting strains termed M. xanthus DK1622 pcy Δ pcyJ, 
pcyK and pcyL, depending on the deleted enzyme. The M. xanthus mutants were extracted according to 
standard protocol and analyzed by LC-MS. Pyxidicycline and anthraquinone production titers of M. xanthus 
DK1622 harboring the pClY pyxidicycline cluster plasmid were compared to the titer of the strains 
harboring the pcyJ, pcyK and pcyL defective plasmids by LC-MS EIC peak area integration (Table S 21). 
 
Figure S 7. Schematic view of the pClY Pyxidicycline vector deletion constructs Δ pcyJ, pcyK and pcyL. PKS type-II 
biosynthesis genes depicted in blue, regulation and resistance genes in red, exporter genes in orange, auxiliary genes 
for the cloning strategy in light green and orfs of unknown function in gray. 
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 In silico analysis of the Pyxidicycline biosynthetic gene cluster 
S 2.2.1 In silico analysis of the pentapeptide repeat protein 
In order to analyze similarities of the found putative topoisomerase self-resistance proteins with self-
resistance proteins against the gyrase poisons ciprofloxacin, albicidin and cystobactamid the pentapeptide 
repeat proteins were aligned via MUSCLE alignment. Alignment of the proteins in general shows them to 
have a rather low overall homology as the proteins are structural proteins with the relaxed consensus 
motiv [S,T,A,V][D,N][L,F][S,T,R][G] for every repeat. Still the similarity of PcyT to McbG in E. coli and CysO 
in C. velatus indicates that this protein might have a similar function.[4] 
S 2.2.2 3D modelling of the pentapeptide repeat self-resistance protein via the Phyre² 
server 
Since the 3D structure of pentapeptide repeat proteins is most likely more important than the 
primary sequence as these proteins are most likely structural proteins that mimic DNA to protect the hosts 
topoisomerases an in silico 3D structure prediction was done.  
 
Figure S 8. 3D structure homology model of the pentapetide repeat protein putatively conferring topoisomerase self-
resistance PcyT modelled by Phyre2 [5] 
The best matching proteins found by psi-blast on the Phyre2 server to obtain a 3D homology model 
were Xanthomonas albilineans AlbG (100.0 confidence scoring; 29 % identity) and the quinolone resistance 
protein QNR from Aeromonas Hydrophilia (99.9 confidence scoring; 17 % identity). Both of these proteins 
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confirm topoisomerase poison resistance and the devised homology model depicted in the picture above 
looks strikingly similar to described topoisomerase inhibitor resistance proteins.[4] 
S 2.2.3 In silico analysis of the Pyxidicycline biosynthetic gene cluster 
Table S 6. Table of all open reading frames belonging to the pyxidicycline (pcy) cluster with proposed function and 
closest homologue according to a blastp search against the nr (non-redundant protein sequences) protein database 
at NCBI 
Name Length [bp] proposed function 
closest annotated homologue – 
organism of origin 
Identity [%] and 
length of alignment 
[AA] 
Accession Nr. 
pcyA 1128 
precursor release from the 
acyl carrier protein 
acyl-CoA thioester hydrolase – 
multispecies 
27.7 / 361 WP_060519218 
pcyB 852 
polyketide cyclisation 
(B-ring cyclisation) 
polyketide cyclase - Streptomyces 
nogalater  
46.3 / 283 AAF01818 
pcyC 963 
polyketide cyclisation 
(A-ring cyclisation) 
polyketide cyclase – Streptomyces 
atratus 
32.9 / 325 WP_072488808 
pcyD 798 C9’ type ketoreductase 
ketoacyl reductase – Sorangium 
cellulosum 
69.1 / 259 WP_061624890 
pcyE 1281 
ketoacyl synthase KSα 
subunit 
3-oxoacyl-ACP synthase II – 
Dendrosporobacter quericolus 
56.0 / 425 SDL92203 
pcyF 1242 
ketoacyl synthase KSβ 
subunit (chain length factor) 
3-oxoacyl-ACP synthase II – Pelosinus 
sp. 
37.7 / 414 WP_038670561 
pcyG 237 acyl carrier protein 
acyl carrier protein – Terriglobus 
saanensis 
33.3 / 78 WP_013566858 
pcyH 372 
4’-phosphopanthenyl 
transferase 
holo-ACP synthase – Sorangium 
cellulosum 
61.5 / 122 WP_061624886 
pcyI 249 - 
hypothetical protein – Myxococcus 
fulvus 
37.9 / 66 WP_052771001 
pcyJ 2088 serine incorporation 
4-coumarate-CoA ligase family protein 
– Modestobater species 
37.3 / 542 WP_082557217 
pcyK 303 heterocyle formation 
muconolactone delta-isomerase – 
Acidovorax valerianellae 
32.5 / 83 SDC81513 
pcyL 717 heterocyle formation 
polyketide cyclase – Streptomyces 
species 
29.3 / 232 WP_053683051 
pcyM 378 - - - - 
pcyN 762 regulation 
MerR family transcriptional regulator – 
Myxococcus fulvus 
76.6 / 252 WP_074955963 
pcyO 2862 - 
glycosyl hydrolase family 31 – 
Mucilaginibacter paludis 
60.4 / 934 WP_008504858 
pcyP 720 - 
hypothetical protein  – 
Mucilaginibacter paludis 
32.2 / 233 WP_008504859 
pcyQ 816 export  
ABC transporter, ATP binding protein – 
Myxococcus xanthus 
93.0 / 272 ABF90137 
pcyR 783 export  
ABC transporter permease -  
Myxococcus xanthus 
90.7 / 259 WP_011552893 
pcyS 1035 export  
ABC transporter substrate binding 
protein -  Myxococcus xanthus 
85.4 / 343 WP_011552892 
pcyT 639 
putative self-resistance 
mechanism 
pentapeptide repeat containing 
protein – Myxococcus fulvus 
70.3 / 209 WP_046715273 
orf1 1431 - 
serine/threonine protein kinase – 
Myxococcus xanthus 
58.5 / 470 WP_011552901 
orf2 993 - hydrolase – Myxococcus fulvus 73.4 / 308 WP_013941483 
orf3 417 - 
elongation factor GreAB – Myxococcus 
hansupus 
86.2 / 138 WP_002640736 
orf4 714 - 
hypothetical protein  – Stigmatella 
aurantiaca 
30.3 / 238 WP_075011090 
orf5 1047 - 
hypothetical protein  – Archangium 
violaceum 
30.8 / 156 WP_043405726 
orf6 2163 - 
serine/threonine protein kinase – 
Archangium gephyra 
38.8 / 707 WP_047858246 
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orf7 375 - - - - 
orf8 1461 - 
dihydropyrimidine dehydrogenase 
subunit A – Myxococcus xanthus 
86.2 / 486 WP_011553928 
orf9 4566 - 
glutamate synthase large subunit  – 
Myxococcus virescens 
90.8 / 1520 SDF16482 
 
The native Pyxidicycline gene cluster will be accessible at GenBank under Accession number 
MH048639 upon publication. All plasmid maps will be provided upon request. 
S 2.2.4 Identification of KSα and KSβ in silico 
Both ketosynthase proteins PcyE and PcyF in this assembly line are predicted to be 3-oxoacyl-ACP 
synthase 2 proteins. Therefore, sequence alignment is done in order to find out which of the sequences 
acts as the KSα protein and which protein acts as the KSβ. These functions can be identified via NCBI 
protein blast as, contrary to the KSβ, it possesses all catalytically active residues (see Figure S 9 and Figure 
S 10). In the PcyF amino acid sequence the catalytically active cysteine residue is mutated to arginine 
rendering it catalytically inactive.[6] 
 
Figure S 9. Identification of the KSα protein on the gene pcyE via blast alignment against the non-redundant protein 
sequences collection (nr) on the NCBI protein server 
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Figure S 10. Identification of the KSβ protein on the gene pcyF via blast alignment against the non-redundant protein 
sequences collection (nr) on the NCBI protein server 
S 2.2.5 In silico analysis of the PcyJ Protein 
The PcyJ protein is responsible for amide bond formation between the polyketide intermediate of 
the pyxidicyline biosynthesis and serine to form the D ring in pyxidicycline A and B. Therefore the protein 
has to have acyl transfer activity to form an amide bond between serine and the polyketide precursor as 
well as hetero cyclisation activity. 
 
Figure S 11. NCBI conserved domain search hits in the PcyJ protein stating the di-domain nature of the protein as a 
AMP dependent synthetase/ligase – aromatase/cyclase fusion protein 
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Analysis of the PcyJ protein by NCBI conserved domain search [7] reveals an aromatase/cyclase 
domain (blue) putatively responsible for hetero cyclisation and an AMP-dependent synthetase and ligase 
function putatively responsible for amide bond formation. 
S 2.2.6 In silico assignment of the pyxidicyclines’ cyclase proteins 
During maturation of the pyxidicyclines there are several cyclase like proteins involved to form the 
tetracene quinone like core structure. In order to assign the first and second ring cyclases which was not 
possible by knockout experiments we relied on protein alignment via the MUSCLE [8] algorithm to group 
the cyclase proteins into groups. 
 
Figure S 12. Neigbour joining tree of the cyclases in the Pyxidicycline, Steffimycin and Oxytetracycline pathways based 
on MUSCLE alignment of the respective proteins 
As one can see, PcyC and PcyL have homology to the first ring cyclase proteins OxyK and StfQ while 
the PcyB cyclase has homology to the second ring cyclases OxyN and StfY.[9,10] The specialized heterocycle 
forming protein PcyJ forms an outgroup in this cyclase in silico comparison. As we could show by knockout 
experiments, PcyL and PcyJ are involved in the cyclisation of the fourth nitrogen containing ring (D ring) 
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and since the third ring closure is spontaneous in these tetracycline like scaffolds,[9] this experiment 
strongly suggests PcyB to be the second ring (B ring) cyclase while PcyC is the first ring (A ring) cyclase. 
 Isolation and characterization of the pyxidicyclines 
S 2.3.1 Bacterial fermentation procedures  
Cultures for UPLC/high-resolution LC-MS analysis were grown in 300 ml shake flasks containing 50 ml 
of culture medium inoculated with 1 ml of pre culture. After inoculation the medium was supplemented 
with 2 % of sterile XAD-16 adsorber resin (Sigma Aldrich) suspension in water. Mutant strains are 
supplemented with concentrations of the respective antibiotics at concentrations as follows: Kanamycin 
50 µg/ml, oxytetracyclin 12 µg/ml, ampicillin 100 µg/ml and apramycin 50 µg/ml. Pyxidicoccus fallax strain 
An d48 was grown in YM medium at 30 °C for 7-9 days using a orbitron shaker (Infors) at 160 rpm, likewise 
Myxococcus xanthus strain DK1622 was grown in CTT medium at 30°C for 5-7 days and Stigmatella 
aurantiaca DW4/3-1 was grown in TS-6 medium at 30°C for 11-14 days. Fermentation cultures of 
Pyxidicoccus fallax strain And48 pcyA :: pFPvan pcyA, pcyJ :: pFPtettn5 pcyJ used for isolation of the 
pyxidicyclines A and B were grown in 5 x 5 L shake flasks containing 2 L of YM medium each. Fermentation 
duration was 14 days post inoculation; inoculation was done with 50 ml of pre-culture and the medium 
was supplemented with 2 % of a sterile XAD-16 adsorber resin suspension in water. Fermentation cultures 
of Pyxidicoccus fallax strain And48 pcyA :: pSBtn5 pcyA used for isolation of the anthraquinone precursors 
anthraquinone 340, 324 and 296 were grown in 5x 5 L shake flasks containing 2 L of YM medium each. 
Fermentation duration was 10 days post inoculation; inoculation was done with 50 ml of pre-culture and 
the medium was supplemented with 2% of sterile XAD-16 adsorber resin suspension in water. 
S 2.3.2 Preparation of small scale bacterial extracts for UHPLC-HRMS analysis 
Pellet and cells were centrifuged at 6500 rcf in a 50 ml falcon centrifuge, the supernatant was 
decanted and the cell pellets were frozen at -20°C. The frozen cell pellet was transferred into a 100 ml 
erlenmeyer flask and a magnetic stirrer added. 50 ml of acetone (fluka analytical grade, redistilled in 
house) were added onto the pellet and the mixture was stirred for 60 minutes on a magnetic stirrer. The 
acetone extract was left to settle in order to sediment cell debris and XAD resin before a second extraction 
step. The supernatant was filtered with a 125 micron folded filter keeping cell pellet and XAD-16 resin in 
the Erlenmeyer flask for the second extraction step. The residual pellet and XAD-16 resin is extracted again 
with 30 ml of distilled acetone for 60 min on a magnetic stirrer and filtered through the same folded filter. 
The combined extracts are transferred into a 100 ml round bottom flask. The acetone was evaporated on 
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a rotary evaporator at 260 mbar and 40 °C water bath temperature. The residual water was evaporated at 
20 mbar until the residue in the flask was completely dry. The residue was taken up in 550 μl of methanol 
(Chromasolv HPLC grade) and transferred into a 1.5 ml Eppendorf tube. This tube was centrifuged at 21500 
rcf for 5 minutes to remove residual insolubilities such as salts, cell debris and XAD fragments. 
S 2.3.3 Standardized UPLC-MS and UPLC-MS² Conditions  
All measurements were performed on a Dionex Ultimate 3000 RSLC system using a Waters BEH C18 
column (50 x 2.1 mm, 1.7 µm) equipped with a Waters VanGuard BEH C18 1.7 µm guard column. Separation 
of 1 µl sample (Crude extract 1/5 dilutions in methanol, section S 3.2) was achieved by a linear gradient 
from (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µL/min and a column temperature of 
45 °C. Gradient conditions were as follows: 0 – 0.5 min, 5% B; 0.5 – 18.5 min, 5 – 95% B; 18.5 – 20.5 min, 
95% B; 20.5 – 21 min, 95 – 5% B; 21-22.5 min, 5% B. UV spectra were recorded by a DAD in the range from 
200 to 600 nm. The LC flow was split to 75 µL/min before entering the Bruker Daltonics maXis 4G hr-qToF 
mass spectrometer using the Apollo II ESI source.  Mass spectra were acquired in centroid mode ranging 
from 150 – 2500 m/z at a 2 Hz full scan rate. Mass spectrometry source parameters were set to 500V as 
end plate offset; 4000V as capillary voltage; nebulizer gas pressure 1 bar; dry gas flow of 5 l/min and a dry 
temperature of 200°C.  Ion transfer and quadrupole settings were set to Funnel RF 350 Vpp; Multipole RF 
400 Vpp as transfer settings and Ion energy of 5eV as well as a low mass cut of 300 m/z as Quadrupole 
settings. Collision cell was set to 5.0 eV and pre pulse storage time was set to 5 µs. Spectra acquisition rate 
was set to 2Hz. Calibration of the maXis4G qTOF spectrometer was achieved with sodium formate clusters 
before every injection to avoid mass drifts. All MS analyses were acquired in the presence of the lock 
masses C12H19F12N3O6P3, C18H19O6N3P3F2 and C24H19F36N3O6P3 which generate the [M+H]+ Ions of 
622.028960, 922.009798 and 1221.990638. The corresponding MS2 method operating in automatic 
precursor selection mode picks up the two most intense precursors per cycle, applies smart exclusion after 
five spectra and performs CID and MS/MS spectra acquisition time ramping. CID Energy was ramped from 
35 eV for 500 m/z to 45 eV for 1000 m/z and 60 eV for 2000 m/z. MS full scan acquisition rate was set to 
2Hz and MS/MS spectra acquisition rates were ramped from one to four Hz for precursor Ion intensities 
of 10kcts to 1000kcts. 
S 2.3.4 Statistical Data Treatment using Principal Component Analysis  
One issue encountered while trying to identify the secondary metabolites produced by the pcy 
biosynthetic gene cluster was that homologous recombination apparently also affected the host strain in 
ways not necessarily linked to the locus of homologous recombination. While the metabolome detectable 
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with LC-MS changed only minimally upon targeted gene cluster disruption, introduction of the promotor 
upstream to the pcyA gene lead to diverse changes in the metabolome (main text Figure 4). It was 
therefore crucial to apply a statistical filter using PCA in order to pinpoint peaks truly unique to the 
‘activation’ mutant and to discriminate those displaying only a fold change in abundance. To search for 
statistically relevant differences between the two pyxidicycline cluster inactivation mutants and the wild 
type as well as between the promotor exchange mutants and the inactivation mutants, 6 LC-HRMS 
measurements from extracts of three independent cultivations per bacterial strain are used for statistical 
data treatment. For preprocessing of MS data the molecular feature finder implemented in Bruker 
Compass Data Analysis 4.2 (Bruker, Bremen) was used with the compound detection parameters SN 
threshold 1; Correlation coefficient 0.9; minimum compound length 10 spectra and smoothing width of 3 
spectra. Bucketing was done with Bruker Compass Profile Analysis 2.1 (Bruker, Bremen) with advanced 
bucketing and window parameters of 30s and 15 ppm. Bucket value was log transformed to avoid under-
evaluating low intensity signals in the presence of high intensity signals [11]. The PCA t-Test function was 
used in order to separate medium derived MS features from the metabolome derived MS features, since 
the t-Test table that can be exported from Bruker Compass Profile Analysis 2.1 (Bruker, Bremen) contains 
information upon how many blanks and how many bacterial extracts contain said feature. 
S 2.3.5 Purification protocols of all pyxidicycline related compounds 
 Isolation of the anthraquinone precursors 296, 324 and 340 
The Pyxidicoccus fallax mutant strain Pyxidicoccus fallax And48 pcyA :: pSBtn5 pcyA is fermented in 
50 ml YM medium supplemented with Kanamycin 50 µg/ml as a seed culture flasks on an Orbiton shaker 
at 160 rpm and 30°C. After the culture reaches OD of 0.8 after 5 to 7 days of fermentation it is used to 
inoculate 6 x 2L YM Kanamycin 50 µg/ml medium supplemented with 2 % XAD-16 resin suspension in 
sterilized water in 6 x 5L baffled shake flasks on an Orbiton shaker at 160 rpm and 30°C. Fermentation is 
complete after 14 days. Cells and XAD-16 resin are harvested by centrifugation on a Beckmann Avanti J-
26 XP with the JLA 8.1 rotor at 6000 rcf. Combined resin and cells are extracted with 2 x 500 ml of technical 
grade methanol (Fluka) and 2 x 500 ml of technical grade acetone (Fluka). The extracts are combined and 
all solvent is evaporated on a rotary evaporator. Residue is taken up in 10 ml of analytical grade methanol 
(Fluka) for chromatographical separation. Purification  was  carried  out  on  a  Waters Autopurifier  
(Eschborn,  Germany)  high  pressure gradient system, equipped with 2545 binary gradient module, SFO 
system fluidics organizer, 2767  sample  manager and  a  2998  photodiode  array  detector  coupled  to  a  
3100  single quadrupole mass spectrometer operated in positive ion mode. Source and voltage settings 
for the MS were as follows: mass range, m/z 300 - 1000; scan duration, 1 s; points per Dalton, 4; capillary 
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voltage, 3.5 kV; cone voltage, 30 V; extractor voltage 3 V; RF lens, 0.1 V; source temperature 120 C, 
desolvation temperature, 250 C; desolvation gas flow, 400 L/hr; cone gas flow, 50 L/hr; ion counting 
threshold, 30. Autopurification is done by setting the fraction collection trigger masses 297.1, 325.1 and 
340.1 which correspond to the [M+H]+ ions of the anthraquinones. Separation was carried out on 
Phenomenex Kinetex Biphenyl 5 µm, 250 x 20 mm column using MeOH + 0.1 % FA as B and H2O + 0.1% FA 
as A with a flow rate of 25 ml/min. Separation is started with a plateau at 95% A for 2 minutes followed by 
a ramp to 32% A during 4 minutes and a ramp to 2% A during 30 minutes. The A content is kept at 5% A 
for 2 minutes. The A content is ramped back to starting conditions during 30 seconds and the column is re 
equilibrated for 5 minutes. Further purification is done using a Dionex Ultimate 3000 SDLC low pressure 
gradient system on a Phenomenex Luna C-18, 5µm 250x10mm  column with the eluents H2O + 0.1 % FA 
as A and MeOH + 0.1 % FA as B, a flow rate of 5 ml/min and a column thermostated at 30°C. The 
Anthraquinones are detected by UV absorption at 256 nm and 432 nm. The gradient that starts with a 
plateau at 95 % A for 2 minutes followed by a ramp to 59 % A during 6 minutes. Then A content is ramped 
to 30 % during 17 minutes and finally ramped to 5 % A during 1 minute. A content is kept at 5 % for 1 
minute and then ramped back to 95 % during 30 seconds. The column is reequilibrated at 95 % A for 5 
minutes. The pure compounds are subsequently dried by lyophilization. All three anthraquinones are 
obtained as dark yellow substances that possess slightly varying fluorescent yellow colors in solution 
depending on the solvent. Upon deprotonation, the color of all three compounds changes to dark red. The 
compounds are analyzed by LCUV and LC-HRMS before NMR spectra are acquired. 
 
Figure S 13. UV absorption spectra of the anthraquinone metabolites acquired with the Dionex Ultimate 3000 diode 
array detector during an LC run using H2O + 0.1% FA and ACN + 0.1% FA as eluents. 
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Figure S 14. LC-UV Chromatograms of the three isolated Anthraquinone metabolites for purity analysis by liquid 
chromatography 
 
Figure S 15. High resolution masses of anthraquinone 340,296 and 325 [M+H]+ in m/z units acquired on our maXis4G 
qTOF high resolution mass spectrometer 
 Isolation of Pyxidicycline A and B 
The Pyxidicoccus fallax mutant strain Pyxidicoccus fallax And48 pcyA :: pFPVan pcyA, pcyJ :: pFPtettn5 
pcyJ (An d48 pcy) is fermented in 50 ml YM medium supplemented with Kanamycin 50 µg/ml as a seed 
culture flasks on an Orbiton shaker at 160 rpm and 30°C. After the culture reaches OD of 0.8 after 5 to 7 
days of fermentation it is used to inoculate 6 x 2L YM Kanamycin 50 µg/ml medium supplemented with 2 
% XAD-16 resin suspension in sterilized water in 6 x 5L baffled shake flasks on an Orbiton shaker at 160 
rpm and 30°C. Simultaneously with inoculation the cultures are supplemented with 5mM Sodium vanillate 
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solution to induce pyxidicycline production. Fermentation is complete after 17 days. Cells and XAD-16 resin 
are harvested by centrifugation on a Beckmann Avanti J-26 XP with the JLA 8.1 rotor at 6000 rcf. Combined 
resin and cells are extracted with 2 x 500 ml of technical grade methanol (Fluka) and 2 x 500 ml of technical 
grade acetone (Fluka). The extracts are combined and all solvent is evaporated on a rotary evaporator. 
The residue is now partitioned between saturated brine and chloroform (2 extractions of 500 ml brine 
with 400 ml of chloroform) in a 2L separating funnel leading to close to complete transfer of the 
pyxidicyclines A and B into the chloroform phase. The chloroform phase is subsequently dried on a rotary 
evaporator. The residue is resuspended in 50 ml of analytical grade Acetonitrile and transferred 
completely into a 50 ml falcon tube (Sarstedt). After vigorous vortexing of the suspension the falcon tube 
is centrifuged for 15 min at 7800 rcf to pellet the pyxidicyclines that are close to insoluble in acetonitrile. 
The dark red residue is taken up in 1 ml of analytical grade formic acid (99 %, Sigma Aldrich) for 
chromatographic separation of pyxidicycline A and B. Purification is done using a Dionex Ultimate 3000 
SDLC low pressure gradient system on an Agilent Zorbax XDB-C8, 5µm 250x10mm column with the eluents 
H2O + 0.5% FA as A and MeOH + 0.5% FA as B, a flow rate of 5 ml/min and a column thermostated at 30°C. 
The pyxidicyclines are detected by UV absorption at 474 nm (pyxidicycline B) and 498 nm (pyxidicycline 
A). The pyxidicyclines are further purified with the gradient that starts with a plateau at 95% A for 2 
minutes followed by a ramp to 74% A during 3 minutes. Then A content is ramped to 56% during 32 
minutes and finally ramped to 5% A during 30 seconds. A content is kept stable at 5% for 1 minute and 
then ramped back to 95% A during 30 seconds. The column is reequilibrated at 95% A for 5 minutes. The 
pure compounds are subsequently dried by lyophilization and obtaines as the corresponding formate 
esters. The pyxidicyclines are obtained as dark red substances that possess slightly varying fluorescent 
orange colors in solution depending on the solvent. Upon deprotonation, the color of both pyxidicycline 
compounds changes to dark blue. In total 5mg of pyxidicycline A and 4 mg of pyxidicycline B are obtained 
from the fermentation culture as formate esters. It is worth noting that the actual theoretical yield of 
pyxidicyclines seems to be at least 50 % higher as on the one hand elution of the pyxidicyclines from the 
XAD-16 resin is incomplete and on the other hand peak shape issues with the compounds in reverse phase 
chromatography due to low insolubility in all tested LC solvents lead to low recovery rates after 
chromatographic separation. Both compounds are very soluble and stable in formic acid while being 
insoluble in most common organic solvents and instable in DMSO and DMF. 
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Figure S 16. UV absorption spectra of pyxidicycline A and B acquired with the Dionex Ultimate 3000 diode array 
detector during an LC run using H2O + 0.1% FA and ACN + 0.1% FA as eluents. 
 
Figure S 17. LCUV Chromatograms of the two Pyxidicyclines for purity analysis by liquid chromatography, the first 
peak belonging to the formate ester, the second to the free pyxidicyclines 
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Figure S 18. High resolution masses of pyxidicycline A and B [M+H]+ in m/z units as well as the corresponding formate 
esters acquired on our maXis4G qTOF high resolution mass spectrometer 
S 2.3.6 Crystallization parameters for the pyxidicycline A and B 
The pure pyxidicyclines A and B are taken up in a minimum of formic acid to an approximate mass 
concentration of 5 mg/ml and filled into a 2 ml glass vial. The solutions are sonicated for a few minutes in 
an ultrasound bath until no visible residues remain. The solutions are subsequently placed into the 
refrigerator with an unscrewed cap. After two days one can observe crystallization of pyxidicycline B as 
dark red needle shaped crystals. After one week one starts to observe crystallization of pyxidicycline A as 
dark red needle shaped crystals.  
S 2.3.7 Crystal structure parameters obtained through single-crystal X-ray diffraction 
experiments 
 The compounds crystallized from formic acid solution as formic acid esters that formed needle 
shaped dark red crystals. The data were collected at low temperature on a BrukerAXS X8Apex CCD 
diffractometer operating with graphite-monochromatized Mo Kα radiation. Frames of 0.5° oscillation were 
exposed; deriving reflections in the θ range of 2 to 27° with a completeness of ~99%. Structure solving and 
full least-squares refinement with anisotropic thermal parameters of all non-hydrogen atoms were 
performed using SHELX [12]. Crystal structure parameters for pyxidicycline B: orthorhombic, Pca21, 
a=7.0231(8) b=17.534(2) c=14.682(2)Å ; and for pyxidicycline A: triclinic, P-1, a=7.090(1) b=7.910(2) 
17.330(3)Å, α=89.56(1) β=84.80(1), γ=74.66(1). All relevant data concerning the crystal structures can be 
found in this section. Crystallographic data for the structure have been deposited with the Cambridge 
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Crystallographic Data Centre, CCDC, 12 Union Road, Cambridge CB21EZ, UK. Copies of the data can be 
obtained free of charge on quoting the depository number CCDC 1831467 and CCDC 1831468.  
www.ccdc.cam.ac.uk/data_request/cif   
able S 7Table S 8Table S 9Table S 10Table S 11Table S 12Table S 13Table S 14Table S 15Table S 16 
S 2.3.8 NMR based structure elucidation of the anthraquinone precursors 
The chemical structures of the anthraquinone secondary metabolite precursors were determined via 
multidimensional NMR analysis. 1H NMR, 13C NMR and 2D spectra were recorded at 700 MHz (1H)/175 
MHz (13C) conducting an Ascend 700 spectrometer using a cryogenically cooled triple resonance probe 
(Bruker Biospin, Rheinstetten, Germany). Samples were dissolved in DMSO-d6, Acetone-d6 and 
Chrloroform-d. Chemical shifts are reported in ppm relative to TMS, the solvent was used as the internal 
standard. NMR data are presented in tabulated form by ascending 13C shifts. 
 
Figure S 19. Structure formula of anthraquinone 296 
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Table S 17. Tabulated NMR data of the anthraquinone 296 in DMSO-d6  
1H J, Multiplicity, Nb. of H 13C H-H Cosy HMBC ROESY 
2.38 s, 3H 20.5 7.66 114.3; 122.5; 136.4; 105.8; 159.6; 203.2 7.66 
2.59 s, 3H 32.1 7.66 203.1; 136.4 - 
- - 114.3 - - - 
- - 116.0 - - - 
7.82 1.15; 7.45, dd, 2H 120.5 7.30; 7.69; 7.66 116.0; 125.2; 181.6 - 
7.66 7.45; 8.48, dd, 2H 137.6 2.38, 7.82 114.3; 136.5; 181.6; 203.1; 20.5 2.38 
7.3 1.2; 8.48, dd, 2H 125.2 7.69, 7.82 116.0; 120.6; 136.4 - 
- - 133.3 - - - 
- - 133.6 - - - 
- - 136.4 - - - 
7.69 s, 1H 122.5 7.30; 7.69; 7.82 162.8; 133.6 - 
- - 145.8 - - - 
- - 159.6 - - - 
- - 162.8 - - - 
- - 181.6 - - - 
- - 192.8 - - - 
- - 203.1 - - - 
11.96 s, 1H - 7.69 116.0; 125.2; 162.8; 120.0; 192.8 - 
12.34 s, 1H - 7.66; 2.59 114.3; 136.4; 159.6; 20.5; 192.8 - 
2D NMR data shown is in good agreement with published structure of protetrone [13]. 
 
Figure S 20. Structure formula of anthraquinone 340 
Table S 18.  Tabulated NMR data of the anthraquinone 340 in Acetone-d6 
1H J, Multiplicity, Nb. of H 13C 
2.61 s, 3H 31.7 
3.93 s, 2H 38.7 
7.82 1.4; 7.0, dd, 1H 120.2 
7.79 7.0; 8.0,dd, 1H 122.9 
7.4 1.0;8.0, dd, 1H 125.2 
7.87 s, 1H 138.4 
Acquired NMR data in good agreement with NMR data published by Zhang et al. [14]. 
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Figure S 21. Structure formula of anthraquinone 324 
Table S 19. Tabulated NMR data of the anthraquinone 324 in Chloroform-d 
1H J, Multiplicity, Nb. of H 13C H-H Cosy HMBC 
1.66 d 20.8 5.98 73.7, 130.2 
3.86 + 3.82 2 x s 34.6 7.63 118.8, 130.4, 139.3, 167.9 
5.98 6.90, q, 1H 73.7 1.66, 3.82 20.7, 130.4, 139.3, 157.6, 167.9 
-  114.6   
-  115.6   
7.63 s, 1H 118.6 3.86, 3.82 34.6, 114.6, 130.2,181.5,197.2 
7.83 0.9; 8.5, dd, 1H 120.4 7.69,7.31 115.6, 125,4, 162.8, 181.5,192.7 
7.31 1; 8.5, dd, 1H 125.1 7.69, 7.83 115.6, 120.4, 162.8, 192.7 
-  130.2   
-  133.2   
7.69 7.4; 8.5, dd, 1H 137.6 7.31, 7.83,11.94 115.6, 133.2, 162.8, 181.5 
- - 139.3 - - 
- - 157.6 - - 
- - 167.9 - - 
- - 162.8 - - 
- - 181.5 - - 
- - 192.7 - - 
- - 197.2 - - 
11.94 s, 1H - 7.69 115.6, 125.0, 137.7, 162.8, 192.7 
12.46 s, 1H - - 114.6, 130.2, 139.3, 157.6, 192.7 
2D NMR data obtained in from anthraquinone 324 in good agreement with published NMR data for 
ekatetrone [15]. 
S 2.3.9 Tandem MS based structure assignment of anthraquinone 340 
Due to poor stability of anthraquinone 340 in most NMR solvents, which led to decarboxylation of 
the compound to anthraquinone 296 via decarboxylation, only a 1H and HSQC spectrum were recorded 
for this compound. To ascertain that the seen anthraquinone possesses the proposed structure, the first 
fragments of the LC-MS² spectrum recorded on the HPLC coupled maXis 4G qTOF spectrometer (section S 
3.3) are interpreted. 
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Figure S 22. MS2 spectrum of anthraquinone 340 with proposed gas phase dissociation reactions acquired during an 
LC-MS2 run of Pyxidicoccus fallax And48 pcyA::pSBtn5 pcyA extract on the HPLC coupled maXis 4G qTOF spectrometer 
One can clearly see the MS2 fragments fitting the proposed structure that is also in accord with the 
reference NMR data. Furthermore, as this scaffold would indeed favor decarboxylation in solution to 
anthraquinone 296 as it is observed during longer NMR experiments one can safely assume the 
anthraquinone 340 to have the presented structure. 
S 2.3.10   Tandem MS based assignment of the incorporated deuterium atoms into 
Pyxidicycline A 
10 mmol 1,2 Ethanolamine 13C2, 2,2-Glycine-d2 and 2,3,3-serine-d3 are fed into a 25 ml CTT medium 
culture of M. xanthus attB :: attP pClY pyxidicycline cluster in order to observe isotopic labelling of the 
pyxidicyclines. Extracts were prepared according to standard protocol (section S 3.2) and analyzed via 
standardized UPLC-MS and UPLC-MS2 (section S 3.3). Only feeding of 3,3,2-serine-d3 into M. xanthus 
DK1622 attB::attP pClY pyxidicycline cluster reveals strong labelling of the pyxidicyclines. To prove the 
incorporation into the side chain of the pyxidicyclines as it was hypothesized in the biosynthesis proposal 
backed up with labelling experiments the labelled compound is subjected to tandem MS measurements. 
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Figure S 23. LC-MS2 CID-fragmentation pattern of d2 labelled pyxidicycline A from M. xanthus DK1622 attB :: attP pClY 
pyxidicycline with proposed gas phase reaction acquired on the HPLC coupled maXis 4G qTOF spectrometer 
As the molecule fragment with the mass of 322.0715 Daltons lost the deuterium atoms as visible by 
the isotope pattern one can assume that both deuterium atoms are present on this 2-hydroxyethyl side 
chain. This fits well with the molecule’s structure as one would assume the linear 2-hydroxyethyl side chain 
to be the most labile part in CID based MS² experiments that likely fragments according to the gas phase 
reactions proposed in Figure S 23. One can therefore experimentally prove the incorporation of serine into 
the structure. 
S 2.3.11  NMR based structure elucidation of the pyxidicyclines 
As the pyxidicyclines are only soluble in DMSO and DMF that both unfortunately lead to degradation 
of the compound over time, NMR data is acquired in formic acid-d2. The pyxidicyclines readily and 
reversibly form formate esters that are soluble in formic acid. 1H NMR, 13C NMR and 2D spectra were 
recorded at 700 MHz (1H)/175 MHz (13C) conducting an Ascend 700 spectrometer using a cryogenically 
cooled triple resonance probe (Bruker Biospin, Rheinstetten, Germany). Samples were dissolved in formic 
acid-d2 Chemical shifts are reported in ppm relative to TMS, the solvent was used as the internal standard. 
NMR reference information for formic acid is taken from Roy Hoffmann.[16] Carbon numbering for NMR 
signal assignment purposes is done in a biosynthetic logic meaning that the carbon first integrated into 
the structure obtains the first number. 
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Figure S 24. Carbon numbering for NMR assignment purposes for pyxidicycline A formate ester 
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Table S 20. Tabulated NMR data of pyxidicycline A formate ester acquired in formic acid-d2. Carbon numbering is 
done according to the scheme in Figure S 24. 
C Number 1H J, Multiplicity, Nb of H 13C H-H Cosy HMBC 
1 3.57 s, 3H 21.4 7.56 108.5, 116.2, 157.5, 168.8 
2 - - 125.5 - - 
3 - - 116.2 - - 
4 - - 168.8 - - 
5 - - 109.3 - - 
6 - - 190.6 - - 
7 - - 116 - - 
8 - - 162.7 - - 
9 7.41 n.d.; 8.3, dd, 1H 125.7 7.81, 7.86 116.0, 120.6, 162.0 
10 7.81 7.3; 8.3, dd, 1H 137.8 7.41,7.86 116.0, 133.6, 162.0 
11 7.86 n.d.; 7.3, dd, 1H 120.6 7.41, 7.81 116.0, 125.7, 137.8,  182.2, 190.6  
12 - - 133.6 - - 
13 - - 182.2 - - 
14 - - 126.6 - - 
15 8.05 s, 1H 118.4 3.57, 7.56 
108.5, 109.3, 116.2, 145.5, 182.2, 
190.6 
16 - - 145.4 - - 
17 7.56 s, 1H 108.5 8.05 
116.2, 125.5, 126.6 
157.5,  162.5, 168.8 
18 - - 157.5 - - 
19 5.14 5.30, t, 2H 47.4 4.81 60.8, 157.5, 162.5 
20 4.81 5.30, t ,2H 60.8 5.14 47.4,162.5,163.3 
FA C21 - - 163.3 - - 
 
 
 
Figure S 25. Carbon numbering for NMR assignment purposes for pyxidicycline B formate ester 
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Table S 21. Tabulated NMR data of pyxidicycline B formate ester acquired in formic acid-d2. Carbon numbering is done 
according to the scheme in Figure S 25. 
C Number 1H J, Multiplicity, Nb of H 13C H-H Cosy HMBC ROESY 
1 3.23 s, 3H 19.1 7.38 113.2, 114.8, 142.2, 159.8, 164.5, 186.4 4.74, 4.65 
2 - - 159.8 - - - 
3 - - 113.2 - - - 
4 - - 186.4 - - - 
5 - - 124.1 - - - 
6 - - 165.1 - - - 
7 - - 108.7 - - - 
8 - - 157.2 - - - 
9 7.1 7.9, d, 1H 115.8 7.54, 7.64 116.0, 122.7, 157.2 - 
10 7.64 7.9; 8.0, dd, 1H 133.5 7.10, 7.54 115.8, 122.7, 137.2, 157.2 - 
11 7.54 8.0, d, 1H 122.7 7.10, 7.64 115.8, 123.0, 137.2, 157.2, 165.1 - 
12 - - 137.2 - - - 
13 8.15 s, 1H 123 7.53 
108.7, 115.8, 122.7, 124,1, 137.2, 
157.2, 165.1, 181.3, 186.4 
- 
14 - - n.d. - - - 
15 - - 181.2 - - - 
16 - - 142.2 - - - 
17 7.38 s, 1H 114.8 3.23 113.2, 142.2, 164.5, 181.6 - 
18 - - 164.5 - - - 
19 4.74 5.52, t, 2H 44.5 4.65 61.1, 159.8, 164.5 3.23 
20 4.65 5.52, t, 2H 61.2 4.74 44.5, 163.0 3.23 
FA C21 - - 163 - - - 
S 2.3.12  Comparative evaluation of the different strains pyxidicycline and pyxidicycline 
precursor production potential 
Table S 22 shows the relative and absolute peak areas measured on the UHPLC coupled maXis 4G 
spectrometer system by injection of 0.5 µL of crude extract of the respective species grown and extracted 
according to standard protocol described in section 3.1 to 3.3. The last four columns contain quotients to 
illustrate the effect of expression in different hosts or gene deletions upon pyxidicycline expression. 
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Table S 22. Comparative peak area analysis measured in [cts x min] of the pyxidicyclines and its precursors in all 
generated producer strains measured by integration the [M+H]+ EIC in the standard LC-MS chromatogram setting 
(section S 3.3). The two anthraquinone metabolites are measured as LC-MS EIC peak area at 341.06 [M+H]+, 325.07 
[M+H]+  and 297.075 [M+H]+, the two pyxidicyclines are measured as LCMS EIC peak areas at 366.10 [M+H]+.  
Producer strain 
Area 
Pyx A 
Area 
Pyx B 
Area 
AQ 340 
Area 
AQ 324 
Area 
AQ 296 
Area 
Pyx A / 
Area 
AQ 
340 
Area 
Pyx B / 
Area 
AQ 
340 
Area 
Pyx A / 
Area 
AQ 
296 
Area 
Pyx B / 
Area 
AQ 
296 
Area Pyx 
A / Area 
Pyxi B 
P. fallax And48 
pcyA :: pSBtn5 pcyA 
- - 1135792 119418 226789 - - - - - 
P. fallax And48 
pcyA :: pFPVan pcyA 
- - 129491 13364 151052 - - - - - 
P. fallax And48 
pcyA :: pFPVan pcyA; 
pcyJ :: pFPtettn5 pcyJ 
1905806 1859927 15991 - 1119844 119.18 116.31 1.70 1.66 1.02 
M. xanthus DK1622 
attB :: attP Pyxidicycline Cluster 
1157822 2240664 126015 - 540949 9.19 17.78 2.14 4.14 0.52 
M. xanthus DK1622 
attB :: attP Pyxidicycline Cluster 
Δ pcyJ 
- - 1173697 - 1580399 - - - - - 
M. xanthus DK1622 
attB :: attP Pyxidicycline Cluster 
Δ pcyK 
170034 137566 1156196 - 2065290 0.15 0.12 0.08 0.07 1.24 
M. xanthus DK1622 
attB :: attP Pyxidicycline Cluster 
Δ pcyL 
153049 132066 1202235 - 2301855 0.13 0.11 0.07 0.06 1.16 
M. xanthus DK1622 
attB :: attP Pyxidicycline Cluster 
T7A1 pcyO 
1400366 3180800 365870 - 399734 3.83 8.69 3.50 7.96 0.44 
S. aurantiaca DW 4/3-1 
attB :: attP Pyxidicycline Cluster 
75069 290585 102942 - 75896 0.73 2.82 1.36 3.83 0.26 
 Bioactivity profiling of the anthraquinones and its precursors 
S 2.4.1 Cell based biological assays to valuate MIC values on bacteria and cancer cell 
lines 
 Antimicrobial Assay  
 All microorganisms were handled according to standard procedures and were obtained from the 
German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung für Mikroorganismen und 
Zellkulturen, DSMZ) or were part of our internal strain collection. For microdilution assays, overnight 
cultures of Gram-positive bacteria in Müller-Hinton broth (0.2 % (w/v) beef infusion, 0.15 % (w/v) corn 
starch, 1.75 % (w/v) casein peptone; pH 7.4) were diluted in the growth medium to achieve a final 
inoculum of ca. 106 cfu ml-1. Serial dilutions of pyxidicyclines and the anthraquinone precursors were 
prepared from freshly prepared DMSO or Methanol stocks in sterile 96-well plates. The cell suspension 
was added and microorganisms were grown on a microplate shaker (750 rpm, 37°C and 16 h). Growth 
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inhibition was assessed by visual inspection and given MIC (minimum inhibitory concentration) values are 
the lowest concentration of antibiotic at which no visible growth was observed. 
 Cytotoxic Activity 
Cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (Deutsche 
Sammlung für Mikroorganismen und Zellkulturen, DSMZ) or were part of our internal collection and were 
cultured under conditions recommended by the depositor. Cells were seeded at 6 x 103 cells per well of 
96-well plates in 180 µl complete medium and treated with pyxidicyclines in serial dilution after 2 h of 
equilibration. Each compound was tested in duplicate as well as the internal solvent control. After 5 d 
incubation, 20 µl of 5 mg ml-1 MTT (thiazolyl blue tetrazolium bromide) in PBS was added per well and it 
was further incubated for 2 h at 37°C. The medium was discarded and cells were washed with 100 µl PBS 
before adding 100 µl 2-propanol/10 N HCl (250:1) in order to dissolve formazan granules. The absorbance 
at 570 nm was measured using a microplate reader (Tecan Infinite M200Pro), and cell viability was 
expressed as percentage relative to the respective methanol control. IC50 values were determined by 
sigmoidal curve fitting. 
S 2.4.2 Topoisomerase inhibition assays performed to determine the target of the 
pyxidicyclines 
All topoisomerase related inhibition assays were performed using topoisomerase inhibition 
evaluation kits for E. coli topoisomerase II, E. coli topoisomerase IV and human topoisomerase I supplied 
by Inspiralis (Inspiralis ltd., Norwich, U.K.). The kits were used according to the manuals. All compounds 
were tested as freshly prepared DMSO solutions. Pyxidicyclines were assayed to be stable in DMSO for 
about 12 hours. Topoisomerase inhibition assays were evaluated by agarose gel electrophoresis using 0.8 
% agarose gels in 1x TAE buffer. Total volume of the assay reaction was 30 µL. All assays are carried out in 
a 96 well micro titer plate. 
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Figure S 26. E. coli DNA gyrase inhibition assay, positive control is 0.5% DMSO, negative control is assay without 
enzyme; Ciprofloxacin, pyxidicycline A and pyxidicycline B are supplied in DMSO to a total concentration of 0.5% DMSO 
and the stated end concentrations in the assay 
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Figure S 27. E. coli DNA topoisomerase IV inhibition assay, positive control is 0.5% DMSO, negative control is assay 
without enzyme; Ciprofloxacin, pyxidicycline A and pyxidicycline B are supplied in DMSO to a total concentration of 
0.5% DMSO and the stated end concentrations in the assay 
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Figure S 28. Human DNA topoisomerase I inhibition assay, positive control is 0.5% DMSO, negative control is assay 
without enzyme, pyxidicycline A and pyxidicycline B are supplied in DMSO to a total concentration of 0.5% DMSO and 
the stated end concentrations in the assay 
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 Abstract 
This study reports the uncovering of new myxobacterial natural products through comprehensive 
analysis of the Myxococcus fulvus secondary metabolome. Statistics-based mining of mass spectrometry 
data paved the way for full structure elucidation of two new secondary metabolites named fulvuthiacene 
A and B, and investigation of the underlying biosynthetic pathway revealed an evolutionary link between 
the fulvuthiacene hybrid polyketide synthase (PKS) and non-ribosomal peptide synthetase (NRPS) gene 
cluster and the related myxothiazol and melithiazol assembly lines. Detailed characterization of the post-
PKS modification enzyme cascade responsible for the fulvuthiacenes’ terminal β-methoxy-methylacrylate 
moiety was pursued by heterologous expression of these enzymes in the myxothiazol producer S. 
aurantiaca DW4/3-1. The discovery of fulvuthiacenes provides new insights into the overall structure-
activity relationship picture for the β-methoxyacrylate class of respiratory chain inhibitors and might thus 
serve as starting point for the development of next-generation β-methoxymethacrylate fungicides. 
 Introduction 
Natural products discovery from microbes is currently undergoing a paradigm change, as genomics 
continues to reveal an impressive genome-encoded capacity for the production of secondary metabolites, 
outweighing the numbers of known compounds for many species. In parallel advances in analytical 
methods and instrumentation allow previously unaccomplished insights into the depth of microbial 
secondary metabolomes.[1] These developments in turn demand for improved data treatment techniques 
and new data mining approaches in order to transform the steadily increasing genomic and metabolomic 
data collections into the true chemical and biological characterization of novel natural products. Whereas 
screening campaigns in the past mainly uncovered compounds produced in large amounts or featuring 
abundant UV and/or mass spectrometry (MS) signals, there is now an urgent need for enabling methods 
to highlight also lower-abundance secondary metabolites including those that lack prominent analytical 
properties. Evidently, production titer or ease of detection is no a priori indicator for the value of newly 
discovered compounds in terms of structural novelty or biological activity. Thus, to overcome this 
conceptual bias, a number of studies aimed at establishing improved or alternative methods to mine the 
‘hidden’ components of compound-rich microbial metabolomes have been conducted recently.[2–5] The 
approaches used can be roughly categorized as “gene-to-compound” or “compound first”, whereas these 
genome-mining techniques are often paired with mass spectrometry workflows based on comprehensive 
metabolite profiling in order to highlight compounds of interest.[5,6] Nevertheless, a staggering discrepancy 
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remains for many microbes between the characterized secondary metabolome and the potential for 
secondary metabolite production as predicted by genome-based analysis, routinely accessible through 
bioinformatics tools such as antiSMASH.[7–9] In this study we describe an analytical procedure to uncover 
new secondary metabolites from myxobacteria, which are often masked in the complex bacterial extracts 
due to low productivity, or represented by low-intensity MS signals. Key features of the devised workflow 
include improved fragmentation coverage for such inconspicuous analytes in tandem-MS measurements 
through statistics-based filtering of relevant MS signals attributable to bacterial metabolism. This is 
performed prior to the evaluation of candidate compounds in terms of structural similarity through 
spectral networking.[2,3,10] Application of our method to Myxococcus fulvus MCy9280 revealed the 
fulvuthiacenes as a new family of secondary metabolites characterized by an intriguing terminal β-
methoxy-methylacrylate moiety. In addition, following the identification of the fulvuthiacene biosynthesis 
gene cluster we complemented our compound discovery with a detailed investigation of the underlying 
biochemistry. 
 Results and Discussion 
Myxobacteria frequently expose a striking discrepancy between the number of biosynthetic gene 
clusters detectable in their genomes and the number of known secondary metabolites, a finding well 
exemplified by M. fulvus MCy9280.[8] Previously, only stipiamide (phenalamide) and rhizopodin were 
detected from MCy9280 although the strains’ genome encodes more than 20 NRPS, PKS or NRPS-PKS 
hybrid pathways.[8,11] This strain was thus considered a worthy subject for our endeavors to reduce the 
gap between genome-deduced potential and secondary metabolite ‘reality’ through a MS-based 
secondary metabolite identification workflow. 
3.3.1 Statistics-based metabolome mining to reveal secondary metabolite families 
 Microbial secondary metabolites often appear as families of multiple derivatives produced by the 
same biosynthetic pathway, as it is seen e.g. for myxothiazols and melithiazols - just like with most other 
natural product classes.[12,13] If these derivatives share the same backbone structure with slightly different 
decorations, one can presume the presence of novel secondary metabolites by observation of grouping 
patterns during similarity-driven clustering of tandem mass spectrometry (MS²) spectra acquired from a 
bacterial crude extract. In recent years, different methods to cluster mass spectra according to similarity 
such as spectral networking, fingerprinting and in silico fragmentation methods have been introduced, 
where particularly the former has been already used for the disclosure of novel secondary metabolite 
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scaffolds.[3,4,14] These methods are typically applied to untargeted MS² data. Nevertheless, this common 
practice comes with severe limitations.[15]  Since biological samples such as bacterial extracts often contain 
abundant medium derived MS signals, picking relevant features for MS² fragmentation using intensity 
based automatic precursor selection is not sufficient. Therefore, as a preselection step to optimize the 
acquisition for a maximum number of meaningful MS² spectra with regard to the subsequent search for 
secondary metabolite families, we intended to create precursor lists that selectively contain mass 
spectrometric features related to compounds produced by the myxobacterium. To account for this 
requirement, the myxobacterium Myxococcus fulvus MCy9280 investigated in this work was grown in 
triplicates in VYGS medium and bacterial extracts as well as triplicates of VYGS medium “blanks” were 
prepared according to a standardized protocol (section S 3). Both sets of extracts were analyzed twice with 
an ultra-performance liquid chromatography (UPLC) coupled high-resolution time of flight (hrToF) 
spectrometer in order to obtain a total of twelve LC-MS data sets (section S 3). These data sets were further 
processed by molecular feature detection and subjected to statistical filtering through principal 
component analysis (PCA), which allows for differentiation between the approximate bacterial 
metabolome and media compounds. The tabulated data generated from this secondary metabolome 
profile analysis were subsequently processed to retain only those molecular features occurring in all 
replicate bacterial extracts but in none of the blank extracts, provided that they exceed a precursor ion 
intensity threshold. This double filtering procedure ensures that precursor ions selected for MS² 
fragmentation are associated with the myxobacterial bacterial metabolome.[2] At the same time, candidate 
signal intensity offers a realistic chance for producing meaningful MS² data. The set of candidate features 
obtained by this method was transferred to a scheduled precursor list (SPL) for targeted MS² experiments 
that specifically cover the supposable myxobacterial metabolome, leaving out medium-derived MS signals. 
The resulting scheduled precursor list-based MS² chromatograms were then fed into Global Natural 
Products Social molecular networking (GNPS) (section S 3).[3] The resulting spectral networks were 
visualized with cytoscape and all single nodes possessing no spectral network neighbors were removed 
(Figure 1, section S 3) in line with the presented rationale that secondary metabolites mostly occur as 
compound families. In principle, spectral networking of MS²  data using automatic precursor selection 
(auto-MS²) already shows the basic capacity of the workflow to highlight novel secondary metabolite 
scaffolds from myxobacteria (Figure 1, section S 3). However, the biggest spectral network obtained from 
that data contains mainly medium-derived peptides (section S 3.1). Thus, a significant amount of auto-MS² 
spectra acquisition time is unnecessarily dedicated to recording medium-related MS² spectra, whilst 
missing co-eluting secondary metabolites. 
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Figure 1. LC-MS² data acquisition, principal component (PC) based MS feature discrimination workflow and 
comparison between the spectral networks obtained from automatic precursor selection MS² (lower right) and SPL-
derived MS² precursor selection (lower left). 
Furthermore, the auto-MS² setting makes it impossible to discern medium derived molecular 
features, which are regarded as not interesting, from the molecular features representing the bacterial 
metabolome. Consequently, data-independent MS² acquisition is inherently suboptimal. Nevertheless, in 
the case of MCy9280 extracts, this approach reveals distinct spectral networks, like the example spanning 
four MS² spectra highlighted in Figure 1 (lower right). In order to ensure that this networking cluster was 
not constructed from medium derived MS signals, specified precursor list derived MS² data were acquired 
and clustered accordingly. The previously highlighted spectral network is still present, indicating that it is 
indeed composed of bacterial secondary metabolite features, but importantly the second version of this 
network comprised significantly more precursor ions (Figure 1 lower left, section S 3). This finding is readily 
explained by the specified precursor list MS²  method, which is able to pick precursors of lower intensity 
that are missed in the automatic precursor selection approach. The observed difference also confirms that 
metabolome-associated features do often exhibit lower intensity and would thus be systematically 
disregarded by automatic precursor selection, because of co-eluting higher-intensity matrix features in the 
LC-MS run.[2] Manual inspection of the precursors forming the target spectral network cluster above 
revealed the candidate compounds in Table 1, whereas it is worth noting that multiple features in the 
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spectral network (Figure 1, section S 3) may represent the same compound.  The entity later characterized 
as fulvuthiacene A (1) for example is responsible for precursor ions 382.197 [M+H]+ and 350.157 [M-
MeOH+H]+ whose MS² spectra obviously cluster. This explains the discrepancy between the size of the 
molecular network in Figure 1 and the number of found fulvuthiacene derivatives in Table 1. 
Table 1. Members of the new fulvuthiacene compound family detected through MS² analysis in this study. 
 
Name Rt [min] m/z [M+H]+ calcd. sum formula 
fulvuthiacene A (1) 14.3 382.197 C20H31NO4S 
fulvuthiacene B (2) 15.9 410.236 C22H35NO4S 
fulvuthiacene C (3) 17.2 438.267 C24H39NO4S 
desmethyl-fulvuthiacene A (6) 12.3 368.189 C19H29NO4S 
desmethyl-fulvuthiacene B (7) 14.0 396.221 C21H33NO4S 
prefulvuthiacene A (4) 11.3 367.205 C19H30N2O3S 
prefulvuthiacene B (5) 13.2 395.236 C21H34N2O3S 
3.3.2 Structure elucidation 
 The predicted sum formulae (Table 1) as well as a methanol loss as an in-source fragmentation 
reaction observed with all members of the highlighted spectral network suggested these molecular 
features to represent a new class of myxobacterial secondary metabolites. We therefore set out to isolate 
these compounds from a 12-liter fermentation of MCy9280 in VYGS medium. Compounds corresponding 
to the target masses of 382.197 and 410.236 [M+H]+ were purified by a series of liquid-liquid extractions 
followed by HPLC separation. The two compounds fulvuthiacene A (1) and fulvuthiacene B (2) were 
obtained as white solids and subsequently structurally elucidated using NMR data (section S 4). Whereas 
the yield of additional minor derivatives of the fulvuthiacenes was by far not sufficient to allow structure 
elucidation by NMR experiments, we propose the structure of fulvuthiacene C (3) based on the MS² 
fragmentation patterns (Figure 2). Compounds 1 and 2, which were structurally elucidated using 
multidimensional NMR spectroscopy, fragment similarly to the putative precursor ion of 3. Furthermore, 
the three largest and most intense product ions are shifted by the mass difference of C2H4, which is 
indicative of an additional C2H4 unit in a fatty acyl side chain.  
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Figure 2. Structures of fulvuthiacenes A (1) and B (2) assigned by NMR and fulvuthiacene C (3) assigned by MS² spectra 
comparison. The fragmentation patterns show the [M - 2MeOH + H]+ ions (A), [M - 3MeOH + H]+ ions (B), [M - 3MeOH 
- CO + H]+ ions (C) and a C11H11O2S+ product ion with an m/z ratio of 207.047 Da that is always observed for the 
fulvuthiacenes. 
This additional mass shift is equally seen between 2 and the putatively identified 3, indicating again 
the observed mass shift difference of exactly 28.031 - which represents C2H4 - very likely to stem from the 
incorporation of an additional malonyl-CoA during biosynthesis of the side chain. Additionally, all three 
structures show a fragment ion with an exact mass of 207.048, which corresponds to C11H11O2S (Figure 2). 
Although the exact structure of this fragment remains elusive, the fact that it contains sulfur and two 
oxygen atoms proves its origin from the conserved central part of the scaffold. The proposed structure of 
the putatively identified 3 (Figure 2) also agrees with biosynthetic considerations (Figure 3). The other MS² 
spectra clustered in the spectral network of the fulvuthiacenes are likely biosynthesis intermediates and 
thus assigned to putative structures according to the biosynthesis scheme, also taking into account 
enzymatic steps responsible for post assembly line modifications (Figure 3). Unfortunately, these minor 
derivatives are produced in minute amounts rendering confirmation by NMR spectroscopy impossible. 
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3.3.3 Fulvuthiacene biosynthesis 
 With the new fulvuthiacene structure at hand, we hypothesized this compound family to be 
produced by a modular type 1 polyketide synthase (PKS) non-ribosomal peptide synthetase (NRPS) hybrid 
pathway. To elucidate the biosynthetic origin of these compounds, genomic DNA of the strain MCy9280 
was sequenced and annotated by antiSMASH to predict secondary metabolite biosynthesis pathways 
encoded in the genome.[7] A candidate biosynthetic gene cluster (BGC) was identified, which can plausibly 
encode the fulvuthiacene assembly line according to retro-biosynthetic reasoning. As this putative BGC 
sequence contained two gaps, these gaps were PCR-amplified, subcloned and resequenced. The cluster 
was then assembled in full and biosynthetic domains were annotated. The fta gene cluster shares 
significant similarity on protein level to the myxothiazol and melithiazol assembly lines, but there are 
several important differences (Figure 7, section S 2, GenBank accession number: MH069655).[16,17]  
Figure 3. Gene cluster organization and biosynthesis proposal for the fulvuthiacenes. NRPS and PKS assembly line 
genes as blue arrows; tailoring enzyme genes as light green arrows, proteins as light green balls; methionine salvage 
pathway genes  as orange arrows, proteins as orange balls; PKS domains (red), NRPS domains (blue), inactive domains 
(gray), thioesterase (TE)(yellow); ACP acyl carrier protein; AT acyl transferase; A adenylation domain ; C condentation 
domain; DH dehydratase; ER enoyl reductase; HET heterocyclisation domain; KR ketoreductase; KS ketosynthase; 
MOX monooxygenase; OMT O-methyltransferase; OX oxidation;   PCP peptidyl carrier protein. Fulvuthiacene A-C, 1-
3; prefulvuthicene A and B, 4 and 5; desmethyl-fulvuthiacene A and B, 6 and 7. 
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Domain predictions  by antiSMASH as well as the predicted gene functions of putative tailoring 
enzymes obtained by blast searches against the NCBI non-redundant protein data base (nr) (Table S 8) 
were used to deduce a biosynthetic model for fulvuthiacene biosynthesis.[7] Fulvuthiacene biosynthesis 
exhibits some peculiarities, such as the first module, which is able to incorporate multiple malonyl-CoA 
extender units by programmed iteration. This reaction sequence forms a branched chain fatty acyl residue 
of variable length starting with 3-methylbutyryl-CoA. This relaxed selectivity is reflected by the different 
fulvuthiacene derivatives detected, which either differ in their post assembly line processing state or in 
the number of iterations performed by the first module. This first module also loads the 3-methylbutyryl-
CoA starter unit indicated by the presence of two copies of the acyl transferase domain (AT). HMM 
predictions according to Minowa et al. suggested the first AT is 3-methylbutyryl-CoA specific, while the 
second AT had a predicted substrate specificity for malonyl-CoA.[18] Moreover, this iterative PKS type I 
module does not feature an enoyl reductase domain (ER), whilst producing completely saturated fatty acyl 
chains. Enoyl reduction is thus likely catalyzed by FtaM as an in trans acting enoyl reductase similar to LovC 
that catalyzes enoyl reduction in the lovastatin biosynthesis.[19] Although primary sequence homology of 
the proteins LovC and FtaM is low (12 % by MUSCLE alignment), they are both composed of the same 
domain architecture. This architecture comprises a crotonase fold and a NAD cofactor binding pocket, both 
of which are crucial for enoyl reduction (section S 2.3). Module 2 is plausibly skipped during the 
biosynthesis as a large part of the AT domain in this module is missing, rendering it inactive (section S 2.2, 
Figure S 8). The following heterocycle forming module incorporates cysteine and synthesizes a thiazoline 
moiety further oxidized by the oxidation domain in module 3, creating the thiazole ring. Further assembly 
of the compound, chain release by the TE-domain and the first modification steps seem to happen 
congruently to melithiazol biosynthesis.[20,21] The oxidative glycine degradation, deamination and methyl 
transfer pathway as depicted in Figure 3 has already been successfully elucidated for the melithiazol 
biosynthesis and successfully transferred to myxothiazol biosynthesis.[20] FtaF, FtaH and FtaG encode 
enzymes of the fulvuthiacene pathway showng high similarity to the corresponding biosynthetic enzymes 
in the melithiazol and myxothiazol clusters and are therefore convincing candidates to produce the methyl 
ester intermediate shown in the biosynthesis scheme (Figure 7, Figure S 14, S 15 and S 16). A peculiar trait 
of fulvuthiacene biosynthesis is encoded by genes FtaI and FtaJ: these two genes encode an extra copy of 
the S-adenosyl homocysteine (SAH) detoxification and methionine-recycling pathway, by specifically 
encoding an extra copy of the S-adenosylhomocysteinase (FtaI) and an extra copy of the 5-
methyltetrahydrofolate cyclohydrolase (FtaJ) (Table S 8). These enzymes appear useful for fulvuthiacene 
production, since three methyl transfer steps per molecule are required.   
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Figure 4. UHPLC MS extracted ion chromatogram (EIC) traces of fulvuthiacene A (B,E; green) and fulvuthiacene B (C,F, 
purple) as [M-MeOH+H]+ ions (350.1783 Da and 378.2096 Da)  in the wild type (A-C) as well as the ftaD single 
crossover inactivation mutant (D-E) crude extracts. Grey traces represent the corresponding base peak 
chromatograms (BPC). E and F are magnified 100x. 
Consequently, cells needs to ensure SAH recycling, as intracellular SAH accumulation is lethal and 
cells also need to refill the S-adenosyl methionine (SAM) pool quickly.[22] 
In order to ultimately prove the compound to gene cluster assignment, the fulvuthiacene 
biosynthesis gene cluster was inactivated via single crossover plasmid insertion. Therefore, a pCR2.1 vector 
carrying a 1kb homology fragment to the ftaD gene was integrated into the ftaD gene on the MCy9280 
chromosome and integration was verified via PCR. The mutant strain was grown in VYGS medium 
supplemented with 50 µg/ml kanamycin and fulvuthiacene production was monitored in the bacterial 
crude extract (section S 1.9). As a result of single crossover inactivation of the ftaD gene, the production 
of 1 and 2 was abolished. Additionally, no other fulvuthiacene derivatives could be detected anymore. This 
finding confirmed the fta cluster as the BGC responsible for biosynthesis of all fulvuthiacene derivatives. 
3.3.4 Determination of the fulvuthiacenes’ absolute configuration 
 The absolute configuration of 1 and 2 could not be solved using solely NMR spectroscopy. With the 
fulvuthiacene BGC confirmed, we approached this problem in silico. Therefore, an established tool to 
predict the stereochemistry outcome afforded by KR domains called profileHMM was used to predict 
fulvuthiacene configuration as produced by  module 5.[23] The stereochemistry prediction for the methoxy 
group as well as the neighboring methyl branch are shown in Figure 8 (section S 2.4).[23] Convincingly, this 
is the same configuration as found in the corresponding PKS part of the myxothiazol natural products.[24] 
Since the configuration of myxothiazol was elucidated via an ozonolysis reaction with subsequent 
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derivatization, we pursued a similar approach for the fulvuthiacenes. In contrast to myxothiazols that are 
produced in high yields, fulvuthiacene could not be isolated at increased scale. Therefore, we used a small-
scale reaction and derivatization cascade that would forcibly create diastereomers out of all four 
hypothetical stereoisomers (Scheme 1). This allows direct comparison of the stereo centers in 
fulvuthiacene and myxothiazol via LC-MS, resembling amino acid conformation determination in Marfey’s 
analysis (section S 4.2).[25] 
 
Scheme 1. Reaction and derivatisation scheme for the elucidation of the fulvuthiacene’s absolute stereochemistry by 
LC-MS. 
The structural elements excised from myxothiazol and fulvuthiacene by ozonolysis and derivatized as 
described in Scheme 1 have the same configuration as they elute at the same retention time. Subsequent 
MS² analysis of given reaction product confirms the reaction product’s structure as seen in Figure 5. On a 
side note, a small peak close to the main peak for the derivatization of the myxothiazols corresponds to a 
small degree of epimerisation of the ozonolysis product during the HATU mediated peptide coupling.[26] 
As this peak is separated from the molecule with the correct stereochemistry we confirm that the 
stereoisomers separate sufficiently, allowing assignment of the fulvuthiacenes’ configuration via LC-MS.  
 
      126      Section 3.3 Results and Discussion 
Figure 5. EIC traces of 485.228 [M+H]+ representing the ozonolysis and derivatization reaction product of Myxothiazol 
A (depicted in blue) and Fulvuthiacen A (depicted in dark red), its structure formula and MS² analysis of the detected 
ozonolysis product. 
3.3.5 Insights into β-methoxymethacrylate formation 
To complete our investigation of fulvuthiacene biosynthesis we sought to shed light onto formation 
of the terminal β-methoxymethacrylate unit. From previous work on the melithiazol pathway in vivo and 
in vitro, it was likely that the fulvuthiacenes’ terminal β-methoxymethacrylate moiety would be formed 
using a route analogous to melithiazol maturation.[20] This is further supported by the detection of the 
corresponding intermediates, the prefulvuthiacenes and desmethyl-fulvuthiacenes in our SPL-based 
spectral networking approach (Figure 1, Table 1) representing the corresponding intermediates. In both 
cases, the assembly line finishes with the addition of a glycine, subsequent alpha oxidation and release of 
a terminal amide from the hemiaminal structure (Figure 3). [20,21] The resulting amide (see Figure 2) that 
can putatively be detected as prefulvuthiacene A (4) and B (5) by mass spectrometry (Table 1) is 
desaminated and methylated by the amidohydrolase FtaH and one of the SAM dependent methyl 
transferase FtaG or FtaN. As MCy9280 proved not amenable to genetic manipulation beyond the basic 
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single-crossover homologous recombination protocol, we chose to work with the myxothiazol producer S. 
aurantiaca DW/3-1 to underpin the reaction sequence that lead to β-methoxymethacrylate 
biosynthesis.[16] Myxothiazol biosynthesis is analogous to the biosynthesis of melithiazol and fulvuthiacene 
but it lacks the post PKS modification steps transforming the compounds’ terminal amide into a methoxy 
group (Figure 7).[16] By transfer of the maturation enzymes FtaG and FtaH into a myxovthiazol producer we 
should be able to transform the amide moiety in myxothiazol A into a methyl ester. Additionally, with 
respect to the biosynthesis model in Figure 3, we lack definite proof for in trans enoyl reduction in module 
1, although there is no ER domain on the ftaA protein (Figure 3). The best candidate for this enzyme is 
FtaM, a protein with a crotonase fold and an NAD binding pocket, showing homology to the FadJ subunit 
as determined by NCBI blast and conserved domain search.[27] We therefore created a plasmid that 
comprises FtaG and FtaH under a tn5 promotor as well as FtaM and FtaN under a vanillate promotor and 
repressor system (section S 1.15) to explore the influence of FtaG and FtaH as well as FtaM and FtaN on 
myxothiazol biosynthesis. After transformation of this plasmid into S. aurantiaca DW4/3-1 we observed 
changes in the myxothiazol production as shown in Figure 6 (section S 1.9). 
Figure 6. Production scheme for the secondary metabolites produced by S. aurantiaca DW4/3-1 WT (A) and DW4/3-
1 attB :: attP pFPVan FtaMN tn5 GH (B). Myxothiazol A (8) is depicted in blue, myxothiazol Z (10) [20] is depicted in 
green and desmethyl-myxothiazol Z (9) [17] is depicted in orange. 
The transformation of 8 to 10 with a ‘hybrid’ myxothiazol cluster does not only work in the previously 
reported melithiazol case but also with the respective fulvuthiacene pathway enzymes named FtaG and 
FtaH.[20] The induction of the enzymes FtaM and FtaN putatively involved in the biosynthesis do not afford 
further changes in the chromatogram, meaning that the transformation of 8 to 10 is still almost complete 
while no further processing of 10 takes place. We can therefore conclude that FtaG and not FtaN is 
responsible for terminal methyl ester formation. Also, this reaction scheme shows that the desmethyl-
fulvuthiacenes as well as the prefulvuthiacenes likely possess the structures assigned in the biosynthesis 
diagram as they are intermediates produced along the fulvuthiacene assembly process (Table 1). Since 
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NMR data for 9 clearly show that this compound represents the free acid (section S 4.1.2 and 4.1.3) it is 
very likely that desmethyl-fulvuthiacene A (6) and B (7) have the same structure, although this couldn’t be 
confirmed by NMR due to the extremely low yields. Finally, heterologous transfer of the ftaM gene from 
the fulvuthiacene pathway to the myxothiazol pathway does not lead to the production of myxothiazols 
featuring a saturated sidechain. As module 1 on the ftaA gene differs quite significantly from mtaB module 
1 (Figure 7, section S 2.2) FtaM is likely unable to dock correctly to mtaB module 1, therefore preventing 
the formation of myxothiazols lacking the double bonds in their fatty acyl sidechain. To further investigate 
this enoyl reduction reaction one would need a heterologous transfer of the enire fulvuthiacene cluster 
into a heterologous host that has a better accessibility for genetic manipulation than MCy9280, which 
would allow gene deletion experiments. 
 
3.3.6 Comparison between fulvuthiacene, myxothiazol and melithiazol BGCs 
 As already pointed out, there is a striking degree of similarity between the BGCs for myxothiazol, 
melithiazol and fulvuthiacene, which is also reflected by similar biosynthesis and maturation steps for 
these compounds. Protein sequences for corresponding functional units in the respective BGCs as 
apparent in Figure 7 were aligned to obtain insights into the divergent evolution process that created these 
different clusters. Firstly, the last three assembly line proteins FtaC, D and E in the fulvuthiacene case, 
MelE, F and G in the melithiazol case and MtaE, F and G in the myxothiazol case share high similarity even 
though the proteins stem from different myxobacterial species (Figure 7, Figure S 7 to S 9). One of the 
major differences in the fulvuthiacene biosynthesis compared to the myxothiazol and melithiazol 
biosynthesis is encoded in the proteins FtaB and MelC/MelD or MtaC/MtaD respectively. While both the 
myxothiazol and the melithiazol assembly line contain two heterocycle forming modules, fulvuthiacene 
contains only one of these. Additionally, the single remaining thiazole forming module encoded on ftaB 
resembles melC/mtaC upstream of the A domain and melD and mtaD downstream of the A domain (Figure 
S 8 and S 9). It is therefore likely that the fulvuthiacene cluster lost one of the thiazole forming units by 
homologous recombination of a melC/mtaC like gene with a melD/mtaD like protein at the site of the A 
domain. Another interesting part of the fulvuthiacene biosynthesis is module 2 on the ftaA gene. This 
module resembles module 1 from the melithiazol BGC with the only exception that parts of the AT domain 
in ftaA module 2 are deleted. This explains the inactivity of module 2 as it does not accomplish 
incorporation of isobutyl-CoA as an alternative starter unit, unlike predicted by hidden markov models 
(HMM). In contrast, the first module of ftaA shows high similarity to the first module on mtaB both of 
which are combined loading and elongation modules. This is peculiar as both modules produce rather 
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different polyketide sidechains. Not only does the ftaA module 1 act iteratively while mtaB module 1 
catalyzes only one chain elongation step, but ftaA module 1 also forms a completely saturated fatty acid 
chain despite lacking an ER domain. This is most likely the effect of a protein encoded on ftaM that 
possesses a crotonase fold and a NAD binding pocket and has no homologs in the myxothiazol cluster. One 
peculiarity of all three clusters is the protein named FtaF, MelH and MtaH, respectively. Although it has 
been shown that this fumarylacetoacetate hydrolase like protein (Figure S 14) is not necessary for 
myxothiazol biosynthesis it seems likely that this hydrolase type protein facilitates removal of the product 
and the oxaloacetate that is released (Figure 3).[28] Finally, as proven by heterologous expression in this 
work, FtaH and FtaG form the methyl ester analogous to the methyl ester formation in melithiazol 
catalyzed by the proteins MelJ and MelK. 
Figure 7. Comparative analysis of the myxothiazol, melithiazol and fulvuthiacene BGCs and the respective biosynthesis 
steps [16,17] 
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3.3.7 Structure-acitivity relationships within the β-methoxyacrylate class of respiratory 
chain inhibitors 
 The fulvuthiacene scaffold contains a β-methoxyacrylate motif, a pharmacophore seen in many 
fungicides targeting the bc-1 subunit of the respiratory chain.[29] As an example, strobilurine has long been 
used successfully in agriculture as an antifungal agent for crop protection. Interestingly, the fulvuthiacenes 
do not display any apparent fungicidal activity or cytotoxicity against M. hiemalis, C. albicans or CHO and 
HCT116 cells  (up to 64 µg/ml), which is remarkable considering their structural relatedness to the strongly 
antifungal and cytotoxic myxothiazols and melithiazols.[29] While the β-methoxyacrylate has long been 
described as the pharmacophore for respiratory chain inhibition at the bc-1 subunit, the biological 
inactivity of the fulvuthiacenes shows that there are missing parts in this rather simplistic structure-activity 
relationship (SAR).[29] While extending the β-methoxymethacrylate core motif in C-2 position - as in the 
strobilurins, oudemansins and cyrmenins - tolerates a wide variety of residues without significant activity 
losses, the SAR for C-3 extended congeners is more narrow (Figure 8 A).[29,30]  
Figure 8. A) Naturally occurring methoxy-methacrylate type respiratory chain inhibitor classes displayed revealing the 
main features of the β-methoxymethacrylate  structure activity relationship (SAR)[12,31] and B) Pharmacophore of 
myxothiazol type C-3 thiazol type respiratory chain inhibitors and the putative pharmacophore of myxothiazol type 
C-3 thiazol type respiratory chain inhibitors considering the oudemansin – strobilurine relationship 
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The β-methoxyacrylamide type bisthiazol compound myxothiazol A and the β-methoxymethacrylate 
type bisthiazol compounds myxothiazol Z and melithiazol B show very strong activity towards the bc-1 
subunit, and the thiazol-thiazolin melithiazol B analogue melithiazol A inhibits the respiratory chain at the 
same order of magnitude. In contrast, the single thiazol derivative melithiazol C inhibits the respiratory 
chain only at a concentration two orders of magnitude higher and fulvuthiacene A and B are non-toxic to 
human cell lines as well as a test panel of fungi and yeast up to 64 µg/ml, indicating the fulvuthiacenes not 
to inhibit the bc-1 subunit at all (Figure 8). Therefore, to produce a strong bc-1 inhibitor with a C-3 
extended β-methoxyacrylate warhead, a bisthiazol or thiazolin-thiazol type structural element is needed. 
Figure 8 A illustrates that only the C-3 connected compounds harboring this bicyclic structural element are 
able to efficiently inhibit electron transfer at the bc-1 subunit. Since the C-3 bisthiazol type compounds 
like myxothiazol and melithiazol are comparably stronger antifungal agents, outperforming the strobilurins 
and oudemansins as fungicides, it is worth revising the SAR to include the bisthiazol unit in order to develop 
efficient antifungal crop protection substances (Figure 8 B). More importantly, considering the structural 
differences between the oudemansins and strobilurins, there is a strong possibility that the 5-methoxy 
moiety is not needed for activity at the cytochrome bc-1 subunit indicating that a structure as depicted in 
Figure 8 B might already be sufficient to exhibit potent antifungal activity. From a synthetic point of view 
this structure would be more readily accessible as it has no stereocenters, significantly facilitating its 
chemical synthesis.  As development of novel β-methoxymethacrylate antifungal agents almost solely 
focused on the strobilurine core structure so far, these results might pave the way for the development of 
a novel fungicide series.[32] 
 Conclusion 
In this work, we pursued a comprehensive MS-based strategy for the discovery of natural products 
from myxobacteria. We combined statistics-based filtering of untargeted high-resolution MS data for 
improved coverage in subsequent targeted tandem-MS measurements with spectral networking for the 
early evaluation of structural similarity, leading to full structure elucidation of a new secondary metabolite 
scaffold from Myxococcus fulvus. Albeit the biological activity of newly identified fulvuthiacenes remains 
currently elusive, investigation of the underlying biosynthetic gene cluster provided insights into 
enzymatic particularities and shed light on the evolutionary relationship to myxothiazol and melithiazol 
biosynthesis. Notably, our finding of fulvuthiacenes extended a diverse family of natural products bearing 
the β-methoxymethacrylate motif, which has been considered crucial for inhibition of the bc-1 subunit of 
the respiratory chain. However, fulvuthiacenes did not show cytotoxicity or fungicidal activity and thus 
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appear unable to effectively inhibit the respiratory chain complexes bc-1 subunit in the way myxothiazol 
does.[29] This study therefore adds a new detail to the overall structure activity relationship scheme of the 
β-methoxymethacrylates that are commercially used as fungicides. Our results may promote the 
development of innovative β-methoxymethacrylate fungicides with higher cytotoxicity compared to 
commercially used derivatives of strobilurins, allowing the desirable reduction of material deployed for 
crop protection.  
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 Molecular biology protocols 
S 3.1.1 Isolation of genomic DNA from myxobacteria 
To isolate total DNA for sequencing purposes such as illumina sequencing, phenol-chloroform gDNA 
extraction is used. 
S 3.1.2 Gene cluster identification and assembly 
The MCy9280 genome was sequenced using illumina sequencing at GMAK at the Helmholtz institute 
for infectious diseases in Brunswick. Three putative fulvuthiacene gene clusters were identified among the 
BGCs predicted by antiSMASH.[1] The identified fulvuthiacene cluster was assembled via PCR amplification 
of the gap sequences followed by cloning into the pJet 1.3 vector utilizing clone Jet kit (Thermo scientific, 
U.S.A.).  
S 3.1.3 List of all primers used in this study 
Table S 1. List of all primer sequences used in this study 
Primer name Primer sequence 
Fulvuthiacene cluster inactivation and inactivation mutant verification 
FtaD_KO_fwd GAATCTGGTCCTGGTTCCCG 
FtaD_KO_rev CTCCCAACCCCTCCATCAAC 
FP pCR2.1 in CCTCTAGATGCATGCTCGAGC 
FP pCR2.1 out GGATCCACTAGTAACGGCCG 
FtaD_KO_fwd_verif TCTCGCTCACCCAATCTCTGTCAGGTGA 
FtaD_KO_rev_verif ACATCACCGCCACCATCCTCCCCACCT 
FP_Kan_fwd GATGGATTGCACGCAGGTTC 
FP_Kan_rev TGATATTCGGCAAGCAGGCA 
Gap closing PCR primer used to complete Fulvuthiacenene gene cluster sequence 
FulvuthiacenGap2_rev GGTGGACATGTTGGAGACCGTCTCC  
FulvuthiacenGap2_fwd AATCTCTGTCAGGTGAGGGCTCAAATG  
FulvuthiacenGap1fwd AGGAGCCTGGAGGAGCTGAAGGAAGAGTT  
FulvuthiacenGap1rev ACTCCCCAGCATCTCCTCCCAATCACTCCT  
Primers used for creation of the heterologous gene transfer plasmid pFPVan FtaMN th5 GH 
Mx8_HindIII_fwd AGTTCTAGACGGCCGCGCTTGTCGAGCG 
Mx8_HindIII_rev ACTCTAGATTCAGAAGAACTCGTCAAGAAGGCGATAGAAG 
FtaMN_fwd AATCATATGAGCGAGCAGAACACCATC 
FtaMN_rev GAAGAATTCAGGGCTTCTCCGCGTGGACG 
FtaGH_fwd TGGGAATTCTATGAGCAAGGAC 
FtaGH_rev GCAAGCTTGGACACTCACCGCCGCGTGAC 
FtaG_tn5_rev CCACATCGCCACACCCAGCGCCGTCCTATCCGCTTGCCGCTTGTCCTTGCTCATATGCTGTACCTCCTTATCCTG
TCTC 
FtaN_CmR_fwd AGTGGCTGACGCTGTTCAACTGCGACGAGTACGCCATCGTCCACGCGGAGAAGCCCTGACTGAACAGGAGGG
ACAGCTG 
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tn5_CmR_fwd GATGAGTGGCAGGGCGGGGCGTAATTGTAATACGACTCACTATAGGG 
tn5_CmR_rev CCCTATAGTGAGTCGTATTACAATTACGCCCCGCCCTGCCACTCATC  
S 3.1.4 Polymerase chain reaction protocols 
 Thermo scientific Taq Polymerase 
Taq Polymerase Protocol: 
2µL NH4SO4 Buffer 
(alternatively 2µL KCl Buffer) 
2µL MgCl2 solution (25mM) 
4µL dNTP’s (2mM) 
4µL 50% Glycerol 
1µL Primer fwd and rev (50mM) 
.2 µL Taq DNA Polymerase 
1µL gDNA Template (~50 ng/µL) 
4.3µL ddH2O 
Taq Polymerase cycler program: 
Table S 2. Taq DNA Polymerase PCR program 
Step Time [min:s] Temperature [°C] 
Initial denaturation 4:00 95 
Cycle, repeat 30x 
0:30 95 
0:15 63 
1:20 72 
Final elongation 10 72 
Store forever 8 
S 3.1.5 Thermo scientific Phusion Polymerase 
Phusion Polymerase Protocol: 
5µL GC Buffer 
2.5µL dNTP’s (2mM) 
1.25µL DMSO 
0.5µL Primer fwd and rev (100mM) 
0.2 µL Phusion DNA Polymerase 
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0.5µL gDNA Template (~50 ng/µL) 
14.55µL ddH2O 
Phusion Polymerase cycler program: 
Table S 3. Phusion DNA Polymerase PCR program 
Step Time [min:s] Temperature [°C] 
Initial denaturation 4:00 95 
Cycle, repeat 30x 
0:30 98 
0:15 63 
1:20 72 
Final elongation 10 72 
Store forever 8 
S 3.1.6 Transformation protocols 
 Transformation protocol E. coli DH10ß TOPO TA kit cloning 
1) Take competent E. coli DH10ß from -80°C on ice 
2) Mix competent cells with pCR2.1 TOPO reaction mixture 
(0.5µL salt solution, 0.5µL pCR2.1 TOPO vector (linearized), 1-5 µL PCR product cleaned by gel 
electrophoresis incubated for 10 minutes) 
3) Electroporate the cells at 1250 V, 25 µF, 200 Ohm and 1mm in a standard electroporation cuvette 
(100 µL). 
4)  Add 500 µL of fresh LB medium 
5)  Incubate on a shaker at 37°C for 1h 
6) Plate on LB Kan50 Agar and incubate the plates overnight at 37°C 
7) Pick around 6 clones and cultivate them for plasmid preparation via alkaline lysis 
 
 Transformation protocol E. coli DH10ß Thermo Scientific pJet 1.2 Kit 
3) Take competent E. coli DH10ß from -80°C on ice 
4) Mix competent cells with pJet 1.2 reaction mixture 
(0.5µL salt solution, 0.5µL pJet 1.2 vector (linearized), 1-5 µL PCR product cleaned by gel 
electrophoresis, 1 µL T4 DNA Ligase, ddH2O to 10µL) 
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3) Electroporate the cells at 1250 V, 25 µF, 200 Ohm and 1mm in a standard electroporation cuvette 
(100 µL). 
4)  Add 500 µL of fresh LB medium 
5)  Incubate on a shaker at 37°C for 1h 
6) Plate on LB Amp100 Agar and incubate the plates overnight at 37°C 
7) Pick around 6 clones and cultivate them for plasmid peparation via alkaline lysis 
S 3.1.7 Ligation protocol used in this study 
Ligations in this study are performed by Thermo scientific T4 ligase. 
T4 DNA Ligase mix: 
2µL vector DNA (carefully dephosphorylated using FastAP (Thermo scientific) 
2 – 6.5 µL insert DNA (triple the molar amount of the vector DNA) 
1 µL T4 DNA ligase buffer 
0.5 µL T4 DNA ligase 
to 10µL ddH2O 
The ligase mix is incubated at 16°C for 15-24h and 1-5 µL ligation mix are subsequently electroporated 
into E. coli DH10ß using standard protocol. 
S 3.1.8 Plasmid verification 
 Plasmid preparation via alkaline lysis 
For verification of created constructs, plasmids are prepared via standard alkaline lysis. 
 Verification of the pCR2.1 and pJet 1.2 constructs  
1) Find a restriction Enzyme that cuts one time on the vector backbone and one time on the insert. 
2) Mix 8.5µL Plasmid from alkaline lysis with 1µL restriction enzyme buffer and 0.5 µL enzyme. 
3) Incubate for 3-4 h 
4) Verify the bands on agarose gel (0.8 %) by gel electrophoresis 
S 3.1.9 Transformation of Myxococcus fulvus MCy9280 
The transformation protocol for M. fulvus MCy9280 was elaborated from CTT medium cultures, since 
CTT medium leads to growth in perfect suspension. This is a prerequisite for efficient electro 
transformation of myxobacteria. 
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 Transformation protocol 
1) Centrifuge 2ml of an MCy9280 culture in CTT Medium at OD600 of approx. 0.3 at 8000 rpm for 2 
minutes at a table centrifuge. 
2) Wash the residual cell pellet 2 times with 500 µL autoclaved ddH2O and discard the supernatant. 
3) Resuspend cells in 50µL of ddH2O, add 5 µL of plasmid solution (prepared from E. coli with Thermo 
Scientific Miniprep Kit) at a conc. of 0.3-0.4 ng/µL and transfer the solution into an 
electroporation cuvette. 
4) Electroporation at 675 V, 400 Ohms, 25µF and 1mm Cuvette Settings for optimum 
electroporation efficiency.  
5) Flush the cells out with 1 mL fresh CTT medium, transfer the Cell suspension into a 2ml Eppendorf 
tube. 
6) Incubate the Cells for 5h on a Shaker thermostated to 37°C at 300 rpm. 
7) Plating the cells on Kan50 CTT Agar after mixing the cell suspension with 3 ml of Kan50 CTT 
Softagar. 
8) Clones appear after 5-7 Days in the 30°C incubator. 
S 3.1.10 Transformation of Stigmatella aurantiaca DW4/3-1 
The transformation protocol for S. auramntiaca DW4/3-1 was elaborated from TS-6 medium cultures, 
since TS-6 medium leads to growth in perfect suspension necessary for efficient electrotransformation. 
 Transformation protocol 
9) Centrifuge 2ml of a S. aurantiaca DW4/3-1 culture in TS-6 Medium at OD600 of approx. 0.3 at 8000 
rpm for 2 minutes at a table centrifuge. 
10) Wash the residual cell pellet 2 times with 500 µL autoclaved ddH2O and discard the supernatant. 
11) Resuspend cells in 50µL of ddH2O, add 5 µL of plasmid solution (prepared from E. coli with Thermo 
Scientific Miniprep Kit) at a conc. of 0.3-0.4 ng/µL and transfer the solution into an 
electroporation cuvette. 
12) Electroporation at 650 V, 400 Ohms, 25µF and 1mm cuvette Settings for optimum 
electroporation efficiency.  
13) Flush the cells out with 1 mL fresh TS-6 medium, transfer the cell suspension into a 2ml Eppendorf 
tube. 
14) Incubate the Cells for 5h on a Shaker thermostated to 37°C at 300 rpm. 
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15) Plating the cells on Kan50 TS-6 Agar after mixing the cell suspension with 3 ml of Kan50 TS-6 
Softagar. 
16) Clones appear after 10-14 Days in the 30°C incubator. 
S 3.1.11 Vector creation for Fulvuthiacene cluster inactivation 
 pCR2.1 FtaD homology 
For single crossover inactivation of the suspected fulvuthiacene secondary metabolite cluster a pCR 
2.1 vector from the TOPO-TA cloning kit (Thermo scientific TOPO-TA cloning Kit) was equipped with a 1 kb 
homology sequence amplified from the FtaD gene in order to obtain single crossover inactivation mutants 
of the Fulvuthiacene biosynthesis gene cluster (main text Figure 3). The homology sequence is amplified 
with the primers FtaD_KO_fwd and FtaD_KO_rev (Table S 1). 
 
 
Figure S 1. Schematic view of pCR2.1 FtaD homology vector used for single crossover inactivation of the fulvuthiacene 
biosynthetic gene cluster 
S 3.1.12 Verification of the Fulvuthiacenes biosynthetic origin via single crossover 
inactivation of the corresponding gene cluster 
In order to verify the predicted gene cluster to secondary metabolite relationship, the assembled 
putative fulvuthiacene gene cluster was inactivated via a single crossover insertion inactivation of the FtaD 
gene by a pCR2.1 vector containing 1kb homology to the said gene. An electroporation protocol for 
Myxococcus fulvus MCy9280 that yields ca. 30 clones per electroporation was elaborated (section S 1.9). 
Verification of the single crossover mutant was done by PCR with Myxococcus fulvus MCy9280 mutant 
gDNA prepared using the Quiagen gDNA isolation kit. The frequency of homologous recombination events 
at the correct position of the MCy9280 seems rather low, as less than 1 per 10 screened clones displaying 
kanamycin resistance contain the plasmid integrated into the correct location on their bacterial 
chromosome. Therefore, further work on the fulvuthiacene biosynthesis elucidation was shifted towards 
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S. aurantiaca DW4/3-1 as this strains displays a much better reliability in genetic manipulation 
experiments. 
S 3.1.13 Protocols for λ-Red prophage mediated recombination (Red/ET) 
The strain used for all λ-Red based recombination experiments was E. coli HS996 carrying the 
thermosensitive pSC101 BAD red gba plasmid. As the origin of this plasmid stops replicating at 37°C the 
strain has to be grown at 30°C for cryo cultures. 
 
 Incorporation of plasmids into the λ-Red recombination (Red/ET) strain 
1) Inoculate 25 ml LB containing 12 µg/ml Oxytetracycline and grow the strain overnight at 30°C 200 
rpm on a rotary shaker 
2) Inoculate 20 µL of the well grown E. coli overnight culture into a 2 ml Eppendorf tube with a 
punctured lid containing 1.5 ml LB with 12 µg/ml Oxytetracycline 
3) Incubate the culture for 4h until OD reaches approx. 0.6 
4) Mix target vector or Ligation mixture (ca.1-3µL) with competent E. coli and pipet the mixture into 
a Electroporation cuvette (100µL) 
5) Electroporate the mixture at 1250V, 25µF, 200 Ohm, 1mm Cuvette 
6) Add 1mL fresh sterile LB medium, incubate for 1h at 900 rpm 30°C in a 2ml Eppendorf tube with 
a punctured lid 
7) Plate on LB Kan50 Otc12 Agar (provided the plasmid has kanamycin resistance, if not use 
appropriate antibiotic) and incubate the plates overnight at 30°C 
8) Pick around 6 clones and cultivate them for plasmid preparation via alkaline lysis 
9) Confirm the electroporated plasmid via restriction digestion 
 Modification of plasmids by Red/ET 
1) Inoculate 25 ml LB containing 12 µg/ml Oxytetracycline and 50 µg/ml Kanamycin and grow the 
strain overnight at 30°C 200 rpm on a rotary shaker 
2) Inoculate 20 µL of the well grown E. coli overnight culture into a 2 ml Eppendorf tube with a 
punctured lid containing 1.5 ml LB with 12 µg/ml Oxytetracycline and 50 µg/ml Kanamycin 
3) Incubate the culture for 2h until OD reaches approx. 0.2 (sometimes longer incubation times are 
necessary) 
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4) Add 20 µL 10% arabinose solution, incubate at 37°C, 200 rpm for additional 45 minutes to ensure 
optimum expression of the recombinases 
5) Centrifuge the culture at 8000 x g for 5 minutes to pellet the cells 
6) Wash the residual cell pellet 2 times with 1000 µL autoclaved milliqH2O and discard the 
supernatant. 
7) Re suspend the cell pellet in 50 µL autoclaved milliq H2O and add the PCR product for modification  
8) Electroporate the mixture at 1300V, 25µF, 600 Ohm, 1mm Cuvette 
9) Add 1mL fresh sterile LB medium, incubate for 1h at 900 rpm 30°C in a 2ml Eppendorf tube with 
a punctured lid 
10) Transfer the mixture into 50 ml LB Kan50 containing appropriate concentration of the antibiotic 
on the modification PCR product (in my case Chloramphenicol 25µg/ml) and incubate over night 
at 30°C 
11) Prepare plasmid from this mixture via alkaline lysis 
12) Electroporate the plasmid mix into E. coli DH10ß according to the E. coli DH10ß electroporation 
protocol and plate it on LB Kan50 Cm25 
13) Pick around 4 clones and cultivate them for plasmid preparation via alkaline lysis 
14) Confirm the electroporated plasmid via restriction digestion 
The retransformation is necessary in order to avoid having clones harboring both plasmids (the 
modified and the unmodified one) in the same E. coli clone as well as to get rid of residual pSC101 BAD 
Red gba plasmid. 
S 3.1.14 Verification of myxobacterial mutant clones  
Verification of the myxobacterial mutant clones is done by PCR with TAQ DNA Polymerase (Thermo 
Scientific). Therefore, genomic DNA from the myxobacterium is isolated with the Puregene Core Kit A 
(Quiagen) according to the protocol for gDNA isolation from gram negative bacteria. The Taq DNA 
Polymerase master mix is prepared according to section S 3.1.5. 
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 Taq polymerase cycler program for mutant verification: 
Table S 4. Taq DNA Polymerase PCR program 
Step Time [min:s] Temperature [°C] 
Initial denaturation 4:00 95 
Cycle, repeat 30x 
0:30 95 
0:15 63 
1:20 72 
Final elongation 10 72 
Store forever 8 
 Verification of the MCy9280::pCR2.1 FtaD homology mutant 
 
Figure S 2. Verification PCRs for the integration of pCR2.1_FtaD_homology into the FtaD gene of the Fulvuthiacene 
biosynthesis cluster  
One can clearly see two 2 kb bands indicating the integration of the vector into the FtaD gene (lanes 
1 and 2) as well as the absence of the band using both verification primers in the mutant gDNA (lane 3) 
that can be amplified from the wild type gDNA (lane 4). Also the control PCR for the presence of the 
kanamycin resistance gene on the pCR2.1 vector backbone is positive meaning that integration of the 
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pCR2.1 FtaD homology plasmid is complete and we do not observe residual intact FtaD that can be 
amplified from the mutant’s gDNA. Presence of a band in lane 3 would mean the mutant is a mixed clone. 
S 3.1.15 Creation of the vector for hybrid Myxothiazol production 
 Creation of the pFPVan FtaMN tn5 GH 
In order to evaluate the functions of the enzymes FtaM, FtaN, FtaG and FtaH, these genes are to be 
transferred from the fulvuthiacene producer Myxococcus fulvus MCy9280 to the Myxothiazol A producer 
Stigmatella aurantiaca DW4/3-1. 
Vector construction starts with the pCR2.1 vector (Thermo scientific TOPO TA cloning kit) featuring a 
vanillate promotor fused to the vanillate repressor called pFPvan as described in literature. [2] The genes 
ftaM and ftaN are amplified by PCR using the Phusion PCR protocol (section 1.4) and ligated into pFPvan 
directly downstream to the vanillate promotor using the restriction endonucleases EcoRI and NdeI. 
 
Figure S 3. pFPVan vector featuring the genes ftaM and ftaN 
After construct verification by restriction digestion and Sanger sequencing (LGC ltd., U.K.), this 
construct is further modified by introduction of a PCR product containing the genes FtaG and FtaH on it 
using the EcoRI restriction endonuclease. 
 
Figure S 4. pFPVan vector featuring the genes ftaM, ftaN, ftaG and ftaH 
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After selection of a clone having the PCR product ligated in the correct orientation using restriction 
digestion and subsequent sanger sequencing the construct is modified by Red E/T to integrate a tn5 
promotor upstream of the ftaGH operon (section 1.11). Therefore, overlap extension PCR using the 
Phusion PCR protocol (section S 1.3) is used to fuse a tn5 promotor with a 50 base overhang of the FtaG 
gene start to a CmR resistance cassette having a 50 base overhang to the end of the FtaN gene.  
Furthermore, the construct pFPVan FtaMNGH is transformed into the RedET strain HS996 pSC101 BAD 
RedγβαA to be able to use λ-red prophage mediated recombination. Linear to circular Red E/T is used to 
integrate this linear DNA fragment harboring homology to the region downstream of ftaN, a 
chloramphenicol resistance cassette fused to a tn5 promotor equipped with a homology to the gene start 
of ftaG. The resulting plasmid is verified by restriction analysis and Sanger sequencing (LGC ltd., U.K.). 
 
Figure S 5. pFPVan vector featuring the genes ftaM and ftaN under the vanillate promotor and repressor control and 
ftaG and ftaH under tn5 promotor control 
In order to integrate this vector into the target organism that is the Myxothiazol A producer S. 
aurantiaca DW4/3-1 we integrated the Mx8 integrase gene into this construct by conventional restriction 
cloning with the endonuclease XbaI to obtain the pFPvan FtaMN tn5 GH construct.[3] 
 
Figure S 6. pFPvan FtaMN tn5 GH Mx8 vector to transfer the genes ftaM,N,G and H into S. aurantiaca DW4/3-1 
This construct is able to integrate into the S. aurantiaca DW 4/3-1 genome via the Mx8 integrase attB 
site.[3,4] The plasmid is electroporated into Stigmatella aurantiaca DW4/3-1 and clones appear after 2 
weeks. The clones are genotypically verified by PCR and grown in TS-6 medium supplemented with 
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50µg/ml Kanamycin. Production of the hybrid Myxothiazol / Fulvuthiacene products is analyzed by 
extraction followed by LC-MS analysis according to standard protocol. We are now able to study the effect 
of ftaG and ftaH on the Myxothiazol production in S. auratiaca DW4/3-1 as well as the combined effects 
of ftaM, ftaN, ftaG and ftaH as the tn5 promotor is constitutionally active while the vanillate repressor can 
be removed by adding 5 mM sodium vanillate into the medium during fermentation. 
 In silico analysis of the fulvuthiacene gene cluster 
S 3.2.1 In silico analysis of the Fta biosynthetic gene cluster 
Table S 5. genes of the fulvuthiacene biosynthesis gene cluster, predicted gene function and their closest homologue 
determined by blastp search against NCBI non-redundant protein database (nr) 
Name Length 
[bp] 
Closest homologue in the 
nr database at NCBI 
Identity [%] and 
length of 
alignment 
Proposed function Accession Nr. 
ftaA 9384 MtaB (Stigmatella Aurantiaca) 63.3% (2846bp) Polyketide synthesis AAF19810 
ftaB 9669 Hybrid NRPS/ type 1 PKS 
(Myxococcus stipitatus) 
70.8%  
(3198bp) 
Polyketide synthesis, 
Thiazole formation 
WP_015350515 
ftaC 5799 Polyketide synthase (Myxococcus 
Stipitatus) 
79.4% 
(1931bp) 
Polyketide Synthesis, 
O-Methylation 
WP_015350514 
ftaD 4071 Polyketide synthase (Stigmatella 
Aurantiaca) 
84.2% 
(1363bp) 
Polyketide synthesis, 
Enolether formation 
WP_002618707 
ftaE 5238 MelG (Melittangium Lichenola) 71.5% 
(1747bp) 
Glycine attachment 
Glycine hydroxylation 
CAD89778 
ftaF 1026 Fumarylacetoacetate hydrolase 
(Myxococcus Stipitatus) 
86.8% 
(341bp) 
Alphahydroxyglycine hydrolysis WP_015350511 
ftaG 909 CtaK (Cystobacter Fuscus) 71.0% 
(297bp) 
Methyl transfer AAW03333 
ftaH 1053 N-Carbamoylputrescine hydrolase 
(Myxococcus Stipitatus) 
80.7% 
(332bp) 
Hydolysis of terminal amide AGC46253 
ftaI 1431 Adenosylhomocysteinase 
(Myxococcus Stipitatus) 
98.8% 
(476bp) 
Adenosylhomocysteine detoxing WP_015350518 
ftaJ 897 bifunctional 5,10-methylene-
tetrahydrofolate 
dehydrogenase/5,10-methylene-
tetrahydrofolate cyclohydrolase 
(Myxococcus Stipitatus) 
93.2% 
(293bp) 
Methionine recycling from 
generated homocysteine 
WP_015350519 
ftaK 534 Hypothetical protein 
(Myxococcus Stipitatus) 
80.9% 
(177bp) 
 WP_015350520 
ftaL 1212 Acetyl-CoA Acetyltransferase / 
Thioesterase 
(Myxococcus Stipitatus) 
95.5% 
(403bp) 
might be proofreading WP_015350521 
ftaM 2178 EnoylCoA dehydratase 
(Myxococcus Stipitatus) 
95% 
(725bp) 
in trans enoyl reduction WP_015350522 
ftaN 969 Methyltransferase Typ11 
(Myxococcus Stipitatus) 
94.4% 
(322bp) 
 WP_015350523 
orf1 198 Lysine Biosynthesis protein LysW 
(Myxococcus Stipitatus) 
93% 
(43bp) 
 WP_063639811 
orf2 864 Phage Major Capsid Protein 
(Micromonospora citrea) 
52.5% 
(276bp) 
 SCL67435 
orf3 1599 Lysyl Endopeptidase 
(Myxococcus Stipitatus) 
90.2% 
(532bp) 
 WP_015350508 
orf4 321 Hypothetical Protein 
(Myxococcus Stipitatus) 
72.9% 
(107bp) 
 AGC46250 
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orf5 474 Hypothetical Protein 
(Stigmatella Aurantiaca) 
74.5% 
(146bp) 
 WP_002609340 
orf6 2004 Thioredoxin 
(Stigmatella Aurantiaca) 
59.8% 
(636bp) 
 WP_002609295 
orf7 639 Hypothetical Protein 
(Stigmatella Aurantiaca) 
44.3% 
(206bp) 
 WP_013377569 
orf8 690 Phage tail fiber Protein 
(Cystobacter fuscus) 
43.0 
(131bp) 
 EPX62440 
orf9 198 No blast hit    
orf10 567 Hypothetical Protein 
(Myxococcus Stipitatus) 
85.1% 
(188bp) 
 WP_015350505 
 
The fulvuthiacene biosynthetic gene cluster from M. fulvus MCy9280 will be deposited in GenBank 
under accession number MH069655. 
S 3.2.2 In silico comparison of the Fulvuthiacene, Melithiazol and Myxothiazol gene 
clusters 
As it became evident that the three assembly lines of Fulvuthiacene, Melithiazol and Myxothiazol are 
strongly related, we did module by module protein alignments in order to determine possible ancestry 
and recombination events leading to the divergence of these clusters. Therefore, all modules having the 
same architecture are compared in a whole model alignment. An overview about the modules that are 
compared here can be found in the gene cluster comparison, main text Figure 7. 
 
Figure S 7. Protein alignment of FtaA module 1 and MtaB module 1 via muscle alignment [5] 
The modules FtaA module 1 and MtaB module 1 share a protein identity of 61.8 %. 
 
Figure S 8. Protein alignment of FtaA module 2 and MelB via muscle alignment [5] 
The modules FtaA module 2and MelB share a protein identity of 53.5 % also it is worth noting that a 
70 amino acid part of the Fta module 2 acyl transferase (AT) is deleted rendering Fta module 2 inactive. 
   Chapter 3 The Fulvuthiacenes Supporting Information    149 
 
 
Figure S 9. Protein alignment of FtaB module 1, MelC and MtaC via muscle alignment [5] 
pairwise 
identity 
FtaB module 1 MelC MtaC 
FtaB module 1 
 
50.42 51.68 
MelC 50.42 
 
65.31 
MtaC 51.68 65.31 
 
 
Considering the genes compared in Figure 9 one can observe that homology of MelC and MtaC is 
generally well, while the homology of FtaB to MtaC and MelC is pretty good until the end of the cysteine 
specific A domain.  
 
Figure S 10. Protein alignment of FtaB, MelD and MtaD via muscle alignment [5] 
pairwise 
identity 
FtaB MelD MtaD 
FtaB 
 
56.21 57.93 
MelD 56.21 
 
63.1 
MtaD 57.93 63.1 
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Once again we observe pretty good homology between MtaD and MelD while the protein FtaB is 
somewhat dissimilar from the gene start to the adenylation domain while the rest of the protein has good 
homology to its counterparts in the Melithiazol and Myxothiazol biosynthesis. It is therefore likely that 
FtaB was created by homologous recombination of a melC/MtaC like protein and a melD/mtaD protein 
and the crossover event occurred at the adenylation domain. 
 
Figure S 11. Protein alignment of FtaC, MelC and MtaC via muscle alignment [5] 
pairwise 
identity 
FtaC MelE MtaE 
FtaC 
 
66.7 67.43 
MelE 66.7 
 
68.08 
MtaE 67.43 68.08 
 
 
Figure S 12. Protein alignment of FtaD, MelF and MtaF via muscle alignment [5] 
pairwise 
identity FtaD MelF MtaF 
FtaD 
 
65.74 68.23 
MelF 65.74 
 
67.89 
MtaF 68.23 67.89 
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Figure S 13. Protein alignment of FtaE, MelG and MtaG via muscle alignment [5] 
pairwise 
identity FtaE MelG MtaG 
FtaE  70.23 70.67 
MelG 70.23  70.53 
MtaG 70.67 70.53  
 
 
Figure S 14. Protein alignment of FtaF, MelH and MtaH via muscle alignment [5] 
pairwise 
identity FtaF MelH MtaH 
FtaF  65.55 66.67 
MelH 65.55  72.53 
MtaH 66.67 72.53  
 
Figure S 15. Protein alignment of FtaF and MelK via muscle alignment [5] 
FtaG and MelK share a protein identity of 68.7 %. 
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Figure S 16. Protein alignment of FtaF and MelK via muscle alignment [5] 
FtaH and MelJ share a protein identity of 66.9 %. 
S 3.2.3 In silico analysis of the FtaM protein  
As described in this work, during the fulvuthiacene biosynthesis there has to be an in trans acting 
enoyl reductase as the FtaA protein does not contain an enoyl reductase (ER) domain while the 
fulvuthiacenes are fully reduced (main text, Figure 3). The most likely candidate for a trans acting enoyl 
reductase is the protein FtaM. This protein that is encoded in the biosynthetic gene cluster right next to 
the assembly line proteins is a homologue of the FabJ protein involved in the fatty acid β-oxidation 
pathway. These proteins consist of a crotonase fold, which can accommodate αβ unsaturated esters with 
their oxyanion hole as well as a NAD binding pocket with the corresponding dehydrogenase domain. The 
domains depicted in Figure S 17 are predicted by NCBI conserved domain (CD) search [6]. 
 
Figure S 17. Position of the crotonase fold, the NAD binding pocket and the dehydrogenase domain on the FtaM 
primary sequence 
FabJ like proteins are mainly acting as oxidoreductases on carbon oxygen bonds and therefore slightly 
different from classical enoyl reductase proteins but since both of these proteins belong to the short chain 
dehydrogenase/reductase family and the crotonase fold has the right substrate specificity for α,β 
unsaturated esters, FtaM is likely to have evolved from FabJ to catalyze the carbon carbon bond reductions 
in module 1 of the Fulvuthiacene biosynthesis. 
 
 
 
 
   Chapter 3 The Fulvuthiacenes Supporting Information    153 
S 3.2.4 In silico analysis of the Fulvuthiacene’s stereochemistry 
In order to elucidate the stereochemistry of the Fulvuthiacenes at C-12 and C-13 in Fulvuthiacene A 
(Figure S 22) we chose to predict the stereochemistry at these two carbon atoms by in - silico analysis of 
the ketoreductase (KR) domain in module 5 on FtaC that forms both stereo centers (main text Figure 3). It 
has been shown by Kitsche et al. that analysis of the KR sequence is sufficient to predict the stereo 
chemistry outcome of a keto-reduction reaction and the stereochemistry of the corresponding α – methyl 
branch incorporated through the use of methyl – malonyl CoA in this module of the biosynthesis (main 
text Figure 3).[7] 
The amino acid sequence of this KR domain used for the predictions is: 
> KR module 5 
GTYLITGGLGGLGVQTAKWLVARGVRHLVLAGRTEVPNAAVWDSLPEDSPHAAHVQMLRGLQAQGASVRYVRCDLG
EPAQVRALVDTCGVGGVPLVGVLHAAGASAHHPWMETGPEVLASVFQAKALGAWLLHEFTRDLPLHCFVLFSSASAV
WGAQGMAAYAAANHFLDALAHHRKARGLPATSVNWGRWSE 
 Prediction of the stereochemistry of the ketoreduction reaction: 
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 Prediction of the stereochemistry of the α – methyl branch originating from 
methylmalonyl CoA incorporation: 
 
 
It is worth noting that D – and L – form as predicted by this analysis correspond to the absolute 
stereochemistry with respect to the thioester bound intermediate. Since Kitsche and Kalesse recommend 
a minimum scoreDiff value of at least ± 15 for  a decision on the predicted stereochemistry we can assume 
our stereochemistry predictions to be valid (values close to 0 would mean an uncertain prediction, values 
above ± 15 were determined to be meaningful).[7] This stereochemistry prediction fits with the 
fulvuthiacene stereochemistry experimentally determined supporting these experimental results to be 
correct.  
 Extract generation, LC-MS data acquisition and clustering 
S 3.3.1 Myxobacterial fermentation conditions 
Cultures for UHPLC/HRMS analysis are grown in 300 ml shake flasks containing 50 ml of VYGS medium 
for Myxococcus fulvus MCy9280 or 50 ml of TS-6 medium for Stigmatella aurantiaca DW4/3-1 inoculated 
with 1 ml of pre culture. Media for mutant S. aurantiaca strains were supplemented with 50 mg/L 
kanamycin (Roth). After inoculation the medium is supplemented with 2% of sterile XAD-16 adsorber resin 
(Sigma Aldrich) suspension in water. Myxococcus fulvus strain MCy9280 is grown in VYGS medium at 30°C 
for 12 Days on an orbitron shaker at 160 rpm. Stigmatella aurantiaca DW4/3-1 is grown in TS-6medium at 
30°C for 10 days. Fermentation cultures of Myxococcus fulvus strain MCy9280 used for isolation of the 
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fulvuthiacenes are grown in 5 5L shake flasks containing 2L of VYGS medium each. Fermentation duration 
is 14 days post inoculation; inoculation is done with 50 ml of pre-culture and the medium is supplemented 
with 2% of sterile XAD-16 adsorber resin suspension in water. Fermentation cultures of Stigmatella 
aurantiaca DW4/3-1 used for isolation of the myxothiazol Z and desmethyl-myxothiazol Z are grown in 4 
5L shake flasks containing 2 L of TS-6 medium each. Fermentation duration is 14 days post inoculation; 
inoculation is done with 50 ml of pre-culture and the medium is supplemented with 2 % of sterile XAD-16 
adsorber resin suspension in water. 
S 3.3.2 Metabolite extraction procedure for analytical scale extractions 
The frozen cell pellet is transferred into a 100 ml Erlenmeyer flask and a magnetic stirrer is added. 50 
ml of acetone (fluka analytical grade, redistilled in house) are added onto the pellet and the mixture is 
stirred for 60 min. on a magnetic stirrer. The Acetone has to be distilled beforehand since fluka analytical 
reagent grade acetone still contains trace amount of polymer impurities that will otherwise concentrate 
in the extract. The acetonic extract is left to settle in order to sediment cell debris and XAD resin for a 
second extraction step. The supernatant is filtered with a 125 micron folded filter keeping cell pellet and 
XAD-16 resin in the Erlenmeyer flask for a second extraction step. The residual pellet and XAD-16 resin is 
extracted again with 30 ml of distilled acetone for 60 min on a magnetic stirrer and filtered through the 
same folded filter. The combined extracts are transferred into a 100 ml round bottom flask. The acetone 
is evaporated on a rotary evaporator at 260 mbar and 40 °C water bath temperature. The residual water 
is evaporated at 20 mbar until the residue in the flask is completely dry. The residue is taken up in 550 μl 
of methanol (Chromasolv HPLC grade, Sigma Aldrich) and transferred into a 1.5 ml Eppendorf tube. This 
tube is centrifuged with Heareus biofuge pico at 13000 rpm for 3 minutes to remove residual insolubilities 
such as salts, cell debris and XAD fragments. 
S 3.3.3 Standardized UHPLC MS conditions 
All measurements were performed on a Dionex (Germering, Germany) 
Ultimate 3000 RSLC system using a Waters (Eschborn, Germany) BEH C18 column (50 x 2.1 mm, 1.7 µm) 
equipped with a Waters VanGuard BEH C18 1.7 µm guard column. Separation of 1 µl sample was achieved 
by a linear gradient from (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µL/min and a 
column temperature of 45 °C. Gradient conditions were as follows: 0 – 0.5 min, 5% B; 0.5 – 18.5 min, 5 – 
95% B; 18.5 – 20.5 min, 95% B; 20.5 – 21 min, 95 – 5% B; 21-22.5 min, 5% B. UV spectra were recorded by 
a DAD in the range from 200 to 600 nm. The LC flow was split to 75 µL/min before entering the Bruker 
Daltonics maXis 4G hrToF mass spectrometer (Bremen, Germany) using the Apollo II ESI source.  Mass 
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spectra were acquired in centroid mode ranging from 150 – 2500 m/z at a 2 Hz full scan rate. Mass 
spectrometry source parameters are set to 500V as end plate offset; 4000V as capillary voltage; nebulizer 
gas pressure 1 bar; dry gas flow of 5 l/min and a dry temperature of 200°C.  Ion transfer and quadrupole 
settings are set to Funnel RF 350 Vpp; Multipole RF 400 Vpp as transfer settings and Ion energy of 5eV as 
well as a low mass cut of 300 m/z as Quadrupole settings. Collision cell is set to 5.0 eV and pre pulse storage 
time is set to 5 µs. Spectra acquisition rate is set to 2Hz. Calibration is done automatically before every LC-
MS run by injection of sodium formate and calibration on the sodium formate clusters forming in the ESI 
source. All MS analyses are acquired in the presence of the lock masses C12H19F12N3O6P3; C18H19O6N3P3F2 
and C24H19F36N3O6P3 which generate the [M+H]+ ions of 622.028960; 922.009798 and 1221.990638. 
S 3.3.4 Methodology for statistics based metabolome filtering 
To obtain all molecular features in the 6 LC/HRMS chromatograms of the bacterial extracts provided 
from three independent cultivations and the 6 LC/HRMS chromatograms of the corresponding three 
independent medium blanks, feature finding is applied that can subsequently be used for statistical data 
treatment.  Therefore, the in-build molecular feature finder implemented in Bruker Compass Data Analysis 
4.2 is used with the compound detection parameters SN threshold 1; Correlation coefficient 0.85; 
minimum compound length 10 spectra and smoothing width of 3 spectra. Bucketing is done with Bruker 
Profile Analysis 2.1 with advanced bucketing and advanced bucketing window parameters of 30s and 15 
ppm. Bucket value is log transformed to avoid under evaluating low intensity signals in the presence of 
high intensity signals.[8]  The PCA t-test function is used in order to separate medium derived MS features 
from the metabolome derived MS features since the t-test table that can be exported from Bruker Profile 
Analysis 2.1 contains information upon how many blanks and how many bacterial extracts contain said 
feature. This t-Test table is subsequently further processed with the KNIME software framework to obtain 
an SPL list that specifically and exclusively targets the bacterial metabolome for the acquisition of MS/MS 
spectra on our Bruker Daltonics maXis 4G hrToF spectrometer (Bremen, Germany).[9] The t-test table from 
the bucketing as well as the processed scheduled precursor list used to acquire SPL-MS/MS data will be 
supplied upon request. 
S 3.3.5 Acquisition parameters for acquiring high-resolution tandem MS data 
LC and MS conditions for SPL guided MS/MS data acquisitions are kept constant according to section 
standardized UHPLC-MS conditions. MS/MS data acquisition parameters are set to exclusively fragment 
scheduled precursor list entries. SPL tolerance parameters for precursor ion selection are set to 0.2 
minutes and 0.05 m/z in the SPL MS/MS method. The method picks up to 2 precursors per cycle, applies 
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smart exclusion after 5 spectra and performs CID and MS/MS spectra acquisition time ramping. CID Energy 
is ramped from 35 eV for 500 m/z to 45 eV for 1000 m/z and 60 eV for 2000 m/z. MS full scan acquisition 
rate is set to 2Hz and MS/MS spectra acquisition rates are ramped from 1 to 4 Hz for precursor Ion 
intensities of 10 kcts. to 1000 kcts.. 
S 3.3.6 Spectral networking details for the acquired tandem MS data 
All supporting GNPS clustering data presented here is created based on exported .mzML files from 
the LC-MS² chromatograms using the parameters specified in the experimental section of the main text.[10] 
The entire MS/MS chromatograms are exported containing all MS/MS data as an .mzML data file and 
uploaded to the GNPS server at University of California San Diego via FileZilla FTP upload to ftp:// ccms-
ftp01.ucsd.edu and all acquired SPL MS/MS spectra are used for spectral network creation. A molecular 
network was created using the online workflow at GNPS. The data was filtered by removing all MS/MS 
peaks within +/- 17 Da of the precursor m/z. MS/MS spectra were window filtered by choosing only the 
top 6 peaks in the +/- 50 Da window throughout the spectrum. The data was then clustered with MS-
Cluster with a parent mass tolerance of 0.05 Da and a MS/MS fragment ion tolerance of 0.1 Da to create 
consensus spectra. Further, consensus spectra that contained less than 1 spectra were discarded. A 
network was then created where edges were filtered to have a cosine score above 0.65 and more than 4 
matched peaks. Further edges between two nodes were kept in the network if and only if each of the 
nodes appeared in each other's respective top 10 most similar nodes.[10] The complete clustered dataset 
is downloaded from the server and subsequently visualized using Cytoscape 3.6.1. 
 Performance comparison of auto-MS² experiments versus SPL based MS² experiments 
As described in this work, the devised SPL based MS² method, as it is specifically designed to target 
the bacterial metabolome of interest, should have a much higher coverage of MS² spectra across our range 
of bacterial metabolome precursor peaks determined by PCA. We evaluated this statement by 
determination of the SPL coverage – a metric that determines the number of PCA precursors actually 
trigger acquisition of a MS² spectrum.  We used sql queries in the KNIME software framework to match 
csv file entries and visualized the results as Venn diagrams. 
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Figure S 18. Comparison of the SPL coverage using the SPL-MS² and the Auto-MS² based LC-MS² experiments for 
measurements on the MCy9280 Vy/2 medium extract 
As expected and in line with previous studies, the SPL coverage reached with a SPL based MS² is 
significantly better than with the auto-MS² method. [9] Compared to the results presented by Hoffmann et 
al. our SPL coverages are overall lower, which is readily explained as we increased the cycle time to obtain 
fewer MS² spectra of better product ion intensity. Although SPL coverage drops, this leads to better 
predictivity of the resulting spectral networks in the spectral networking step. If one considers now that 
in AutoMS² mode there is a total of 997 MS² spectra acquired while only 193 of those are dedicated to 
cover the metabolome of interest one can estimate that around 4/5 of the MS² acquisition time in Auto 
MS² mode is dedicated to acquiring a priori non-interesting spectra. 
S 3.3.7 Clustering of tandem MS² data acquired in auto-MS² mode 
The complete set of MS² spectra clusters can be seen in Figure S 19. The cytoscape data can be 
provided as a .cys file upon request. 
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Figure S 19. GNPS based MS² clustering of the automatic precursor selection MS² data visualized with Cytoscape 
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As already mentioned in the main text, automatic precursor selection lacks the ability to selectively 
target the bacterial secondary metabolome. Therefore, the spectral network shown in Figure S 19 is not 
only comprised of features belonging to the bacterial metabolome but also of features that were 
fragmented that provide from the bacterial culture medium. Fragmentation of these features belonging 
to the culture medium represent wasted MS² acquisition time, as these spectra do not add any information 
about the microorganism in question. These features providing from the medium blank are best 
represented by the medium peptide block in the top left corner. 
 
Figure S 20. Medium peptide cluster appearing in automatic precursor selection based GNPS MS² clustering 
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These features are characterized by a regular amino acid fragmentation as well as the fact that they 
are also present in the medium blank. The fact that the spectrometer is occupied with measuring MS² 
spectra of these peptide fragments while possibly features belonging to the secondary metabolome of 
lower intensity are eluting also explains the higher sensitivity of the SPL based precursor selection mode 
(Figure S 21). This finding is also verified by the incapacity of the automatic precursor selection MS² method 
to detect the fulvuthiacenes’ biological precursors (the prefulvuthiacenes and desmethyl-fulvuthiacenes) 
as well as the minor derivative fulvuthiacene C. 
S 3.3.8 Clustering of tandem MS² data acquired in SPL-MS² mode 
The complete set of MS² spectra clusters can be seen in Figure S 21. The cytoscape data can be 
provided as a .cys file upon request. 
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Figure S 21. GNPS based MS² clustering of the SPL directed precursor selection MS² data visualized with Cytoscape 
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Scheduled precursor list based MS² methods to specifically target the bacterium’s secondary 
metabolome has multiple advantages. On the one hand, all nodes displayed in Figure S 21 are linked to 
bacterial metabolic activity of the bacterium significantly simplifying the distinction between bacterial 
metabolome and medium blank derived MS signals in the MS and MS² spectra. On the other hand, as less 
time is lost acquiring MS² spectra of medium derived molecular features we have a significantly greater 
coverage of low intensity bacterium derived molecular features as exemplified by the discovery of the 
fulvuthiacenes’ biological precursors prefulvuthiacene A and B as well as desmethyl-fulvuthiacene A and 
B and the minor derivative fulvuthiacene C in the spectral network in the top middle of Figure S 21. It is 
worth noting that the cluster on the top left side includes spectra providing from the homospermidine 
lipid compound family as exemplified by their member Cmp-522 in the middle of the spectral network.[11] 
As this SPL based MS² fragmentation clustering method by design only acquires MS² spectra of compounds 
belonging to the bacterial metabolome and the corresponding MS² spectra show peptidic fragments 
including hydroxyvalins one could assume the cluster on the top right hand side around m/z of 749.507 
and the cluster in the middle around m/z of 745.409 to be somewhat related to myxoprincomide 
biosynthesis but this remains to be investigated. [12] Still, as they show irregular peptidic fragmentation 
they seem to provide from non-ribosomal peptide biosynthesis. I would assume the two remaining 
spectral networks comprising more than two nodes to be also related to secondary metabolism although 
– judging from the tandem MS spectra – they don’t seem to be peptides. The cluster comprising the m/z 
of 847.471 and 833.456 also seems to comprise non-ribosomal peptides as judged by its fragmentation 
pattern. A key issue in using the presented technique is that it efficiently reduces the number of molecular 
features to investigate manually from around 2000 to a handful of derivatives, which subsequently have 
to be mined for the most promising candidates based on like uncommon heteroatoms (as the sulfur atom 
in the fulvuthiacenes) interesting fragmentation patterns or biological activity. 
 Isolation and structure elucidation  
 Isolation and structure elucidation of the fulvuthiacenes 
The Myxococcus fulvus strain MCy9280 is fermented in 50 ml VYGS medium as a seed culture flasks 
on an Orbiton shaker at 160 rpm and 30°C. The culture medium becomes translucid and red M. fulvus 
biofilm balls are visible after 5 to 7 days of fermentation. This preculture is used to inoculate 6 x 2L VYGS 
medium supplemented with 2 % XAD-16 resin suspension in sterilized water in 6 x 5L baffled shake flasks 
on an Orbiton shaker at 160 rpm and 30°C. Fermentation is complete after 14 days. Cells and XAD-16 resin 
are harvested by centrifugation on a Beckmann Avanti J-26 XP with the JLA 8.1 rotor at 6000 rcf. Combined 
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resin and cells are extracted with 2 x 500 ml of technical grade methanol (Fluka) and 2 x 500 ml of technical 
grade acetone (Fluka). The extracts are combined and all solvent is evaporated on a rotary evaporator. 
The crude extract from this 10 L fermentation in VYGS medium is separated on the Waters AutoPurification 
system preparative HPLC system. Purification  was  carried  out  on  a  Waters Autopurifier  (Eschborn,  
Germany)  high  pressure gradient system, equipped with 2545 binary gradient module, SFO system fluidics 
organizer, 2767  sample  manager and  a  2998  photodiode  array  detector  coupled  to  a  3100  single 
quadrupole mass spectrometer operated in positive ion mode. Source and voltage settings for the MS 
were as follows: mass range, m/z 300 - 1000; scan duration, 1 s; points per Dalton, 4; capillary voltage, 3.5 
kV; cone voltage, 30 V; extractor voltage 3 V; RF lens, 0.1 V; source temperature 120 C, desolvation 
temperature, 250 C; desolvation gas flow, 400 L/hr; cone gas flow, 50 L/hr; ion counting threshold, 30. 
Autopurification is done by setting the fraction collection trigger masses 317.2 and 354.3 which 
correspond to the [M-2MeOH]+ ions of the fulvuthiacenes. Separation was carried out on a Waters X-
Bridge prep C-18 5 µm, 150 x 19 mm column using MeOH + 0.1% FA as B and H2O + 0.1% FA as A and a 
flow rate of 25 ml/min. Separation is started with a plateau at 95% A for 2 minutes followed by a ramp to 
72% A during 2 minutes and a ramp to 5% A during 29 minutes. The A content is kept at 5% A for 1.5 
minutes. The A content is ramped back to starting conditions during 30 seconds and the column is re 
equilibrated for 3 minutes. This separation step provides two fractions, one enriched in fulvuthiacene A 
and one enriched in fulvuthiacene B. Further purification is done using a Dionex Ultimate 3000 SDLC low 
pressure gradient system on a Phenomenex Polar RP 250x10mm 4µm column with the eluents H2O + 0.1% 
FA as A and ACN + 0.1% FA as B, a flow rate of 5 ml/min and a column thermostated at 30°C. fulvuthiacene 
A and B can be detected by UV absorption at 210 nm and 260 nm. Fulvuthiacene A is further purified with 
the gradient that starts with a plateau at 90 % A for 1 minute followed by a ramp to 70 % A during 1 minute. 
Then B content is ramped to 10 % A during 25 minutes and finally ramped to 95 % A during 30 seconds. A 
content is kept stable at 95 % for 1 minute and then ramped back to 90% A during 30 seconds. The column 
is reequilibrated at 90 % A for 3 minutes. Fulvuthiacene B is further purified with the gradient that starts 
with a plateau at 90 % A for 1 minute followed by a ramp to 58 % A during 1 minute. Then A content is 
ramped to 20 % during 25 minutes and finally ramped to 95 % A during 30 seconds. A content is kept stable 
at 95 % for 1 minute and then ramped back to 90 % A during 30 seconds. The column is reequilibrated at 
90 % A for 3 minutes. The pure compounds are subsequently dried under nitrogen gas flow. Fulvuthiacene 
A and B are obtained as white solid. 
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 Isolation and structure verification of Myxothiazol Z and Desmethyl-Myxothiazol Z 
Myxothiazol Z as well as desmethyl-myxothiazol Z are isolated from the mutant strain Stigmatella 
aurantiaca DW4/3-1 attB :: attP pFPVan FtaLM tn5 FtaGH created in this study. The S. aurantiaca strain is 
fermented in 50 ml TS-6 medium as a seed culture flasks on an Orbiton shaker at 160 rpm and 30°C. After 
the culture medium reached OD of 0.8 after 4 to 5 days of fermentation it is used to inoculate 6 x 2L TS-6 
medium supplemented with 2 % XAD-16 resin suspension in sterilized water in 6 x 5L baffled shake flasks 
on an Orbiton shaker at 160 rpm and 30°C. Fermentation is complete after 12 days. Cells and XAD-16 resin 
are harvested by centrifugation on a Beckmann Avanti J-26 XP with the JLA 8.1 rotor at 6000 rcf. Combined 
resin and cells are extracted with 2 x 500 ml of technical grade methanol (Fluka) and 2 x 500 ml of technical 
grade acetone (Fluka). The extracts are combined and all solvent is evaporated on a rotary evaporator. 
The crude extract from is partitioned in a liquid-liquid extraction step between chloroform and saturated 
brine water. Both myxothiazol derivatives end up quantitatively in the chloroform layer. Purification of 
desmethyl-myxothiazol Z was  carried  out  using a Dionex Ultimate 3000 SDLC low pressure gradient 
system on a Phenomenex Luna C18 250x10mm 5µm column with the eluents H2O + 0.1% FA as A and ACN 
+ 0.1% FA as B, a flow rate of 5 ml/min and a column thermostated at 30°C. Desmethyl-myxothiazol Z is 
detected by UV absorption at 315 nm and purification is done by time dependent fraction collection. 
Separation is started with a plateau at 70% A for 3 minutes followed by a ramp to 45% A during 2 minutes 
and a ramp to 5% A during 20 minutes. The A content is kept at 5% A for 2 minutes. The A content is 
ramped back to starting conditions during 30 seconds and the column is re equilibrated for 4.5 minutes. 
After evaporation, desmethyl-myxothiazol Z is obtained as an orange-red amorphous solid. 
Purification of Myxothiazol Z was carried out on a Waters preparative SFC system, equipped with a 
Thar fluid delivery module, 2767  sample  manager, an ABPR 20, a GLS system featuring a 515 GLS pump, 
a column oven thermostated to 45°C and  a  2998  photodiode  array  detector  coupled  to  a Waters 
Acquity QDA mass analyzer operated with a 515 Make up pump. Autopurification is done by setting the 
fraction collection trigger mass to 503.20 corresponding to myxothiazol Z [M+H]+. QDA probe temperature 
is set to 600°C, Cone voltage is set to 25 V while spray voltage was set to 1.75 kV. Separation was carried 
out on a Phenomenex Luna Silica 250x10mm 5µm column using MeOH as co solvent and a flow rate of 25 
ml/min. GLS solvent was Methanol and make up solvent 80/20 Methanol/Water + 0.2 % formic acid. 
Separation started by keeping 5% Cosolvent for 1 minute followed by a co solvent ramp to 15% during 5 
minutes. Cosolvent concentration is subsequently ramped to 50% during 1 minute and kept constant 
during 1 minute. Cosolvent concentration is ramped back to initial conditions during 30s and the column 
is reequilibrated for 1 minute prior to the next injection. After evaporation, myxothiazol Z is obtained as 
an orange-red amorphous solid. 
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S 3.4.2 Elucidation of the fulvuthiacenes’ absolute stereochemistry 
 Synthesis of L-Phenylalanin-O-methylester 
We dissolved 10g of L-phenlyalanin in 30 ml of methanol and add 5ml on concentrated hydrochloric 
acid. The reaction mixture is stirred under reflux conditions overnight in a 250 ml round bottom flask and 
subsequently dried on a rotary evaporator. 
 The derivatization and analysis method 
In order to elucidate the absolute stereochemistry of fulvuthiacene A and B the compounds as well 
as myxothiazol A are ozonolysed and the ozonolysis products are coupled twice to L-phenylalanin-O-
methylester. The created product possesses two stereo centers that are forcibly L-configured stemming 
from the phenylalanine moieties and therefore all different stereoisomers of the two stereo centers in the 
fulvuthiacene structure will forcibly generate diastereomers. It will thus be possible to separate them via 
LC/MS and confirm the equivalence of the stereochemistry of myxothiazol and the stereochemistry of 
fulvuthiacene.[13] There has already been proof that ozonolysis with oxidative workup works but the used 
method is not applicable here as the overall isolated yield of fulvuthiacenes is extremely low. To perform 
the ozonolysis reactions, 0.2 mg of fulvuthiacene A, 0.2 mg of fulvuthiacene B as well as 0.3 mg of 
myxothiazol A are dissolved in 20 ml of methanol and brought to -77°C. Ozone is passed through the 
solution until the methanol turns slightly ozone blue. The ozone is eliminated from the solution by flushing 
it with air and the mixture is mixed with 2 ml of 30% aqueous hydrogen peroxide solution(Sigma Aldrich, 
contains inhibitor). The mixture is gently stirred at 30°C for 3 hours and subsequently dried completely on 
a rotary evaporator. After drying, the mixture is taken up in 1 ml of DMF (Sigma Aldrich >99%). 10 
equivalents of L-Phenylalanin-O-methylester and subsequently 10 equivalents of HATU coupling reagent 
(carbolution chemicals, Germany) are added (section S 2.4.1). After adding of two droplets of DIPEA (Sigma 
Aldrich >99%) the mixture is stirred in a 4 ml glass vial overnight. After 24 hours the mixture is extracted 
with 1ml ethyl acetate and the organic layer is taken for LC/MS analysis. The UHPLC gradient was 
elaborated to separate the possible stereoisomers as follows. All measurements were performed on a 
Dionex (Germering, Germany) Ultimate 3000 RSLC system using a Waters (Eschborn, Germany) BEH C18 
column (50 x 2.1 mm, 1.7 µm) equipped with a Waters VanGuard BEH C18 1.7 µm guard column. Separation 
of 1 µl sample was achieved by a linear gradient from (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow 
rate of 600 µL/min and a column temperature of 45 °C. Gradient conditions were as follows: 0 – 1 min, 5% 
B; 1 – 2 min, 5 – 10% B; 2 – 16 min, 35% B; 16 - 21 min, 55% B; 21 - 22 min, 80% B; 22 – 26 min, 80% B; 26 
– 26.5 min, 80-5% B; 26.5 – 32 min, 5% B. UV spectra were recorded by a DAD in the range from 200 to 
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600 nm. The LC flow was split to 75 µL/min before entering the Bruker Daltonics maXis 4G hrToF mass 
spectrometer (Bremen, Germany) using the Apollo II ESI source. MS data acquisition parameters are kept 
the same as in the acquisition of crude extract LC-MS chromatograms. LC/MSMS data to verify the 
presence of the correct species is acquired with the same gradient but MS/MS with automatic precursor 
selection. MS/MS parameters are kept as in the acquisition of automatic precursor selection MS² data. 
 Derivatization analysis results 
All four theoretical stereoisomers of the fulvuthiacenes would lead to synthesis of an entity of a mass 
of 484.221 Daltons according to main text Scheme 1. We could clearly detect the reaction product with 
the correct exact mass for both derivatization reactions that occur at the same retention time. Therefore, 
the structural element excised from myxothiazol and fulvuthiacene by ozonolysis and derivatized as 
described in Scheme 1, has consequently the same configuration in both molecules. Spiking experiments 
of the two reaction mixtures and subsequent gradient variation did not lead to any peak splitting of the 
main product peak. Therefore, as the stereochemistry of the L-Phenylalanin-O-methylester is fixed, the 
reaction product stemming from 1 and 8 have the same configuration. As (since fulvuthiacenes are 
produced in very low amounts) the resulting entity could not be analyzed via NMR or in a polarimeter one 
had to prove the observed mass to actually represent the expected entity with a m/z value of 485.228 
[M+H]+. Therefore the modified Marfey’s analysis method was run to acquire tandem MS spectra that 
clearly showed the observed entity to be the derivatized ozonolysis product (main text Figure 5). 
 NMR based structure elucidation of the fulvuthiacenes 
As the two methyl groups at the tips of the fatty acyl side chain of the structure solely couple to C-3 
they form a clean doublet. The – for saturated carbons – unusually high carbon shift of C-4 further validates 
the iso-structure of the fatty acyl side chain in both cases for fulvuthiacene A and B. The rest of the fatty 
acyl chain is characterized by proton shifts around 2 ppm and carbon shifts of around 30 ppm as one would 
expect for these carbons. The thiazol heterocycle connected to the fatty acyl side chain is characterized by 
a very downfield singulett proton at 7 ppm on a downfield shifted carbon at around 120 ppm which shows 
HMBC coupling to the two quarternary aromatic carbons of the thiazole at 170 and 150 ppm. The right 
hand side of the molecule can be solved in good agreement to myxothiazol A and  myxothiazol Z. [13,14] 
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 NMR data of the fulvuthiacenes and recombinantly produced myxothiazols 
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Figure S 22. Structures and carbon numbers of the isolated compounds named fulvuthiacene A and fulvuthiacene B  
As both fulvuthiacene derivatives are rather hydrophobic and show low solubility in methanol, 2D 
NMR data used for structure elucidation is acquired in DMSO-d6 and CDCl3 on a Bruker Ascend 700 
spectrometer with a 5 mm TXI cryoprobe (1H at 700 MHz, 13C at 175 MHz) NMR spectrometer. To elucidate 
the planar structure of the molecules 1H, 13C as well as H-H DQFCOSY, HSQC and HMBC data are acquired. 
DQFCOSY, HSQC, HMBC, and ROESY experiments were recorded using standard pulse programs. The NMR 
signals are grouped in the tables below and correspond to the numbering in the scheme above. 
Table S 6. NMR Signals of fulvuthiacene A in DMSO-d6 
Carbon 
number 
δ 1H  
[ppm] 
Multiplicity, J 
[Hz] and proton 
number 
δ 13C [ppm] 
COSY 
correlations 
[ppm] 
HMBC correlations [ppm] 
1+2 0.895 d, 6.5, 6H 22.09 1.559 26.89, 37.7  
3 1.559 d t, 6.8, 1H 26.89 0.895, 1.236 22.09, 37.04, 26.89 
4 1.236 m, 2H 37.70 1.689, 0.895  26.86, 26.81, 32.7 
5 1.689 t t, 7.5, 8.1, 2H 26.86 1.236, 2.910 26.89, 32.7, 37.4, 170.2 
6 2.910 t, 7.5, 2H 32.70 1.689 26.86, 37.4, 170.2 
7 - - 170.20 - - 
8 7.320 s, 1H 115.40   151.5, 170.2 
9 - - 151.50 - - 
10 6.468 d, 15.5, 1H 125.80 6.140 83.2, 115.4, 129.6, 151.5 
11 6.140 dd, 15.5 8.0, 1H 129.60 3.68, 6.442 38.8 , 83.3, 115.4, 126.2, 151.5  
12 3.680 dd, 8.5 7.8, 1H 83.40 6.14, 4.07 38.8, 126.2, 129.6, 56, 175.6 
12a 3.200 s, 3H 56.00 - 83.40 
13 4.074 d q, 6.9 8.7, 1H 38.80 1.118, 3.680  83.3, 90.6, 129.5, 175.6    
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13a 1.118 d, 6.9, 2H 14.05 4.074 38.8, 83.4, 175.66 
14 - - 175.60 - - 
14a 3.500 s, 3H 55.96 - 166.50, 167.50 
15 4.999 s, 3H 90.60   38.8, 166.3, 175.6  
16 - - 166.30 - - 
16a 3.500 s, 3H 50.15 - 166.50, 167.50 
 
 
Table S 7. NMR Signals of fulvuthiacene B in CDCl3 
Carbon 
number 
δ 1H  
[ppm] 
Multiplicity, J [Hz] 
and proton 
number 
δ 13C 
[ppm] 
COSY correlations 
[ppm] 
HMBC correlations [ppm] 
1+2 0.845 d, 6.5, 6H 22.98 1.502, 1.155 28.2, 39.2 
3 1.502 m, 1H 28.20 0.845, 1.155 0.845, 1.155 
4 1.155 m, 2H 39.26 1.502, 1.315 22.7, 27.4, 28.8 
5 1.315 m, 2H 27.36 1.155, 1.370 29.50 
6 1.370 m, 2H 29.50 1.315, 1.761 27.4, 30.3, 34.0, 39.3 
7 1.761 t t, 7.4 7.9, 2H 30.31 1.377, 2.959 27.36, 29.5, 34.0, 171.1 
8 2.959 t, 7.9, 2H 34.00 1.761 171.1, 29.5 
9 - - 171.10 - - 
10 6.915 s, 1H 113.70   126.4, 153.2, 171.1 
11 - - 153.20 - - 
12 6.495 d, 15.6, 1H 126.40 6.274, 3.762 153.2, 131.0, 113.7, 84.3 
13 6.274 d d, 15.6 8.0, 1H 131.80 3.726,6.459 40.00, 84.30, 153.2, 113.7  
14 3.762 m, 1H 84.90 6.274, 6.495, 6.274 
126.4, 131.8, 176.4, 57.3, 40.0, 
14.35  
14a 3.280 s, 1H 57.30 - 84.90 
15 4.116 d q, 6.9 7.8, 1H 40.00    131.8, 176.4, 57.3, 91.5  
15a 1.182 d, 6.9, 2H 14.35 4.126 176.8, 84.9, 40.0 
16 - - 176.40 - - 
16a 3.569 s, 3H 55.90 - 176.40 
17 4.931 s, 3H 91.50 - 40.0, 167.6, 176.4 
18 - - 167.60 - - 
18a 3.642 s, 3H 51.00 - 167.50 
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Figure S 23. Structures and carbon numbers of the Myxothiazol derivatives produced in the S. aurantiaca attB :: attP 
pFPVan FtaMN tn5 GH Mx8 strain 
1D and 2D NMR data used for structure elucidation of the myxothiazol derivatives is acquired in 
Methanol-d4 and CDCl3 on a Bruker Ascend 700 spectrometer with a 5 mm TXI cryoprobe (1H at 700 MHz, 
13C at 175 MHz) NMR spectrometer. To elucidate the planar structure of the molecules 1H, 13C as well as 
H-H DQFCOSY, HSQC and HMBC data are acquired. DQFCOSY, HSQC, HMBC, and ROESY experiments were 
recorded using standard pulse programs. The NMR signals are grouped in the tables below and correspond 
to the numbering in the scheme above. NMR data fits well to the data for myxothiazol A, desmethyl-
myxothiazol Z and myxothiazol Z in the original publications. [13,14] 
Table S 8. NMR Signals of desmethyl-myxothiazol Z in CDCl3 
Carbon 
number 
δ 1H  
[ppm] 
Multiplicity, J 
[Hz] and proton 
number 
δ 13C 
[ppm] 
COSY correlations 
[ppm] 
HMBC correlations [ppm] 
1+3 1.000 d, 7.10, 6H 22.20 2.330 30.9, 141.8 
2 2.330 d sp, 7.10 ,1H 30.90 1.00, 5.68 22.20,  126.4, 142.3,  
4 5.680 d d, 7.1 14.5, 1H 143.30 2.33, 6.01 22.20, 30.9, 131.7 
5 6.010 d d, 10.5 15.3, 1H 126.40 5.68, 6.01 22.20, 30.9, 126.4, 132.2 
6 6.170 d d, 10.5 15.0, 1H 131.00 5.78, 6.01 41.0, 126.7,132.2, 142.3, 176.1 
7 5.780 d d, 7.5 15.0, 1H 132.20 6.17, 3.93 41.0, 20.5, 126.5, 131.7, 142.3, 176.1 
8 3.930 d q, 7.4 7.5, 1H 41.00 1.53, 5.78 20.5, 126.4, 132.2, 143.3, 148.4, 176.1 
8a 1.560 d, 7.4, 3H 20.50 3.930 41.0, 132.2, 176.1 
9 - - 176.10 - - 
10 7.810 s, 1H 115.72 - 148.4, 176.6 
11 - - 148.40 - - 
12 - - 162.40 - - 
13 7.100 s, 1H 115.40 - 125.7, 148.4, 154.10, 162.4 
14 - - 154.10 - - 
15 6.580 d, 15.8, 1H  125.70 6.380 39.90, 83.30,115.40,131.40,154.10 
16 6.380 
d d, 8.1 15.8, 1H 
  
131.10 3.81, 6.58 39.90, 83.30, 115.40,125.70, 154.10 
17 3.810 dd, 8.0 8.9, 1H 84.30 4.15,6.38 
14.3, 39.90, 56.70, 125.7, 131.1, 
154.10, 178.2 
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17a 3.330 s, 3H 56.70 - 84.30 
18 4.150 dq, 7.0 8.0, 1H 39.90 1.22, 3.81 14.3, 56.7, 84.3, 90.90, 178.2 
18a 1.220 d, 7.0, 3H 14.03 4.150 39.9, 84.30, 178.20 
20 - - 178.200 - - 
20a 3.620 s, 3H 55.60 - 90.9, 171.2, 178.2 
21 4.980 s, 1H 90.90 - 39.9, 171.2, 178.2 
22 - - 171.20 - - 
 
 
Table S 9. NMR Signals of myxothiazol Z in Methanol-d4 
Carbon 
number 
δ 1H  
[ppm] 
Multiplicity, J 
[Hz] and proton 
number 
δ 13C 
[ppm] 
COSY correlations 
[ppm] 
HMBC correlations [ppm] 
1+3 1.009 d, 6.74, 6H 22.61 2.340 32.2, 143.0 
2 2.340 d sp,7 7.52, 1H 32.20 1.009, 5.68 22.6, 143.3, 127.7 
4 5.680 d d,7 15.5, 1H 143.00 2.34, 6.03 22.6, 32.2, 133.1 
5 6.030 d d,10.4 15.5, 1H 127.70 5.68, 6.21 32.2, 133.1, 133.3 
6 6.210 d d, 10.4 15.3, 1H 133.10 5.78, 6.03 41.8, 127.7, 133.3, 143.3, 177.8 
7 5.780 d d, 7.8, 15.3 1H 133.30 3.92, 6.21 21.0, 41.8, 127.7, 143.3, 170.2, 177.8 
8 3.920 d q, 6.9 7.8, 1H 41.80 1.52, 5.78 21.0, 133.1, 133.3, 177.8 
8a 1.520 d, 7.0,1H 21.00 3.920 41.8, 132.3, 177.8 
9 - - 177.800 - - 
10 8.000 s, 1H 116.90 - 41.8, 149.8, 164.2, 177.8 
11 - - 149.80 - - 
12 - - 164.20 - - 
13 7.351 s, 1H 117.10 - 126.8, 164.2, 155.3 
14 - - 155.30 - - 
15 6.580 d, 15.4 1H 126.80 6.340 85.6, 117.1, 132.0, 155.3 
16 6.340 d d, 8.6 15.4, 1H 132.00 6.58, 3.81 41.3, 85.6, 126.8, 155.3 
17 3.805 d d, 8.6, 1H 85.60 4.18, 6.34 14.8, 41.3, 57.0, 126.8, 132, 178.4 
17a 3.320 s, 3H 57.00 - 85.60 
18 4.183 m, 1H 41.30 1.21, 3.81 14.8, 57.0,  85.6, 178.4 
18a 1.210 d, 6.8, 3H 14.80 4.180 41.3, 85.6,178.4 
20 -   178.400 - - 
20a 3.610 s, 3H 56.80 - 91.8, 178.4 
21 5.040 s, 1H 91.80 - 41.3, 169.5,178.4 
22 - - 169.50 - - 
22a 3.610 s, 3H 51.30 - 91.8, 169.5 
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 Abstract 
Soil-living microbes are an important resource for the discovery of new natural products featuring 
great structural diversity, reflective of underlying biosynthetic pathways incorporating a wide range of 
intriguing small molecule building blocks. We report here the full structural elucidation, total synthesis and 
biosynthesis of chloromyxamides, new tetrapeptides from myxobacteria that display an unprecedented 6-
chloromethyl-5-methoxypipecolic acid (CMPA) substructure. Chemical synthesis – including an approach 
to access the CMPA unit – was pursued to confirm the structure of chloromyxamides and enabled 
determination of the absolute configuration in the CMPA ring. A model for non-ribosomal assembly of 
chloromyxamides was devised based on the combined evaluation of biosynthetic gene cluster sequence 
information and feeding of stable isotope labelled precursors, providing an insight into formation of the 
various chloromyxamide derivatives and CMPA biogenesis. 
 Introduction 
Natural products of microbial origin are a structurally diverse and ever increasing group of small 
molecules often exhibiting potent biological activity. Accordingly, bacterial secondary metabolites (SM) 
have a strong track record to become valuable lead structures in human disease areas and agriculture.[1] 
During evolution, bacteria developed complex biosynthetic machinery for SM biosynthesis that involves a 
wide range of enzymes catalyzing particular biotransformations. One prominent type of such machinery 
are the non-ribosomal peptide synthetases (NRPS). These multimodular megasynthetases accomplish the 
formation of peptide bonds independent from ribosomal translation, opening up the possibility to 
incorporate building blocks beyond the canonical amino acids.[2] Thus, non-ribosomally made peptides 
(NRP) cover an extended chemical space compared to ribosomally produced peptides. Structural diversity 
is further broadened by post-assembly modifications through the action of dedicated tailoring enzymes. 
Mirroring their wide structural variety, NRP fulfil diverse biological functions including defense against 
competing microorganisms or chemotaxis.[3] Several strategies are commonly employed for the discovery 
of new NRP from bacteria, including genome-mining, bioactivity-guided isolation and metabolome-mining 
approaches.[4] All three strategies have proven fruitful with myxobacteria, which are well-established 
producers of SM whilst being less extensively screened compared to e.g. the actinobacteria.[5] In this study, 
we applied a “compound first” screening method to uncover chloromyxamides as novel NRP from the rich 
secondary metabolomes of myxobacteria. Elucidation of their uncommon structures - including a building 
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block that is to date without precedent in known NRP - prompted confirmation through total synthesis as 
well as investigation of the underlying biosynthetic route. 
 Results and Discussion 
The starting point of our present work is defined by the identification of a family of chlorinated 
peptides from the myxobacterium Myxococcus sp. MCy10608 based on high-resolution mass 
spectrometric data. Isotope pattern analysis indicated mono-chlorination and MS2 analysis revealed non-
standard amino acid fragments, suggesting that these signals belong to a novel chlorinated NRP scaffold 
(Figure 1, section S 5.2 to 5.3).[6] Production titers for the new molecules from MCy10608 were however 
unstable, therefore structural characterization was only possible following the identification of alternative 
producers using our myxobacterial metabolome repository, revealing that Myxococcus sp. MCy10608, 
MCy10615 and Pyxidicoccus sp. MCy10649 produce congeners 1 to 5 in varying patterns (Figure 1).  
Figure 1. I) Phylogenetic tree constructed from 16S RNA gene sequence similarity of producer strains A) MCy10608, 
B) MCy10649 and C) MCy10615 within the order Myxococcales. II) Comparative LC-MS analysis of the three 
chloromyxamide producers highlights different variants in their extracts (1 chloromyxamide A, C24H39N4O6Cl; 2 
chloromyxamide B, C25H41N4O6Cl; 3 chloromyxamide C, C24H39N4O7Cl; 4 chloromyxamide D, C23H37N4O7Cl; 5 
chloromyxamide E, C25H41N4O6Cl). III) Structures of chloromyxamides elucidated by NMR and/or tandem MS 
spectrometry. IV) Key NMR correlations used for the structure elucidation of 1 (COSY correlation as a black dash, 
HMBC correlations as red arrow and ROESY correlation as green arrow). 
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Only strain MCy10615 afforded reliable production at increased scale, permitting the purification of 
chlorinated peptides named chloromyxamide A (1) and B (2) with yields sufficient for full structure 
elucidation. NMR spectroscopy using 1D and 2D homo- and heteronuclear experiments in combination 
with mass spectrometric analysis showed that these peptides contain the unprecedented chlorinated 
amino acid 6-chloromethyl-5-methoxypipecolic acid (CMPA). In addition, valine, pipecolic acid, proline, 
and 4-methylproline moieties were identified in the 2D NMR analyses of 1 and 2. Marfey’s analysis showed 
that these compounds contained L-Val, L-Pip and L-Pro (in 1), and L-Val, L-Pip, and (2S,4S)-4-MePro (in 2) 
(section S 5.5).[7] Tandem-MS analysis confirmed amino acid sequences for all chloromyxamides and 
provided structural information for family members C (3), D (4) and E (5) not isolated due to low yields in 
larger scale cultures (Figure 2, section S 5.2). Subsequent feeding studies using stable isotope labelled 
amino acids proved that all chloromyxamides are synthesized via a common route and shed light on the 
biogenesis of incorporated non-canonical amino acids (Figure 2, section S 5.3).  
Figure 2. I) Fragmentation of 1 in tandem MS experiments when targeting the native form (black) or after feeding 
with labelled biosynthetic precursors (red, Glu-2,3,3,4,4-d5; blue, Lys-13C6,15N2; green, Lys-13C5,15N), II) corresponding  
tandem MS spectra of 1 after selectively targeting the  MS peaks of the native structure (black) and after labelled 
precursor feeding (red, blue, green) and  III) Fragmentation of 2 to 5 in tandem MS experiments when targeting the 
native form and color coding of the amino acid precursor incorporation (purple, L-Leu-5,5,5-d3) 
Taken together, we conclude that i) biosynthesis of the CMPA substructure found in all 
chloromyxamides starts with glutamic acid that is extended with a C2 unit and subsequently cyclized, ii) 
pipecolic acid units in 1, 2, 3 and 5 originate from lysine, iii) hydroxyproline (Hyp) in 3 and 4 stems from 
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direct oxidation of proline, and iv) biosynthesis of the methyl proline unit in 2 is analogous to the methyl 
proline pathway described in griselimycin biosynthesis (Figures 2 and 3, section S 5.3 to 5.4).[8] 
Unfortunately, isolation of 3 and 4 in amounts sufficient for NMR analysis was unsuccessful; we were thus 
unable to determine whether these chloromyxamide congeners contain 3- or 4-hydroxyproline (section S 
5.3 and 5.4). We next sought to elucidate the absolute stereochemistry of the CMPA moiety in 
chloromyxamides, but could not achieve this by Marfey’s method since we lacked standard material. 
Therefore, we chose to determine its relative configuration via determination of the homonuclear coupling 
constants in an S3 HMBC experiment. By analysis of JHH and δH and comparison to reference values and 
coupling constants calculated by molecular modelling (section S 5.7), the relative configuration could be 
either (2S,5S,6S) or (2R,5R,6R).[9] In order to confirm the structure of the novel chloromyxamide scaffold 
and to clarify the absolute stereochemistry of the CMPA unit we set out for total synthesis of 1. The 
synthesis of the C-terminal tripeptide 9 was straightforward, beginning with protected L-proline 6 (Scheme 
1).  
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Scheme 1. Synthesis of the tripeptide building block 9. 
The synthesis of the unusual S,S,S-configured N-terminal amino acid started from protected D-serine 
10 which was first converted into the corresponding Weinreb amide 11 (Scheme 2). Treatment of 11 with 
Grignard reagent led to the ketone 12 which was stereoselectively reduced to alcohol 13.[10,11] To 
determine the configuration of the new formed stereogenic center, 13 was converted into oxazolidinone 
14 with sodium hydride. The coupling constant of 7.8 Hz is in agreement with literature values for the syn-
oxazolidinone.[11] Selective O-methylation of 13 failed under several tested conditions (MeI/NaH, 
MeI/LHDMS, MeOTf/2,6-DTBMP or (MeO)3BF4/ proton sponge).[12] We either observed the formation of 
oxazolidinone 14, N-methylation or low conversion rates.  
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Scheme 2. Synthesis of chloromyxamide A 
Finally, we achieved selective O-methylation by converting 13 into the corresponding benzylidene 
imine, which was then selectively methylated to 15, which was converted into Cbz-protected 16. To 
optimize the following Sharpless dihydroxylation several ligands and solvents have been tested, the best 
results delivered 17 in 96% yield and with an d.r. of 80:20. After selective TBS-protection of the primary 
alcohol, the secondary alcohol was transformed into mesylate 18. Other leaving groups like tosylates or 
an epoxide led to unsatisfactory results in the ring closing reaction. To access the piperidine ring, 18 was 
subjected to sodium hydride, which afforded the two diastereomers 19a and 19b. The low 
diastereoselectivity might be caused as the reaction proceeds via an SN1-mechanism. Both diastereomers 
19a and 19b were then desilylated with acetyl chloride in methanol and converted into the corresponding 
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oxazolidinones 21 as described above. Their configuration was assigned by comparing NOE-DIFF-spectra 
and the crystal structure of 21a, which possesses the natural product’s configuration. 20a was 
subsequently oxidized using a variant of the Epp-Widlanski oxidation to 22.[13] The initial route towards 1 
was designed to introduce the chlorine directly to the tetrapeptide at a late stage. To achieve this, we first 
coupled the two building blocks 22 and 9 to the linear tetrapeptide, but unfortunately, we were not able 
to cleave the benzyl ether from the N-terminus even under harsh hydrogenation conditions.[14] Therefore, 
we decided to synthesize CMPA before incorporation into the tetrapeptide. Esterification, catalytic 
hydrogenation and subsequent treatment with thionyl chloride provided the chlorinated methyl ester, 
which was cleaved to the free acid 23. Coupling with 9 using COMU provided 24 which was purified by 
HPLC (section S 6.2.20). Cleavage of the tert-butyl ester with formic acid finally provided chloromyxamide 
A (1). The analytical data were in accordance with the isolated natural product proving the unprecedented 
CMPA amino acid to be (S,S,S)-configured (section S 6.3.2). 
Bioinformatic analysis of the genome of Myxococcus sp. MCy10608 uncovered a non-ribosomal 
peptide synthetase (NRPS) biosynthesis gene cluster (BGC) matching the chloromyxamide scaffold (Figure 
3, Table S 2).[15] Core functions of the cmx NRPS system are encoded by cmxA-R, including a three module 
NRPS assembly line encoded by cmxB, complemented by export-related (CmxC) and tailoring (CmxA, CmxD 
to CmxH) functions and enzymes involved in the biosynthesis of CMPA from glutamic acid (CmxI to CmxR). 
Since MCy10608 was inaccessible through genetic manipulation despite serious efforts, we devised a 
biosynthesis hypothesis based on feeding experiments and in-silico analysis (Figure 3). Chloromyxamide 
biosynthesis begins with formation of the CMPA unit: the integral adenylation domain of CmxM adenylates 
glutamic acid and transfers it to the amino acyl carrier protein CmxD, a homolog of LysW, which is bound 
to L-glutamate during lysine biosynthesis.[16] Next, the acetyl-CoA acetyltransferase-like protein CmxP 
catalyzes chain elongation of said glutamate through decarboxylative Claisen condensation utilizing 
malonyl-CoA. The CmxD bound reduced species is likely dehydrated by the enoyl-CoA hydratase protein 
CmxJ to produce the α,β- unsaturated precursor that is subsequently reduced by one of several 
dehydrogenase enzyme candidates (Table S 2). The crucial cyclisation step in CMPA biosynthesis is 
probably a chlorination-induced cyclisation giving rise to the pipecolic acid type backbone structure (Figure 
3 panel II). CmxH encodes a matching diheme dioxygenase that might serve as a chloroperoxidase forming 
the Cl+ species necessary for electrophilic attack on the remaining double bond. This halogenated cationic 
intermediate would be prone to intramolecular cyclisation, thus completing the observed six-ring 
structure of CMPA. Similar halogenation-induced cyclisation reactions are used for six membered ring 
formation in chemical synthesis.[17] Chlorination induced cyclisation to synthesize non-canonical amino 
acids has also been described for cyclopropyl ring formation during coronatin biosynthesis, although in 
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that case the chlorine does not remain on the CMA as it is lost in an SN2 reaction.[18] The SAM-dependent 
O-methyl transferase CmxG finally methylates the amino acid’s hydroxyl group to form the methoxy group 
of CMPA. Although we were not yet able to biochemically underpin all steps in the biosynthesis of the 
unprecedented CMPA unit, incorporation of five deuterium atoms into the chloromyxamides upon feeding 
with L-glutamic acid-d5 proves the CMPA unit to be synthesized via glutamic acid. CMPA is transferred to 
the NRPS assembly line encoded on CmxB as CmxD-bound intermediate. The three modules with predicted 
substrate specificities for Val, Pip and Pro form the three peptide bonds present in all chloromyxamide 
derivatives. Pip required for the biosynthesis of 1, 2, 3 and 5 is synthesized by the TubZ-homolog CmxA 
(Figure S 2) as concluded from 13C6 15N2 L-Lys feeding: loss of one 15N atom is congruent with lysine 
cyclization.[19] Module 1 of the NRPS assembly line encoded on cmxB strictly incorporates valine into the 
final structure, whereas module 2 alternatively allows the incorporation of proline as seen in 4.  
Figure 3. I) Chloromyxamide BGC (~47000 bps, 28 ORFs) and proposed biosynthesis of 1 to 5 (blue: NRPS 
genes/domains, green: tailoring genes/enzymes, red: regulatory gene, grey: ORFs of unknown function). II) Proposed 
formation of the CMPA unit from L-glutamic acid. III) Reactions that lead to supply of non-canonical amino acids used 
in chloromyxamide biosynthesis; the asterisk marks reactions proven by stable isotope labelling that could not be 
attributed to a candidate biosynthetic enzyme encoded within the BGC.  
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The flexibility of module 3 on CmxB is a noteworthy feature of chloromyxamide biosynthesis due to 
incorporation of cyclic amino acids proline, methyl proline, hydroxy proline or pipecolic acid, with ratios 
apparently depending on the specific producer. However, a methyl proline operon as known from 
griselimycin biosynthesis and a proline hydroxylation pathway for 3- or 4- hydroxyproline is not encoded 
within the cmx BGC.[8,20] These functions are thus likely encoded at distant genomic loci and the necessary 
building blocks recruited to CmxB as free amino acids. Despite their intriguing biosynthesis, identification 
of the biological role of chloromyxamides requires further studies as testing a panel of microorganisms 
and cell lines did not reveal significant biological activities (section S 5.9). 
 Conclusion and Outlook 
The vast diversity of yet unidentified natural products contained in myxobacterial secondary 
metabolomes translates into outstanding chances for the discovery of new scaffolds through “compound 
first” approaches, exemplified in this study by applying a simple yet effective filter (i.e. halogenation and 
informative MS2 fragmentation) to highlight NRP compounds likely to represent structural novelty. At the 
same time, our work underpins the importance of combining analytical, genomics-based and synthetic 
efforts for natural product discovery, since full structural elucidation of chloromyxamides including the 
absolute configuration of the unprecedented CMPA unit was achieved with the help of total synthesis. The 
CMPA building block present in chloromyxamides is peculiar both because of its biogenesis starting from 
glutamic acid and its intriguing substructure, as amino acids bearing a chlorine atom attached to an sp3 
carbon are rare in nature. 
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 Taxonomic evaluation of the chloromyxamide producer strains 
The myxobacterial strains analyzed in this study belong to the cystobacterinae suborder among the 
myxobacteria. MCy10608 and MCy10615 were isolated by Ram Prasad Awal and MCy10649 was isolated 
by Ronald Garcia from top soil samples. As the strain MCy10608 has been sequenced by Pac-Bio 
sequencing (Pacific Biosciences, Menlo Park, CA, USA) while the other two strains (MCy10615 and 
MCy10649) were characterized by 16s RNA gene similarity (TAQ Polymerase, Thermo Scientific; 
sequencing at LGC Biosciences) we can investigate their phylogeny more closely.  
 
Figure S 1. Phylogenetic tree of the published myxobacteria belonging to the Myxococcaceae family and highlighting 
of the different chloromyxamide producer strains MCy10608, MCy10615 and MCy1049 
The strains MCy10608 and MCy10615 belong to the Myxococcus clade and are related to the type 
strain for Myxococcus macrosporus. Still, sequence homology is too low to characterize MCy10608 and 
MCy10615 as a Myxococcus macrosporus meaning the strains will be referred to as Myxococcus species in 
this work. MCy10649 on the other hand is more closely related to the type strain of Pyxidicoccus fallax 
meaning that this bacterium most likely represents a new species of the Pyxidicoccus genus and will thus 
be referred to as Pyxidicoccus species. Although the three strains MCy10608, MCy10615 and MCy10649 
produce the same secondary metabolite (chloromyxamide A, 1) they are phylogenetically rather far apart. 
More astoundingly, the two myxobacterial strains MCy10615 and MCy10649 producing 1 and the 4-
methylproline derivative chloromyxamide B are actually more distantly related than MCy10615 and 
MCy10608 which only share the metabolite 1 (Table S 3). The distribution of the different types of 
chloromyxamide biosynthetic gene clusters is therefore rather widespread across the Myxococcaceae 
family and more closely related gene clusters are actually present in less closely related bacteria. It is thus 
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likely that this biosynthetic gene cluster has been passed on during evolution via horizontal gene transfer 
steps rather than divergent evolution. 
 Myxobacterial growth conditions and analytical setup 
S 4.2.1 Myxobacterial culture media 
Table S 1. Medium recipe of VY/2-S medium used for cultivation of all myxobacteria in this study 
VYGS – Medium 
Amount Ingredient Concentration Supplier 
5 g/L Baker’s Yeast - Lynco 
10  g/L Starch (soluble) - Roth 
1 g/L CaCl2 - Sigma Aldrich 
1 g/L MgSO4  x 7H2O - Grüssing 
10 mL/L TRIS pH 8 1M Sigma Aldrich 
100 µL/L 
Sterile Vit. B12 solution 
(add after autoclaving) 
1 mg/ml Roth 
200 µL/L 
Sterile FeEDTA solution 
(add after autoclaving) 
8 mg/ml Sigma Aldrich 
50 µL/L 
Sterile Riboflavin 
solution 
(add after autoclaving) 
1 mg/ml Roth 
Dissolved in milliq. water pH adjusted to 7.2 with 1N KOH 
 
For the preparation of agar media, medium was prepared adding 14 g/L agar (BD) to the liquid 
medium. 
S 4.2.2 Small scale myxobacterial fermentations for acquisition of UPLC-HRMS data 
Cultures for UHPLC/HRMS analysis are grown in 300 ml Erlenmeyer flasks containing 50 ml of VY/2S 
medium for Myxococcus sp. MCy10608, Pyxidicoccus sp. MCy10649 or Myxococcus sp. MCy10615 
inoculated with 1 ml of pre culture. After inoculation the medium is supplemented with 2% of sterile XAD-
16 adsorber resin (Sigma Aldrich) suspension in water. The strains are grown in VYGS medium at 30°C for 
12-15 days on a gyratory shaker at 160 rpm. Fermentation is complete once the white VY/2-S medium 
turned transparent and spherical myxobacterial bio-film clumps are visible in the shake flask. 
S 4.2.3 Extraction procedures of myxobacterial fermentation cultures in analytical 
scale 
The frozen cell pellet is transferred into a 100 ml Erlenmeyer flask and a magnetic stirrer is added. 50 
ml of acetone (Fluka analytical grade, redistilled in house) are added onto the pellet and the mixture is 
stirred for 60 min. on a magnetic stirrer. The acetone has to be distilled beforehand since Fluka analytical 
reagent grade acetone still contains trace amount of polymer impurities that will otherwise concentrate 
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in the extract. The acetonic extract is left to settle in order to sediment cell debris and XAD resin for a 
second extraction step. The supernatant is filtered with a 125 micron folded filter keeping cell pellet and 
XAD-16 resin in the Erlenmeyer flask for a second extraction step. The residual pellet and XAD-16 resin is 
extracted again with 30 ml of distilled acetone for 60 min on a magnetic stirrer and filtered through the 
same folded filter. The combined extracts are transferred into a 100 ml round bottom flask. The acetone 
is evaporated on a rotary evaporator at 260 mbar and 40 °C water bath temperature. The residual water 
is evaporated at 20 mbar until the residue in the flask is completely dry. The residue is taken up in 550 μl 
of methanol (Chromasolv HPLC grade, Sigma Aldrich) and transferred into a 1.5 ml Eppendorf tube. This 
tube is centrifuged with Heareus biofuge pico at 13000 rpm for 3 minutes to remove residual insolubilities 
such as salts, cell debris and XAD fragments. 
S 4.2.4 Standardized UHPLC MS method for screening of myxobacterial crude extracts 
All measurements were performed on a Dionex (Germering, Germany) 
Ultimate 3000 RSLC system using a Waters (Eschborn, Germany) BEH C18 column (50 x 2.1 mm, 1.7 µm) 
equipped with a Waters VanGuard BEH C18 1.7 µm guard column. Separation of 1 µl sample was achieved 
by a linear gradient from (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µL/min and a 
column temperature of 45 °C. Gradient conditions were as follows: 0 – 0.5 min, 5% B; 0.5 – 18.5 min, 5 – 
95% B; 18.5 – 20.5 min, 95% B; 20.5 – 21 min, 95 – 5% B; 21-22.5 min, 5% B. UV spectra were recorded by 
a DAD in the range from 200 to 600 nm. The LC flow was split to 75 µL/min before entering the Bruker 
Daltonics maXis 4G hr-qToF mass spectrometer (Bremen, Germany) using the Apollo II ESI source.  Mass 
spectra were acquired in centroid mode ranging from 150 – 2500 m/z at a 2 Hz full scan rate. Mass 
spectrometry source parameters are set to 500 V as end plate offset; 4000 V as capillary voltage; nebulizer 
gas pressure 1 bar; dry gas flow of 5 l/min and a dry temperature of 200°C.  Ion transfer and quadrupole 
settings are set to Funnel RF 350 Vpp; Multipole RF 400 Vpp as transfer settings and Ion energy of 5 eV as 
well as a low mass cut of 300 m/z as Quadrupole settings. Collision cell is set to 5.0 eV and pre pulse storage 
time is set to 5 µs. Spectra acquisition rate is set to 2Hz. Calibration is done automatically before every LC-
MS run by injection of sodium formate and calibration on the sodium formate clusters forming in the ESI 
source. All MS analyses are acquired in the presence of the lock masses C12H19F12N3O6P3; C18H19O6N3P3F2 
and C24H19F36N3O6P3 which generate the [M+H]+ ions of 622.028960; 922.009798 and 1221.990638. 
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S 4.2.5 UHPLC Coupled SPL-MS² method to determine stable isotope labelled amino 
acid incorporation 
All measurements were performed on a Dionex (Germering, Germany) 
Ultimate 3000 RSLC system using a Waters (Eschborn, Germany) BEH C18 column (50 x 2.1 mm, 1.7 µm) 
equipped with a Waters VanGuard BEH C18 1.7 µm guard column coupled to the Bruker Daltonics maXis 
4G hr-qToF mass spectrometer (Bremen, Germany) as described in S 4.2.4. LC and MS conditions of the 
SPL guided MS/MS data acquisitions are kept constant according to section standardized UHPLC-MS 
conditions. MS/MS data acquisition parameters are set to exclusively fragment scheduled precursor list 
entries. Scheduled precursor list entries are edited manually to selectively target the precursor masses of 
the stable isotope labelled chloromyxamides (section S S 4.5.3). This allows following up the labelled part 
in the tandem MS spectrum. SPL tolerance parameters for precursor ion selection are set to 0.2 minutes 
and 0.05 m/z in the SPL MS/MS method. The method picks up to 2 precursors per cycle, applies smart 
exclusion after 5 spectra and performs CID and MS/MS spectra acquisition time ramping. CID Energy is 
ramped from 35 eV for 500 m/z to 45 eV for 1000 m/z and 60 eV for 2000 m/z. MS full scan acquisition 
rate is set to 2Hz and MS/MS spectra acquisition rates are ramped from 1 to 4 Hz for precursor Ion 
intensities of 10 kcts. to 1000 kcts.. 
 Molecular biology protocols 
S 4.3.1 Isolation of genomic DNA for PacBio sequencing 
To isolate total DNA for sequencing purposes such as illumina sequencing, phenol-chloroform gDNA 
extraction is used. In silico analysis of the chloromyxamide gene cluster 
 In silico analysis of the cmx biosynthetic gene cluster 
Identification of the biosynthetic gene cluster was done upon identification of a three modular NRPS 
gene called cmxB with a NRPS predictor 2 hidden markov model prediction of valine, proline and proline, 
which fits well to the structures observed for the chloromyxamides.[1] Prediction of the cluster borders was 
done by examination of the flanking regions to the right and to the left of the central cmxB gene. While 
cmxA to cmxS encode biosynthesis genes, open reading frame (orf) 1 to orf 10 encode genes most likely 
unrelated to natural products biosynthesis or natural product tailoring and are therefore excluded from 
the putative chloromyxamide biosynthesis gene cluster. 
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Table S 2. Genes of the chloromyxamide biosynthesis gene cluster, predicted gene function and their closest 
homologue determined by blastp search against NCBI non-redundant protein database (nr) 
Gene Length 
[bp] 
Closest homologue 
[Organism of origin] 
Identity [%] 
/length of 
alignment 
[AA] 
Proposed function Accession Nr. 
cmxA 1101 Ornithine cyclodeaminase 
[Pseudomonas sp.] 
71.2 / 341 Pipecolic acid synthesis WP_057005626 
cmxB 10347 hybrid non-ribosomal peptide 
synthetase/type I polyketide 
synthase [Archangium gephyra] 
70.8 / 3200 Non-ribosomal peptide 
synthesis 
WP_047856741 
cmxC 1257 MFS transporter [Myxococcus 
xanthus] 
75.3 / 391 Compound secretion WP_014442384 
cmxD 198 lysine biosynthesis protein LysW 
[Corallococcus coralloides] 
73.0 / 50 Chloromethyl-Methoxy-
Pipecolic acid carrier Protein 
WP_014394897 
cmxE 864 Phage major capsid Protein 
[Micromonospora peucetia] 
73.8 / 271 - SCL73402 
cmxF 1125 hypothetical protein [Stigmatella 
erecta] 
79.4  / 324 - WP_093525581 
cmxG 969 SAM-dependent 
methyltransferase [Myxococcus 
fulvus] 
94.6 / 322 O-Methyltransfer WP_046714637 
cmxH 2022 rubber oxygenase A [Myxococcus 
fulvus] 
83.5 / 674 Chloroperoxidase AGT20509 
cmxI 417 hypothetical protein 
[Myxococcus hansupus] 
68.5 / 124 - WP_082282800 
cmxJ 843 enoyl-CoA hydratase 
[Myxococcus fulvus] 
88.2 / 280 Dehydration reaction in 
Chloromethyl-Methoxy-
Pipecolic acid synthesis 
WP_074955256 
cmxK 687 TetR/AcrR family transcriptional 
regulator [Myxococcus fulvus] 
85.1 / 228 Chloromyxamide regulation WP_046714629 
cmxL 828 NAD(P)-dependent 
oxidoreductase [Myxococcus 
fulvus] 
92.4 / 275 Reduction in Chloromethyl-
Methoxy-Pipecolic acid 
synthesis 
WP_074955260 
cmxM 1839 AMP-dependent synthetase 
[Myxococcus fulvus] 
85.9 / 612 Glutamic acid activation and 
loading protein 
WP_046714631 
cmxN 1140 acyl-CoA dehydrogenase 
[Myxococcus fulvus] 
87.9 / 381 Reduction in Chloromethyl-
Methoxy-Pipecolic acid 
synthesis 
WP_074955266 
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cmxO 1149 acyl-CoA dehydrogenase 
[Myxococcus fulvus] 
91.9 / 382 Reduction in Chloromethyl-
Methoxy-Pipecolic acid 
synthesis 
WP_046714633 
cmxP 1212 acetyl-CoA acetyltransferase 
[Myxococcus stipitatus] 
92.6 / 403 Glutamic acid acetyl transfer WP_015350521 
cmxQ 2178 3-hydroxyacyl-CoA 
dehydrogenase [Myxococcus 
fulvus] 
92.0 / 725 Reduction in Chloromethyl-
Methoxy-Pipecolic acid 
synthesis 
WP_074955272 
cmxR 1407 aldehyde dehydrogenase family 
protein [Myxococcus virescens] 
84.0 / 468 Reduction in Chloromethyl-
Methoxy-Pipecolic acid 
synthesis 
WP_090487166 
cmxS 1008 zinc-binding alcohol 
dehydrogenase family protein 
[Pseudomonas composti] 
72.5 / 338 Reduction in Chloromethyl-
Methoxy-Pipecolic acid 
synthesis 
WP_061240899 
orf1 1437 DUF3375 domain-containing 
protein [Myxococcus fulvus] 
88.3 / 478 - WP_074955289 
orf2 615 DUF4194 domain-containing 
protein [Myxococcus stipitatus] 
77.1 / 201 - WP_015350529 
orf3 3384 ATP-dependent exonuclease 
SbcCD, C subunit-like protein 
[Myxococcus fulvus] 
76.2 / 1127 - WP_074955283 
orf4 1188 hypothetical protein 
[Ectothiorhodospira sp. PHS-1] 
53.6 / 390 - WP_008932172 
orf5 1284 phosphopyruvate hydratase 
[Myxococcus stipitatus] 
94.3 / 425 - WP_015350527 
orf6 1032 hypothetical protein 
[Myxococcus fulvus] 
81.5 / 343 - WP_074955281 
orf7 1545 VCBS repeat-containing protein 
[Cystobacter fuscus] 
57.6 / 488 - WP_002632442 
orf8 516 hypothetical protein 
[Myxococcus stipitatus] 
50.3 / 178 - WP_015350520 
orf9 903 bifunctional 5,10-methylene-
tetrahydrofolate 
dehydrogenase/ 5,10-
methylene-tetrahydrofolate 
cyclohydrolase [Myxococcus 
fulvus 124B02] 
91.8 / 291 - AKF82340 
orf10 1719 cobalamin-binding protein 
[Myxococcus fulvus] 
84.1 / 571 - WP_046711853 
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The chloromyxamide biosynthetic gene cluster from Myxococcus species MCy10608 will be deposited 
in GenBank under accession number MH168382 upon publication. 
S 4.4.1 In silico evaluation of the cmxA gene 
In order to validate CmxA to be a pipecolic acid producing lysine cyclodeaminase the protein is aligned 
with the TubZ protein from An d48 that furnishes pipecolic acid in the tubulysin biosynthesis.[2] 
 
 
Figure S 2. MUSCLE alignment of the CmxA gene to the TubZ protein, a validated lysine cyclodeaminase from 
Pyxidicoccus fallax An d48 [3] 
 Isolation and structure elucidation of chloromyxamide A and B 
S 4.5.1 Isolation of chloromyxamide A and B from MCy10615 
A 10-liter culture of MCy10615 in liquid VY/2 medium [4] added 2% amberlite resin XAD-16 (Sigma) 
was grown for 5 days at 160 rpm and 30 °C and after centrifugation the cell pellet and XAD-16 was 
extracted with 1:1 acetone/MeOH (8x250 mL) to yield 4.16 g of raw extract. This was dissolved in 10 ml 
MeOH and after centrifugation the extract was loaded onto a sephadex LH-20 column (Ø 2.5 × 80 cm) and 
eluted with MeOH at a reduced flow of about 4 sec/drop. Fractions of 450 droplets were collected and 
fractions were pooled based on LCMS analysis. Liquid extraction using water/CHCl3 yielded 
chloromyxamide A (1) and chloromyxamide B (2) in the chloroform fraction containing a total of 425 mg 
solid material. This was further purified on a preparative Waters HPLC-MS system with H2O and MeOH 
(+0.1 % FA) on an XBridge C18 column (5 µm, 19x150 mm) at a flow rate of 17.06 ml/min going from 20-
45% MeOH in 27 min with compound 1 eluting at 16 min (1.9 mg semipure fraction) and 2 eluting at 21 
min (3.3 mg semipure fraction). Final purification steps on a semipreparative HCT HPLC-MS system using 
a Luna C18 column (4.6 x 250 mm, 5µm) at 45 °C with H2O and MeCN (+0.1% FA) going from 5% MeCN to 
15% in 4 min, then to 25% (to 28% for 2) in 18 min yielded pure 1 (0.31 mg, 14.6 min) and 2 (0.28 mg, 17.2 
min). 
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S 4.5.2 Characterization of all detected chloromyxamides 
 
Chloromyxamide A (1): white amorphous solid, [α] = 48.2° (c 0.19, MeOH); NMR (700 MHz, 
methanol-d4 and DMSO-d6) see NMR tables; HRESIMS m/z 515.2636 [M+H]+ (calcd. for C24H40ClN4O6, 
515.2631, Δ = 0.9 ppm). 
 
Chloromyxamide B (2): white amorphous solid, [α] = 34.1° (c 0.15, MeOH); NMR (700 MHz, 
methanol-d4) see NMR tables; HRESIMS m/z 529.2791 [M+H]+ (calcd. for C25H42ClN4O6, 529.2787, Δ = 0.8 
ppm). 
 
Chloromyxamide C* (3): HRESIMS m/z 531.2583 [M+H]+ (calcd. for C24H40ClN4O7, 531.2580, Δ = 0.6 
ppm). This compound was not isolated due to low yields and unstable production. 
 
Chloromyxamide D* (4): HRESIMS m/z 517.2424 [M+H]+ (calcd. for C23H38ClN4O7, 517.2424, Δ = 0.1 
ppm). This compound was not isolated due to low yields and unstable production. 
 
Chloromyxamide E* (5): HRESIMS m/z 529.2793 [M+H]+ (calcd. for C25H42ClN4O6, 529.2789, Δ = 0.7 
ppm).  This compound was not isolated due to low yields and unstable production. 
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Figure S 3. Exact masses of all chloromyxamide derivatives as [M+H]+ ion acquired with our maXis 4G qTOF HRMS 
spectrometer in ESI positive mode, the retention time in the top right corner corresponds to the compounds retention 
time using our standard gradient, the number in the lower right corner corresponds to the respective chloromyxamide 
derivative 
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 Chloromyxamide production potential 
As mentioned in the main text, the three chloromyxamide producer strains MCy10608, MCy10615 
and MCy10649 produce different chloromyxamide derivatives. The chloromyxamide derivatives detected 
in each strain are grouped in Table S 3. 
Table S 3. Chloromyxamide production potential per strain 
Strain MCy10608 MCy10615 MCy10649 
Chloromyxamide A + + + 
Chloromyxamide B - + + 
Chloromyxamide C + - - 
Chloromyxamide D + - - 
Chloromyxamide E - - + 
Circular dichroism measurements were performed for natural chloromyxamide A and B as well as for 
synthetic chloromyxamide A at 1.0 mM in MeCN (Figure S 21 and Figure S 22). 
S 4.5.3 Stable isotope labelling of the chloromyxamides 
The non-canonical amino acids present in the chloromyxamide scaffold e.g. methyl proline, hydroxy 
proline and pipecolic acid are likely to be produced via the biosynthesis routes described in literature. 
These routes include the pipecolic acid synthesis by the TubZ analogon CmxA (Table S 2), methyl proline 
biosynthesis via oxidation and cyclisation of leucine as described in griselimycin biosynthesis and 
hydroxylation of proline by a prolyl-4-hydroxylase.[2,5,5,6] Secondly, according to our biosynthesis 
hypothesis as described by main text Figure 3, we hypothesized the novel 6-chloromethyl-5-
methoxypipecolic acid (CMPA) amino acid to be synthesized from glutamic acid. In order to support these 
theories with experimental evidence we fed the stable isotopically labelled amino acid precursors L-
leucine-5,5,5-d3, L-glutamic acid-2,3,3,4,4-d5, L-Lysine dihydrochloride-13C6,15N2 and L-proline-13C5,15N 
(Cambridge Isotope Labs). Feeding was achieved by adding a total amount of 2ml of a 25mM amino acid 
stock solution of the respective amino acid into a 25ml MCy10608 VY/2-S medium fermentation culture 
(for 1,3 and 4) or a MCy10649 VY/2-S medium fermentation culture (for 1,2 and 5) in a 100ml Erlenmeyer 
flask. The amino acid stock solutions are prepared in dd-H2O except for L-leucine-5,5,5-d3 that is dissolved 
in 50:50 H2O:MeOH due to solubility issues. Extraction is done according to standard protocol for LC-MS 
samples (section S S 4.2). 
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 Feeding of L-glutamic acid-2,3,3,4,4-d5 
As expected, feeding of L-glutamic acid-2,3,3,4,4-d5 led to a mass shift of approx. +5 Da in all the 
chloromyxamide derivatives as all of them possess the CMPA unit. The +4 Da peak is also elevated as amino 
acids featuring a deuterium atom in C-2 position suffer from H-D exchange that forms L-glutamic acid-
3,3,4,4-d4 which is also incorporated to a minor extent. 
 
Figure S 4. Exact masses of all chloromyxamide derivatives as [M+H]+ ion acquired with our maXis 4G qTOF HRMS 
spectrometer in ESI positive mode after feeding of L-glutamic acid-2,3,3,4,4-d5, the number in the lower right corner 
corresponds to the respective chloromyxamide derivative, exact monoisotopic mass of the unlabeled derivative is 
depicted in black, exact mass of the chloromyxamide-d5 derivatives is depicted in red 
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 Feeding of L-lysine dihydrochloride-13C6,15N2 
Since during pipecolic acid biosynthesis by the CmxA protein Lysine is cyclized we observe loss of one 
labelled nitrogen atom in L-lysine -13C6,15N2 during the formation of L-pipecolic acid-13C6,15N. This explains 
the observed +7 Da shifts upon lysine incorporation as pipecolic acid. Since 4 does not contain pipecolic 
acid, no mass shift is observed. 5 displays incorporation of two labelled pipecolic acid building blocks as 
one would expect since the structure contains two pipecolic acid amino acids (main Text Figure 2).  
 
Figure S 5. Exact masses of all chloromyxamide derivatives as [M+H]+ ion acquired with our maXis 4G qTOF HRMS 
spectrometer in ESI positive mode after feeding of L-lysine dihydrochloride-13C6,15N2, the number in the lower right 
corner corresponds to the respective chloromyxamide derivative, exact monoisotopic mass of the unlabeled derivative 
is depicted in black, exact mass of the chloromyxamide-13C6,15N2 and chloromyxamide-13C12,15N4 derivatives is 
depicted in blue 
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 Feeding of L-proline-13C5,15N 
As explained in S 4.5.3, the hydroxyproline in 3 and 4 as well as obviously the proline residues in 1 
and 2 provide from proline either via direct incorporation or via incorporation after hydroxylation. Ass all 
of these proline containing chloromyxamide derivatives are produced by MCy10608, labelled proline was 
not fed to the strains producing 2 and 5. Unfortunately, as explained in the main text, we were never able 
to isolate the hydroxyproline derivatives 3 and 4 in sufficient amounts to allow NMR based structure 
elucidation. Proline feeding as done in Figure S 6 proves that all hydroxyprolines provide from proline 
leading to labelling of 1 and 3 while double labelling 4 that contains proline and hydroxyproline. It is 
therefore likely that the hydroxyproline moiety is in fact 4-hydroxyproline as this amino acid is often 
observed in nature and also directly synthesized by hydroxylation of proline.[5] Unfortunately, as also 3-
hydroxyproline is observed in natural products we are unable to determine the exact position of the 
hydroxyl group on the terminal proline moiety.[7] 
 
Figure S 6. Exact masses of all chloromyxamide derivatives as [M+H]+ ion acquired with our maXis 4G qTOF HRMS 
spectrometer in ESI positive mode after feeding of L-proline-13C5,15N, the number in the lower right corner corresponds 
to the respective chloromyxamide derivative, exact monoisotopic mass of the unlabeled derivative is depicted in black, 
exact mass of the chloromyxamide-13C5,15N and chloromyxamide-13C10,15N2 derivatives is depicted in green 
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 Feeding of L-leucine-5,5,5-d3 
Since at this point, the origins of all non-canonical amino acids were determined except for the 
biosynthesis of the 4-methylproline we fed labelled lysine to MCy10649, the producer strain of the 4-
methylproline containing 2. According to the work on griselimycins, this amino acid should be synthesized 
from L-leucine although, as no genetic information is available on the producer strains of 2, we were 
unable to search for the corresponding genes.[6] Nevertheless, feeding of L-leucine-5,5,5-d3 to a MCy10649 
VY/2-S medium culture led to observation of extensive labelling of 2 indicated by the +3 Da precursor mass 
shift. Thus, Pyxidicoccus sp. MCy10649 most likely uses analogous enzymology to synthesize 4-
methylproline. 
 
Figure S 7. Exact masse of 2 as [M+H]+ ion acquired with our maXis 4G qTOF HRMS spectrometer in ESI positive mode 
after feeding of L-leucine-5,5,5-d3, exact monoisotopic mass of the unlabeled derivative is depicted in black, exact 
mass of the chloromyxamide B-d3 (2) is depicted in violet 
S 4.5.4 Determination of the position of the labelled amino acids by tandem MS 
experiments 
The chloromyxamides show very regular fragmentation in tandem MS experiments done according 
to our standard MS² protocol on our UHPLC hyphenated HRMS qTOF system (section S S 4.2). Therefore, 
upon stable isotope labelling of the chloromyxamides we can not only observe the general mass shifts of 
the precursor mass as described in S 4.5.3 but also follow up to determine the exact position of the labeled 
amino acid via MS² experiments. 
 Color-coded structure formulas indicating the incorporation of the different amino acids 
into the chloromyxamide scaffolds 
In order to assign every labelled amino acid to their respective position in the chloromyxamide 
scaffold we applied scheduled precursor list based MS² experiments that specifically target the labelled 
chloromyxamide precursor. Therefore, we can validate the position the labelled amino acid ends up in by 
following up labelling to the respective product ion in the tandem MS experiment. 
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Figure S 8. Color coded structure formulas indicating the incorporation of the different amino acids into the 
chloromyxamide scaffolds, the numbers represent the tandem MS product ions acquired with our maXis 4G qTOF 
HRMS spectrometer in ESI positive mode, the color coded parts represent carbon atoms providing from canonical 
amino acids as proven by tandem MS experiments on stable isotope labelled chloromyxamides as seen in S 4.5.4. 
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 Tandem MS analysis of stable isotope labelled chloromyxamide A (1) 
 
Figure S 9. Tandem MS² spectra of chloromyxamide A (1) of the control and from feeding experiments with different 
stable isotope labelled precursors 
  Chapter 4 The Chloromyxamides Supporting Information    201 
 Tandem MS analysis of stable isotope labelled chloromyxamide B (2) 
 
Figure S 10. Tandem MS² spectra of chloromyxamide B (2) of the control and from feeding experiments with different 
stable isotope labelled precursors 
 Tandem MS analysis of stable isotope labelled chloromyxamide C (3) 
 
Figure S 11. Tandem MS² spectra of chloromyxamide C (3) of the control and from feeding experiments with different 
stable isotope labelled precursors 
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 Tandem MS analysis of stable isotope labelled chloromyxamide D (4) 
 
Figure S 12. Tandem MS² spectra of chloromyxamide D (4) of the control and from feeding experiments with different 
stable isotope labelled precursors 
 
 Tandem MS analysis of stable isotope labelled chloromyxamide E (5) 
 
Figure S 13. Tandem MS² spectra of chloromyxamide E (5) of the control and from feeding experiments with different 
stable isotope labelled precursors 
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Tandem MS analysis of all chloromyxamide derivatives confirmed the amino acid sequences and 
furthermore made it possible to obtain structural information for additional chloromyxamide family 
members from MCy10608 and MCy10649 not isolated due to low yields in larger scale cultures. These 
compounds were named chloromyxamide C (3, C24H39N4O7Cl), D (4, C23H37N4O7Cl) and E (5, C25H41N4O6Cl). 
To obtain information-enriched tandem MS data for amino acid sequence analysis of chloromyxamides 
and to gain first insights into their biosynthesis, we supplemented MCy10615 cultures with stable isotope 
labelled amino acids. Feeding of L-glutamic acid-2,3,3,4,4-d5, L-leucine-5,5,5-d3, 13C5,15N-L-proline and 
13C6,15N2-L-lysine proved not only that the minor derivatives 3-5 are synthesized via the same route as 1 
and 2 but also shed light on the biogenesis of all non-canonical amino acids in chloromyxamide (main text 
Figure 3). MS² experiments focusing on the isotopically labelled chloromyxamides allowed to follow up on 
the position of every labelled amino acid in the peptide, supporting the biosynthetic origin not only for 1 
and 2 but also for 3-5.The CMPA-Val substructure is conserved in all chloromyxamide congeners as judged 
on the basis of the corresponding product ion (main text Figure 2). Furthermore, L-glutamic acid-2,3,3,4,4-
d5 feeding shows incorporation of glutamic acid into the CMPA unit as proven by MS² analysis selectively 
applied to the labelled chloromyxamide. Therefore, CMPA biosynthesis has to start from glutamic acid that 
is extended with a C2 unit and subsequently cyclized (main text Figure 3). All chloromyxamide congeners 
except 4 show a prominent product ion attributed to the CMPA-Val-Pip fragment, suggesting that 3 and 5 
also contain Pip as the third amino acid. Furthermore, feeding of 13C6, 15N2 L-lysine led to a +7 Da shift in 
the mass spectra of 1, 2 and 3 while a +7 and a +14 shift is observed for 5 indicating the presence of 1 
respective 2 pipecolic acid units in the molecule originating from lysine. Compound 4 shows instead a 
weaker fragment that is one CH2-unit smaller than CMPA-Val-Pip and which is not labelled by 13C6, 15N2 L-
lysine feeding. This fragment is assigned to CMPA-Val-Pro. Fragmentation is favored on the N-terminal 
side of Pro as well as on the C-terminal side of Pip, which in this case makes this position ideal for 
dissociation.[8] Compound 4 favors the formation of CMPA-Val and CMPA-Val-CO ions instead of the 
dissociation between the two proline residues. Contrary to all other chloromyxamides, 4 is not labelled by 
feeding of 13C6, 15N2 L-Lysin, which is the precursor of pipecolic acid, but instead displays a +12 Da shift 
upon feeding of 13C5, 15N L-proline; compound 4 thus seems to contain two proline moieties. As 1 and 2 
show a +6 Da shift upon feeding of 13C5, 15N L-proline we can draw two conclusions: i) Tandem MS data 
and feeding studies suggest 4 to possess a proline residue instead of the pipecolic acid moiety, and ii) the 
hydroxyproline residue present in 3 and 4 is synthesized via direct oxidation of proline. Labelling of 2 by L-
leucine-5,5,5-d3 at amino acid 4 ultimately reveals biosynthesis of the methyl proline unit in 2 as analogous 
to the methyl proline pathway described in griselimycin biosynthesis.[6] Unfortunately, isolation of 3 and 4 
in amounts sufficient for NMR analysis was unsuccessful; we were thus unable to determine whether these 
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chloromyxamide congeners contain 3- or 4- hydroxyproline. We can thus tell that the sequence of 1 to be 
CMPA-Val-Pip-Pro, the sequence of 2 to be CMPA-Val-Pip-4-MePro, the sequence of 3 to be CMPA-Val-
Pip-4-HydroxyPro, the sequence of 4 to be CMPA-Val-Pro-4-HydroxyPro and the sequence of 5 to be 
CMPA-Val-Pip-Pip. Furthermore, we verified CMPA to contain glutamic acid, hydroxyproline to be 
synthesized from proline, while 4-methylproline is synthesized from leucine. All these findings are in good 
agreement with the biosynthesis hypothesis we drafted for the chloromyxamides in main text Figure 3. 
S 4.5.5 Marfey’s analysis of 1 and 2 
Two portions each of 15 µg 1 and 2 were hydrolyzed in 100 µl 6 M HCl at 110 °C for 16 hours and 
redissolved in 50 µl H2O followed by addition of 20 µl 1 M NaHCO3 and 20 µl 1% L- or D-Marfey’s reagent 
in acetone (L-FDLA and D-FDLA, respectively). After reaction at 40 °C for 90 min, 10 µl 2 M HCl was added 
to neutralize the mixtures and then diluted with 150 µl MeCN. 
Derivatives of L- and D-amino acid standards (50 µl, 0.05 M of D- and L-Val, L-Pro, and L-Pip) were 
produced by the same procedure except the final dilution was done with 300 µl MeCN for the pure amino 
acids. Standard derivatives of (2S,4R)-4MePro and a mixture with all 4-MePro was generously provided by 
Kevin Sours. Analysis by LCMS on a Acquity BEH C18 (2.1 x 100 mm, 1.7 µm) using H2O-MeCN (0.1 % FA) 
at 0.55 ml/min going from 5-10 % MeCN in 1 min, to 35% in 14 min, to 50 % in 7 min and to 80 % in 3 min. 
Detection by DAD and UHPLC maXis4G qTOF HRMS in positive mode. 
L-FDLA derivatives eluted at 15.36 min (L-Pro), 17.02 min (L-Val), 17.07 min (D-Pro), 17.57 min (2S,4R-
4MePro), 18.80 min (D-Pip), 19.65 min (L-Pip), and 21.05 min (D-Val). D-FDLA derivatives eluted at 15.45 
min (D-Pro), 17.13 min (D-Val), 17.14 min (L-Pro), 18.68 min (L-Pip), 19.12 min (2S,4R-4MePro), 19.67 min 
(D-Pip), and 21.11 min (L-Val). Derivatives of the 4-MePro mixture eluted at 17.04, 17.54, 19.12, and 19.28 
min for both L- and D-FDLA.[9] 
Marfey’s analysis of 1 and 2 showed that the compounds contained L-Val, L-Pip and L-Pro (for 1), and 
L-Val, L-Pip, and (2S,4S)-4-MePro for 2.[9] The structure of 1 thus has the amino acid sequence 
CMPA-L-Val-L-Pip-L-Pro (Figure 1), whereas in 2 the proline is replaced by a (2S,4S)-4-methylproline giving 
the sequence CMPA-L-Val-L-Pip-(2S,4S)-4MePro. 
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S 4.5.6 Structure elucidation of chloromyxamide A and B using multi-dimensional NMR 
analysis 
As described in the main text, only MCy10615 produces the chloromyxamides in large scale cultures. 
Therefore, as seen in S 4.5.1, we were only able to obtain sufficient amounts of 1 and 2 to perform multi-
dimensional NMR based structure elucidation. The other derivatives only occurring in MCy10608 and 
MCy10649 could only be assigned to their putative structures by tandem MS experiments combined with 
stable isotope labelling (section S 4.5.2 and S 4.5.3). Structure elucidation of 1 was achieved employing 1H, 
DQF-COSY, HSQC, HMBC and ROESY experiments, while structure elucidation of 2 was achieved using 1H, 
DQF-COSY and HSQC experiments. 2D NMR data used for structure elucidation is acquired in methanol-d4 
on a Bruker Ascend 700 spectrometer with a 5 mm TXI cryoprobe (1H at 700 MHz, 13C at 175 MHz) NMR 
spectrometer. DQFCOSY, HSQC, HMBC, and ROESY experiments were recorded using standard pulse 
programs. To elucidate the relative configuration of the chloromyxamides’ CMPA unit, S3 HMBC 
experiments are employed as described under S 4.5.7. 
 
Figure S 14. I) Structure of 1 (R=H) and 2 (R=CH3), showing key NMR correlations (black COSY, red HMBC, and green 
ROESY). II) Atom numbers for assignment of the NMR data in the natural products for 1 (R=H) and 2 (R=CH3). 
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Table S 4. Tabulated 1D and 2D NMR data (700 MHz, methanol-d4) for 1 and 2 
Chloromyxamide A (1) Chloromyxamide B (2)b 
# H, multiplicity, (J in Hz) C HMBC ROESY H, multiplicity, (J in Hz) C 
Pro/4MePro      
1  176.0     
OH       
2 4.42, 1H, dd (8.5, 5.0) 60.6 1, 3, 4  4.33, dd, 1H, 10, 7 62.1 
3a 
3b 
2.25, 1H, m 
1.97, 1H, m 
29.9 1, 2, 4, 5 
1, 2, 4, 5 
 2.45, m, 1H 
1.48, m, 1H 
38.2 
4a 
4b 
2.05, 1H, m 
2.00, 1H, m 
25.9 2, 3, 5 
2, 3, 5 
 2.31, m, 1H 35.0 
4-Me     1.10, d, 3H, 6.5 16.6 
5a 
5b 
3.74, 1H, m 
3.63, 1H, m 
48.0 (2), 3, 4 
3, 4 
8 
8 
3.93, dd, 1H, 10.2, 7.5 
3.14, dd, 1H, 11, 10 
55.4 
6-N       
Pip       
7  172.1     
8 5.20, 1H, dd (6.3, 2.8) 52.6 7, 9, 10, 12, (14) 5a, 5b 5.25, dd, 1H, 6, 3 52.5 
9a 
9b 
2.12, 1H, m  
1.76, 1H, m 
26.2 (11) 
7, (8), 10 
 2.17, m, 1H 
1.73, m, 1H 
26.3 
10 1.66, 2H, m  20.1 (9)  1.65, m, 2H 20.2 
11a 
11b 
1.79, 1H, m  
1.58, 1H, m  
25.7  
(12) 
 1.78, m, 1H 
1.56, m, 1H 
25.7 
12a 
12b 
3.97, 1H, br d (12.7) 
3.74, 1H, m  
44.6 8, 10, 11, 14 
14 
15 
15 
3.96, br d, 1H, 12 
3.76, m, 1H 
44.5 
13-N       
Val       
14  173.4     
15 4.84a, 1H 55.0 14, 16, 17, 18, 20 12a, 12b 4.85a, 1H 54.8 
16 2.12, 1H, m 31.4 14, 15, 17, 18  2.12, m, 1H 31.3 
17 0.97, 3H, d (6.8) 20.0 15, 16, 18  0.97, 3H, d (6.8) 19.9 
18 0.88, 3H, d (6.8) 17.7 15, 16, 17  0.87, 3H, d (6.8) 17.6 
19-NH       
CMPA       
20  174.4     
21 3.56, 1H, dd (5.6, 2.8) 55.6 20, 22, 23, 25  3.55, 1H, dd (5.5, 2.7) 55.6 
22a 
22b 
2.32, 1H, m 
1.63, m, 1H 
25.9 21, 23 
20, 21, 23, 24 
 2.32, 1H, m 
1.63, 1H, m 
25.9 
23a 
23b 
2.13, m, 1H 
1.23, m, 1H 
26.5 21, 22, 24, 25 
21, 22, 24, 25 
 2.12, 1H, m 
1.22, 1H, m 
26.4 
24 3.09, ddd, 1H, 10, 9, 4.0 77.8 (22), 25, 26, 27  3.09, 1H, ddd (10, 9, 4.1) 77.8 
25-OMe 3.35, s, 3H 56.1 24  3.35, 3H, s 56.1 
26 2.83, ddd, 1H, 9, 6.1, 3.1 58.8 (23), 24  2.82, 1H, ddd (8.6, 6.0, 3.1) 58.8 
27a 
27b 
3.83, dd, 1H, 11.0, 3.1 
3.75, dd, 1H, 11.0, 6.1 
46.4 24, 26  3.83, 1H, dd (11.0, 3.1) 
3.74, 1H, dd (11.0, 6.1) 
46.4 
28-NH       
a Obscured by HDO resonance. b Only 1H, DQF-COSY and gHSQC data available. 
S 4.5.7 Molecular modelling and S3 HMBC 
Minimum energy calculations of the structures were performed in Maestro 10.1 using the 
Schrödinger software package. Conformational searching and minimum energy calculations were 
performed using Macromodel. Calculations were done in CHCl3 with the OPLS2005 force field and 
minimum 10000 iterations and gradient converging for the minimizations. All calculations converged to 
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the structure in Figure S 17. 3JHH coupling constants were calculated with the built-in coupling constant 
analyzer, and therefore only standard range coupling constants were used in comparison to experimental 
coupling constants determined with the S3 HMBC experiment.[10] 
 Molecular modelling of chloromyxamide A (1) 
Minimum energy calculations of 1 with all S stereochemistry shows a strong hydrogen bond between 
the two peptide ends, which suggests that the peptide adopts a pseudo-cyclic structure in solution. 
 
 
Figure S 15. Proposed configuration of the 2S,5S,6S-CMPA as well as measured and calculated 1H-1H coupling 
constants in the ring system. Two key ROESY correlations are shown with green arrows. * seen as a large splitting 
bigger than 10 Hz. 
 
Figure S 16. Example cross peaks from S3 HMBC of 1, used for determination of homonuclear coupling constants. See 
full spectrum in section Fehler! Verweisquelle konnte nicht gefunden werden.. 
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Figure S 17. Minimum energy conformation for 1 in CHCl3 showing a strong intramolecular hydrogen bond between 
the carboxyl group of Pro and the –OMe of CMPA. Using water as solvent yields a similar result. 
S 4.5.9 Biological activity evaluation of the chloromyxamides 
Chloromyxamide A has been subjected to antimicrobial testing against our standard set of pathogens 
and cancer cell lines to evaluate biological activity of chloromyxamide A. 
Table S 5. MIC determinations for chloromyxamide A against common pathogens and cancer cell lines 
Pathogenic strain MIC Chloromyxamide A [µg/ml] 
S. aureus Newman >64 
E. coli ΔTolC >64 
E. coli DSM 1116 >64 
M. smegmatis mc2-155 >64 
P. aeruginosa PA14 >64 
B. subtilis DSM10 >64 
M. luteus DSM1790 >64 
M. hiemalis DSM2656 >64 
C. albicans DSM1665 >64 
P. anomala DSM6766 >64 
Chinese hamster ovary CHO-K1 >64 
Since isolation yields of the other chloromyxamides B-E were very low, we were not able to subject 
these for MIC testing. 
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 Comparison of synthetic and natural chloromyxamide A (1) 
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Figure S 18. HSQC spectrum of natural 1. 
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Figure S 19. HSQC spectrum of synthetic 1. 
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Figure S 20. HSQC spectra overlay of synthetic 1 (red) and the isolated natural product (blue). 
 
Figure S 21. CD-Spectrum of 1 (synthetic chloromyxamide A) at 0.1 mM in MeCN in the area 190-250 nm (with 
smoothing). 
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Figure S 22. CD spectra of natural chloromyxamide A (blue) and B (green) at 0.1 mM in MeCN in the area 190-250 nm 
(with smoothing). 
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 Abstract 
In our search for new secondary metabolites from myxobacteria, a strain from the genus Pyxidicoccus 
was investigated. This led to the identification of a new natural product class showing structural novelty 
and interesting biological activity. Isolation and structure elucidation of two analogs led to the 
identification of pyxipyrrolone A and B, harboring the novel 3-methylene-2,3,4,5,6,7,8,9-octahydro-1H-
benzo[e]isoindol-1-one scaffold. Mosher’s ester analysis combined with NMR studies allowed the 
determination of all stereocenters but one. Genome sequencing of the producer strain led to the 
identification of a putative biosynthetic gene cluster for the pyxipyrrolones. The compounds showed 
activity against several cancer cell lines (µM range) with pyxipyrrolone B having 2- to 11-fold higher activity 
than A, although they differ only by one methylene group. 
 Introduction 
Microorganisms remain a highly prolific source of biologically active molecules for drug development. 
Novel chemical scaffolds exhibit the potential for unprecedented biological functions, and are therefore 
inherently interesting with respect to drug discovery.[1]  
Myxobacteria are Gram-negative bacteria which are most noted for their large genomes and their 
ability to form fruiting bodies upon starvation. They have received considerable attention as a prominent 
source of novel secondary metabolites exhibiting new chemical scaffolds.[2] As part of our ongoing program 
involved in the screening and chemical profiling of myxobacterial strains, one such strain (MCy9557), 
identified as belonging to the under-explored genus Pyxidicoccus (section S2), was investigated.  
 Results and Discussion 
HPLC-DAD-MS analysis of small scale cultivations (100 mL) revealed the presence of two analogs 
harboring a triene chromophore (max 280 nm). Fractionation of repeated larger scale cultivations (10 L) 
permitted the isolation and structure elucidation of pyxipyrrolone A (1) and B (2) (Figure 1).  
An account of the spectroscopic analysis leading to the assignment of 1 and 2 is presented below, 
followed by the description of a putative gene cluster for these novel molecules, and finally an initial 
characterization of their biological activities.  
HRESIMS analysis of 1 revealed a protonated molecule at m/z 482.2897 [M+H]+ (calcd for C29H40NO5, 
482.2901, Δ = 0.7 ppm) indicative of a molecular formula C29H39NO5 requiring eleven double bond 
equivalents. 
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Figure 1. Structure of pyxipyrrolone A (1, R = CH3) and B (2, R = H). 
The NMR (methanol-d4) data (Table S4) indicated resonances for two carbonyls (C 173.8 and 171.3) 
and 12 sp2 carbons (C 94.7 – 143.3), requiring 1 to incorporate three rings. The 1H NMR spectrum contains 
five olefinic protons (H 5.57-6.31) and a singlet downfield methylene resonance (H 4.89). Interpretation 
of the 1H-1H COSY correlations led to the identification of two isolated spin systems, with the first one 
delineating the sequence from the two secondary methyls H-29 and H-30 (H 0.91 and 0.86), through the 
oxymethine H-27 (H 3.07), and extending via the secondary methyl H-26 (H 1.03) to five olefinic methines 
H-24 (H 5.57) to H-20 (H 5.90) (Figure 2). 
 
Figure 2.  Key 2D NMR correlations in methanol-d4 used for the structure elucidation of pyxipyrrolone A (1). 
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The second spin system includes two sets of heterotopic methylenes H-14 (H 2.40, 2.02) and H-13 
(H 1.83, 1.73), continues through the oxymethine H-12 (H 3.97), and terminates at the secondary methyl 
H-11 (H 1.08). HMBC correlations from the methylene H-14 to the quaternary carbons C-9 (C 131.6) and 
C-15 (C 138.0), and from the secondary methyl H-11 to C-9, defined the structural fragment ring B, a 
2-methylcyclohex-3-enol moiety (Figure 2). The triene fragment C-18 to C-24 is assigned E configuration 
based on two characteristically large coupling constants (J = 14.9 and 14.5 Hz, H-24/H-23 and H-22/H-21) 
along with a strong ROESY correlation from methyl H-19 (H 1.76) to H-21 (H 6.31). This structural 
fragment A is further extended by HMBC correlations from the methyl H-19 to C-16, C-18 and C-20. The 
methyl H-17 (H 1.36) shows HMBC correlations to C-2, C-15, C-16 and C-18 which further extends 
structural fragment A. The downfield methine H-2 (H 3.62) displays eight HMBC correlations to nearby 
non-protonated sp2 carbons C-15, C-18, C-1, C-3, C-4, C-8, the quaternary C-16, as well as the tertiary 
methyl at C-17 which establishes the carbon connectivity between C-2 and C-16. The downfield methylene 
singlet resonance H-5 (H 4.89, C 94.8) correlates to several downfield non-protonated carbons C-3 (C 
143.3), C-4 (C 140.1), and C-7 (C 171.3). A long-range HMBC correlation from H-5 to C-9 (C 131.6) is also 
observed through the conjugated π-system. The characteristic methylene group at C-5 (H 4.89, C 94.8) 
must be very electron-rich to be shifted this far upfield, and the chemical shifts resemble those observed 
for dehydroalanine in e.g. the myxobacterial compound argyrin.[3] The methylene protons, however, show 
a strong HMBC correlation to another olefinic carbon atom C-3 (C 143.3), which would not be consistent 
with dehydroalanine in a linear peptide chain, and a combination of HMBC and 15N-HMBC correlations in 
DMSO-d6 (15N to C-3, C-4, C-7, and C-8) warrant the identification of a 5-methylene-1,5-dihydropyrrol-
2-one ring (fragment D, Figure 2). The downfield sp2 hybridized C-3 and C-8 are connected to the last ring 
(fragment C), also shown by correlations from H-2. Furthermore, a single ROESY correlation from H-5 to 
H-2 suggests spatial proximity between these protons as well as H-5 pointing away from other protons. C-
8 is correlated to only H-2 and H-10 which suggests linking fragments B and C at C-9, resulting in a highly 
substituted cyclohexadiene ring (fragment C) connected to the B ring at C-9 and C-15 and to the D ring at 
C-3 and C-8. The key HMBC correlations which establish the connection of the structural fragments A and 
B through C-16 are (i) H-17 to C-15, C-16, and C-18 and (ii) H-2 to C-15, C-16, C-17, and C-18. The final 
missing piece of the puzzle is C-1 (C 173.8) associated only with H-2 by a strong HMBC correlation, which 
suggests a carboxylic acid functionality here. The numerous HMBC correlations to H-2 support the multiple 
branching points around C-2 and neighboring carbon atoms. The acid functionality is further verified by 
the observation of strong [M-H-CO2]- fragment ions in negative mode ESIMS as well as the analytical scale 
preparation of a methyl ester with decreased polarity, allowing extraction into EtOAc from aqueous 
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solution, whereas 1 remains predominantly in the aqueous phase (sat. NaHCO3 solution). The chemical 
shifts in the D fragment are in good agreement with those of a similar synthetic building block (4-ethyl-3-
methyl-5-methylene-1,5-dihydropyrrol-2-one) which further supports the assignment.[4]  
By sequencing the genome of the producing myxobacterium and subsequent retrobiosynthetic 
analysis, a putative biosynthetic cluster was found to be responsible for pyxipyrrolone production which 
was characterized by the presence of a single adenylation domain that had serine specificity. Feeding 
studies with [2,3,3-d3]-L-serine indeed showed incorporation with a mass shift of +2 Da. This is in 
accordance with the structure and suggests that a dehydration reaction takes place to form the exocyclic 
double bond, although it is unclear when this takes place. An analog named pyxipyrrolone B (2) at m/z 
468.2743 [M+H]+ (calcd for C28H38NO5, 482.2745, Δ = 0.4 ppm) indicative of a molecular formula C28H37NO5, 
was identified and by 2D NMR spectroscopy it was shown to be missing one methyl group (C-30), and thus 
harbored an ethyl group in place of the isopropyl group in the chain end of 1. This is the result of the 
incorporation of different starter units in the biosynthetic machinery (Figure 3). The absolute configuration 
of the two secondary alcohols of 1 (C-12 and C-27) were determined by Mosher’s method (Figure S4.3a).[5] 
Through interpretation of 2D NMR data for the (12,27)-bis-Mosher’s esters of 1 the 1H SR values were 
calculated (Figure S4.3b and section S4.3). This revealed the absolute configuration of both C-12 and C-27 
as R. Taking advantage of this, the configurations of three other stereogenic centers were elucidated. 
Through inspection of ROESY correlations and J coupling constants, the relative configurations in the B-C 
rings in combination with the knowledge from the Mosher analysis yielded the configuration of the 
stereogenic centers at C-2, C-10, C-16 (see section S4). The configuration at C-25 was not determined due 
to the free rotation at this position. H-2 and methyl H-17 are also correlated, but since this has weaker 
intensity than to H-19, we assume that H-2 and methyl C-17 have anti-orientation. A long-range ROE 
between H-12 and H-20 suggests that the triene adopts a conformation where H-20 is below the B 
fragment, and this observation also supports the C-16 stereochemistry. Altogether, these analyses 
resulted in assignment of the overall novel structures of pyxipyrrolone A and B (Figure 1). The 
3-methylene-2,3,4,5,6,7,8,9-octahydro-1H-benzo[e]isoindol-1-one scaffold is novel, and only structural 
fragments are comparable to known compounds. The A fragment (Figure 2) shows similarity to 
delaminomycins,[6] which has a side chain like pyxipyrrolone B, but with only two conjugated double bonds, 
and similar pyrrole moieties (ring D, Figure 2) are known from e.g. congoensin A [7] and pyranonigrin E,[8] 
for which a protease homologue was responsible for the exo-methylene formation through dehydration 
of serine.[9] AntiSMASH analysis of the MCy9557 genome led to identification of a trans-AT PKS-NRPS 
hybrid gene cluster putatively responsible for pyxipyrrolone biosynthesis (see Figure 3).[10]  
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Figure 3. Biosynthesis hypothesis for the pyxipyrrolones (A: adenylation domain; ACP: acyl carrier protein; AT: acyl 
transferase; C: condensation domain; cMT: carbon methyl transferase domain; DH: dehydratase domain; Dock: 
acyltransferase docking domain; ECH: enoyl-CoA hydratase; ER: enoyl reductase domain; HMG: 
hydroxymethylglutaryl-CoA synthase; KS: ketosynthase; mal: malonyl-CoA; PCP: peptidyl carrier protein; SER: serine; 
gene color code: blue: trans-AT PKS assembly line, black: in trans acyl transferase; orange: beta branching cassette; 
green: assigned and unassigned tailoring enzymes, respectively; gray: open reading frames in proximity to the 
pyxipyrrolone cluster). The box in gray shows the reaction cascade that might lead to synthesis of the mature product 
and the tailoring enzymes putatively involved in these transformations (see table S5.1). 
It contains eleven PKS modules and one NRPS module encoded on 6 genes (pyxA-F) as well as 13 
additional genes encoded by pyxG-T (further info in section S5; GenBank accession number KY765914). 
The difference between the pyxipyrrolone analogs is the result of incorporation of different starter units. 
Module 2 seems to be skipped, as no malonyl-CoA incorporation for this module is seen in the final 
product, a behavior often observed for trans-AT PKS clusters, e.g. in leinamycin biosynthesis.[11] Module 3 
contains an inactive dehydratase (DH) domain whereas module 4 has neither a keto reductase (KR) nor a 
DH domain that could explain the double bond at C-24/25 in the final product. We propose that the KR 
domain of module 3 acts twice during chain elongation in module 3 and 4, while the DH in module 3 acts 
only after ketosynthesis and ketoreduction in module 4. Not only would this explain the alcohol moiety at 
C-27, for which the KR stereochemistry predictor by Kitsche and Kalesse predicts the correct 
stereochemistry,[12] but also the double bond formed in module 4. The genes pyxK-O encode a β-branching 
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cassette which is likely to create the β-methyl branch in module 7 as it was described for myxovirescin.[13] 
The dehydroalanine moiety is created  from a serine moiety incorporated in module 11, correctly predicted 
by Stachelhaus code based NRPS predictor 2[14] and confirmed by an isotopic labeling experiment (see 
above) although no candidate enzyme for this transformation is found in the cluster. A Bayesian KS domain 
alignment for trans-AT PKS structure prediction further validates this biosynthesis hypothesis as the 
predicted building blocks fit the final pyxipyrrolone structure (see section S5).[15] A series of cyclization and 
maturation steps occur to form the polycyclic end product. The linear chain holds a β-keto amide moiety 
that is likely to be partially enolized (C7/8) and thus might act as Michael donor in a cyclization event. 
Additionally, the α,β-unsaturated carboxylic acid at C-2/3 as well as the vinylogous system (C-12 to C-16) 
could act as Michael acceptors and therefore it is likely that the polyketide chain is pre-oriented and two 
subsequent Michael additions lead to the formation of the tricyclic ring system. There are alternative 
possibilities to explain the cyclization reactions, e.g. radical-based mechanisms, but based on the gene 
cluster and chemical considerations the reaction cascade presented here seems most likely. The C-10 
stereocenter is probably created during the second ring formation and not during C methyl transfer in 
module 9, as it is part of a 1,3-diketo functionality that racemizes fast and the final product is solely S-
configured. The final biosynthetic steps are probably reduction at C-12 to C-14 and dehydrogenation to 
form the second double bond in the C ring.  The enzymes PyxT, -S, and -P are believed to perform the 
remaining redox steps needed (see section S5). Finally, the enzyme PyxR shows homology to myxobacterial 
ABC transporters and is therefore likely to be involved in compound export. Unfortunately and despite 
serious efforts we were unable to mutagenize MCy9557, and thus this biosynthesis hypothesis is based on 
in silico analysis.  
Table 1. Half-inhibitory concentrations (IC50 in µM) for pyxipyrrolone A (1) and B (2) on a panel of cell lines.  
Cell line 1 2 
A549 (human lung carcinoma) > 200 190.3 
HCT-116 (human colon carcinoma) 68.3 12.6 
HEC-1-BG (human endometrial adenocarcinoma) 71.4 46.0 
L929 (murine subcutaneous connective tissue fibroblasts) 116.1 10.3 
SW480 (human colon adenocarcinoma) 34.3 7.9 
THP1 (human acute monocytic leukemia) 45.3 8.3 
 
Pyxipyrrolone B (2) displayed cytotoxic activity in the micromolar range against a panel of cell lines. 
In contrast, 1 showed much lower activity, which highlights the importance of the side chain for biological 
activity. In general, human colon and leukemia cells and murine fibroblasts were most sensitive towards 
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treatment with pyxipyrrolones. SW480 cells were used for microscopic studies to get first insights into the 
mechanism of action. Following treatment with the approximately 10-fold IC50 concentration of 2 for 
1-4 days, the cells showed typical morphological changes, such as cellular enlargement and rounded-up 
(apoptotic) cells. Furthermore, staining with acridine orange revealed lysosomal membrane 
permeabilization (increased lysosomal pH), which is a hallmark of the lysosomal death pathway (Figure 4).  
Pyxipyrrolones 1 and 2 were inactive against most of the tested Gram-positive and Gram-negative 
bacteria, yeast and molds. However, 2 displayed some weak inhibitory effect (MIC 32-64 µg/mL) on Mucor 
hiemalis and Staphylococcus aureus (see Table S6 for details). 
Figure 4. Effects on SW480 cells after 4 days treatment with 2. A) Light microscopy images of control (left) and treated 
cells (right). B) Fluorescence microscopy images of control (left) and treated cells (right) that were stained with 
acridine orange (red: acidic compartments, green: neutral compartments) and Hoechst33342 (blue: nuclei). 
 Conclusion and Outlook 
In conclusion, the findings summarized in this communication highlights myxobacteria as producers 
of novel molecules with attractive biological activities. We identified the pyxipyrrolones as new 
metabolites with unique chemical structures and report a first glimpse of their biological potential. 
Intriguingly the small difference of the methyl group at C-28 gives a remarkable change regarding biological 
activity. To fully characterize these structures and further investigate the biological role of the 
pyxipyrrolones, total synthesis should be considered, despite the inevitable challenges to be expected with 
this novel scaffold.  
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 General experimentals 
Chiroptical measurements ([]D) were obtained on a Perkin Elmer (Model 341) polarimeter in a 100 
 2 mm cell at 20 C. NMR spectra were acquired on a Bruker Ascend 700 MHz and a Bruker UltraShield 
500 MHz equipped with 5 mm cryoprobes using standard pulse sequences. The signals of the residual 
solvent were used as internal reference (δH 3.31 and δC 49.0 ppm for methanol-d4). LC-HRESI-DAD-MS 
were acquired on a Bruker maXis 4G mass spectrometer or a Bruker Amazon ion trap instrument, both 
coupled with a Dionex Ultimate 3000 RSLC system using a BEH C18 column (100 × 2.1 mm, 1.7 µm, Waters, 
Germany) with a gradient of 5-95% MeCN + 0.1% FA in H2O + 0.1% FA at 0.6 ml/min and 45 °C over 18 min 
or a BEH C18 column (50 × 2.1 mm, 1.7 µm, Waters, Germany) with a gradient of 5-95% MeCN + 0.1% FA in 
H2O + 0.1% FA at 0.6 ml/min and 45 °C over 9 min, with UV detection by a diode array detector at 200-600 
nm. Mass spectra were acquired from 150 to 2000 m/z at 2 Hz. 
 Isolation and Identification of MCy9557  
Pyxidicoccus sp. MCy9557 was isolated in 2010 from a soil sample taken at the Saarland University 
campus, Saarbrücken, Germany. The strain was recognized for fruiting bodies on a standard isolation 
medium containing bacterial prey.[1,1,2] After successive transfers of the colony swarm edge, the 
myxobacterium was finally purified. The identification was performed by morphology characterization of 
growth stages on buffered VY/2 agar,[3] and together by molecular phylogenetics using 16S rRNA gene 
sequencing. 
>MCy9557 complete 16S rRNA gene sequence 
AGAGTTTGATCCTGGCTCAGAACGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAGCGCGAATAGGGGCAAC
CCTTAGTAGAGCGGCGCACGGGTGCGTAACACGTGGATAATCTGCCTGGATGCCCGGGATAACCAGTCGAAAGAT
TGGCTAATACCGGATAAGCCCACGGCCTCTTCGGAGACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACA
ACCAGATGAGTCCGCGGCCCATCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGCGACGACGGGTAGCTGGTCT
GAGAGGACGATCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGC
GCAATGGGCGAAAGCCTGACGCAGCAACGCCGCGTGTGTGATGAAGGTCTTCGGATTGTAAAGCACTTTCGACCG
GGACGAAAACCCGTAGCCCAACACGCTACGGCTTGACGGTACCGGGAGAAGAAGCACCGGCTAACTCTGTGCCAG
CAGCCGCGGTAATACAGAGGGTGCAAGCGTTGTTCGGAATTATTGGGCGTAAAGCGCGTGTAGGCGGCGTGACA
AGTCGGGTGTGAAAGCCCTCAGCTCAACTGAGGAAGTGCGCCCGAAACTGTCGTGCTTGAGTGCCGGAGAGGGT
GGCGGAATTCCCCAAGTAGAGGTGAAATTCGTAGATATGGGGAGGAACACCGGTGGCGAAGGCGGCCACCTGGA
CGGTAACTGACGCTGAGACGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAAC
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GATGAGAACTAGGTGTCGTGGGAGTTGACCCCCGCGGTGCCGAAGCTAACGCATTAAGTTCTCCGCCTGGGAAGT
ACGGTCGCAAGACTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGACG
CAACGCGCAGAACCTTACCTGGTCTTGACATCCTTGGAATCCCTCAGAGATGAGGGAGTGCCCGCAAGGGAACCA
AGAGACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCC
TCGCCTTTAGTTGCCACGCAAGTGGATCTCTAGAGGGACTGCCGGTGTTAAACCGGAGGAAGGTGGGGATGACGT
CAAGTCCTCATGGCCTTTATGACCAGGGCTACACACGTGCTACAATGGCCGGTACAGAGCGTTGCCAACCCGCGAG
GGGGAGCTAATCGCATAAAACCGGTCTCAGTTCAGATTGGAGTCTGCAACTCGACTCCATGAAGGCGGAATCGCT
ATTAATCGCAGATCAGCACGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGGGAGTC
GATTGCTCCAGAAGTCATCTCACCAAGAGATGCCCAAGGAGTGGTCGGTAACTGGGGTGAAGTCGTAACAAGGTA
GCCGTAGGGGAACCTGCGGCTGGATCACCT 
S 5.2.1  Extraction Protocol for Pyxidicoccus sp. SBCy002 (MCy9557) and compound 
optimization 
For cultivation of MCy9557, the strain was grown in 10 L TS-6 medium[1] containing 2% amberlite 
resin XAD-16 (Sigma) and seeded with 5% bacterial culture. The inoculum was prepared by cultivating the 
strain in the same medium for 4 days at 180 rpm and 30 °C. The culture was grown for 10-12 days at 30 
°C, 160 rpm. At the end of fermentation, both resin and cells were harvested together by centrifugation 
(8000 rpm, 4 °C, 30 min).   
 Isolation of pyxipyrrolone A (1) and B (2) 
The adsorber resin XAD-16 and cell pellet were extracted four times with 300 ml methanol. The crude 
extract was filtered, concentrated in vacuo, and subjected to solvent partitioning with 300 ml 90% MeOH 
in H2O and 100 ml heptane. The polar fraction was concentrated in vacuo and partitioned between 150 ml 
H2O and 250 ml EtOAc and the aqueous phase was further washed with 100 ml EtOAc to yield 0.7 g of 
organic extract containing pyxipyrrolones. This was wet loaded on C18 and dried under nitrogen before it 
was fractionated on C18 (120 g SNAP, Biotage). After equilibration with 400 ml of 10% MeOH/H2O, a 
multistep gradient was run at 50 ml/min (10% MeOH for 5 min, then 10-90% MeOH over 26 min and 90% 
MeOH for 10 min). Fractions of 20 ml were collected, and pyxipyrrolones eluted after about 30 min over 
seven fractions which were pooled to give 22 mg of pyxipyrrolone-containing extract. Final purification by 
RP-HPLC (Luna II C18, Phenomenex, 250 × 10 mm, 100 Å) using H2O/MeCN with 0.1% formic acid (25-50% 
MeCN over 40 min, 4 ml/min, 45 °C) yielded pure pyxipyrrolone B (29 min, 0.5 mg) and pyxipyrrolone A 
(34 min, 1.1 mg). 
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Several 10 L cultures were produced to obtain sufficient material for analyses and derivatizations. 
Pyxipyrrolone A (1): weakly yellow amorphous solid; []D  270 (c 0.1, MeOH); UV (MeOH) max 222, 
270, 281, 292, 350 nm; NMR (500 MHz, methanol-d4) see Table S4 and section 7.1; HRESIMS m/z 482.2897 
[M+H]+ (calcd for C29H40NO5, 482.2901, Δ = 0.8 ppm). 
Pyxipyrrolone B (2): weakly yellow amorphous solid; []D  500 (c 0.1, MeOH); UV as 1; NMR (500 
MHz, methanol-d4) see Table S4 and section 7.2; HRESIMS m/z 468.2743 [M+H]+ (calcd for C28H38NO5, 
468.2745, Δ = 0.4 ppm). 
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Figure S4a. Atom numbering for pyxipyrrolone A (R = CH3) and B (R = H). 
Table S4. NMR data for pyxipyrrolone A (1) and B (2) at 700 MHz in methanol-d4. 
Pyxipyrrolone A (1) 
# H, multiplicity, (J in Hz) C HMBC ROESY 
1  173.8   
2 3.62, 1H, s 47.8 1, 3, 4, 8, 15, 16, 17, 18 5, 17, 19, 20 
3  143.3*   
4  140.1*   
5 4.89, 2H, s 94.7 3, 4, (7), (9) 2 
6-N     
7  171.3   
8  130.6   
9  131.6   
10 3.57, 1H, m 34.2 (8), 9, 11, 12, 13, 15  
11 1.08, 3H, d (6.8) 14.1 9, 10, 12 13a 
12 3.97, 1H, ddd (10.9, 5.1, 3.6) 69.9 11, (13) 14b, 20 
13a 1.83, 1H, m 26.4 10, 12, 14, 15 11 
13b 1.73, 1H, m 26.4   
14a 2.40, 1H, m 26.5 9, 12, 13, 15 17 
14b 2.02, 1H, m 26.5 9, 13, 15 12, 20 
15  138.0   
16  48.6   
17 1.36, 3H, s 21.2 2, (14), 15, 16, 18 2, 14a, 19, 20 
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18  138.4   
19 1.76, 3H, s 12.8 16, 18, 20 2, 17, 21 
20 5.90, 1H, d (11.0) 126.3 16, 19, 22 2, 12, 14b, 17, 22 
21 6.31, 1H, dd (14.5, 11.0) 128.3 18, 20, 23 19, 23 
22 6.03, 1H, dd (14.5, 10.6) 134.1 20, 24 20, 24 
23 6.10, 1H, dd (14.9, 10.6) 131.1 21, 25 21, 25 
24 5.57, 1H, dd (14.9, 8.6) 138.6 22, 25, 26, 27 22, 26, 27 
25 2.31, 1H, m 41.8 23, 24, 26, 27 23, 29, 30 
26 1.03, 3H, d (6.6) 16.2 24, 25, 27 24, 27 
27 3.07, 1H, dd (7.0, 4.8) 80.8 24, 25, 26/30, 28, 29 24, 26, 29, 30 
28 1.71, 1H, m 31.7 27, 29, 30  
29 0.91, 3H, d (6.8) 20.3 27, 28, 30 25, 27 
30 0.86, 3H, d (6.7) 16.2 27, 28, 29 25, 27 
Pyxipyrrolone B (2) 
# H, multiplicity, (J in Hz) C HMBC ROESY 
1  175.0   
2 3.59, 1H, s 48.9 1, 3, 4, 8, 9, 15, 16, 17, 18 5, 17, 19, 20 
3  143.5a   
4  141.2a   
5 4.89b, 2H 94.6 3, 4, (7) 2 
6-N     
7  171.6   
8  130.1   
9  131.2   
10 3.54, 1H, m 34.2 (8), 9, 11, 12, 13, 15 13b 
11 1.10, 3H, d (6.8) 14.2 9, 10, 12 13a 
12 3.96, 1H, ddd (10.7, 5.3, 3.5) 70.0 11 14b, 20 
13a 1.84, 1H, m 26.7 (12) 11 
13b 1.71, 1H, m 26.7  10 
14a 2.37, 1H, m 26.2 (9) 17 
14b 1.99, 1H, m 26.2 (9), (15) 12, 20 
15  137.9   
16  48.7   
17 1.36, 3H, s 21.1 2, 15, 16, 18 2, 14a, 19, 20 
18  138.9   
19 1.77, 3H, s 12.8 16, 18, 20 2, 17, 21, 22 
20 5.89, 1H, d (11.0) 126.1 16, 19, 22 2, 12, 14b, 17 
21 6.31, 1H, dd (14.3, 11.0) 128.6 18, 20, 23 19, 24 
22 6.02, 1H, dd (14.3, 10.6) 133.8 20, 24 19 
23 6.10, 1H, dd (14.8, 10.6) 131.6 21, 25 25, 26 
24 5.59, 1H, dd (14.8, 8.4) 137.9 22, 25, 26, 27 21, 26, 27 
25 2.21, 1H, m 44.2 23, 24, 26, 27, 28 23, 28ab 
26 1.02, 3H, d (6.8) 16.1 24, 25, 27 23, 27 
27 3.25, 1H, m 77.6 (24), 26, 29 24, 26, 29 
28a 1.53, 1H, m 28.2 25, 27, 29 24, 25 
28b 1.31, 1H, m 28.2 25, 27, 29 25 
29 0.93, 3H, t (7.4) 10.5 27, 28 27 
* The assignment of C3 and C4 may be interchanged.  
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Figure S4b. ROESY and DQF-COSY correlations for H-12 used to find the absolute stereochemistry of C-2, C-10, and C-
16. 
From DQF-COSY NMR data it is evident that the large coupling constant for H-12 is to H-13a, and a 
smaller coupling constant is seen to H-11 and the correlation to H-13b is very weak, in good agreement 
with the trans-relationship from H-12 to H-13a and cis-relationship to H-11 and H-13b supported by the 
ROESY correlations shown. A correlation from H-12 to H-20 establishes the triene-chain as pointing down. 
Strong ROE correlations from H-2 to H3-19 and H-20 firmly establish the stereochemical relationship 
between C-2 and C-16 as shown. This is supported by a ROE correlation between H3-17 (pointing up) and 
H-14a as well as the correlation between H-14b and H-12 (pointing down). 
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S 5.4.1  Analytical scale synthesis of the methyl ester of 1 
15 µg of 1 (1 µg/µl) was reacted with TMS-diazomethane in MeOH (2.1 µl of 2 M TMS-diazomethane 
in ether diluted with 200 µl MeOH, then 5 µl of diluted reagent added), and although the conversion was 
not complete, the produced methyl ester of pyxipyrrolone A could be analyzed by LCMS. 
 
Figure S4.1a. LCMS after esterification reaction. 
LC-UV chromatograms (top) and BPCs (bottom) of a) the esterification reaction mixture before liquid-
liquid extraction, b) the EtOAc extract redissolved in MeOH containing the methyl ester (6.9 min) and a bit 
of pyxipyrrolone A (6.0 min), and c) the NaHCO3-water phase containing primarily pyxipyrrolone A (6.0 
min). The fact that pyxipyrrolone A can be extracted with weak base in water supports the presence of a 
carboxylic acid moiety in the structure. The peak at 6.8 min (before the ester) is an unrelated impurity 
(m/z 415). 
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Figure S4.1b. Positive-mode MS2 spectra and interpretation of fragmentation patterns for pyxipyrrolone A and its 
methyl ester. 
The bottom spectrum is HR-MS2 (maXis) of pyxipyrrolone A, whereas the two upper MS2 spectra 
(Amazon) are from after the esterification reaction, showing the ester (top) and unreacted pyxipyrrolone 
A with a relative mass shift of 14 Da.   
346.32
1+
364.27
1+
392.30
1+
406.33
1+
424.39
1+
446.51
1+ 460.40
1+
478.42
1+LKJ280031b_methylester_BE8_01_26091.d: +MS2(496.42), 6.9min #794
336.29
1+
348.34
1+
364.34
1+
392.27
1+
410.33
1+
418.37
1+
436.36
1+ 446.37
1+
464.39
1+
LKJ280031b_methylester_BE8_01_26091.d: +MS2(482.42), 6.0min #676
346.2159
1+
364.2270
392.2214
1+
410.2317
1+
446.2669
1+ 464.2807
1+ 482.2899
1+
LKJ280031b_BD6_01_32676.d: +MS2(482.2918), 29.7-39.7eV, 9.24min #1067
0
1
2
7x10
Intens.
0.0
0.5
1.0
8x10
0
1000
2000
3000
340 360 380 400 420 440 460 480 m/z
      230      Section  S 5.4 Structure elucidation of pyxipyrrolones 
 
OH
NH
O
OH
[M-H-CO2]
- = 436.2857
242.1187
364.2282
 
Figure S4.1c. Negative-mode ESI-MS and MS2 spectra of pyxipyrrolone A (grey, top) and pyxipyrrolone B (green, 
bottom), showing a prominent decarboxylation fragment (m/z 436/422), then loss of water. The low molecular weight 
fragments are the same for pyxipyrrolone A and B because they involve fragmentation of the chain (see structure of 
decarboxylated pyxipyrrolone A).  
S 5.4.2  Isotopically labelled feeding with d3-Ser 
Two 50 ml cultures of MCy9557 were grown in 2SWT medium (Bacto tryptone 0.3%,  Bacto soytone 
0.1%, glucose 0.2%, soluble starch 0.2%, maltose monohydrate 0.1%, cellobiose 0.2%, CaCl2·2H2O 0.05%, 
MgSO4·7H2O 0.1%, HEPES 10 mM, pH adjusted to 7.0 with KOH before autoclaving) and for four 
consecutive days 50 µl of a 0.1 M solution of [2,3,3-d3]-L-serine in sterile water was added to one of them 
(the other used as control). After 10 days at 30 °C and 160 rpm, the cultures were harvested by 
centrifugation at 8000 rpm for 5 min, the supernatant was discarded, and the residual material extracted 
with 50 ml MeOH/acetone (1:1) for 60 min. This was then filtered and concentrated in vacuo, redissolved 
in 1 ml MeOH and analyzed by HRMS.  
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Figure S4.2. Partial ESI+MS spectra for pyxipyrrolone A (left) and B (right) with [2,3,3-d3]-L-serine feeding (top) and 
control (bottom). The isotopic patterns of the pyxipyrrolones for the d3-Ser fed culture shows intensified peaks at m/z 
484 and 485, corresponding to a mass shift of +2 Da, caused by the incorporation of deuterium-labelled Ser in the 
form of dehydroalanine.  
S 5.4.3  Pyxipyrrolone A Mosher analysis 
The absolute configuration of the secondary alcohols of 1 was determined by preparation of (R)- and 
(S)-Mosher’s ester derivatives and assignment of the 1H chemical shift differences, ΔδSR. Treatment of 1 
with (R)- and (S)-MTPA (-methoxy--trifluoro-methylphenylacetic acid), DCC and DMAP gave the (R)- and 
(S)-MTPA bis-Mosher ester derivatives (1a and 1b) (Figure S4.3a). 1H NMR and COSY data was acquired 
(see section 7.3), assigned and chemical shift differences were calculated as SR = S - R (Figure 4.3b). 
 Preparation: 
A solution of 1 (1.2 mg, 2.5 µmol), (S)-MTPA (3.6 mg, 15.4 µmol), DCC (3.7 mg, 17.5 µmol) and DMAP 
(1.0 mg, 8.2 µmol) in dry CH2Cl2 (1 mL) was stirred at room temperature for 16 h. A second reaction was 
performed in an analogous manner using (R)-MTPA in place of (S)-MTPA. The products were semi-purified 
by HPLC (Phenomenex, Synergi 4µm, Fusion-RP, 250  10 mm, gradient from 10 – 100% ACN – H2O over 
30 mins with a hold at 100% ACN for 20 mins) to afford pyxipyrrolone A (R)-Mosher ester (1a) (tR = 35.4 , 
0.4 mg) and pyxipyrrolone A (S)-Mosher ester (1b) (tR = 35.7 , 0.4 mg). (Note: Two repeated batch 
fermentation (10 L) and isolation of pyxipyrrolone A was performed to generate pyxipyrrolone A (R) and 
(S)-Mosher esters (1a and 1b) under similar conditions.) 
      232      Section  S 5.4 Structure elucidation of pyxipyrrolones 
   
Figure S4.3a. Structure of bis-Mosher’s ester derivatives of pyxipyrrolone A, 1a and 1b. 
 
Figure S4.3b. ΔδSR values of the bis-Mosher’s ester of pyxipyrrolone A (1). 
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 Gene cluster organization and proposed biosynthesis 
S 5.5.1 Genes encoded in the pyxipyrrolone biosynthetic gene cluster 
Table S5.1.  Table of all open reading frames belonging to the putative pyxipyrrolone cluster with proposed function 
and closest homologue according to a blastp search against the nr (non-redundant protein sequences) protein 
database at NCBI 
Name Length [bp] proposed function closest homologue 
Identity [%] and length 
of alignment [AA] 
Accession Nr. 
PyxA 12162 polyketide biosynthesis - - - 
PyxB 6441 polyketide biosynthesis CorL 39.8 / 1230  ADI59534 
PyxC 7128 polyketide biosynthesis 
MalonylCoA acyl carrier protein 
transacylase 
38.1 / 2038 AKQ22681 
PyxD 11478 polyketide biosynthesis - - - 
PyxE 5652 
polyketide biosynthesis 
and serine incorporation 
trans-AT hybride polyketide synthase 34.0  / 1911 ADA69239 
PyxF 3633 polyketide biosynthesis NosB 61.6 / 508 AAF15892 
PyxG 723 unknown hydroxyacylglutathione hydrolase 45.9 / 207 AEB63405 
PyxH 477 unknown hypothetical protein 29.0 / 162 AFC321425 
PyxI 3585 transAT acyl transfer S-Malonyltransferase 45.4 / 1197 WP_037678075 
PyxK 255 beta branching acyl carrier protein 39.1 / 87 SFQ69131 
PyxL 1254 beta branching beta ketoacyl synthase 51.8 / 417 WP_018792602 
PyxM 1239 beta branching 
3-hydroxy-3-methylglutaryl ACP 
synthase 
60.7 / 412 KJS64697 
PyxN 807 beta branching enoyl-CoA hydratase 35.8 / 265 WP_076891482 
PyxO 741 beta branching enoyl-CoA hydratase 53.9 / 253 WP_030547341 
PyxP 636 keto reduction  Short chain dehydrogenase/Reductase 68.8 / 199 WP_002609846 
PyxQ 1473 - carotenoid oxygenase 48.0 / 487 WP_047858220 
PyxR 1344 export ABC transporter 34.2 / 450 WP_071059359 
PyxS 1458 
carbon-carbon bond 
reduction 
Lycopene cyclase  / geranylgeranyl 
reductase 
80.0 / 484 WP_047854616 
PyxT 1542 
aromatization of the 
middle ring 
Isorenierate synthase 80.2 / 510 WP_075335863 
Orf1 288 - transposase 46.7 / 92 WP_023173142 
Orf2 228 - HTH domain containing protein 49.3 / 74 SFU95209 
Orf3 405 - transposase 86.6 / 134 SEU39003 
Orf4 381 - transposase 96.0 / 126 SEL21147 
Orf5 1734 - transposase 88.3 / 474 SEU38991 
Orf6 882 - endonuclease/exonuclease 61.9 / 289 WP_015346002 
Orf7 666 - sugar O-Acetyltransferase 43.9 / 223 ADY30429 
Orf8 1119 - 
sugar ABC transporter substrate 
binding protein 
77.8 / 347 WP_014399543 
The nucleotide sequence of the pyxipyrrolone gene cluster has been deposited in GenBank and is 
accessible under accession Nr. KY765914. 
S 5.5.2 In detail description of the pyxipyrrolone biosynthesis model 
Genomic DNA of Pyxidicoccus sp. MCy9557 was sequenced using PacBio technology,[4] yielding a 
complete genome of approximately 13 Mbp. After antiSMASH prediction of biosynthetic gene clusters 
encoded on the genome,[5] a candidate gene cluster for pyxipyrrolone biosynthesis is identified by 
retrobiosynthetic reasoning. As it was not possible to mutagenize Pyxidicoccus sp. MCy9557, the 
identification of the gene cluster as well as the following biosynthesis proposal are solely based on in silico 
analysis.  The putative gene cluster responsible for pyxipyrrolone biosynthesis spans 19 open reading 
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frames (ORFs). The biosynthesis cluster that is identified to be a type 1 trans-acyltransferase (AT) 
polyketide synthase (PKS) – non-ribosomal peptide synthetase (NRPS) hybrid gene cluster contains 12 
modules, eleven of which are PKS derived and one NRPS module (pyxE), encoded on 6 genes (pyxA-F). The 
biosynthetic gene cluster contains 13 additional genes encoded on the ORFs pyxG-T. The polyketide mega 
synthase genes lack acyltransferase domains identifying the biosynthesis to be part of the trans-AT PKS 
cluster family. The two corresponding in trans acting AT’s are encoded on the gene pyxI, with a domain 
specificity of the loading AT for malonyl-CoA. One would expect one of the two AT domains to transfer the 
starter unit while the other AT would probably be responsible for malonyl-CoA extender loading. 
Unfortunately, it was impossible to predict which acyl transferase catalyzes which reaction as both of the 
AT domains have predicted substrate specificities for malonyl CoA. The biosynthesis of the pyxipyrrolones 
features some intriguing steps especially during post-PKS compound maturation.  First of all, the 
pyxipyrrolones exist as two analogues called pyxipyrrolone A and pyxipyrrolone B.  These two analogues 
differ only by a single methyl group at C-28. This difference is originating from alternative starter unit 
usage. In the case of pyxipyrrolone A the biosynthesis starts with an isobutyryl starter unit while 
pyxipyrrolone B is extended from a propionyl starter unit. This broadened specificity for multiple starter 
units is often seen in polyketide derived natural products as for example in myxalamid biosynthesis in M. 
xanthus and S. aurantiaca.[6] The second module is likely to be skipped as no malonyl-CoA incorporation 
for this module is seen in the final product. The consecutive modules 3 and 4 are also peculiar. While 
module 3 possesses a dehydratase (DH) domain that is inactive in this elongation step, module 4 has 
neither a keto reductase nor a dehydratase domain that could explain the appearance of a double bond 
at position C-24 to C-25 in the final product. One could propose that the ketoreductase (KR) domain of 
module 3 acts twice during chain elongation in module 3 and 4 while the dehydratase present in module 
3 only acts after ketosynthesis of module 4 has already been performed. There is evidence that KRs can 
have a broader substrate specificity spectrum as the bacillaene KR in the pksJ gene is able to reduce α- and 
β-keto groups.[7] This hypothesis is further supported by the fact that the motif containing the catalytic 
histidine residue as well as the motif containing the catalytic aspartate residue of the DH domain is present 
indicating it to be catalytically active. Additionally, the reduction of the carbonyl to a secondary alcohol at 
position C-27 has to produce a D-alcohol (according to Fischer projection with respect to the acyl carrier 
protein bound substrate) to fit the stereochemistry observed in the final structure. This is predicted with 
a score Diff of 59.87, using the profile HMM tool by Kitsche and Kalesse, [8] indicating a good prediction. 
Furthermore, the pyxipyrrolone structural formulae contain an uncommon β-methyl branch that is 
attached to the polyketide chain during chain elongation in module 7. This type of β-branching has already 
been shown to take place in myxobacteria, for example in the corallopyronin pathway.[9] The genes for the 
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corresponding β-branching cassette are located on pyxK-O encoding an acyl carrier protein (ACP), a 
ketosynthase (KS), a Hydroxymethylglutaryl-CoA Ligase (HMG) and two enoyl-CoA-hydratases (ECH). The 
assembly of this β-branching cassette is in accord with the β-branching cassette found in myxovirescin.[10] 
The next uncommon feature of this biosynthetic pathway is the incorporation of a serine moiety during 
chain elongation in module 11 that is dehydrated to form the dehydroalanine moiety present in the final 
molecule. Stachelhaus code based NRPS predictor 2 [11] predicts incorporation of serine into the polyketide 
chain and [2,3,3-d3]-L-serine feeding experiments performed with the native producer Pyxidicoccus sp. 
MCy9557 confirm this finding. Unfortunately it was not possible to determine a candidate enzyme 
responsible for dehydration of the incorporated serine meaning this biosynthesis step remains elusive but 
dehydroalanine formation from serine moieties is well known from the biosynthesis of lantibiotics such as 
nisin.[12] It was not possible to detect an AT docking domain nor an AT in module 12 although one can see 
in the final product that malonyl-CoA is integrated to form C-1 and C-2. But since the KR and DH domains 
of this module are putatively active and the formed double bond is vital for any cyclization reaction during 
product maturation the AT docking domain in this region is likely to have a somewhat uncommon 
sequence and is not detected by in silico tools.   The next biosynthetic steps in pyxipyrrolone biosynthesis 
are the cyclisation reactions leading to the final pyxipyrrolone scaffold. It is unclear whether the cyclisation 
reactions that essentially involve two subsequent Michael additions as well as one intramolecular 
cyclisation reaction happen on the assembly line or after release of the product but as the thioester has a 
higher carbonyl activity that facilitates the nucleophilic attack in the first Michael addition it is likely that 
this reaction cascade already happens on the assembly line. The enzyme PyxQ, which is an iron dependent 
dioxygenase-like protein, might take part in isomerizing the compound in order to pre-orient the 
compound for the cyclization reaction cascade. These enzymes have already been characterized to be able 
to catalyze these kinds of isomerization reactions.[13] The structure possesses one β-keto amide function 
that is likely to be mostly present as an enol at C-8 to C-9. This moiety can act as a Michael donor while 
the α,β-unsaturated carboxylic acid at C-1 to C-2 and the vinylogous Michael system from C-12 to C-16 can 
act as Michael acceptors. Therefore, there is high probability that a protein pre-orients the linear 
polyketide chain, and two subsequent Michael additions lead to formation of the uncommon tricyclic ring 
system. The configuration of the stereo center at position C-10 is also most likely determined during the 
second ring closure, and not during C methyl transfer in module 9, as it is part of a 1,3-diketo function that 
racemizes very fast before this reaction and it was experimentally confirmed by Mosher’s analysis that the 
methyl group’s stereocenter in the final product is only S-configured. The last steps in the pyxipyrrolone 
biosynthesis are probably the reduction at C-12 to C-14 and the dehydrogenation to form the second 
double bond in the central pyxipyrrolone ring.  The enzyme PyxT encodes an isorenierate synthase-like 
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protein that catalyzes dehydrogenations in six-membered rings. This enzyme might be involved in 
dehydrogenation of the central ring moiety.  Moreover, the genes pyxS and pyxP encode reductase-like 
proteins that might play a role in final reduction of the α,β-unsaturated ketone at C-12 to C-14. Finally, the 
enzyme PyxR shows homology to myxobacterial ABC transporters and is therefore likely to be involved in 
compound export.  
S 5.5.3  In silico prediction of the KS substrate specificity using the Bayesian KS 
alignment method 
The structural outcome of trans-AT polyketide systems can be predicted by alignment of the KS 
domains into a Bayesian tree that classifies the precursor selectivity of the decarboxylative Claisen 
condensation of a ketosynthesis reaction according to the primary amino acid sequence of the KS 
domain.[14] According to Nguyen et al. KS of trans-AT PKS clusters fall into 16 distinct categories (I to XVI) 
which leads to some predictability if one looks at the synthesis of the nascent polyketide chain. The 
pyxipyrrolone biosynthesis comprises 12 KS domains named pyxKS1 to pyxKS12 as well as the stand-alone 
KS on the gene pyxL from the β-branching cassette called pyxKSbetabranching. In our analysis (Figure S5.3) 
the substrate specificity of the KS domains in the putative pyxipyrrolone gene cluster fits perfectly the 
predicted nascent polyketide chain (preferred substrate structure formulae are shown for the KS domain 
categories that the pyxipyrrolone KS domains fall into). 
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Figure S5.3. KS domain alignment tree containing the pyxipyrrolone KS domains according to Nguyen et al.[14]  
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S 5.5.4 Stereochemistry prediction of the secondary alcohol moiety during chain 
elongation in PKS module 3 
Profile hidden Markov models of KR domains in PKS assembly lines make it possible to predict the 
stereochemical outcome of the KR domain in module 3. Therefore the profile HMM online tool under 
https://akitsche.shinyapps.io/profileHMM_App/ (Accessed February 2017) by Kitsche and Kalesse is 
used.[8] 
The query sequence used for stereochemistry prediction is the translation of the KR domain in 
module 3 on the pyxA gene (FASTA format): 
 
>pyxA KR 
LEGEPLECAVFFSSAQSFLGNVGASNYAAGCTFQDAYAAWLREEKGVPTYVLNWGSWG 
 
In silico prediction score for the D-form of secondary alcohols is + 59.87. 
The D-form of the secondary alcohol at position C-27 of the pyxipyrrolone scaffold which is 
synthesized by the KR domain in module 3 fits the structure experimentally determined by Mosher’s 
method (see SI 4.3). 
S 5.5.5  In silico analysis of the dehydratase domain in PKS module 3 
The situation of the dehydratase domain in module 3 of the PyxA protein is peculiar as it does not act 
directly in module 3 but might be responsible for dehydration of the nascent polyketide chain in module 
4 where there is no dehydratase present. Therefore the DH domains of PyxA, PyxB, PyxC the dehydratase 
domain on the CorL protein of the corrallopyronin biosynthesis [9] that is predicted to be the nearest 
neighbor of the pyxipyrrolone assembly line by blast analysis and the dehydratase from the erythromycin 
biosynthesis that has been crystallized by keatinge and clay are aligned to obtain an insight into the 
catalytic residues.[15] 
Table S5.5a. Conserved region containing the catalytic histidine residue of the DH domains 
Motiv X X H * X X X G X X X X P X 
DH pyxA N E H * R V R G H A I L P G 
DH4 ery A E H * V V G G R T L V P G 
DH corL T Q H * Q V H G Q P V M P G 
DH pyxB R D H * V I Q G R R V L P G 
DH pyxC A E H * R V R G S A M L P G 
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Table S5.5b. Conserved region containing the catalytic aspartate residue of the DH domains 
Motiv X X X X D * X X X Q X X X X 
DH pyxA P G M L D * G A M Q T V - - 
DH4 ery P V L L D * A V A Q T L S - 
DH corL P V L L D * S V L Q S V S L 
DH pyxB P S L V D * G A I Q S L - - 
DH pyxC P G M L D * G A I Q S I - - 
 
As both the catalytic histidine as well as the catalytic aspartate are present, the DH domain of PyxA 
module 3 is possibly active.  
 Biological activity testing 
Cytotoxicity testing: Cell lines were obtained from the German Collection of Microorganisms and Cell 
Cultures (Deutsche Sammlung für Mikroorganismen und Zellkulturen, DSMZ) or the American Type Culture 
Collection (ATCC). All cell lines were cultured under conditions recommended by the depositor. Media 
were purchased from Sigma, fetal bovine serum (FBS Gold) from PAN, and other reagents were from 
Sigma. Cells were seeded at 5 x 104 cells/mL of 96-well plates in 180 μL complete medium and treated with 
pyxipyrrolones in serial dilution after 2 h of equilibration. After 5 d incubation, 20 μL of 5 mg/mL MTT 
(thiazolyl blue tetrazolium bromide) in PBS (phosphate-buffered saline; pH 7.4) was added per well and it 
was further incubated for 2 h at 37 °C. The medium was then discarded and 100 μL 2-propanol/10 N HCl 
(250:1) was added in order to dissolve formazan granules. The absorbance at 570 nm was measured using 
a microplate reader (Tecan M200Pro) and cell viability was expressed as percentage relative to the solvent 
control. IC50 values were determined by sigmoidal curve fitting.   
Microscopy studies: SW480 cells were harvested and seeded at 5 x 103 cells/well in 96-well imaging 
plates (BD Falcon) and after 2 d, cells were treated with pyxipyrrolones. The cellular morphology was 
checked every day and after 4 d treatment images were recorded. The cells were washed with PBS and 75 
μL of a staining solution (5 μg/mL acridine orange and 10 μg/mL Hoechst33342 in PBS) was added for 15 
min. After staining at 37 °C, cells were washed with PBS and imaged on an automated microscope (BD 
Pathway 855) in 200-fold magnification with appropriate filter sets for green/red fluorescence and 
Hoechst. 
Antimicrobial testing: Pyxipyrrolones were tested in microbroth dilution assays on the following 
panel of microorgansism: Chromobacterium violaceum DSM-30191, Escherichia coli DSM-1116, E. coli 
(TolC-deficient), Pseudomonas aeruginosa PA14, Bacillus subtilis DSM-10, Micrococcus luteus DSM-1790, 
Mycobacterium smegmatis mc2155, Staphylococcus aureus Newman, Mucor hiemalis DSM-2656, Candida 
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albicans DSM-1665, and Pichia anomala DSM-6766. Overnight cultures were prepared from cryopreserved 
cultures and were diluted to achieve a final inoculum of 104-105 cfu/mL. Serial dilutions of compounds 
were prepared in sterile 96-well plates in the respective test medium. The cell suspension was added and 
microorganisms were grown for 18-48 h at either 30 °C or 37 °C. Growth inhibition was assessed visually.  
Table S6. Biological activities for pyxipyrrolone A (1) and B (2) against a panel of microbial organisms, cancer cell 
lines, and Plasmodium falciparum. A parenthesis indicates partial inhibition. 
Indicator 1 2 
Microorganisms MIC [µg/mL] 
E. coli DSM-1116 > 64 > 64 
E. coli (TolC-deficient) > 64 > 64 
P. aeruginosa PA14 > 64 > 64 
M. luteus DSM-1790 > 64 > 64 
M. smegmatis mc2155 > 64 > 64 
C. violaceum DSM-30191 (64) (64) 
S. aureus Newman (64) 32-64 
B. subtilis DSM-10 > 64 > 64 
M. hiemalis DSM-2656 (64) 32 
P. anomala DSM-6766 > 64 > 64 
C. albicans DSM-1665 (64) 64 
Cell lines IC50 [µM] 
HCT-116 68.3 12.6 
L929 116.1 10.3 
HEC-1-BG 71.4 46.0 
THP1 45.3 8.3 
A549 > 200 190.3 
SW480 34.3 7.9 
Parasites IC50 [µM] 
P. falciparum 3D7 > 2.6 > 2.6 
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 Abstract 
The fascinating ability of myxobacteria to form multicellular spore filled fruiting bodies under 
starvation conditions was widely studied as a model for cooperative microbial behavior. The potential of 
a life cycle induced change of secondary metabolism, as a means to discover novel natural products, 
remains largely underexplored. We therefore studied the model organism Myxococcus xanthus DK1622 
under submersed and solid cultivation conditions to find putatively life-cycle related compounds by 
applying statistical analysis on analytical data. Utilizing the advantageous characteristics of LC-MS, LC-
MS/MS, and MALDI-MSI allowed the identification of compounds unambiguously associated with 
myxobacterial fruiting bodies. Our screening effort resulted in the purification and structure elucidation 
of a novel compound, the homospermidine lipid, from cultures that had undergone the fruiting process. A 
combination of molecular networking and targeted LC-MS/MS in conjunction with our in-house 
metabolomics database subsequently revealed alternative producers of the respective compound as well 
as a number of compounds belonging to the same structural class. Three further members of this 
compound class were isolated from an alternative producer and structurally elucidated by NMR. Insights 
into the biosynthesis of this novel compound class was gained by feeding of isotopically labeled substrates 
and in silico analysis. 
 Introduction 
Microbial secondary metabolism is a long-standing source of novel structural scaffolds used in drug 
discovery, especially concerning antibiotic agents.[1] Among microbes, myxobacteria are remarkably well 
suited to provide a variety of secondary metabolites.[2] Details concerning these outstanding 
characteristics can be found in the literature.[3] Briefly, myxobacteria have exceptional biosynthetic 
potential due to their large genomes harboring dozens of secondary metabolite encoding gene clusters.[4] 
Advances in genome sequencing technologies and bioinformatics tools allowed assignment of biosynthetic 
gene clusters in a large number of complete genome sequences,[5,6] but the number of these clusters is 
often contrasted by a far lower quantitiy of known secondary metabolites.[5,7] A common explanation for 
the “absence” of secondary metabolites is that gene clusters might be tightly regulated under laboratory 
growth conditions leading to low or zero basal expression levels due to missing environmental signals 
required for activation. A pronounced change in secondary metabolism in response to culturing conditions 
could be shown for a range of marine actinomycetes in terms of detected molecular networks.[8] For the 
myxbacterial model species M. xanthus DK1622, five compound families and 18 presumed PKS/NRPS 
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biosynthetic gene clusters are known, but combined transcriptomics and proteomics efforts indicated that 
17 out of the 18 clusters were transcriptionally active. Detection of transcription of these clusters with 
unknown products (on the transcriptome level) is another clear indication that tightly regulated 
biosynthetic gene clusters require a stimulus to raise their otherwise low basal levels of transcripts.[9] Even 
though a gene cluster might be functionally expressed, the detection and identification of the 
corresponding metabolite remains challenging. It is common sense and well documented in the literature 
that instrumental setup as well as sample preparation have a major impact on the coverage of 
compounds.[8,10] To harness the biosynthetic potential of bacteria, it is thus mandatory to have a sound 
analytical platform that allows identifying target compounds from metabolome data with the important 
additional demand of dereplication to avoid rediscovery of known compounds. More information 
regarding dereplication of metabolome data can be found in recent reviews.[11,12] As argued above, 
discovery of novel natural products essentially requires an easy and reliable cultivation method. Over the 
course of the past decades, cultivation processes in a shaking flask using liquid media with added 
adsorbents has become the method of choice for myxobacteria. It remains a matter of debate, though, 
whether this cultivation approach is ideal for soil-dwelling bacteria, which pass through various life cycle 
stages in their natural environment.[13] This is supported by the fact that many isolated myxobacterial 
species could not yet be successfully cultivated in liquid media. It can easily be imagined that external 
stimuli required to activate certain biosynthetic gene clusters (e.g., interspecies cell–cell interaction) are 
missing in shake flask cultivation. Only limited data of studies aiming at the comparison of liquid and solid 
cultivation on a larger scale are available. It could be shown, however, that a substantial difference 
between submerged and solid cultivation can be observed for a range of 30 actinomycetes, with only a 
minimal overlap of 6.8%.[8] It is thus clear that any study aiming to gain insights into the fruiting body 
formation on a metabolome level requires an analysis technique that connects phenotypic changes to the 
metabolome to avoid false positive hits caused by differences in cultivation. Hence, we applied mass 
spectrometry imaging (MSI) as a tool to correlate the appearance of fruiting body specific metabolites for 
cultures grown on agar in a time dependent manner. In particular, we were interested in metabolic 
changes during fruiting body formation to find presently unknown natural products as a follow-up study 
that addressed semiquantitative changes of known metabolites.[14] We decided to use the well-studied M. 
xanthus DK1622, which shows favorably fast growth alongside reproducible fruiting body formation. We 
studied changes in the metabolome based on extracts of cultures after fruiting body formation grown on 
agar and cultures grown in suspension. Imaging mass spectrometry served as a tool to filter false positives 
by correlating the appearance of fruiting body specific metabolites for cultures grown on agar in a time 
dependent manner. 
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 Results and Discussion 
Fruiting body formation in myxobacteria was extensively studied on the genome and transcriptome 
level to gain a better understanding of the underlying regulatory and signaling mechanisms, which lead to 
cell aggregation and sporulation.[15] Effects of fruiting body formation on the metabolome level to increase 
the structural diversity of experimentally accessible structures however is underexplored. We thus 
designed an experiment to assess the prospects of fruiting body formation for the discovery of novel 
secondary metabolites. As a first hypothesis-generating step, cultures grown in suspension were 
compared to sporulated cultures grown on a solid medium. Possible novel target compounds putatively 
connected to the myxobacterial life cycle were obtained by statistical comparison of five biological 
replicates grown in liquid medium and five biological replicates grown on agar (each biological replicate 
consisted of five agar plates). The resulting distinguishing features can be attributed both to the growth 
condition as well as to the life cycle, since the presence of vegetative cells on the extracted agar plates 
cannot be fully excluded. A MALDI mass spectrometry imaging (MALDI-MSI) approach allows achieving 
this distinction by correlation of putative candidate m/z values with fruiting body formation observed on 
light microscopic images over a time course covering the development from vegetative cells to fruiting 
body formation. 
6.3.1 Submersed Cultures versus Fruiting Bodies 
Comparison of both cultivation conditions first required a methodology for extraction of cultures 
grown on agar plates. Submersed cultures were treated following the well-established approach of 
cultivation in the presence of an adsorber resin.[16] To promote fruiting body formation, M. xanthus 
DK1622 was cultivated on a minimal agar medium as well as on cellulose membranes placed on top of agar 
plates containing minimal medium. Liquid cultures used to inoculate plates were washed with minimal 
medium prior to inoculation. Cultivation on membranes placed on the agar surface was dropped at an 
early stage due to poor growth characteristics and the lack of fruiting body formation. The presence of 
adsorber resin randomly spread over agar plates to increase the production of secondary metabolites to 
avoid feedback inhibition of production and self-toxicity was found to be nonbeneficial. Small amounts of 
XAD-16 beads on the agar surface favored the extraction of media compounds while signals related to 
bacterial growth were under-represented as compared to plates without adsorber resin (Figure S1). 
Apparently, production and extraction efficiency of secondary metabolites cannot be improved for solid 
cultivation by this approach. The workup of solid cultures was performed by scraping off cells and fruiting 
bodies using a glass microscope slide (Figure 1). Extraction of complete cultures including agar media 
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turned out to be inadequate, as the concentration of extracted media compounds is orders of magnitude 
higher than the compounds related to bacterial growth (data not shown). 
 
Figure 1. Overview of the two workflows applied for detection and verification of fruiting body related metabolites. 
To obtain chromatographic resolved MS data, vegetative cells and fruiting bodies were scraped from the agar surface 
using a microscope slide, extracted with methanol, and measured using LC-MS. Spatially resolved MS data were 
received by following a MALDI-IMS approach. An agar piece including cells and fruiting bodies was transferred to a 
MALDI target, dried, had a matrix applied, and measured using MALDI-ToF MS. 
Extracts obtained from five biological replicates for both conditions (solid and submersed) were 
subsequently screened as two technical replicates by LC-MS to generate a set of m/z values putatively 
connected to changes in metabolism. The highly reduced background observed for extracts from agar 
plates allowed the highlighting of many signals exclusive to fruiting body samples by mere visual 
comparison of the base peak chromatograms (BPC; Figure 2). A statistically sound list of candidates was 
generated using principal component analysis (PCA) in conjunction with t tests to reveal significant 
differences in the metabolic profiles. Compounds found in at least four out of five biological replicates 
were considered as a significant hit, as long as no appearance could be detected in media blanks. A total 
of 62 discriminating molecular features (RT, m/z, intensity) were detected by this means (Figure 3). 
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Figure 2. Comparative base peak chromatograms (150–2500 m/z) of an extract derived from M. xanthus DK1622 
cultivation on an agar plate (blue) and one derived from cultivation in a liquid medium with adsorber resin (red). Time 
range with predominantly media component is marked in gray (based on Figure S2). 
 
Figure 3. Workflow toward the detection of discriminating compounds, which are verifiably due to cultivation on solid 
media, possibly also fruiting body formation. Five replicates of culture as well as five replicates of blanks were 
prepared for both cultivation methods. Subsequently, all extracts were injected into the LC-MS twice, and the 
molecular features were determined. On the basis of the molecular features, a principle component analysis and a t 
test were performed to reveal the discriminating peaks for cultures grown on agar. Dereplication of these data led to 
62 compounds, which are directly related to cultivation on agar. 
   Chapter 6 The Homospermidine Lipids    249 
Although cultivation of M. xanthus DK1622 on minimal agar over 5–7 days mainly results in the 
formation of fruiting bodies, the presence of vegetative cells cannot be excluded.[17] A comparison to 
vegetative cells grown on agar would be required to further specify the obtained data, which can hardly 
be achieved using minimal medium, as the presence of fruiting bodies can also not be fully excluded. We 
thus regarded the set of 62 features as a hypothetical data set that needed to be tested by a suitable 
additional analysis technique. 
6.3.2 MALDI-MSI of M. xanthus DK1622 
Mass spectrometry imaging of bacterial cultures became well accepted by the research community 
due to its inherent strength to provide complementary information to other well established molecular 
analysis workflows.[18,19] MSI excels at providing spatially resolved molecular information in combination 
with light microscopic images. This allows direct linking to visually observed phenotypic changes to the 
metabolome in the form of m/z values. MALDI-MSI was thus the method of choice to correlate the 62 
features obtained from LC-MS measurements with the development of fruiting bodies. The overall 
workflow is illustrated in Figure 1, while details regarding the method can be found in the literature.[20]  
Four time points covering different life cycle stages, including the fruiting body formation of M. 
xanthus DK1622, were analyzed for the presence of the 62 features in question. Mass spectral images were 
analyzed toward the presence of the 62 features as [M + H]+, [M + Na]+, [M + NH4]+, and [M + K]+ ions. 
Surprisingly, only two out of the 62 features could be detected in mass spectral images as sodium and 
potassium adducts. One of the substances was specifically found in areas covered by fruiting bodies 
(590.4669 m/z), while the other was characteristic for the surrounding cells (724.3979 m/z). The mass 
spectral image of m/z 724.3979 shown in Figure 4 illustrates the necessity of an analysis technique that 
connects phenotypic changes and molecular information, as this compound is clearly specific for 
vegetative cells grown on agar. The sodiated species with m/z 590.4669 corresponds to the compound 
eluting at 15.9 min with a mass to charge ratio of 552.5104 (Cmp-552) in LC-MS runs. The predominance 
of cationization observed for these two compounds is likely owed to the presence of salts in the agar 
medium—a phenomenon that is well-known for biological samples of all sorts.[21] Possible causes for the 
inability to detect the remaining 60 compounds found by LC-MS are numerous but can only be speculated 
about. Some of the analytes might simply be present in amounts below the detection limit, which can be 
additionally impaired by ion suppression as often encountered in MALDI measurements of biological 
samples.[22] Another important influence on the outcome of MALDI-MSI is the efficiency of analyte 
extraction, as low efficiency results in a lack of analyte-doped matrix crystals.[23]  
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Figure 4. Cultivation time dependent MALDI-MSI data of Cmp-552 and Cmp-686 (both shown as [M+K]+). The light 
microscopic images in the upper part of the figure show the respective samples on a MALDI target prior to matrix 
application. The red borders are indicating the area of vegetative cells, while the blue borders indicate areas where 
fruiting bodies are observed. 
Several of the distinguishing m/z values found by LC-MS are likely specific for fruiting bodies as well, 
since they share similar MS/MS patterns and belong to the same molecular network (for details, see 
below). Unambiguous evidence, however, could not be obtained for the respective candidates. Correlation 
of the MALDI images of m/z 590.4669 and the respective light microscopic images revealed that the 
biosynthesis of Cmp-552 starts at a later stage of fruiting body formation since the signal intensity was the 
highest after 116 h of cultivation, although fruiting bodies could already be observed after 44 h (Figure 4). 
We next set out to purify Cmp-552 as the only fruiting body specific compound that could be confirmed 
by MALDI imaging. 
6.3.3 Structure Elucidation and Identification of Derivatives 
Purification and structure elucidation of microbial compounds discovered by imaging mass 
spectrometry is a challenging task. Only one metabolite obtained from MSI data of solid cultivation could 
be successfully purified and structurally confirmed by NMR.[18,24] Owing to the limited amount of biomass 
per agar plate, a substantial amount of Petri dishes was necessary to provide sufficient crude extract for 
subsequent purification attempts. 
We could isolate 300 μg of Cmp-552 by semipreparative LC from a methanolic extract of fruiting 
bodies of M. xanthus DK1622 grown on roughly 500 Petri dishes. The structure of Cmp-552 was elucidated 
by NMR and turned out to be a sym-homospermidine core structure with fatty acyl residues attached to 
the secondary and the two primary amine groups (Figure 5). Since the compound is reminiscent of a lipid, 
it was named homospermidine lipid 552. As a descriptive shorthand notation based on the lipidmaps 
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nomenclature, the following form is suggested: HS(iso5:0/5:0/iso15:0), where HS stands for 
homospermidine and the three substituents are given as fatty acyl moieties on the two primary amines of 
sym-homospermidine followed by the substituent on the secondary amine. According to the lipidmaps 
classification system, the compound belongs to the subclass of N-acyl amines (FA0802).[25]  
 
Figure 5. Chemical structures of the homospermidine lipids (HS). Compounds were named based on the lipidmaps 
guidelines. 
Use of our in-house metabolome database allowed identification of Myxococcus fulvus MCy9290 as 
a strain that seemed to form the homospermidine lipid in liquid cultures.[12] Since the results shown above 
prove the relation between the biosynthesis of Cmp-552 and fruiting body formation of M. xanthus 
DK1622, we assume that fundamental differences in regulation lead to an activation of the respective gene 
cluster during cultivation of M. fulvus MCy9290 in a liquid medium. The lipid-like structure of 
HS(iso5:0/5:0/iso15:0) led to the expectation that further derivatives might be found among the 64 
putatively fruiting body related compounds as well as in extracts of M. fulvus MCy9290. A powerful and 
very well received tool to identify such structurally related compounds based on MS/MS similarity is the 
molecular networking workflow provided within the Global Natural Product Social Molecular Networking 
(GNPS) platform.[26]  Molecular networking is perfectly suited to identify compound classes and is 
increasingly implemented in dereplication and discovery campaigns.[27]  
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Extracts of five biological replicates of M. fulvus MCy9290 and fruiting bodies of M. xanthus DK1622 
were obtained from liquid and solid cultivation, respectively. Each sample was measured twice, and results 
were subjected to PCA analysis with subsequent t tests as described above. The resulting culture specific 
features were used for the acquisition of targeted MS/MS data as an input for spectral networking. The 
resulting MS/MS networks are shown in Figure 6. 
 
Figure 6. A precursor directed MS/MS based on PCA and t test results exemplified by the 62 discriminating unknown 
compounds in agar grown cultures. B Cmp-552 including MS/MS networks derived from extracts of M. fulvus 
MCy9290 (grown in suspension) and M. xanthus DK1622 (grown on agar). Red colored nodes indicating derivatives, 
which were isolated, and structures elucidated. Nodes bordered in red marking derivatives of Cmp-552, which were 
also found in extracts of M. xanthus DK1622. 
As liquid cultures are more accessible for preparing larger amounts of extract, we cultivated M. fulvus 
MCy9290 on a larger scale to isolate further derivatives of the novel compound class. We were able to 
isolate three additional main derivatives differing mainly by alkyl chain length and saturation degree while 
showing similar bioactivities (Figure 5 and Table 1). The configuration of the double bonds was determined 
to be trans due to the allylic carbon shifts. The vinylic hydrogens form second order signals that prevent 
the evaluation of coupling constants.[28]  
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Table 1. Minimum Inhibitory Concentration (MIC) of Homospermindine Lipids 1–4 
test organism MIC/IC50 
Staphylococcus aureus 16 μg/mL 
Bacillus subtilis 16 μg/mL 
Micrococcus luteus 8 μg/mL 
Mucor hiemalis 64 μg/mL 
Chinese hamster ovary CHO-K1 10–15 μg/mL 
As observed activities do not differ for the individual derivatives, values are not listed separately. 
6.3.4 Bioactivity and Biosynthesis of Homospermidine-Lipids 
Testing 24 compounds for bioactivity against a panel of microorganisms and cell lines revealed 
cytotoxicity values in the range of 20 μM and moderate activity against some Gram-positive bacteria 
ranging from 14 to 28 μM (Table 1). Since the purpose of fruiting body formation is to endure times of low 
nutrient supply, we hypothesize that the organism tries to defend the fruiting body against predators and 
thereby increases its chances of survival. Although comparably high, MIC values might represent a spore 
defense mechanism, as the local concentrations of the lipids in the fruiting bodies is relatively high. 
Another biological function of these lipids might be carbon and nitrogen storage during the low nutrient 
supply. 
 
Figure 7. (A) MS spectrum of feeding experiment with l-arginine-13C6,15N4 confirms the incorporation of up to two 
arginine building blocks in Cmp-552. (B) Putative biosynthesis of the homospermidine lipids according to in silico 
analysis. 
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The biosynthesis of the homospermidine lipids was elucidated based on the assumption that the 
homospermidine lipids derive from sym-homospermidine and thereby originate from arginine via the 
putrescine pathway (Figure 7).[29] For this reason, [13C6,15N4]-l-arginine was fed to a liquid culture of M. 
fulvus MCy9290, and the obtained extracts were checked for the corresponding mass shift of the 
compounds. LC-MS analysis confirmed the incorporation of two arginine moieties, substantiating the 
homospermidine origin of this substance class (Figure 7). Since the genome sequence of M. xanthus 
DK1622 is available, we searched for the responsible biosynthetic gene cluster. A genetic island containing 
the homospermidine synthase, an N-acyltransferase, and a fatty acid acyltransferase was identified by 
searching for the homospermidine synthase analogues known as deoxyhypusine synthases available on 
NCBI Protein using BLAST.[30] More details regarding the potential biosynthesis can be found in the 
Supporting Information. 
 Conclusion 
In this work, we present the first secondary metabolomics study devoted to the influence of fruiting 
body formation in a myxobacterium. Application of a broad scope of measurement and analysis techniques 
allowed unambiguous identification, purification, and structural elucidation of a novel compound that is 
directly connected to fruiting body formation of M. xanthus DK1622. We present one of the very few cases 
where imaging mass spectrometry leads to the isolation of a compound obtained from cultures grown on 
a solid medium. The data obtained from mass spectral images impressively show the necessity of applying 
a molecular imaging technique that allows connection of spatial information with visually observed 
phenotypic changes to establish clear-cut evidence for the localization of a candidate m/z value on fruiting 
bodies of M. xanthus DK1622. Further database and spectral networking based analysis resulted in the 
identification of a new compound family and allowed us to isolate three more derivatives from an 
alternative and deregulated producer capable of forming homospermidine lipids in liquid culture. Data 
obtained from spectral networking indicates that other members related to HS(iso5:0/5:0/iso15:0) are 
also specific for fruiting bodies, but confirmation by MALDI MSI was not possible due to the inability to 
detect the respective m/z values. 
Owing to the observed cytotoxicity and activity against several Gram-positive bacteria, these 
compounds might be part of the bacterium’s defense strategy or play a role in carbon storage. As the 
activities of the compounds were rather nonselective, it can be assumed that they are part of a more 
general defense against competitors. We believe that we have shown a very promising workflow that will 
not only lead to the identification of additional novel natural compounds but also offer unique 
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opportunities to gain fundamental insights into metabolic processes taking place during fruiting body 
formation. 
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 Methods 
S 6.1.1 Extract Preparation - Cultures grown in suspension. 
Pre-cultures of Myxococcus xanthus DK1622 and Myxococcus fulvus MCy9290 were grown at 30 °C 
for 3 days in 25–50 mL CTT medium (2 g L-1 MgSO4 x 7H2O, 10 g L-1 casitone, 1.2 g L-1 TRIS, 136 mg L-1 
K2HPO4; pH 7.6) and VY/2 medium (5 g L-1 bakers yeast, 50 mg L-1 CaCl2 x 2H2O, 1.2 g L-1 HEPES, 10 g L-1 
starch; pH 7.0), respectively. Main cultures were inoculated by the well-grown pre-cultures (2 % (v/v)) and 
cultivated at 30 °C for 7 days. Two days after inoculation, XAD-16 absorber resin was added to the culture 
(1 % (w/v)). Extracts were prepared by extracting the resin including cells with methanol, evaporation of 
solvent and re-dissolving in methanol. 1 µL of crude extract was analyzed by LC-hrMS. For purification 
purposes of M. fulvus MCy9290, a total of 7.5 L suspension culture including XAD-16 was grown and 
extracted in accordance to the method described above. 
S 6.1.2 Extract Preparation - Cultures grown on agar. 
All cultures were cultivated in standard Petri dishes on HS agar medium (1 g L-1 MgSO4 x 7H2O, 1 g L-1 
KNO3 , 1.5 g L-1 casitone, 2 g L-1 TRIS, 4 g L-1 Glucose, 8 mg L-1 Fe-EDTA, 75 mg L-1 CaCl2 x 2H2O, 6.25 mg L-1 
K2HPO4, 2 % agar (w/v); pH 7.2) at 30 °C for 7 days. Pre-cultures, cultivated in liquid CTT medium, were 
washed with CF medium (2 g L-1 MgSO4 x 7H2O, 150 mg L-1 casitone, 1.2 g L-1 TRIS, 174 mg L-1 K2HPO4, 
0.2 mg L-1 (NH4)SO4, 1 g L-1 sodium pyruvate, 2 g L-1 sodium citrate; pH 7.6) and 10-fold concentrated. Petri 
dishes were inoculated with 150 µLplate-1 of the concentrated pre-culture. Extracts were prepared by 
scraping off the cells and fruiting bodies from the agar surface, extraction with methanol, evaporation and 
re-dissolving in methanol. 
In total, approximately 500 Petri dishes were prepared, harvested, and extracted to obtain sufficient 
amounts of Cmp-552. 
S 6.1.3 LC-hrMS Methods. 
All measurements of crude extracts were performed on a Dionex Ultimate 3000 RSLC comprising a 
high pressure gradient pump (HPG-3400RS) with a 150 µl mixing chamber. All LC connections are realized 
by 0.13 µm stainless steel capillaries before the column. The method is based on separation with BEH C18, 
100 x 2.1 mm, 1.7 µm dp column (Waters, Eschborn, Germany). One µl sample is separated by a linear 
gradient from (A) H2O + 0.1 % (v/v) formic acid to (B) ACN + 0.1 % (v/v) formic acid at a flow rate of 
600 µL min-1 and 45 °C. The gradient is initiated by a 0.5 min isocratic step at 5 % B, followed by an increase 
to 95 % B in 18 min to end up with a 2 min step at 95 % B before reequilibration under the initial conditions. 
UV spectra are recorded by a DAD in the range from 200 to 600 nm with 2 nm slit width. The LC flow is 
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split to 75 µL min-1 before entering the maXis 4G hr-ToF mass spectrometer (Bruker Daltonics, Germany) 
using the Apollo ESI source. A fused silica (f.s.) capillary (20 cm, 100 µm ID, 360 µm OD) coming from the 
mass spectrometer’s switching valve is connected to an Upchurch PEEK microtight T-junction. Another f.s. 
capillary of 20 cm and 75 µm ID is connected to the inlet of the mass spectrometer whereas an f.s. capillary 
of 10 cm and 100 µm ID is directed to waste. The split is approximately 1:8 based solely on the f.s. capillary 
ratio. The real split is even more than 1:8 as the effect of the ESI needle is not taken into account here. 
The ion source parameters are: capillary, 4000 V; endplate offset, -500 V; nebulizer, 1 bar; dry gas, 5 L min-
1; dry gas temperature, 200 °C. Ion transfer parameters were: funnelRF, 350 Vpp; multipoleRF, 400 Vpp; 
quadrupole ion energy, 5 eV @ low m/z 120. Collision cell is set to 5 eV with a collisionRF of 1100 Vpp; 
transfer time, 110 µs; pre puls storage, 5 µs in full scan mode. Mass spectra are acquired in centroid mode 
ranging from 150–2500 m/z at a 2 Hz scan rate in full scan positive ESI mode. Each measurement is started 
with the injection of a 20 µL plug of basic sodium formate solution, which is introduced by a loop that is 
connected to the system’s 6-port switching valve. The resulting peak is used for automatic internal m/z 
calibration. In addition, three lock masses (622, 922, 1222 m/z) are present in the ion source all the time 
and allows recalibration of each spectrum.  
Fractions obtained by semi-preparative purification were measured on the same setup using a 50 mm 
instead of a 100 mm column of the same series. Hence, only the gradient was slightly adjusted. Initiation 
by a 1 min isocratic step at 5 % B, followed by an increase to 95 % B in 6 min to end up with a 1.5 min step 
at 95 % B before reequilibration under the initial conditions.  
Statistical evaluation of the data was performed using ProfileAnalysis V2.1 (Bruker Daltonics, 
Germany) 
S 6.1.4 MALDI-MSI Method. 
Experimental details regarding strain cultivations, sample preparation, and instrumental parameters 
can be found in literature.[1] All MS imaging data were evaluated and visualized with SCiLS Lab 2015 (Bruker 
Daltonics, Germany). 
S 6.1.5 MSn Experiments and Molecular Networking. 
All LC-MS/MS measurements were based on the already described 18 min gradient separation using 
the U3000-maXis 4G setup. Fragmentation spectra were achieved either by auto-MS/MS measurements 
or by targeted precursor selection. Selected precursor list (SPL) were generated by taking into account the 
dereplication and PCA results respectively. Fixed MS/MS parameters were an m/z-adjusted precursor 
isolation width and fragmentation energy. Values are interpolated in between the set points [300 m/z / 
4 m/z / 30 eV], [600 m/z / 6 m/z / 35 eV], [1000 m/z / 8 m/z / 45 eV], and [2000 m/z / 10 m/z / 55 eV]. The 
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precursor intensity threshold is always set to 5000. All methods are set up with an active precursor 
exclusion, which puts precursors after two spectra on an exclusion list. Each precursor m/z remains there 
for 0.2 min. 
A molecular network was created using the online workflow at GNPS (Global Natural Products Social 
Molecular Networking). The data was filtered by removing all MS/MS peaks within +/- 17 Da of the 
precursor m/z. MS/MS spectra were window filtered by choosing only the top 6 peaks in the +/- 50 Da 
window throughout the spectrum. The data was then clustered with MS-Cluster with a parent mass 
tolerance of 0.05 Da and a MS/MS fragment ion tolerance of 0.1 Da to create consensus spectra . Further, 
consensus spectra that contained less than 1 spectra were discarded. A network was then created where 
edges were filtered to have a cosine score above 0.65 and more than 4 matched peaks. Further edges 
between two nodes were kept in the network if and only if each of the nodes appeared in each other's 
respective top 10 most similar nodes. Data were visualized with Cytoscape V 3.5.0.[2] 
MSn fragmentation experiments were conducted by direct infusion MS using a solariX XR (7T) FT-ICR 
mass spectrometer (Bruker Daltonics, Germany) equipped with an Apollo ESI source. In the source region, 
the temperature was set to 200 °C, the capillary voltage was 4500 V, the dry-gas flow was 4.0 L min-1 and 
the nebulizer was set to 1.1 bar. While MS/MS spectra were obtained by collision-induced dissociation 
(CID) in the collision cell, all further fragmentations were obtained by isolating the respective precursor in 
the ICR cell and applying sustained off resonance irradiation (SORI) CID. Parameters were individually 
adjusted for each measurement.   
S 6.1.6 Purification of HS(iso5:0/5:0/iso15:0) from M. xanthus DK1622. 
Purification was carried out on a Thermo Dionex (Germering, Germany) Ultimate 3000 low pressure 
gradient system, equipped with SR3000 solvent rack, LPG-3400SD pump module, WPS-3000TSL 
autosampler, Knauer (Berlin, Germany) Jetstream column oven, DAD-3000 photodiode array detector with 
a cell volume of 10 µL and an AFC 3000 fraction collector. LC separations were performed using 50 µL 
injections on a Phenomenex Kinetex Biphenyl column (10 x 250 mm, 5 µm) at 40°C and a flow rate of 
5 mL min-1 with the following gradient conditions: 0–55 min, 5–95 % B; 55–59 min, 95 % B; 59–59.5 min, 
95–5 % B; 59.5–70 min, 5 % B. Mobile phases were (A) water + 0.1 % (v/v) formic acid and (B) acetonitrile 
+ 0.1 % (v/v) formic acid. Fractions of 18 s width were collected from 20–55 min. The resulting fractions 
were combined, evaporated to dryness and reconstituted in 1 mL of methanol. 
S 6.1.7 Purification of HS-derivatives from M. fulvus MCy9290. 
First separation was done on a Sephadex LH20 gravitation column and follow-up separation was done 
on Waters preparative HPLC using a Waters X-Bridge C-18, 150 x 19 mm, 5 µm dp column. Separation was 
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performed using (A) water + 0.1 % (v/v) formic acid and (B) acetonitrile + 0.1 % (v/v) formic acid and a flow 
rate of 5 mL min-1 with the following gradient: 0–3 min, 5 % B; 3–7 min, 5–55 % B; 7–32 min, 55–98 % B; 
32–35 min, 98 % B; 35–36 min, 98–5 % B; 36–40 min, 5 % B. 
Residual impurities were removed by an additional semi-preparative chromatography step on a 
Phenomenex Synergi Fusion-RP, 250 x 10 mm, 4 µm dp column. Separation was performed using the same 
eluent as described above and a flow rate of 5 mL min-1 by using the following gradient: 0–3 min, 5 % B; 
3–7 min, 5–65 % B; 7–27 min, 55–85 % B; 27–28 min, 85–98 % B; 28–31 min, 98 % B; 31–32 min, 98–
5 % B; 32–36 min, 5 % B. 
S 6.1.8 Antimicrobial Assay. 
All microorganisms were handled according to standard procedures and were obtained from the 
German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung für Mikroorganismen und 
Zellkulturen, DSMZ) or were part of our internal strain collection. For microdilution assays, overnight 
cultures of Gram-positive bacteria in Müller-Hinton broth (0.2 % (w/v) beef infusion, 0.15 % (w/v) corn 
starch, 1.75 % (w/v) casein peptone; pH 7.4) were diluted in the growth medium to achieve a final 
inoculum of ca. 106 cfu ml-1. Serial dilutions of homospermidine lipids were prepared from Methanol stocks 
in sterile 96-well plates. The cell suspension was added and microorganisms were grown on a microplate 
shaker (750 rpm, 37°C and 16 h). Growth inhibition was assessed by visual inspection and given MIC 
(minimum inhibitory concentration) values are the lowest concentration of antibiotic at which no visible 
growth was observed. 
S 6.1.9 Cytotoxic activity. 
Cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (Deutsche 
Sammlung für Mikroorganismen und Zellkulturen, DSMZ) or were part of our internal collection and were 
cultured under conditions recommended by the depositor. Cells were seeded at 6 x 103 cells per well of 
96-well plates in 180 µl complete medium and treated with homospermidine lipids in serial dilution after 
2 h of equilibration. Each compound was tested in duplicate as well as the internal solvent control. After 
5 d incubation, 20 µl of 5 mg ml-1 MTT (thiazolyl blue tetrazolium bromide) in PBS was added per well and 
it was further incubated for 2 h at 37°C. The medium was then discarded and cells were washed with 100 µl 
PBS before adding 100 µl 2-propanol/10 N HCl (250:1) in order to dissolve formazan granules. The 
absorbance at 570 nm was measured using a microplate reader (Tecan Infinite M200Pro), and cell viability 
was expressed as percentage relative to the respective methanol control. IC50 values were determined by 
sigmoidal curve fitting. 
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 Supplementary Figures & Tables 
 
Figure S 1. Base peak chromatograms (150–2500 m/z) showing the effect of XAD addition during cultivation on agar. 
 
Figure S 2. Comparative base peak chromatograms (150 – 2500 m/z) of a M. xanthus DK1622 extract originating from 
suspension culture in CTT medium and the respective blank. 
   
0 2 4 6 8 10 12 14 16 18 Time [min]
DK1622 on agar with XAD
XAD on agar blank
0 2 4 6 8 10 12 14 16 18 Time [min]
CTT-medium blank
Culture in CTT-medium
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Figure S 3. MS fragmentation tree of Cmp-552 based on MSn experiments performed on FT-ICR. 
 
Figure S 4. Overlaid base peak chromatogram and extracted ion chromatogram (552.50986 ±0.005 m/z) of the Cmp-
552 containing fraction indicated sufficient purity for NMR analysis. The respective fraction was received by semi-
preparative isolation effort of M. xanthus DK1622 extracts from cultivation on agar. 
552.50987
C33H66N3O3+
310.29030
C18H36N3O+
328.30087
C18H38N3O2+
451.42869
C28H55N2O2+
468.45489
C28H58N3O2+
227.24676
C13H27N2O+
126.13138
C8H16N+
156.14249
C9H18NO+
367.37277
C23H47N2O+
296.29998
C19H38NO+
368.35688
C23H46NO2+
- C15H28O
--
--
0 2 4 6 8 Time [min]
552.51043
∆m/z = 1.0 ppm
1104.01368
200 600 1000 1400 1800 m/z
MS
Ca
li
br
an
t
BPC (150-2500) m/z
EIC (552.50986 ±0.005) m/z
      264      Section S 6.2 Supplementary Figures & Tables 
 
Figure S 5. Explained variance plot of the PCA model considered in Figure 3. 
 Table S 1. All open reading frames (orfs) belonging to the putative homospermidine lipid biosynthesis cluster with 
proposed function and closest homologue according to a blastp search against the non-redundant protein database 
and the position of the orfs on the published M. xanthus DK1622 genome (NCBI reference sequence NC_008095.1) 
Name 
Length 
[bp] 
Proposed 
function 
Closest homologue 
Identity 
[%] and length of 
alignment [AA] 
Accession of 
closest homologue 
Locus 
tag on the 
DK1622 
genome 
hslA 1023 
Homospermidine 
synthesis 
Homospermidine synthase 
(Myxococcus virescens) 
98,5 / 339 SDF06447 MXAN_1678 
hslB 1896 
fatty acyl chain 
dehydrogenation 
oxidase – FAD/FMN dependent 
(Myxococcus fulvus) 
97,2 / 631 WP_043712221 MXAN_1676 
hslC 2607 
fatty acyl chain 
transfer 
glycerol-3-phosphate acyl 
transferase (Myxococcus 
virescens) 
99.5 / 868 SDF06388 MXAN_1675 
hslD 990 unknown 
NAD dependent epimerase 
(Myxococcus virescens) 
98.5 / 329 SDF06360 MXAN_1674 
hslE 1542 unknown 
hypothetical adventurous 
gliding motility protein N 
(Myxococcus xanthus) 
 98.8 / 344 AAO66306 MXAN_1673 
hslF 1005 unknown 
hypothetical Protein 
(Stigmatella aurantiaca) 
71.6 / 334 WP_075004684 MXAN_1687 
hslG 897 
N-acylation of the 
homospemidine 
moiety 
Acetyltransferase GNAT family 
(Myxococcus virescens) 
93.6 / 298 SDF06648 MXAN_1686 
hslH 174 unknown 
hypothetical protein 
(Myxococcus virescens) 
92.9 / 56 SDF06632 MXAN_1685 
hslI 558 regulation 
histidine kinase (Myxococcus 
fulvus) 
75.9 / 191 WP_013938788 MXAN_1684 
hslK 2280 unknown 
Dipeptidyl aminopeptidase 
(Myxococcus virescens) 
98.3 / 747 SDF06517 MXAN_1682 
hslL 798 unknown 
Dienelactone hydrolase 
(Myxococcus virescens) 
97.7 / 265 SDF06504 MXAN_1681 
hslM 675 regulation DNA binding response regulator 99.6 / 224 SDF06483 MXAN_1680 
hslN 1167 regulation 
signal transduction histidine 
kinase 
96.6 / 338 SDF06456 MXAN_1679 
hslO 2610 compound sensing 
tonB like protein (Myxococcus 
virescens) 
96.8/ 869 SDF06711 MXAN_1688 
hslP 1269 unknown 
hypothetical protein 
(Myxococcus virescens) 
98.7 / 422 SDF06729 MXAN_1689 
hslQ 945 unknown esterase (Myxococcus fulvus) 79.9 / 313 WP_013935160 MXAN_1690 
hslR1 525 regulation 
TetR family regulator 
(Myxococcus virescens) 
99.4 / 174 SDF06422 MXAN_1677 
hslR2 906 regulation 
LysR family regulator 
(Myxococcus virescens) 
99.3 / 301 SDF06540 MXAN_1683 
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Figure S 6. Gene organization of the putative homospermidine lipid biosynthesis cluster. Biosynthesis genes depicted 
in blue; regulatory elements depicted in red; genes of unknown function or genes putatively not involved in 
homospermidine lipid biosynthesis depicted in gray. 
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Figure S 7. Chemical structures of homospermidine-lipid derivatives with numbered carbon atoms corresponding to 
the NMR-data tables (Table S 2 to Table S 5)ure S 8:   
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Table S 2. NMR data for Cmp-552, 1; HS(iso5:0/5:0/iso15:0); (a–c HSQC signals overlapping) 
Carbon number δ 1H  [ppm] Multiplicity, J [Hz] and proton number δ 13C [ppm] COSY correlations  HMBC correlations  
1/2 0.84 d, 6.73, 6 23.0 3 1/2, 3, 4 
3a 1.49 - 28.2 1/2, 4 1/2, 4 
4b 1.13 - 39.4 3, 5, 6 1/2, 4, 5, 6 
5/6/7c 1.23 - 30.1 4, 8/9/10 4, 8/9/10 
8/9/10a 1.58 - 26.0 5/6/7, 8/9/10, 11/12 5/6/7, 8/9/10, 11/12 
11/12c 1.29 - 30.1 8/9/10, 13 8/9/10, 11/12, 13, 14 
13 1.59 - 26.1 12, 14 11, 12, 14, 15 
14 2.25 t, 7.59, 2 33.6 12, 13 12, 13, 15 
15 - - 173.5 - 14, 16, 25 
16 3.30 - 45.5 17 15, 17, 25 
17a 1.52 - 25.1 17, 18 16, 18, 19 
18a 1.47 - 26.7 17, 19 16, 17, 19 
19 3.27 - 39.0 18 17, 18, 20 
20 - - 177.7 - 19, 21, 22 
21 2.35 m 33.8 22 22, 23/24 
22 2.35  36.0 21, 23/24 20, 21, 23/24 
23/24b 1.13 t, 6.69, 6 20.0 21, 22 20, 21, 22, 23/24 
25 3.23 t, 7.59, 2 48.0 26 15, 16, 26/27 
26/27a 1.54 - 26.1 25, 27 25, 26/27, 28 
28 3.27 - 39.0 26/27 25, 26/27, 29 
29 - - 173.7 - 28, 30, 31 
30 2.14 t, 7.64, 2 39.1 31 31, 32, 33 
31 1.64 m 19.5 30, 32, 33 30, 32, 33 
32c 1.29 - 25.9 31, 33 30, 31, 33 
33 m - 14.3 31, 32 31, 33 
Figure S 9 Figure S 10 Figure S 11 
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Table S 3. NMR data for Cmp-564, 2; HS(5:0/iso5:0/iso15:0(6E)) 
Carbon 
number 
δ 1H [ppm] 
Multiplicity, J [Hz] and proton 
number 
δ 13C 
[ppm] 
COSY correlations 
[ppm] 
HMBC correlations [ppm] 
1 + 2 0.91 d 6.7 Hz 2H 23.58 1.55 29.50, 40,69 
3 1.55 m 1H 29.7 0.91, 1.21 23.57, 40.32 
4 1.21 m 2H 40 1.55,  1.31 23.4, 29.6, 32.0 
5 1.31 m 2H 32 1.2, 1.3 31.0, 30 
6 ca 1.3 m ca. 30 ca 1.3 ca. 30 
7 ca 1.3 m ca. 30 ca 1.3 ca. 30 
8 ca 1.3 m ca. 30 ca 1.3 ca. 30 
9 1.37 m 2H 30.9 2.0, 1.34 132.0, 33.8 
10 2 m 2H 33.8 1.37, 5.43 132.0, 30.9 
11 5.43 m 1H 132 2.0, 5.37 - 
12 5.37 m 1H 131.1 2.07, 5.43 28.8 
13 2.07 m 2H 28.8 1.42, 5.34 131.1, 31.3 
14 1.42 m 2H 31.3 2.07, 1,65 131.1, 33.4, 26.8, 28.1 
15 1.62 m 2H 26.9 1.42, 2.26 31.3, 175.0 
16 2.27 t 2H 36.9 1.62 26.9, 31.3, 179.5 
17 - - 176.5 - - 
18 3.34 m 2H 48.07 1.58, 3.2 26.5, 176.5 
19 1.58 m 2H 26.5 1.508, 3,34 48.1,28.5 
20 1.508 m 2H 28.5 1.58, 3.34 26.5, 40.3 
21 3.21 t 2H 7.19 Hz 40.3 1.51, 1.58 28.5, 180.3 
22    180.3     
23 2.454 dq 1H 36.9 1.133 20.3, 180.3 
24+25 1.133 CH3 2 mal 20.36 2.467 36.9, 20.28, 180.0 
26 3.35 m 2H 47.26 1.58, 3.20 26.5, 176.5 
27 1.58 m 2H 26.5 1.51, 3.35 47.3, 28.5 
28 1.507 m 2H 28.5 1.58, 3.20 26.5, 36.9 
29 3.22 t 2H 7.19 Hz 36.9 1.50, 1.58 28.5, 176 
30    175.93     
31 2.378 t 2H 34.45 1.6442,  26.7, 30.9 
32 1.6442 m 2H 26.7 1.347, 3,36   
33 1.35 m 2H 30.1     
34 0.934 1 3H 6.7 Hz 14.8 1.347   
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 Table S 4. NMR data for Cmp-578, 3; HS(5:0/5:0/iso17:0(6E)) 
Carbon 
number 
δ 1H  [ppm] 
Multiplicity, J [Hz] and proton 
number 
δ 13C 
[ppm] 
COSY correlations 
[ppm] 
HMBC correlations [ppm] 
1 + 2 0.9 d 6.7 Hz 6H 23.67 1.54 29.08, 40.8 
3 1.55 m 1H 29.67 0.9, 1.2 23.37, 28.11, 40.71 
4 1.2 m 2H 40.72 1.54 23.6, 29.6, 33.75 
5 1.31 m 2H 33.75 1.2, 1.3 40.7, ~30 
6 ca 1.3 m ca. 30 ca 1.3 ca. 30 
7 ca 1.3 m ca. 30 ca 1.3 ca. 30 
8 ca 1.3 m ca. 30 ca 1.3 ca. 30 
9 1.38 m 2H 30.3 1.3, 2.0 34.1, 132.0 
10 2 m 2H 34.1 1.38, 5.45, 5,34 30.3, 131.1, 132.0 
11 5.45 m 1H 132 2.0, 5,34, 2.07 34.1, 132.0, 33 
12 5.375 m 1H 131.1 2.07, 2.2, 5.45 31.0, 131.1, 132.0 
13 2.07 m 2H 31 1.42, 5.375 30.9, 131.5, 132.0 
14 1.42 m 2H 30.9 2.07, 1.62,  131.1, 31, 26.89, 33.78 
15 1.6 m 2H 26.8 1.42, 2.31 30.9, 33.68,176.3 
16 2.375 t, 2H, 7.2Hz 33.7 1.63 26.8, 31.0, 176.3 
17 - - 176.3 - - 
18 3.36 m 2H 47.04 1.58, 3.2 26.6, 176.5 
19 1.57 m 2H 26.65 1.508, 3,34 47.0, 28.4 
20 1.5 m 2H 28.38 1.58, 3.34 26.7, 40.2 
21 3.21 t 2H 7.19 Hz 40.19 1.51, 1.58 28.3, 178.5 
22    178.3     
23 2.3 t 2H 35.62 1.62 28.8, 31, 178.5 
24 1.62   26.8 1.34 35.46 
25 1.34   33.4 0.93 35.4, 14.7 
26 0.93   14.7 1.34 33.4 
27 3.36 m 2H 47.04 1.58, 3.20 26.6, 176.5 
28 1.57 m 2H 26.65 1.51, 3.35 47.0, 28.4 
29 1.5 m 2H 28.38 1.58, 3.20 26.7, 40.2 
30 3.21 t 2H 7.19 Hz 40.19 1.50, 1.58 28.3, 178.5 
31    178.3     
32 2.3 t 2H 35.62 1.62 28.8, 31, 178.5 
33 1.62 m 2H 26.8 1.34 35.46 
34 1.34 m 2H 33.4 0.93 35.4, 14.7 
35 0.93 1 3H 14.7 1.34 33.4 
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Table S 5. NMR data for Cmp-522, 4; HS(2:0/2:0/iso19:0(6E)) 
Carbon 
number 
δ 1H  
[ppm] 
Multiplicity, J [Hz] and proton 
number 
δ 13C 
[ppm] 
COSY correlations 
[ppm] 
HMBC correlations 
[ppm] 
1 + 2 0.88 d, 6.7 Hz, 6H 22.9 1.51 29.0, 39.8 
3 1.51 m, 1H 29 0.88, 1.18 39.8, 22.9, 28.3 
4 1.18 m, 2H 39.8 1.29, 1.51 22.9, 29.0, 28.3 
5 1.29 m, 2H 28.3 1.18, 1.3 30, 39.8 
6 ca. 1.3 m, 2H ca. 30  ca. 1.3 ca. 30 
7 ca. 1.3 m, 2H ca. 30 ca. 1.3 ca. 30 
8 ca. 1.3 m, 2H ca. 30 ca. 1.3 ca. 30 
9 ca. 1.3 m, 2H ca. 30 ca. 1.3 ca. 30 
10 ca. 1.3 m, 2H ca. 30 ca. 1.3 ca. 30 
11 1.35 m, 2H 30.4 1.98, ca.1.30 131.6, 33.3, 30 
12 1.98 m, 2H 33.3 1.35, 5.45, 5.39 30.4, 131.6, 130.6 
13 5.45 m, 1H 131.6 1.98, 2.01, 5.39 30.4, 33.3,130.6 
14 5.39 m, 1H 130.6 2.01, 1.98, 5.45 33.0, 30.0, 131.6 
15 2.01 m, 2H 33 1.40, 5.39 30.2, 33.3, 130.6, 131.6 
16 1.4 m, 2H 30.2 1.59, 2.35, 2.01 33.0, 26.0 
17 1.59 m, 2H 26 1.40, 2.35 33.7, 30.2 175.2 
18 2.35 t, 7.6 Hz, 2H 33.7 1.59, 1.40, 3.32 30.2, 26.0, 175.2 
19 - - 175.2 - - 
20 3.32  m, 2H 46.3 1.56, 3.35, 2.35 25.9, 48.5, 175.2 
21 1.56 m, 2H 25.9 3.32, 1.48 46.3, 27.1 
22 1.48 m, 2H 27.1 3.17, 1.56 25.9, 46.3, 39.6 
23 3.17 t, 6.2 Hz, 2H 39.6 1.48, 1.92 27.1, 25.9, 173.3 
24 - - 173.3 - - 
25 1.92 s, 3H 22.1 3.17 39.6, 173.3 
26 3.35 m, 2H 48.5 1.59, 3.32, 2.35 27.0, 46.3, 175.2 
27 1.59 m, 2H 27 3.35, 1.52 48.5, 27.5 
28 1.52 m, 2H 27.5 3.20, 1.59 48.5, 27.0, 39.4 
29 3.2 t, 6.2 Hz, 2H 39.4 1.52, 1.94 27.5, 27.0, 173.5 
30 - - 173.5 - - 
31 1.94 s, 3H 22.1 3.2 39.4 ,173.5 
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Figure S 12. Base Peak Chromatograms of pure homospermidine lipids for NMR analysis 
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 Abstract 
The determination of the molecular formula is one of the earliest and most important steps when 
investigating the chemical nature of an unknown compound. Common approaches use the isotopic pattern 
of a compound measured using mass spectrometry. Computational methods to determine the molecular 
formula from this isotopic pattern require a fixed set of elements. Considering all possible elements 
severely increases running times and more importantly the chance for false positive identifications as the 
number of candidate formulas for a given target mass rises significantly if the constituting elements are 
not prefiltered. This negative effect grows stronger for compounds of higher molecular mass as the effect 
of a single atom on the overall isotopic pattern grows smaller. On the other hand, hand-selected 
restrictions on this set of elements may prevent the identification of the correct molecular formula. Thus, 
it is a crucial step to determine the set of elements most likely comprising the compound prior to the 
assignment of an elemental formula to an exact mass. In this paper, we present a method to determine 
the presence of certain elements (sulfur, chlorine, bromine, boron, and selenium) in the compound from 
its (high mass accuracy) isotopic pattern. We limit ourselves to biomolecules, in the sense of products from 
nature or synthetic products with potential bioactivity. The classifiers developed here predict the presence 
of an element with a very high sensitivity and high specificity. We evaluate classifiers on three real-world 
data sets with 663 isotope patterns in total: 184 isotope patterns containing sulfur, 187 containing 
chlorine, 14 containing bromine, one containing boron, one containing selenium. In no case do we make 
a false negative prediction; for chlorine, bromine, boron, and selenium, we make ten false positive 
predictions in total. We also demonstrate the impact of our method on the identification of molecular 
formulas, in particular on the number of considered candidates and running time. The element prediction 
will be part of the next SIRIUS release, available from https://bio.informatik.uni-jena.de/software/sirius/. 
 Introduction 
Hyphenated high-resolution mass spectrometry, mostly coupled to liquid chromatography (LC–MS) 
or gas chromatography (GC/MS), is the predominant experimental platform for untargeted metabolomics 
and also plays an important role in other analytical fields requiring high information content and increased 
sample throughput, such as natural products research. Because of the underlying study designs, these 
applications regularly bring about high numbers of unidentified mass spectral features, leading to the 
analytical challenge to identify as many as possible of the corresponding unknown compounds. One of the 
decisive steps investigating unknown compounds is to determine its molecular formula, which can serve 
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as a starting point for the structural elucidation. High-throughput molecular formula annotation workflows 
are required for the analysis of complex biological samples. The vast numbers of unknowns detected in 
mass spectral data sets acquired from these samples necessitate efficient methods for formula generation, 
since the process is computationally expensive and error-prone. As an example, a bacterial extract could 
contain 600–700 unknown substances,[1] and studies of the metabolomes of higher organisms exceed 
these numbers: the human serum metabolome contains more than 4000 metabolites visible by LC–MS 
analysis.[2] Especially for nonmodel organisms, an astounding number of metabolites to date remain 
uncharacterized with respect to their structure and function. Contrary to proteins and other biopolymers, 
which are constructed from a well-defined set of building blocks, the structure of metabolites is much less 
defined and thus the structure elucidation process is labor-intensive and usually requires additional 
techniques like NMR spectroscopy. The capability to efficiently compute high-confidence molecular 
formulas facilitates this objective. 
In the following, we will limit ourselves to biomolecules; that is, molecules that are products of nature 
or synthetic products with potential bioactivity. Many biomolecules, among them an overwhelming 
number of substances found ubiquitously across the domains of life, are composed of six elements, i.e., 
carbon, hydrogen, nitrogen, oxygen, phosphorus, and sulfur.[3] In contrast, secondary metabolites and 
other biomolecules, such as drugs or pesticides, occasionally contain less frequently occurring elements, 
which we refer to as uncommon elements throughout this paper. To name a few examples, marine 
organisms and some terrestrial bacteria produce halogenated compounds incorporating bromine or 
chlorine;[4,5] antibiotics containing boron have been reported;[6]  metabolites of higher plants can contain 
selenium;[7]  finally, fluorine and iodine have been detected in the metabolism of certain organisms.[8,9] 
Microbial secondary metabolites are the subject of natural product screening workflows forming the basis 
for the discovery of novel drug candidates, thus strengthening our motivation to improve computational 
tools for their identification.[10] However, it is understood that methods developed for biomolecule 
identification are likely to find application in other analytical areas too, since the underlying fundamental 
challenge of unknown characterization is common to many varieties of small-molecule investigations using 
mass spectrometry, ranging from in vitro drug metabolism studies to pesticide screening. 
Mass spectrometric instrumentation has seen significant improvement in terms of resolution and 
mass accuracy over the last 2 decades; however, exact (monoisotopic) mass alone is insufficient to 
determine the molecular formula of a compound even for sub ppm mass accuracy.[11] To this end, several 
approaches use the natural isotopic distributions of elements to improve molecular formula 
determination,[12] assuming a mass accuracy of about 10 ppm or better. Certain approaches limit 
computation to molecular formulas present in a database;[13] but since many natural compounds are 
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absent from any database, this restriction is unacceptable. Other approaches compute all candidate 
molecular formulas (considering a fixed set of elements) that are sufficiently close to the measured peak 
mass,[14] simulate an isotope pattern for each candidate molecular formula,[11,15–17] and compare it to the 
measured one.[17–20] Here, the isotope pattern may also contain accurate masses of isotope peaks. Some 
approaches additionally take the fragmentation pattern of compounds into account.[21,22,23] All of these 
approaches require the researcher to specify the set of elements to be considered. 
For compounds above 400 Da, the number of molecular formulas increases rapidly,[11,17,23] in 
particular when considering a set of elements beyond CHNOPS. This severely increases not only running 
time but also chances for false identifications. On the other hand, manually adjusted restrictions on 
elements, or the maximum allowed number of atoms of a particular element, could exclude the correct 
molecular formula from the candidate set[24] and hence prevent the discovery of an interesting compound 
featuring an uncommon element. The presence of certain uncommon elements can be inferred by manual 
inspection of the isotope pattern in mass spectra, see Figure 1 in ref [25] for an instructive example. 
Transforming such observations into robust classifiers is nevertheless a challenging problem, as both 
masses and intensities are perturbed in real-world measurements. Previous efforts along these lines have, 
for example, been related to estimating the number of chlorine and bromine atoms from electron 
ionization mass spectra as part of the NIST Mass Spectral Search Program.[26] Here, we present a fully 
automated method to robustly determine the elements for the compound under study from the isotope 
pattern. The set of elements determined by our method then serves as input for the next step of the 
analysis, where accurate masses, isotope pattern (and potentially other information) are used to 
determine the molecular formula of a compound under investigation. The four most abundant elements 
in living organisms, carbon, hydrogen, nitrogen, and oxygen, form our basic set of elements. We add 
phosphorus to this set, as it is relatively common in biocompounds (e.g., nucleotides, ATP) and, in addition, 
has only a single stable isotope, thus cannot be predicted on the basis of isotope pattern (the latter applies 
also to iodine and fluorine). We present a method to predict the presence of the elements sulfur (S), 
chlorine (Cl), bromine (Br), boron (B), and selenium (Se) from isotope patterns. 
Our method uses Machine Learning, that is, algorithms that can learn from data, and make 
predictions based on data. We employ Supervised Machine Learning where the computer is presented 
with example inputs and desired outputs (the training data), and the goal is to learn rules that map inputs 
to outputs. For each element, we use a binary classifier that classifies the data into two groups (contains 
the element vs does not contain the element). For classification, we use random forests.[27] For each 
element, we present three classifiers based on the number of observed isotope peaks (three, four, and 
five or more peaks). We find that the more unique the isotopic distribution of an element is, the more 
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precise our predictions are. Furthermore, availability of more isotopic peaks from the mass spectrum also 
improves prediction quality. Evaluating the classifiers on three real-world data sets of a total of 663 isotope 
patterns measured on three different instruments results in no false negative predictions and few false 
positive predictions for all elements but sulfur. We show that our method significantly decreases the 
number of molecular formulas that have to be considered by subsequent analysis steps, resulting in a 
massive decrease of running time, while at the same time also slightly improving identification rates. The 
method presented here will be integrated in an upcoming release of the SIRIUS 3 software package.[17,23]  
 Background 
The most common method to determine a molecular formula is to simulate an isotope pattern for 
each candidate molecular formula and compare it to the measured one.[17–20] This requires a fixed set of 
elements to be considered for the generation of candidate molecular formulas. Obviously, the number of 
candidates increases considerably with the size of the set of elements. For example, consider rifampicin 
with monoisotopic mass 822.405 Da and mass accuracy 6 ppm: we reach 2 358 candidates for the set of 
elements CHNOP and 117 029 candidates for CHNOPSClBr, an almost 50-fold increase caused by only three 
uncommon elements. (The above numbers ignore molecular formula filters such as the “Senior rules”,[28](  
but the effect is comparable.) On the theoretical side, the number of decompositions of a certain mass can 
be approximated with high accuracy using a polynomial:[17] Assuming a relative error, this polynomial has 
degree k for k elements. 
Isotopes are variants of an element with different numbers of neutrons. Different isotopes of the 
same element have nearly identical chemical properties but different mass. Most elements in nature have 
more than one stable isotope, and each of these isotopes occurs in nature with a certain abundance. [29] 
The totality of isotopes is the isotopic distribution of an element. The mass difference of successive 
isotopes differs from element to element, despite the fact that in all cases, one or more neutrons are 
added: For example, the mass difference of 12C and 13C is 1.00335 Da (Dalton), whereas the mass difference 
of 10B and 11B is 0.99637 Da. The different isotope abundances and masses of the isotopes that are 
contained in a compound generate a characteristic set of peaks, called an isotope pattern. In comparison 
to C, H, N, O, and P (referred to as “CHNOP” in the following), the elements S, Cl, Br, B, and Se lead to more 
“distinctive” isotope patterns, as the most abundant isotope of these elements has relative abundance 
less than 95%. 
In this paper, we will not consider the isotopic fine structure (isotopologues) of a compound; instead, 
we limit ourselves to the mean peak masses[17] (or accurate masses[16]) of isotopic peaks, combining all 
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isotopologues with identical nominal mass. Throughout this paper, the isotopologue where each atom is 
the isotope with the lowest nominal mass is referred to as monoisotopic, see, for example, ref [30]. For 
certain elements such as boron or selenium, this is not the most abundant isotope. We refer to the peak 
at the monoisotopic mass as the monoisotopic peak or + 0 peak, which is followed by the + 1, + 2 ... peaks. 
Referring to a peak “before” (“after”) another peak, means it has a smaller (higher, respectively) mass. 
The isotopic distribution of elements influences the isotope pattern of the compound in both mass 
differences and intensities of peaks. Small compounds containing only CHNOP have an intense 
monoisotopic peak; the + 1 peak has much lower intensity, and intensity of subsequent peaks decreases 
further. The more “distinctive” isotopic distributions of S, Cl, Br, B, and Se are reflected in the shape of the 
isotope pattern of a compound, see Figure 1 and section S.1, Supporting Information. 
Figure 1. Effect of the uncommon elements S (yellow), Cl (green), Br (red), B (magenta), and Se (blue) on the isotope 
pattern. [M + H]+ ionization is assumed. Individual isotopic distributions of the corresponding uncommon elements 
are shown in the colored boxes. All molecular formulas come from the molecular structure databases. 
 Methods 
We use a set of binary classifiers to predict the presence of uncommon elements from isotope 
patterns of compounds using supervised machine learning. We create one classifier for the presence of 
each of the uncommon elements Cl, Br, B, S, and Se. Further, we create a classifier “CHNOPS” for 
compounds that contain only the elements C, H, N, O, P, and S; we use this classifier to demonstrate the 
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discriminative power of the isotope pattern for identifying uncommon elements. The classifier cannot rule 
out the presence of fluorine or iodine in a compound or any other element that has only a single stable 
isotope. 
To learn and predict the presence of uncommon elements from isotope patterns, the patterns need 
to be transformed to a set of numerical features characterizing the data. Those features are based on the 
masses and intensities of the peaks. Measured isotope patterns vary in the number of detected peaks. In 
particular for small compounds, we get very short isotope patterns, as only a few peaks are intense enough 
to be detected as signal. Using classifiers for arbitrary peak number would result in missing (peak) features 
for smaller isotope patterns, making the training more complicated. Hence, we construct different 
classifiers for isotope patterns of size three, four, and five. In total, we train 18 classifiers (five uncommon 
elements plus CHNOPS times three isotope pattern sizes). 
Isotope patterns with less than three peaks do not contain enough information for uncommon 
element prediction. However, for isotope patterns with less than three peaks, the presence of an 
uncommon element is very unlikely since the + 2 should be intense enough for detection if an uncommon 
element is present (see Figure 1). For isotope patterns with more than five peaks, we consider only the 
first five peaks. Classifiers for isotope patterns with more than five peaks did not improve the results 
significantly (data not shown). 
7.4.1 Features 
We use features based on the intensity and mass of the isotope peaks. The full list of features can be 
found in Table S.1. The number of features varies according to the number of peaks in the isotope pattern: 
There are 21 (38, 39) intensity features and 4 (7, 11) mass features for three (four, five, respectively) 
isotope peaks. 
7.4.2 Intensity Features 
We use the intensity of each peak as well as the minimal, maximal, and median peak intensity. Since 
the presence of some elements results in zigzag shaped isotope patterns, we further use the sums, minima, 
and maxima of intensities for even and odd peaks, respectively. Furthermore, we use the index of the most 
intense, second most intense, and third most intense peak. We use quotients and differences of all pairs 
of peak intensities for the first four peaks. Finally, we use all combinations of sums of peak intensities. 
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7.4.3 Mass Features 
We use monoisotopic mass, and all pairwise mass differences between isotope peaks as features. 
Mass is included, since the influence of uncommon elements on the shape of the isotope pattern is 
stronger for small compounds than for large ones. The mass difference between consecutive peaks of the 
isotope pattern is influenced by elements with more than one stable isotope: For example, if Cl is present, 
the mass difference between the monoisotopic peak and + 2 peak decreases due to the mass difference 
of 1.99705 Da between 35Cl and 37Cl. 
7.4.4 Random Forests 
For classification we use random forests, a supervised machine learning method.[27]  A random forest 
consists of a set of unpruned decision trees. Each tree is trained on a random sample (with replacement) 
of the training data. This technique is called bagging.[31] For the determination of a split (a node in a 
decision tree), we use a subset of m ≈ √M features, where M is the total number of features.[32] We use 
the random forest implementation of the Mahout library (version 0.9, https://mahout.apache.org/) for 
training. 
We set m = 5 for isotope patterns of size three, and m = 7 for isotope patterns of size four and five. 
For each classifier, we generate a random forest consisting of 100 trees. For all other parameters we use 
the default values of the Mahout library. The classes DecisionTreeBuilder and Bagging are used to 
construct the trees. By default, the minimum set size for a split is 2 and the minimum variance proportion 
is 0.001. We use the OptIgSplit class to compute the best split. 
For classification, the input is run through all of the decision trees in the random forest, and the final 
classification is done by voting: every decision tree votes for true or false. A threshold for the ratio of 
positive votes is used to determine the classification of the forest. 
7.4.5 Data Sets 
For the training and evaluation of the classifiers, we want to use a very large set of isotope patterns. 
Unfortunately, there is only limited experimental data available for isotope patterns of biomolecules. In 
this paper, we use three measured data sets from different instruments for evaluation; in addition, we use 
simulated isotope patterns of molecular formulas from several compound databases (see Table 1). 
 
 
      280      Section 7.4 Methods 
Table 1.  Overview of the Datasets Used for Training and Evaluation 
  simulated measured 
  training evaluation myxo pesticide CASMI 
all 1 128 059 51 097 88 43 532 
CHNOPS 604 506 42 713 78 15 370 
sulfur S 502 529 9 892 24 14 146 
chlorine Cl 345 799 5 502 8 27 152 
bromine Br 171 596 3 015 0 1 13 
boron B 56 808 141 1 0 0 
selenium Se 16 680 98 1 0 0 
Total number of molecular formulas and numbers of molecular formulas that are positive examples 
for the different classifiers are given. In addition to the simulated evaluation set, the measured datasets 
are used exclusively for evaluation. 
 
The myxo data set consists of 88 isotope patterns measured on a Bruker MaXis 2G qTOF spectrometer 
(Bremen, Germany). The corresponding compounds are secondary metabolites from Myxobacteria, with 
several exceptions mentioned below. Compounds range in mass from 192.009 to 2213.962 Da, with an 
average mass 623.277 Da and median mass 591.307 Da. From these compounds, 24 contain sulfur (20 
contain a single sulfur atom, 2 contain two, and 2 contain three sulfur atoms), 8 contain chlorine (6 with 
one chlorine atom, 2 with two chlorine atoms), and one compound contains a single boron atom. We 
added selenomethionine to this data set as a positive example for a selenium-containing compound. Nine 
compounds have a measured isotope pattern of length three, 47 of length four, and 32 of length five or 
more (3 of length six, 5 of length seven, 1 of length nine). The myxo data set is available from 
https://bio.informatik.uni-jena.de/data/. 
The pesticide data set is taken from Stravs et al.[22]  The data set consists of isotope patterns from 
different pesticides measured on a LTQ Orbitrap XL from Thermo Fisher Scientific (San José, CA) with 
electrospray ionization in positive and negative modes. Compounds range in mass from 198.056 to 
443.125 Da, with average mass 275.353 Da and median mass 260.016 Da. From the 60 mass spectra, 43 
show an isotope pattern with at least three peaks. For the 18 shorter isotope patterns, none of the 
compounds contains any of the elements SClBrBSe. For the remaining 43 isotope patterns, 14 isotope 
patterns contain a single sulfur atom, 27 chlorine (22 with a single chlorine atom, 4 with two, and 1 with 
three chlorine atoms), and one isotope pattern contains a single bromine atom. The data set contains 18 
isotope patterns with a measured isotope pattern of length three, 18 of length four, and 7 of length five 
or more (1 of length six). 
The CASMI data set was measured by Martin Krauss (Helmholtz Centre for Environmental Research, 
Leipzig, Germany) and processed by Emma Schymanski (Eawag, Dübendorf, Switzerland) as part of the 
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Critical Assessment of Small Molecule Identification Challenge 2016 (http://www.casmi-
contest.org/2016/) using RMassBank.[22] Measurements were performed on a Q Exactive Plus Orbitrap 
(Thermo Scientific) with electrospray ionization in positive and negative mode. MS1 spectra were 
extracted for substances with [M + H]+ (positive) and [M – H]− (negative mode) ions. We removed one 
compound containing silicon. The remaining data set contains 628 independent mass spectra from 512 
compounds. Compounds range in mass from 67.042 to 776.687 Da, with an average mass 259.500 Da and 
median mass 246.071 Da. From the 628 mass spectra, 532 show an isotope pattern with at least three 
peaks. For the 96 shorter isotope patterns, none of the compounds contain any of the elements SClBrBSe. 
For the remaining 532 isotope patterns, 146 patterns contain sulfur (128 with a single sulfur atom, 17 with 
two, and 1 with four sulfur atoms), 152 chlorine (84 with a single chlorine atom, 42 with two, 19 with 
three, 3 with four, and 3 with six chlorine atoms) and 13 bromine (11 with a single bromine atom and 2 
with two bromine atoms). The data set contains 140 isotope patterns with a measured isotope pattern of 
length three, 220 of length four, and 172 of length five or more (49 of length six, 2 of length seven, and 1 
of length 8). 
For training and evaluation, we use simulated isotope patterns of molecular formulas of compounds 
from 11 compound databases: ChEBI (Chemical Entities of Biological Interest),[33] ChEMBL version 19,[34] 
DrugBank version 4.2,[35]  HMDB (Human Metabolome Database) version 3.6,[36]  Indofine 
(http://indofinechemical.com/), KEGG (Kyoto Encyclopedia of Genes and Genomes),[37] KNApSAcK,[38] 
MolMall (http://www.molmall.net/), PubChem,[39] UNPD (Universal Natural Product Database),[40] and 
ZINC (ZINC Is Not Commercial) version 12,[41] see section S.3 and Table S.2 for details. 
Some of the databases, in particular PubChem, contain many records which are uncommon for 
biomolecules. To remove such molecular formulas, we filtered all data sets using the following ad hoc 
rules: (1) the compound has a monoisotopic mass between 100 and 1500 Da; (2) the compound contains 
only elements from CHNOPSClBBrSe and contains at least one carbon and one hydrogen atom; (3) the 
compound contains at most five atoms of sulfur, chlorine, boron, or bromine. For the training data only, 
we also discarded (4) charged or generic compounds or complexes. We stress that molecular formulas 
passing these restrictions do not necessarily correspond to biomolecules, and that biomolecule molecular 
formulas may fail one or more of these rules; these data are used to train and evaluate our method. 
We split the databases into a large training set that is used to construct the classifiers and a smaller 
evaluation set. As the training set, we use PubChem, ChEMBL, and ZINC. PubChem is the largest data set 
and contains reasonably many compounds even for Se and B. It is particularly useful to train cases such as 
compounds incorporating a high number of uncommon elements or unlikely combinations of uncommon 
elements. We observe that molecular formulas from ChEMBL and ZINC are almost completely covered by 
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PubChem. As the evaluation set, we use HMDB, ChEBI, DrugBank, Indofine, KEGG, KNApSAcK, MolMall, 
and UNPD. 
Several molecular formulas are contained in more than one database; clearly, we consider only a 
single occurrence of each. Further, the training set should be independent from the evaluation set. To this 
end, all molecular formulas from the evaluation set are removed from the training set. In total, the training 
set contains 1 128 059 molecular formulas, and the evaluation set contains 51 097 molecular formulas 
(see Table 1). 
7.4.6 Isotope Pattern Simulation 
For the simulation of isotope patterns, we use SIRIUS[17] to compute the exact isotope pattern. For 
the training and evaluation set, we add noise to the peak intensities to simulate measured isotope 
patterns. In Machine Learning, adding noise often improves classification results, as it forces the method 
to search for complex patterns and improves generalizability. It is not necessary that the added noise has 
the same characteristics as noise observed in the real-world data. For each peak, we calculate the 
simulated intensity  where is a normally distributed relative noise with 
mean one and is a normally distributed absolute noise with mean zero. After adding noise to all 
peaks of an isotope pattern, the peak intensities are normalized to 100%. 
In addition, we add noise to the peak masses. For each peak, we calculate the simulated mass
, where  is an additive, normally distributed absolute noise with mean zero. We 
are aware that mass deviation is not constant throughout the mass range but rather depends on the mass 
of the compound. Nevertheless, we refrain from using a multiplicative mass noise: The features for the 
classifiers are built on mass differences between the peaks instead of peak masses. To our knowledge, the 
distribution of deviation of dependent mass differences has not been investigated. To make our classifiers 
robust, we prefer to consider the worst case scenario, which is an additive noise with the highest mass 
deviation we have observed. 
7.4.7 Noise Parameters of the Evaluation Set 
To find realistic noise parameters, we investigate measured isotope patterns from a Bruker Maxis 2G 
qTOF mass spectrometer, measured at different concentration levels. On the basis of the accuracy of these 
patterns, we define a standard noise profile with standard deviations σIA = 0.0015, σIR = 0.04, and σM = 
0.0013 Da. In addition, we define a high noise profile with standard deviations σ IA = 0.006, σIR = 0.07, and 
σM = 0.0018 Da to generate particularly hard cases. The reader is reminded that we measure mass 
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differences between isotope peaks. Both noise profiles are used for generating isotope patterns for the 
evaluation set. 
7.4.8 Noise Parameters of the Training Set 
Instead of using exact simulated isotope patterns, we found that adding noise to the training data 
improves classification results. We found that using relatively high noise during training, improves 
classification results even for the standard noise profile. Thus, for simulating the training set, we choose 
noise parameters that are higher than the standard noise profile of the evaluation set, namely, σIA = 0.005, 
σIR = 0.05, and σM = 0.0015 Da. 
7.4.9 Learning Phase 
For most classifiers, we have many more negative examples than positive examples in the training 
set. Because of the optimization function of random forests, unbalanced data leads to suboptimal 
classification results for the smaller class.[42]  For each classifier, we generate a training subset by randomly 
drawing without replacement to reach the same number of positive and negative examples. The CHNOPS, 
S, Cl, Br, and B classifiers are trained using a subset of 100 000 molecular formulas (50 000 positive and 
50 000 negative examples) and Se with 25 000 molecular formulas (12 500 positive and 12 500 negative 
examples). 
There exist improved downsampling techniques to balance the data, such as distance based 
methods.[43] Because of the large number of compounds and high dimensionality of the training data, 
computation would be very time-consuming. We found that random downsampling delivers very good 
results and refrained from testing improved techniques. 
 Results 
For each element, we present three classifiers based on the number of observed isotope peaks (3, 4, 
and 5 or more peaks). Classifiers are trained using simulated isotope patterns of more than a million 
compounds. The resulting classifiers give excellent separation, with the area under curve (AUC) above 0.99 
for all elements but sulfur. We then concentrate on classifiers with very high sensitivity, so that we almost 
never miss an occurrence of an uncommon element. In contrast, we put less focus on the specificity of our 
classifiers, resulting in more false positive predictions for certain elements. The reasoning for doing so is 
that our classifiers are meant as a first step of an automated pipeline for isotope pattern analysis: After 
generating and scoring candidates, the downstream method can sort out cases where our classifiers made 
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a false positive prediction. In contrast, if our classifiers make a false negative prediction, wrongly stating 
that some uncommon element is absent from a compound, the downstream analysis has no means to 
correct this. 
Training of all 18 classifiers required 3.5 h on two Intel Sandy Bridge processors at 2.3 GHz with six 
cores and 64 GB RAM. We find that training requires more time and the decision trees are larger, the less 
unique the isotopic distribution of the element is (see Tables S.3 and S.4). For example, in the random 
forest of the four peaks sulfur classifier, the resulting trees have a median of 9 450 nodes (median tree 
depth 47). Construction of this random forest required 23 min. In contrast, for the four peaks boron 
classifier, trees contain only a median of 13 nodes (depth four) and learning required only 7 min. For an 
example of a decision tree, see Figure 2. 
Figure 2. Example decision tree from the random forest of the boron classifier for isotope patterns with five peaks. 
This tree is combined with 99 other decision trees to reach the final decision whether or not boron is present in the 
unknown compound. 
7.5.1 Prediction Quality on Simulated Data 
There exist two types of wrong classifications: On the one hand, a classifier may return false 
(“element not present”) although the element is part of the compound (false negative); on the other hand, 
a classifier may return true (“element present”) when an element is not part of the compound (false 
positive). 
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In Machine Learning, one is generally interested in classifiers with high sensitivity (true positive rate) 
and high specificity (1 − false posiƟve rate), where       . 
It must be understood that reaching both high sensitivity and specificity simultaneously is usually not 
possible and that we might have to trade in sensitivity for specificity or vice versa. For the downstream 
analysis we have in mind (identification of the molecular formula), false negative predictions are much 
worse than false positive predictions. Once an element that is actually part of the compound is not 
considered for molecular formula identification, it is difficult or impossible to counteract this failure in the 
subsequent analysis steps. In contrast, a false positive prediction will “only” increase the running time and 
the probability of identifying a wrong molecular formula. Thus, sensitivity needs to be very high, even at 
the cost of specificity. For the CHNOPS classifier, which is included to evaluate the overall power of the 
approach, we treat sensitivity and specificity as equally important. 
Receiver Operating Characteristic (ROC) and the area under the ROC curve (AUC) can be used to 
evaluate the ability of a classifier to distinguish between true and false examples. The ROC curve is created 
by plotting the true positive rate (TPR) against the false positive rate (FPR) at all possible threshold settings 
of the classifier. When decreasing the threshold, both the true positive rate and the false positive rate 
increase. A perfect classifier would result in an area under curve of 1, that is, there is a threshold where 
the classifier reaches TPR of 1 without predicting any false positives. Random classifiers have an area under 
the curve of 0.5. 
ROC curves for the classifiers with three peaks are shown in Figure 3. Results for four and five peaks 
can be found in Figure S.1 in the Supporting Information. For all classifiers, we achieve area under curve 
above 0.97 even for the high noise profile, see Table 2. The lowest area under curve was achieved for the 
S classifier on three peaks. Compared to the other elements to be detected, sulfur has the least distinctive 
isotopic distribution and is hard to distinguish from isotope patterns containing only CHNOP. The more 
unique the isotopic distribution of the elements get, the higher the area under curve of the corresponding 
classifier. For Se and B we get an area under the curve of 1 in all cases. 
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Figure 3. (A) ROC curves for all classifiers using three peaks at the standard noise profile. (B–D) ROC curves for S 
(yellow), Cl (green), and Br (red) using three peaks at the standard noise profile and the high noise profile. In 
comparison to part A, ROC curves parts C and D are zoomed in to the top left corner. AUCs for all ROC curves can be 
found in Table 2. The chosen trade-offs between FPR and TPR for the analysis on the measured data sets are marked 
with ×. 
Table 2. AUCs for the Standard Noise Profile and the High Noise Profile 
noise profile: standard high 
no. of peaks: three four five three four five 
CHNOPS 1.0 1.0 1.0 1.0 1.0 1.0 
S 0.992 0.996 0.999 0.974 0.985 0.996 
Cl 0.998 0.999 1.0 0.994 0.997 0.999 
Br 0.997 0.997 1.0 0.994 0.997 1.0 
B 1 1 1 1 1 1 
Se 1 1 1 1 1 1 
If decimals are given, the given values are rounded. 
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We find that for all elements, area under curve increases for classifiers using isotope patterns with 
more peaks. This is not surprising, since isotope patterns with more peaks contain more information. In 
particular for the high noise profile, using more peaks improves the prediction. 
To further evaluate the trade-off between sensitivity and specificity, we analyze the FPRs for all 18 
classifiers at fixed TPRs for the standard noise profile (see Table 3; results for the high noise profile can be 
found in Table S.5). For Cl, FPR is below 6.5% in all cases, and for Br, FPR is below 1.5% in all cases. As 
expected, FPR improves when using more isotope peaks. For S, we get higher FPRs than for the other 
classifiers. For three peaks, we do not reach a TPR of 100%. 
Table 3. How Many False Positive Predictions Do We Have to Accept in Order to Reach a Certain Sensitivity? 
    three peaks four peaks five peaks 
  
resulting FPR 
desired TPR 0.998 0.999 1 0.998 0.999 1 0.998 0.999 1 
CHNOPS 0.0 0.0 0.005 0.0 0.0 0.001 0.0 0.0 0.001 
S 0.265 0.313 N/A 0.162 0.173 0.332 0.055 0.072 0.160 
Cl 0.056 0.057 0.063 0.054 0.055 0.060 0.004 0.008 0.027 
Br 0.012 0.013 0.013 0.012 0.012 0.013 0.0 0.0 0.0 
B 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Se 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
We report false positive rates (FPR) for all 18 classifiers at fixed true positive rates (TPR). TPR 0.998 
corresponds to two missed positive predictions in 1000 examples; TPR 1 means missing not a single 
positive example. Results for the standard noise profile. FPR and TPR used for the analysis on the measured 
datasets in bold. “N/A”, classifier cannot reach the desired TPR. 
 
We additionally evaluated the B classifiers against isotope patterns with an extremely high noise level 
(σIA = 0.008, σIR = 0.1, and σM = 0.002 Da) to account for the range of natural variation in the isotopic 
distribution of B. The prediction quality remains the same. For CHNOPS, we get a FPR 0.0 up to a TPR of 
99.9%. Even for 100% true positives, the FPR is below 1%. 
We manually chose the trade-off between FPR and TPR used for the analysis on the measured data 
sets, see Table 3. If several voting thresholds fall into the particular FPR/TPR trade-off, we choose a 
reasonable one (see Table S.6). 
We have also tested the training of different classifiers for different mass ranges, since the mass of a 
compound influences the shape of its isotope pattern. However, using two or three classifiers for different 
mass ranges did not improve prediction quality (data not shown). 
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7.5.2 Prediction Quality on Measured Data 
In the second part of our evaluation, we apply our classifiers to three measured data sets. The 
measured isotope patterns have different numbers of peaks; for each pattern, we choose the appropriate 
classifier. For each classifier, we use the voting threshold with the best trade-off between FPR and TPR 
(see Table 3 and Table S.6). Note that there is only one positive example each for B and Se. 
Table 4. Classification Results on the Three Measured Datasets 
 
Number of real positives (P) and negatives (N) as well as number of true positive (TP), true negative 
(TN), false positive (FP), and false negative (FN) predictions. Recall that false positive predictions (orange) 
can be corrected in the downstream analysis of molecular formula identification; in contrast, false negative 
prediction (red) cannot. 
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See Table 4 for prediction results. In no case do we observe a false negative prediction for elements 
S, Cl, Br, B, and Se. To this end, our classifiers have perfect sensitivity for the measured data. A false 
negative prediction would result in an element being excluded from further analysis, despite being present 
in the compound. Recall that false positive prediction, in contrast, can be corrected in the downstream 
analysis of identifying the exact molecular formula. For Cl, we get seven false positive predictions: See 
Figure S.2 for the isotope patterns of bromazil (C9H13BrN2O2) and pinensin A (C96H139N27O30S2). We note 
that pinensin A with mass 2213.962 Da is much larger than the mass range used for training our classifiers. 
For both compounds, the CHNOPS classifier reports a conflicting prediction. For Br, we have three false 
positive predictions in the CASMI data set. For B and Se we do not get any false positive predictions. 
For S, we get 40 false positive predictions and, thus, would use an unnecessary element for the 
molecular formula computation. Of these, 18 compounds are from the myxo data set. Compounds in the 
myxo data set are much larger than compounds in the other data sets; for larger compounds, the presence 
of sulfur is more veiled, in particular if only a single sulfur atom is contained. See Figure S.3 for an example. 
7.5.3 Molecular Formula Identification 
To show the use of our predictors in a pipeline for molecular formula identification, we integrated it 
into the SIRIUS pipeline for molecular formula identification using isotope patterns,[17] see refs [24] and [44] 
for details. Since biomolecules in the three data sets may potentially contain elements CHNOPSClBrBSe, 
we use this set of elements when running SIRIUS to compare against. For our predictors, we use elements 
CHNOP plus those from SClBrBSe that were predicted (including false positive predictions) to be present 
in the biomolecule. We use a mass deviation of 10 ppm. 
For the myxo data set, we excluded pinensin A (C96H139N27O30S2, 2213.962 Da). Processing this 
compound using the alphabet CHNOPSClBrBSe, we ran into an out-of-memory exception. Processing it 
with the predictor-based version, 19 746 670 candidate molecular formulas were evaluated in 15 min, and 
the correct molecular formula was at rank 10414. For three compounds in the myxo data set, we had to 
extend the mass deviation to 30 ppm to include the correct molecular formula. 
For the CASMI data set, we excluded four compounds and mass spectra, as these were solvents and 
contain an exceptionally high number of fluorines. For the remaining compounds, we used an upper bound 
of 6 fluorines (the remaining compound with the highest number of fluorines was flufenoxuron, 
C21H11ClF6N2O3, an insecticide). We assume for both approaches that we know whether iodine is present 
in the compound; as discussed below, the presence of iodine can be determined using the fragmentation 
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pattern of the compound. All running time measurements were performed on an Intel Sandy Bridge 
processor at 2.3 GHz with 128 GB RAM. 
We observe a massive decrease in the number of candidate molecular formulas we have to consider 
(see Table 5): We observe a 32-fold to 261-fold decrease in candidate molecular formulas filtered with 
SENIOR rules,[28] compared to the default method. As expected, this results in a similar decrease in running 
times: The total running time for processing all three data sets decreased from 18.6 min to 9.5 s. We also 
observe a slight improvement in identification performance. 
Table 5. Results of the Molecular Formula Identification Using SIRIUS 
  data set myxo pesticide CASMI 
  no. of spectra 87 43 528 
  median mass (Da) 592.315 260.016 281.484 
without element prediction 
correct identifications 12 13 287 
top 3 identifications 20 36 360 
top 10 identifications 30 42 433 
avg no. decompositions       
...before SENIOR filtering 2737085 2242.0 44007.4 
...after SENIOR filtering 571072.4 836.2 13052.5 
avg running time (ms) 11277.2 20.1 256.9 
          
with element prediction 
correct identifications 13 13 287 
top 3 identifications 21 37 364 
top 10 identifications 32 42 435 
avg no. decompositions       
...before SENIOR filtering 12708.8 73.4 597.6 
...after SENIOR filtering 2181.0 26.1 174.9 
avg running time (ms) 64.5 1.0 7.2 
We use CHNOPSClBrBSe when running the identification without element prediction (top). For our 
predictors, we use CHNOP plus those elements from SClBrBSe that were predicted to be present (bottom). 
For CASMI, we also added I to the set of elements for all compounds that contain iodine and allow up to 
six fluorines for all compounds. We report correct identifications (top 1, top 3, top 10), average number of 
decompositions (before and after SENIOR filtering) and average running time for all three datasets. 
 Conclusion 
We have presented classifiers to predict the presence of uncommon elements, based on the isotope 
pattern of the biomolecule. The thresholds have been chosen with regards to the setting discussed in the 
introduction, where an extremely high sensitivity is more important than a low false positive rate. 
Evaluating the classifiers on a real-world data set, we found no false negative predictions and would, thus, 
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never miss an element for molecular formula identification. Depending on the application, it is also 
possible to select thresholds based on other criteria, e.g., keeping the false positive rate low. 
We have shown how our classifiers improve the subsequent steps of analyzing isotope patterns, in 
particular by significantly reducing the number of candidate molecular formulas we have to consider. 
Molecular formula identification based on isotope patterns alone is not adequate in practice (see Table 5), 
but results can be much improved by accompanying the isotope pattern data by fragmentation data: For 
example, for 56 of 60 compounds in the complete pesticide data set, Böcker and Dührkop[23] inferred the 
correct molecular formula using both data types combined; in all cases, the correct answer was ranked in 
the top 5. Running time differences will be much larger if we also analyze tandem mass spectra, as 
processing a single candidate may require several seconds: Böcker and Dührkop[23] report an instance 
where 3106 candidates were considered, requiring a total of 12.5 h for this compound. 
We have used random forests for the prediction as they deliver high-quality predictions and are not 
susceptible to noise, as has been shown in the noise parameter evaluation. Classifiers have been trained 
on simulated data with relatively high noise and have not been tailored toward any particular instrumental 
platform. Training on instrument-specific data may further increase prediction quality. 
From the uncommon elements we have considered in this paper, sulfur is the most abundant one 
(Table 1). It is also the element which is hardest to predict, since the effect of a single sulfur atom on the 
isotope pattern is less pronounced than for other uncommon elements. We have not taken into account 
the presence of the characteristic peak at + 1.995796 Da from the monoisotopic peak in the isotopic fine 
structure, as detection of this peak is dependent on the resolution of the MS instrument, which is not 
covered in this paper. Assuming adequate resolution, combining the classifiers presented here with a 
classifier based on the + 1.995796 Da peak will result in improved classification performance for sulfur. 
Using the isotope pattern alone, it is not possible to predict the presence of iodine and fluorine. To a 
certain degree, it is possible to predict iodine using tandem mass spectral data, based on characteristic 
common losses and fragments.[23] In contrast, the presence of fluorine is hard to predict using tandem MS 
data, too; hence, it might be advisable to allow for a few fluorine atoms in the molecular formula 
candidates, if there is any reason to believe that fluorine might be present in the sample compounds.[4,8] 
Predicting the presence of other elements that have characteristic isotope distributions, such as silicon, is 
also possible by the methods presented here if required by the application. 
Selenium-containing compounds result in a monoisotopic peak with small intensity, which may not 
be detected in the mass spectrum. In this case, we cannot proceed by decomposing the monoisotopic 
peak. Instead, we can decompose the average mass (that is, the molecular mass) of the compound;[17]  the 
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average mass can be estimated from the experimental spectrum by taking the weighted average of isotope 
peak masses. 
Until now, the selection of elements to include for the calculation of molecular formulas has been a 
manual decision. This has not been seen as a critical bottleneck in the past, as molecular formula 
determination was mainly performed as a manual “low throughput” procedure in the course of structural 
elucidation. Today, methods for small molecule analysis are being applied at a large scale in numerous 
research fields, including diverse applications such as the investigation of industrially relevant plants and 
microbes, clinical pharmacology studies, and natural products discovery. The underlying mass 
spectrometry applications share a tendency to produce data sets from which hundreds to thousands of 
unknown molecules have to be analyzed. Generation of molecular formulas is among the most commonly 
performed first-pass analyses in unknown identification workflows, and several advanced methods rely on 
this upfront evaluation step.[23,45] Whereas efforts have been made to evaluate the fit of a measured 
isotope pattern against the theoretical isotope pattern of a molecular formula as well as evaluation of the 
corresponding statistical significance and robustness of the method,[46] the issue of predicting the presence 
or absence of elements has been widely disregarded. To this end, we believe that our method is an 
important step in the automated annotation of novel biomolecules from mass spectrometry data. 
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 Isotope patterns 
The isotope distribution of elements influences the isotope pattern of the molecule in both, mass 
differences and intensities of peaks. Small molecules containing only CHNOP have an intense monoisotopic 
peak; the +1 peak has much lower intensity, and intensity of subsequent peaks is further decreasing. The 
more “distinctive” isotope distributions of S, Cl, Br, B, and Se are reflected in the shape of the isotope 
pattern of a compound as follows: 
– Sulfur-containing compounds have slightly higher +2 peaks compared to CHNOP 
compounds. With an increasing ratio of S atoms to CHNOP atoms, the +2 peak in the isotope 
pattern of the molecule has an intensity higher than the +1 peak. We will deliberately ignore 
that sulfur containing compounds may be identified by an additional +2 peak at the 
characteristic mass difference of 1.995796Da from the monoisotopic peak.1 
– Chlorine has two stable isotopes with a mass difference of 1.99705Da.1 Isotope patterns of 
molecules containing Cl have a +2 peak of higher intensity than CHNOP compounds. Often 
the intensity of the +2 peak is higher than the intensity of the +1 peak. For a large number 
of Cl atoms in a molecule, the isotopic peaks with even indices have higher intensity than 
their preceding peaks. The most intense peak may not be the monoisotopic peak. 
– Bromine also has two stable isotopes with a mass difference of 1.997954Da.1 The intensity 
of the second isotope is higher than for Cl. Thus, the effects described for Cl are even 
stronger for Br. 
– Boron has two stable isotopes in nature, 10B and 11B. Different from the other elements, the 
abundance of boron isotopes varies between habitats. The presence of B produces an 
isotope pattern that resembles a bell curve. The effect gets stronger with increasing B atom 
number. The most intense peak is often the +1 peak. 
– Selenium has six stable isotopes and a very characteristic “zigzag shaped” isotope pattern, 
which is also reflected in the molecules containing Se. Selenium-containing compounds are 
often not accessible to methods decomposing the monoisotopic peak. 
                                                            
1 http://www.sisweb.com/referenc/source/exactmas.htm 
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 Features 
To learn and predict the presence of rare elements from isotope patterns, the isotope patterns need 
to be transformed to a set of numerical features characterizing the data. The number of features varies 
according to the number of peaks. The full list of mass and intensity features can be found in 
Supplementary Table S.1. 
 Compound databases 
For ChEBI (Chemical Entities of Biological Interest) we downloaded the Chebi complete.sdf on 
19/03/15 and extracted the molecular formulas from the Formulae field. ChEMBL version 19 was also 
downloaded as SDF file on 26/01/15. The SDF file was converted to InChI files using Open Babel 2.3.2 to 
extract the molecular formulas. DrugBank version 4.2 was downloaded as SDF on 19/03/15. Molecular 
formulas were extracted from the JCHEM FORMULA field. HMDB version 3.6 was downloaded on 19/03/15 
as SDF. Molecular formulas were extracted from the CHEMICAL FORMULA field. Indofine2 was downloaded 
on 20/03/2015 and converted to InChI files. From this database, we use Chalcones, Chromatrography-
Standards, Chromones, Coumarins, Flavanones, Flavones, Flavonoids-Coumarins, Herbal Standards, 
Isoflavones, Life-Science, Natural-Products, Rare-Organics- Biochemicals and Specialty-Chemicals. For 
Kegg, we downloaded the mol file from KEGG MEDICUS on 20/01/15. KNApSAcK was downloaded on 
02/01/15 using the KNApSAcK Keyword Search. Molmall3 was downloaded on 14/03/15 using the XLS 
table. PubChem was downloaded between 23/03/15 and 25/03/15 as SDF files using the PubChem FTP. 
The PUBCHEM MOLECULAR FORMULA field was used for extracting the molecular formulas. UNPD was 
downloaded as SDF on 23/03/15 and the Molecular Formula field was used. ZINC version 12 was 
downloaded on 20/03/15. We use the Standard-filtered Lead Like, Fragment Like, Drug Like and Shards 
subsets. We downloaded the property files and extracted the molecular formulas by converting the SMILEs 
to INCHIs using Open Babel 2.3.2. 
 Learning phase 
We train the classifiers on two Intel Sandy Bridge processors at 2.3 Ghz with six cores and 64 GB RAM. 
Training of all 18 classifiers required 3,5 h (see Supplementary Table S.3). We find that training requires 
                                                            
2 http://indofinechemical.com/resources/sdf/sdf.aspx 
3 http://www.molmall.net/download.html 
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more time the less unique the isotope pattern of the element. This is also reflected in the size of the trees 
in the random forests (see Supplementary Table S.4). 
 Prediction quality of the classifiers 
For evaluating the prediction quality of the classifiers, we compute Receiver Operating Characteristic 
(ROC) curves (see Figure 3 in the main document and Supplementary Figure S.1). To evaluate the tradeoff 
between sensitivity and specificity, we analyze the false positive rates (FPRs) for all 18 classifiers at fixed 
true positive rates (TPRs) (see Table 3 in the main document and Supplementary Table S.5). Voting 
thresholds for the random forests result from the best tradeoff between FPR and TPR for each classifier 
(see Supplementary Table S.6). 
 
Figure S.1. ROC curves for all classifiers using three peaks (left), four peaks (middle) and five peaks (right) at standard 
noise profile (top) and high noise profile (bottom). Note the different scales for both axes in the single plots. 
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Figure S.2. Two false positive examples for the chlorine classifier. Left: Bromazil with molecular formula C9H13BrN2O2 
and exact mass 260.016 Da. Right: Pinnensin A with molecular formula C96H139N27O30S2 and exact mass 2213.962 
Da, triple charge. We observe no significant differences between the measured (top) and the theoretical (bottom) 
mass spectrum. 
 
Figure S.3. False positive example for the sulfur classifier, chivosazol A methyl ester with molecular formula 
C50H73NO12 and theoretical mass 879.513 Da. We observe no significant differences between the measured (top) and 
the theoretical (bottom) mass spectrum. 
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Table S.1. Full list of mass and intensity features used for the training of the classifiers for isotope pattern with three 
peaks, four peaks or five peaks. px is the peak at position x, where x = 0 is the monoisotopic peak, x = 1 is the +1 peak 
and so on. int(px) is the intensity of peak px, mass(px) is the mass of peak px. 
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Table S.2. Compound databases used for simulating isotope patterns for the training set and the evaluation set. 
Number of molecular formulas after filtering. 
 
*Note that the total numbers are after removing double occurrences of molecular formulas, 
removing molecular formulas from the measured datasets, and removing formulas in the evaluation set 
from the training set. 
Table S.3. Running times for training and prediction. Running times for training were measured on a processor with 
twelve cores, whereas running times for prediction were measured on a single core. Prediction is measured including 
loading the classifier from hard disk, and running times are reported for the complete evaluation set (standard noise 
profile) with 51,097 molecular formulas. We report minimum running time over five independent runs. 
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Table S.4. Tree depth and number of nodes for all 18 classifiers. Values are medians over all trees in the forest. 
 
Table S.5. How many false positive prediction do we have to accept, in order to reach a certain sensitivity? We report 
false positive rates (FPR) for all 18 classifiers at fixed true positive rates (TPR). TPR 0.998 corresponds to two missed 
positive prediction in 1000 examples; TPR 1 means missing not a single positive example. Results for the high noise 
profile. ‘N/A’, classifier cannot reach the desired TPR. 
 
Table S.6. Resulting voting thresholds for all 18 classifiers. For the respective false positive and true positive rates, see 
Table 3 in the main document. 
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8 Discussion and Outlook 
 Challenges to access bacterial secondary metabolite diversity 
Natural products continue to represent a viable source for novel chemical entities exhibiting various 
biological activities.[1] In former times, most bioactive natural products have been found by bioactivity 
guided isolation approaches.[2] However, as the ‘low hanging fruits’ of bacterial secondary metabolism 
such as strongly active secondary metabolites produced in high amounts have mostly been found (a 
notion that appears especially evident for producer groups such as the actinomycetes, being screened 
already over decades), new approaches increasingly focus on accessing the ‘hidden’ bacterial secondary 
metabolome. ‘Hidden’ metabolites in this case comprise compounds whose production levels are too 
low to detect the corresponding activity in primary assays, or the – oftentimes rather limited – panel of 
bioactivity assays was unable to detect their bioactivity because the matching assay was simply not 
available. Furthermore, secondary metabolites that evade detection by the instrumental analytics set-
up, either due to their low abundance or as the applied analysis system is suboptimal for detection of the 
specific secondary metabolite, are oftentimes also referred to as parts of the ‘hidden’ metabolome. 
Conclusive estimates about the proportion of metabolome constituents that could be regarded as 
‘hidden’ are generally unavailable, but some basic insights can be derived from genome analysis of 
secondary metabolite-producing bacteria. For myxobacteria, an early notion of the fraction of secondary 
metabolites belonging to the ‘hidden’ metabolome came from an analysis of Myxococcus xanthus 
DK1622, where the majority of biosynthetic gene clusters could not be correlated to any known 
secondary metabolite, although transcriptomic and proteomic analysis suggested that most BGCs were 
expressed under the conditions tested.[3,4] This is a finding that is reflected among other secondary 
metabolite producing bacteria as well although under debate.[5] The number of BGCs in bacteria 
altogether clearly exceeds the number of known secondary metabolites to date.[3] Another 
myxobacterial study that focused on Chondromyces crocatus Cmc5 – a relatively well investigated 
myxobacterial strain – reflects this finding: although 5 compound families from this strain were already 
known before it was genome-sequenced, additional compounds were readily discovered and connected 
to their BGCs by genome-mining after its whole genome sequence became available.[6]  
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Figure 1. The three pillars of contemporary natural products discovery, representing the fundamentally different 
approaches for secondary metabolite identification. 
It is thus of vital importance to further develop innovative ways of secondary metabolite searching 
and detection, which includes the application of improved analytical setups as well as pursuing 
genomics-driven approaches, both of which are exemplified in this work. Improved access to 
myxobacterial secondary metabolites by lowering detection limits and streamlined mass spectrometry 
data processing to filter the complex data according to discovery-rationales will improve chances to 
‘harvest’ from the vast chemical space of myxobacterial secondary metabolites. Access to this structural 
diversity in turn is key to finding novel biologically active molecules with innovative targets, instead of 
rediscovering the ‘low hanging fruits’ of the secondary metabolome that come with the risk of previous 
description. Throughout the studies presented here, the use of recently emerging techniques has been 
highlighted to uncover novel secondary metabolites of myxobacterial origin, reaching beyond the 
‘classical’ activity guided secondary metabolite identification, isolation and structure elucidation. Careful 
evaluation of novel developments in instrumental analytics, statistical data treatment of MS and MSn 
data, DNA sequencing techniques as well as in silico analysis of genomic big data function together in 
these studies to reveal both prospects and limitations of each technique in terms of their utility for the 
identification of novel secondary metabolite scaffolds.[7] 
8.1.1 Prospects of novel analysis techniques for secondary metabolite detection 
Depending on used extraction and analysis methods, different secondary metabolites may be easily 
detectable or readily fall below their individual limit of detection. In recent years, most metabolomics 
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labs have switched to exclusively apply UPLC-ESI-MS hyphenated analytics – a versatile method that is 
able to detect a wide variety of secondary metabolites – albeit disregarding all molecular features 
detectable using other ionization techniques like APCI, or such solely visible in direct infusion MS. While 
solely relying on UPLC-ESI-MS analytics has been very successful in the past, it appears reasonable to 
assume that a significant proportion of the so-called ‘hidden’ secondary metabolome is probably unseen, 
because corresponding molecules are in the blind spot of UPLC-ESI-MS. Application of state of the art 
UPLC-ESI-MS analytics should be therefore in the future amended with additional techniques to venture 
into the unknown chemical space in bacterial secondary metabolomics that could be – according to 
genome analyses – even larger than the already known chemical space.[3] Some of these techniques, 
used in this work to a varying degree – will be discussed in the following. 
8.1.2 Improvements in UPLC-MS based instrumental analytics 
Since the development of ultra-performance liquid chromatography (UPLC) that operates at LC 
pressures above 400 bars on sub 3 µm particles, liquid chromatography separation power received a 
tremendous boost. Combined with electrospray ionization (ESI) and a fast scanning high resolution mass 
spectrometer (HRMS, mostly a QqToF device in this work) as a second dimension, the detection of 
thousands of molecular features in a short UPLC-MS analysis run is feasible.[8] The accuracy of the high 
resolution mass spectrometers additionally allows for prediction of plausible molecular formulas for 
every detected feature, thus unlocking additional information early during the discovery process.[9] 
However, chemical screening efforts in bacterial secondary metabolomics are still complicated by matrix 
effects, as it is impossible to discern a priori molecular features that are constituents of the bacterial 
secondary metabolome from molecular features originating from the medium ingredients (see section 
8.1.6). Moreover, the abundant matrix of biological samples can lead to severe ion suppression during 
the ESI process.[10,11] Among the main agents causing ion suppression effects in LC-ESI-MS are salts, ion 
paring agents e.g. phospholipids, primary metabolites such as amino acids as well as residual proteins, all 
of which occur in bacterial extracts.[10] Furthermore, bacterial secondary metabolites occupy an 
extremely wide range of polarities. Nucleoside antibiotics such as pseudouridimycin or aminoglycosides 
such as kanamycin are problematic to detect by UHPLC-ESI-MS, as they elute very close to void volume 
leading to their MS signal being suppressed by co-eluting salt.[12] Very non-polar components of the 
bacterial secondary metabolome such as slightly oxygenated polyketide or terpene scaffolds might be 
too hydrophobic for elution from a RP-HPLC column, thus evading detection in UPLC-MS. Furthermore, 
most standard detection and quantification protocols for terpenes such as steroids rely on atmospheric 
pressure chemical ionization (APCI)-MS, as they are hardly accessible to protonation in liquids, making 
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them invisible in ESI.[13] While ESI based UPLC-HRMS is without question currently the most versatile 
technique to detect bacterial secondary metabolites and therefore widely employed by most natural 
products analysis labs, the aforementioned limitations should serve as a word of caution that exclusive 
usage of this technique is likely to miss secondary metabolite scaffolds that simply evade detection using 
this technique. 
8.1.3 Emergence of DI-FTICR based secondary metabolomics 
Recently, Fourier transform ion cyclotron resonance spectrometers have become more accessible 
to natural products research laboratories. These spectrometers exceed the resolution of QqToF or 
Orbitrap spectrometers, reaching up to 1000000 in resolving power whilst having at the same time very 
low limits of detection.[14] Still, contrary to ToF or Orbitrap spectrometers, the FTICR needs significantly 
longer acquisition times to reach these resolving power values, as mass accuracy rises with the residence 
time of ions in the acquisition cell. Thus, LC-FTICR applications are bound to create coverage problems as 
long cycle times would mean high resolving power but also miss some molecular features. If one reduces 
the cycle time to lower values to fix this problem, resolving power would drop to values one can reach 
with Orbitrap or ToF systems, removing the resolving power advantage of the FTICR over said systems. 
Therefore, FTICR systems are currently mainly used in direct infusion (DI) mode. Due to the impressively 
low limit of detection, biological samples can be measured as highly diluted samples to limit ion 
suppression effects. Thereby, a full scan of a biological sample with ultra-high resolution can be 
measured in less than 4 minutes giving this technique a competitive edge to LC-HRMS applications that 
often take around 20 minutes per sample. Furthermore, resolving power of the FTICR allows dissection 
of the isotopic fine structure allowing much higher precision in determination of molecular formulas 
than using ToF or Orbitrap machines.[15] Still, DI-FTMS measurements have significant drawbacks 
compared to LC-HRMS analysis. First of all, because chromatography as an orthogonal analysis 
dimension is missing, it is impossible to characterize compounds based on chromatographic retention 
time that provides insights into compound polarity and provides a second comparison parameter in 
addition to the high resolution mass. Furthermore, as natural products occupy only a limited chemical 
space it is likely to encounter isobaric compounds in a sample. By design, DI-FTICR would be unable to 
distinguish these compounds while LC based application can discern them via retention time differences. 
Last but not least, DI-FTMS applications suffer to a higher extend from ion intensity modulation by 
suppression and enhancement meaning that absolute feature intensity in DI-FTICR experiments does not 
necessarily relate to the amounts of the corresponding compound in the biological sample.[11] One can 
thus conclude that some of the features seen in these experiments account for compound amounts that 
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are insufficient for structure elucidation even if large scale fermentations are applied. Published results, 
as for example a comprehensive study on ginseng metabolites, as well as preliminary in house data 
(Bader, Haack, Panter; unpublished results) suggest DI-FTICR to provide insights into the bacterial 
secondary metabolome that are complementary to widely used LC-HRMS applications, indicating this 
technique to be a valid asset to tap the biosynthetic dark matter of bacterial secondary metabolism in 
the future.[16] 
8.1.4 Mass spectrometry imaging (MSI) in bacterial secondary metabolomics 
 One core premise in secondary metabolism is that secondary metabolites are often produced 
under specific conditions only, e.g. when certain cultivation parameters are met, or at distinct time 
points during the bacterial growth curve. In order to study secondary metabolism under very specialized 
conditions such as in bacterial interaction zones on an agar plate or during fruiting body formation, 
spatial resolution of mass spectrometry data is necessary.[17] Mass spectrometry imaging realizes the 
acquisition of mass spectrometric data in a spatially resolved manner in order to identify compounds 
associated with a topological range. The main ionization techniques applied in MSI of biological samples 
are matrix associated laser desorption/ionization (MALDI) and desorption electrospray ionization (DESI). 
Both techniques rely on spatially resolved desorption of analytes from a surface, in case of MALDI using a 
laser beam, in case of DESI using an electrospray source.[18] The big advantage of this technique for 
investigation of bacterial secondary metabolites is spatial resolution of the results. As demonstrated in 
this work (chapter 6), MALDI MSI has been successfully used to uncover the homospermidine lipids, 
compounds that exclusively form during myxobacterial fruiting body formation, by differential analysis of 
vegetative myxobacterial cells compared to the fruiting body.[17] In principle, this technique could be 
used to monitor myxobacterial predation and one might be able to find compounds belonging to the 
bacterial chemical warfare arsenal, which might become candidates as novel antibiotic drug leads. On 
the other hand, as matrix embedded biological samples are very densely concentrated, both MALDI and 
DESI experiments suffer from strong ion suppression effects. It is thus close to impossible to directly 
detect weakly ionizable compounds directly from the solid surface, which severely limits MALDI and DESI 
techniques to easily ionizable secondary metabolites. 
8.1.5 Chromatography applications using supercritical CO2 as mobile phase 
A technique that has long existed, but has only recently been developed to become a reliable 
chromatography technique is supercritical fluid chromatography or SFC. While being underused so far in 
bacterial secondary metabolomics, the technique has proven its applicability and usefulness in 
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phytochemistry.[19]  SFC applications use most commonly supercritical CO2 as a mobile phase to which a 
gradient of an organic co solvent is added during separation. The fluid used for separations combines 
desirable qualities of gas chromatography such as the high diffusivity with desirable qualities of a liquid, 
i.e. high solubility. Polarity wise, SFC applications are more reminiscent of normal phase applications as 
polarity of supercritical CO2 is approximately the polarity of hexane, which also explains why mainly 
normal phase column material is used in these kinds of separations. The method has proven to be 
orthogonal to liquid chromatography allowing the separation of many mixtures that are inseparable 
using standard UPLC.[19,20] Furthermore, with the development and improvement of SFC-MS hyphenation 
the technique develops more and more towards an additional analytical asset for screening approaches 
of biological samples. The real strength of SFC in natural products research turns out to be its 
applicability in domains where UPLC-MS is notoriously difficult to use due to the non-polarity and 
insolubility of the analytes, such as for terpenes, flavonoids and in fatty acid analysis.[21] Some of these 
non-polar analytes can be analyzed by GC-MS, but this requires derivatization and thermostability, which 
is often a major issue with molecules of biological origin. Additionally, due to the high diffusivity of 
analytes in supercritical CO2, SFC separations are faster than their UPLC counterparts.[20,22] Although SFC 
is mainly used in phytochemical applications, the preparation of Myxothiazol Z on SFC, as it has been 
done in this work, demonstrates that application utility of SFC for natural products purification. Still, SFC 
applications have drawbacks as for example the incompatibility with water which is immiscible with 
supercritical CO2. Thus polar compounds, especially larger hydrophilic peptides are mainly insoluble in 
SFC solvents meaning that bacterial secondary metabolomics with regard to polar non-ribosomal 
peptides cannot be transferred to SFC. This highlights once again the technique to be a complementary 
one in cases that are difficult to treat by reversed-phase LC, but it will likely not replace conventional 
UPLC.[7] 
8.1.6 Statistical means for big data processing 
High end UPLC-HRToF as well as DI-FTMS equipment nowadays easily records more than 10,000 
molecular features in one single bacterial extracts, comprising both medium borne matrix features as 
well as features representing constituents of the bacterial secondary metabolome.[8,16] It is thus of 
utmost importance to automate workflows separating the ‘unimportant’ matrix features from the 
bacterial metabolome. A crucial point in this analysis is the dissection of LC-MS or DI-MS data into 
molecular features. With the improvement of feature finding and adduct detection algorithms from 
earlier simplistic forms to the contemporary algorithms for DI-MS and LC-MS data, the number of 
detectable and discernable molecular features rises significantly.[23] Combined with well-controlled 
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chromatography conditions that lead to reproducible retention times, buckets can be confined more 
precisely, leading to increasing numbers of features that can be used as input for statistical tools like 
principle component analysis, as exemplified in the fulvuthiacene study (chapter 3). Therefore, in line 
with increases in mass spectrometric performance, the data processing capacity needs to evolve as well. 
Recent developments in the timeframe of this thesis indicates continuous improvement in this respect, 
since the vendor-specific analysis framework (“Metaboscape”, Bruker Daltonics, Bremen) became 
significantly better in feature finding compared to previous software products. As most metabolomics 
experiments rely on ‘big data’ in some form that cannot be treated manually, it is of utmost importance 
that software development keeps up with developments in mass spectrometric instrumentation in order 
to fully exploit the potential of state of the art mass spectrometry. The ever increasing amounts of data 
created in state of the art metabolomics approaches urgently need intelligent post processing and data 
mining approaches to extract a limited amount of valuable data that can be treated manually out of the 
‘big data’ that is created in these approaches. To achieve this, other considerations have to be taken into 
account, like for example to look at the bacterial secondary metabolome in a taxonomy resolved 
manner.[24] Another approach is the extraction of a maximum of structural information at an early time 
point in the analysis as it was exemplified by the discovery of the fulvuthiacenes in chapter 3 of this 
work. 
8.1.7 Developments in extraction of structural information from MSn data 
A key limiting factor in natural products science remains full structure elucidation of molecules as 
on the one hand, bacterial secondary metabolites tend to be complex often exceeding 600 Daltons, 
while on the other hand production and separation is often not trivial. This finding is well exemplified for 
several molecules purified as part of this thesis.[3,7,9,25] Thus, especially since secondary metabolite 
detection performance received a large boost in recent times, mainly due to advances in mass 
spectrometry instrumentation, the most costly and time consuming steps in secondary metabolite 
research are still the isolation and NMR based structure elucidation efforts. It is therefore of vital 
importance to make well-informed decisions about candidate compounds for isolation - considering 
presumed structural novelty - in order to avoid isolation of ‘less interesting’ molecules. While NMR data 
used for full structure elucidation require rather large amounts of pure substances, mass spectrometry 
data can be acquired much faster and directly from crude mixtures. Recent advances in computational 
mass spectrometry such as fragmentation trees and molecular networking boosted the utility of MSn 
fragment spectra.[26,27] In this work, both the assignment of the fulvuthiacenes’ as well as the 
chloromyxamides’ minor derivatives relied on extracting early structural information out  of mass 
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spectrometry data.[28] With the above-mentioned enhancements of the detection stage fueled by both 
advancements in analytical systems as well as advancements in ‘big data’ treatment software, the 
application of pre-filters to judge, which MS signals represent compounds worth focusing on becomes 
imperative. An element to support these efforts is realized by community curated projects such as GNPS 
as large scale data repositories for MS² data in order to be able to extract as much CID MS² based 
information as possible from an open source platform.[27] Spectral comparison, whether it is done by 
spectral networking or fragmentation tree computation can thus help place an uncommon MS² spectrum 
in context using publicly available CID fragmentation information.[26,27] While such database-powered 
identification and association tools have long become standard in Protein MS, e.g. the MASCOT database 
and GC-MS using NIST database identification for decades, LC-ESI-CID based MS² experiments were 
always presented with additional challenges.[29,30] GC-MS applications capitalize on the fact that they 
almost exclusively use electron impact ionization which is very reliable and reproducible across a wide 
variety of instruments. Protein MS on the other hand is simplified by peptide bond fragmentation that 
follows established rules, which makes protein fragmentation patterns predictable and comparable to 
theoretical fragments.[30] Small molecule ESI-CID-MS always suffered from limited comparability of MS² 
spectra across different MS platforms, which was the main obstacle of developing these community 
projects so far. Advances in software solutions to tackle this problem as well as improving open access 
data repositories to store natural product MS² data will be key to make better decisions on structural 
novelty of a natural product in the future. This can guide isolation and structure elucidation efforts 
towards unexplored subspaces in the chemical universe of natural products diversity, which translates 
into chances to discover the much-desired new targets and biological activities. 
8.1.8 Improvements in sequencing technology and biosynthetic pathway prediction 
Since the development of fast and cheap genome sequencing techniques, bacterial secondary 
metabolism is increasingly tackled from an in silico point of view. DNA sequencing techniques such as 
illumina sequencing and the development of PacBio (Pacific Biosciences) sequencing enabled elucidation 
of bacterial genomes starting from minimal amounts of DNA.[31] In recent years prices per sequencing 
run dropped significantly leading to an explosion of genome information available to the public domain. 
Furthermore, automated predictions of coding sequences combined with easy access to computing 
power made high throughput genome annotations possible.[32] Community curated gene repositories 
such as GenBank that provide an ever increasing source of annotated genes improve comparative 
annotations as more reference genes of known function exist that the various algorithms can compare 
to.[33,34] This is particularly helpful as proteins of unknown function in a biosynthetic gene cluster that can 
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be linked to an enzymatic activity – even though this enzymatic activity might have been found in a 
completely different organism and field of interest – can help clarify unprecedented biosynthetic steps in 
a secondary metabolite biosynthesis. The predictive power of comparative tools is dependent on a 
database of assigned genes which will increase with every gene with an assigned function. In 
combination with one of the main advances in the field of genomics-driven natural products discovery, 
the automated procedures to predict and annotate secondary metabolite biosynthetic gene clusters, 
nowadays routinely available through the online software platforms antiSMASH and Prism, one can not 
only predict the core biosynthetic machinery but also explain tailoring enzyme steps.[35,36,37] These tools 
allow users to assess in silico the biosynthetic potential of large numbers of secondary metabolite 
producing organisms in a very short time, streamlining both the search for biosynthetic gene clusters 
corresponding to known secondary metabolites as well as getting a glimpse on the predicted 
biosynthetic potential of an organism. To efficiently prioritize bacterial – in our case myxobacterial – 
strains, this is of vital importance, as the biosynthetic potential varies from strain to strain. Analyses 
across genomes allow natural products scientists to focus on strains showing high numbers of 
architecturally interesting biosynthetic gene clusters, disregarding those strains with a limited number 
yet unassigned of BGCs. Additionally, self-resistance predictor tools such as ARTS come with the promise 
to automate the finding of self-resistance determinants in biosynthetic gene clusters that provide 
additional guidance for gene cluster prioritization.[38] In this work, the presence of a topoisomerase 
inhibitor self-resistance protein – a so-called pentapeptide repeat protein – in a cryptic gene cluster has 
been explicitly shown to confer self-resistance to the corresponding secondary metabolite, which in the 
end turned out to be a strong topoisomerase IV poison.[39]  Further advances in secondary metabolite 
biosynthetic gene cluster community curation have been made by the MiBiG repository that allows 
storage and comparison of biosynthetic gene cluster information as well as easy access free of 
charge.[40,41]  Like in the case of mass spectrometry data, community sharing and data curation of 
biosynthetic gene cluster data (sometimes termed the ‘clustome’) will be a key aspect to further 
secondary metabolite research as it provides scientists with tools to judge biosynthetic potential of an 
organism prior to compound isolation, as well as enabling the better understanding of complex 
biocatalysis involved in secondary metabolite biosynthesis. 
8.1.9 Conclusions for bridging the genome to metabolome gap 
As laid out in this work there are several important aspects to improving the prospects of finding 
novel biological entities from natural sources. Natural products research is a interdisciplinary field where 
high performance chemical analytics meets experimental biological and bioinformatics-driven 
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evaluation, e.g. by varying cultivation conditions, genetics experiments such as promotor exchanges and 
in silico analysis.[17,35,36,39] As discussed before, analysis of high resolution mass spectrometric ‘big data’ as 
well as in silico secondary metabolite gene cluster mining increasingly rely on large community curated 
databases. Examples of such are GenBank or MiBiG for in silico genetic analysis as well as GNPS, 
MetFrag, SIRIUS and – in this work – the in-house Myxobase project concerning treatment of mass 
spectrometric data.[27,33,40,42] Still, with all these bioinformatics tools available, the genome to 
metabolome link is not a trivial endeavor. While there are clear translation rules to transform genes into 
proteins – which are readily exploited in MS and MSn based proteomics – the biosynthetic gene cluster to 
secondary metabolite connection generally lacks concise in silico prediction methods.[30] Some advances 
in this field were made for non-ribosomal peptides, a compound class that often abides by the 
collinearity rule during biosynthesis and shows rather ‘predictable’ amino acid fragments in 
multidimensional mass spectrometry analysis, as exemplified by the software Pep2Path.[43] Still, these 
methods rely on biosynthetic collinearity as well as somewhat ‘regular’ MS fragmentation, thus limiting 
their utility for many other chemical classes of natural products. Progress in artificial intelligence based 
machine learning might become helpful for narrowing the gap between the bacterial metabolome and 
its genome or ‘clustome’ in the future, but automated annotation of secondary metabolites to the 
respective clusters is neither generally feasible nor is it on the horizon. Currently, it seems even likely 
that secondary metabolite structure prediction will never be fully automatable as it appears impossible 
to predict enzyme reactions that trigger complex reaction cascades for, example. In the foreseeable 
future, as exemplified also in this work, correctly linking secondary metabolites to their respective gene 
clusters and understanding their biosynthesis will continue to comprise a lot of manual and experimental 
labor, although the mentioned software tools do indeed facilitate the rate and depth of insights gained. 
 Biochemistry lessons from myxobacteria 
In addition to the instrumental analytics and data mining part of this work, a large part of this thesis 
was dedicated to investigating biosynthesis. Along the lines of this work, insights into three different, 
very peculiar structural elements of myxobacterial natural products as well as their underlying 
biosynthesis were obtained.  
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8.2.1 A dual function protein for heterocycle formation using amino acids 
During pyxidicycline formation (chapter 2), the enzyme PcyJ is able to catalyze a cascade of 
enzymatic reactions that amend the polyketide precursor originating from PKS type II biosynthesis with a 
nitrogen containing heteroaromatic system via incorporation of an amino acid.[39]  
 
Scheme 1. Enzymatic reaction cascade leading to the formation of the heterocycle in pyxidicycline biosynthesis 
The reaction starts with the polyketide precursor from the type II PKS assembly line depicted in 
scheme 1. This polyketide precursor is in an equilibrium with amino acid hemiaminal structures (Scheme 
1). If a hemiaminal is formed with serine, this adduct should fit into the binding pocket of PcyJ, a protein 
that by design of its binding pocket probably already encourages the formation of exactly this 
hemiaminal structure. Once this moiety is formed, ATP is used to activate the carboxylic acid present on 
the precursor to form an activated carboxyl-AMP ester that subsequently undergoes intramolecular 
cyclisation with the hemiaminal nitrogen. This reaction is clearly enzyme catalyzed as it relies on the 
presence of PcyJ and no pyxidicyclines can be detected in PcyJ deletion mutants, while the polyketide 
precursor accumulates.[39] Furthermore, and contrarily to the case of jadomycin, PcyJ uniquely 
incorporates serine into the pyxidicycline scaffold.[44]  Therefore, pyxidicycline biosynthesis reveals a new 
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method to synthesize nitrogen containing six membered heteroaromatic systems, which might be 
relevant in other type II PKS biosynthesis pathways that will be characterized in the future. 
8.2.2 Biosynthesis of β-methoxymethacrylates in myxobacteria 
There is a wide variety of compounds that are currently used as antifungal agents having a β-
methoxymethacrylate moiety as part of their pharmacophore.[45] Biosynthesis of this peculiar unit has 
been of special interest in order to understand enzymatic processes behind biogenesis of this moiety to 
finally attempt to create derivatives usable as fungicides. One peculiarity of this biosynthetic 
transformation is that it is partly formed on the assembly line and partly in post assembly line tailoring 
steps.[46] The fulvuthiacenes that have been treated extensively in this work also contain a β-
methoxymethacrylate moiety which has been subject of intense study (chapter 3). Already on the 
assembly line in fulvuthiacene biosynthesis we observe peculiar biosynthesis steps, for example the 
direct methylation of a keto-function by an O-methyl transferase (OMT). 
 
Figure 2. Last part of the fulvuthiacene assembly line including direct methylation of a keto-function and glycine 
degradation as known from nitriloacetate degrading enzymes 
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This reaction creates a methyl vinyl ether – a rather uncommon structural feature in polyketide 
biosynthesis – that will later be part of the terminal β-methoxymethacrylate. The terminal module in 
fulvuthiacene biosynthesis catalyzes an even more uncommon step in fulvuthiacene biosynthesis that is 
addition and break down of a glycine residue to the terminal carboxylic acid of the fulvuthiacene 
precursor. Adenylation and condensation modules that attach glycine to the fulvuthiacene precursor are 
not particularly different from most glycine specific domains, but there is an unusual monooxygenase 
(MOX) inserted into this module. Blast comparison of the sequence of this monooxygenase reveals high 
similarity to nitriloacetate degradation enzymes that catalyze the α-oxidation and breakdown reaction 
depicted in Figure 2. These enzymes are an excellent example of nature reutilizing similar enzymology to 
fulfill completely different tasks, which highlights again the necessity to characterize as many 
biochemical reactions as possible as they might become important in completely different contexts. 
After release combined with glycine breakdown with the assembly line releases a fulvuthiacene 
acrylamide structure which is then converted into fulvuthiacene using two post assembly line tailoring 
steps, catalyzed by an amidase called FtaH and another O-methyltransferase called FtaG. 
 
Scheme 2. Post assembly line modification steps in the fulvuthiacenene biosynthesis 
The fulvuthiacene cluster contains the genes FtaH and FtaG which encode an amidase and a methyl 
transferase respectively. While the corresponding reactions are readily expected from these enzymes, as 
was discussed in the fulvuthiacene study (chapter 2), this reaction sequence shows biosynthesis to 
sometimes undertake seemingly ‘unnecessary’ detours. If one would remove the precursor from the 
penultimate module of the assembly line as depicted in Figure 2, one would directly obtain fulvuthiacene 
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acrylic acid without having to add and completely degrade a glycine molecule. This finding suggests that 
evolution of secondary metabolite biosynthesis pathways is to some degree genetic trial and error; in a 
wider sense Nature, although efficient at optimizing biosynthesis through evolution, is apparently not 
error proof in its quest to find the easiest pathway to a desired product. More importantly, the discovery 
of this biosynthetic ‘detour’ can be seen as direct evidence that in studying living organisms we are not 
looking at ‘completed evolution’, which by design does not exist, but we are rather looking at a snapshot 
of evolution in progress. 
8.2.3 Biogenesis of CMPA as a new amino acid in NRPS biosynthesis 
As mentioned in this work, the most peculiar part of chloromyxamide biosynthesis is the 
biosynthesis of a new natural amino acid building block called 6-chloromethyl-5-methoxy-pipecolic acid 
or CMPA. Feeding experiments followed by targeted tandem MS experiments have proven the 
corresponding moiety not to originate from lysine - like pipecolic acid in tubulysin biosynthesis - but to 
be derived from glutamate.[47]  A key element in CMPA biosynthesis is its carrier protein, a LysW analog 
that, like in lysine biosynthesis, performs condensations at the γ-Glu position of the terminal Glu residue 
in CmxD.[48] The big difference between CmxD and LysW is, that while LysW accepts α-aminoadipate as a 
substrate for lysine biosynthesis, CmxD utilizes a glutamate as a starting point for CMPA 
biosynthesis.[28,48] The next peculiarity in CMPA biosynthesis is the final chlorination induced cyclization 
step. Here, although the present study could not obtain ultimate proof for the reaction sequencing on 
the molecular level, several hypothetical alternative deviations from the presented scheme can be 
excluded from a chemical reactivity point of view. In scheme 3 the reduction of the δ-carbonyl function is 
presented before addition of the generated chloronium ion to the terminal double bond. This is highly 
likely as on the one hand, the α,β-insaturated carbonyl function is probably too electron depleted to 
allow electrophilic attack of the cloronium and on the other hand, as seen in Scheme 4, the δ-carbonyl 
function would direct the intramolecular cyclisation reaction toward seven membered ring formation 
instead of formation of the pipecolic acid ring. 
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Scheme 3. Presented reaction scheme for the first part of CMPA biosynthesis 
 
Scheme 4. Differential chlorination schemes regarding whether chlorination occurs before or after δ-ketoreduction 
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It could not yet be clarified whether methyl transfer to complete the CMPA unit occurs as a last step 
as it is described in the chloromyxamide study (chapter 3), or whether an intermediate as seen on the 
top right side of Scheme 4 exists. The current working hypothesis consists of late stage methylation as 
methyl transfer is often the last step in the production of non-canonical building blocks, e.g. in 
tomaymycin and vioprolide biosynthesis.[49] Insights into CMPA biosynthesis might have additional value 
as chloromyxamides are unlikely to be the only NRPS systems to contain CMPA as a building block. Other 
CMPA containing NRPS systems will likely use the same machinery to produce CMPA unit, as reproducing 
this machinery via heterologous gene transfer is more likely during evolution in contrast to development 
of an alternative CMPA pathway from scratch. 
8.2.4 Conclusions regarding the importance of understanding biosynthesis 
During biochemical evaluation of the three biosynthetic pathways for pyxidicycline, fulvuthiacene 
and chloromyxamide biosynthesis, light was shed on key biosynthetic steps that might become 
important in completely different biochemical contexts. Biochemical evaluation of natural products in 
conjunction with their gene clusters will continue to reveal intriguing biotransformation steps to build up 
complex structural moieties at an accelerating pace. During evolution the underlying enzymology has 
been shared among producing organisms, meaning that similar structure elements in natural products 
are often constructed using similar enzymatic steps by homologous enzymes. Thus, in order to better 
understand secondary metabolite biosynthesis at large, it is essential to build a better understanding of 
the biosynthetic steps bacteria use to synthesize specific substructures. This has implications not only for 
the formation of the specific compound at hand but also allows logical deductions for different assembly 
lines responsible for the productions of yet to-be-discovered molecules featuring the same structural 
element. This concept highlights once again the importance of in-detail investigation of biochemical 
processes in secondary metabolite research that extends beyond the traditional “grind and find” 
approach to natural products discovery. 
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 Curriculum vitae 
Personal information 
   Born on 04.07.1989 in Homburg 
1999−2008     Saarpfalzgymnasium in Homburg/Saar, A level (1,4) 
 
Education 
Nov.  2014 - Today PhD studies at Helmholtz-Institute for Pharmaceutical Research Saarland, 
   Department of microbial natural products (MINS) 
 Identification and structure elucidation of novel biologically active 
substances from myxobacteria 
 Application of high resolution LC-QqTOF/MS and LC-QqTOF/MS² methods as 
well as 1D and 2D NMR spectroscopy 
 Genetic manipulation of the corresponding bacterial strains to elucidate the 
corresponding biosynthesis pathways 
 
Apr.-Oct. 2014  Master’s thesis at Helmholtz-Institute for Pharmaceutical Research Saarland, 
Department of microbial natural products (MINS) (1.0) 
 LC-MS und LC-MS2 profiling of myxobacterial extracts via high resolution LC-
QqTOF/MS and LC-QqTOF/MS² 
 Statistical data treatment with principal component analysis to find novel 
metabolite scaffolds 
 Purification and structure elucidation of identified interesting metabolites 
via NMR spectroscopy 
 
2009 - 2014   Integrated bilingual master at Saarland University and Ecole européenne 
   de chimie polymères et matériaux (ECPM) in Strasburg, France 
Diplôme d'Ingénieur (17.126/20) 
Saarland University, Saarbrücken Master of Science (1.0) 
 Work on micro projects with industrial partners during the program ECPM 
innov‘, Development of methods to remove vinyl chloride from waste water 
 Law, economics and toxicology courses 
 Trilingual lecture program consisting of German, English and French courses 
 Choice of analytical chemistry major 2012-2014 
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Experience 
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central laboratory 
 Elemental analyses by ICP-OES of different metals and ceramic materials 
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